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Abstract 
 Trichloroethylene (TCE), an organic solvent with multiple industrial uses, is associated 
with adverse pregnancy outcomes in epidemiological studies. In timed-pregnant Wistar rats, 
TCE exposure reduces fetal weight. Additionally, the TCE metabolite S-(1,2-dichlorovinyl)-L-
cysteine (DCVC) stimulates reactive oxygen species (ROS) generation and apoptosis in HTR-
8/SVneo placental cells as mechanisms of toxicity. By using aminooxyacetic acid (AOAA) to 
decrease cysteine conjugate beta-lyase (CCBL) activity and resulting toxicity of DCVC, prior 
studies in kidney cells demonstrated that the metabolism of DCVC into 1,2-dichlorovinylthiol 
(DCVT) by CCBL is critical for producing cell death. N-acetyl-L-cysteine (NAC) is a compound 
with ROS-scavenging properties and a supplier of an acetyl group that contributes to N-
acetylation of DCVC. Because metabolism of DCVC is crucial for TCE toxicity, this dissertation 
hypothesizes that modification of TCE or DCVC metabolism during pregnancy modulates TCE 
or DCVC-stimulated apoptosis and toxicity. This dissertation uses AOAA and NAC as 
modulators of TCE or DCVC-stimulated toxicity. 
 Chapter 2 described TCE-induced decreased fetal weight in timed-pregnant Wistar rats 
that was prevented by AOAA but not NAC pre/co-treatment. However, AOAA reduced CCBL 
activity in maternal kidney, but not maternal liver or placenta, suggesting that inhibition of 
kidney metabolism may have a role in the AOAA effect. Morphometric analysis of the placenta 
indicated that NAC pre/co-treatment with TCE relative to TCE treatment alone altered placental 
dimensions consistent with a delayed developmental phenotype. Treatments failed to stimulate 
any indication of placental apoptosis. 
xvi 
 
Chapter 3 findings showed that TCE exposure stimulates changes in amniotic fluid of the 
rats. Changes in amniotic fluid of both sexes include decreased adenosine triphosphate, 
decreased adenosine diphosphate, decreased guanosine diphosphate, and altered pentose 
phosphate pathway and folate biosynthesis. 
 Chapter 4 described mechanisms of DCVC-stimulated toxicity in the in vitro human 
trophoblast BeWo cell model. BeWo cells are known to syncytialize, or multinucleate and fuse, 
in response to forskolin to create the syncytiotrophoblast cell type that is the maternal-fetal 
interface in vivo. DCVC was found to increase caspase 3/7 activity and nuclear condensation or 
fragmentation, markers of apoptosis, in unsyncytialized BeWo cells, BeWo cells undergoing 
syncytialization, and syncytialized BeWo cells. DCVC also stimulated changes consistent with 
increased ROS production in all three BeWo cell types, including increased hydrogen peroxide 
abundance and decreased PRDX2 mRNA expression.  
Chapter 5 showed NAC and AOAA pre/co-treatment modulation of DCVC-stimulated 
toxicity. NAC either exacerbated or did not affect the DCVC-stimulated response. Because NAC 
exerted a significant effect on increased CYP3A4 mRNA expression, it is possibile that NAC 
could have contributed to the CYP3A4-generation of the toxic N-acetyl DCVC sulfoxide 
(NAcDCVCS) metabolite. AOAA did not modify CCBL activity in BeWo cells regardless of 
differentiation status. However, syncytialized BeWo cells exhibited higher CCBL activity than 
unsyncytialized BeWo cells, which could explain increased susceptibility of syncytialized BeWo 
to DCVC apoptosis compared with unsyncytialized BeWo cells.  
Chapter 6 revealed that DCVC treatment during syncytialization could either exacerbate 
or reverse some cellular energy metabolism changes stimulated by syncytialization by itself. 
Notable reversal effects included ratios within purine metabolism. 
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 This research indicates a critical role for CCBL in DCVC- and TCE-stimulated toxicity 
during pregnancy and raises the possibility that NAC pre/co-treatment with TCE or DCVC could 
be detrimental. Apoptosis and disrupted energy metabolism could be major mechanisms of TCE 
or DCVC-stimulated toxicity. Important future work includes detection of reactive TCE 
metabolites and identification of enzyme targets of TCE. 
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Chapter I. Introduction 
Adverse pregnancy outcomes as a major public health concern 
 Adverse pregnancy outcomes are numerous and can be severe in nature. These outcomes 
can range from maternal mortality, infant mortality, stillbirth, miscarriage, preeclampsia, low 
birth weight, intrauterine growth restriction, and preterm birth (World Health Organization, 
1970). The most serious adverse outcomes are common. The maternal mortality ratio was 
reported as 216 per 100,000 live births globally in 2015, with an estimate of 12 per 100,000 for 
high-income countries and 546 per 100,000 in sub-Saharan Africa (Alkema et al., 2016). In the 
United States in 2013, infant mortality occurred at a rate of 596 per 100,000 live births, which is 
high compared to that of other developed countries (Murphy et al., 2017). 
 Along with the occurrence of maternal and infant mortality, adverse pregnancy outcomes 
of preeclampsia, intrauterine growth restriction, and preterm birth are also common with 
profound consequences. Preeclampsia, or hypertension with proteinuria during pregnancy, 
affected 4.6% of all deliveries in a study involving 39 million women from 40 countries 
worldwide (Abalos et al., 2013). Preeclampsia also increases risk of maternal death from other 
diseases such as cardiovascular disease (2.7-8.1 hazard ratio compared to control) and stroke 
(1.6-5.1 hazard ratio compared to control) (Fraser et al., 2012). Intrauterine growth restriction 
occurs in 10-15% of pregnancies (Longo et al., 2013) and is associated with higher insulin, lower 
adiponectin, and higher abdominal fat in the offspring (Crume et al., 2014). Finally, preterm 
birth is estimated to have a rate of 10.02% in the United States in 2018 (Martin et al., 2019), and 
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is the primary cause of death in infants below five years of age (World Health Organization, 
2016). 
Exposures and health conditions as associated with adverse pregnancy outcomes 
 Despite the aforementioned knowledge of adverse pregnancy outcomes, causes of such 
outcomes remain largely unknown and are an active area of research. It has been reported that 
low energy intake, short stature, low body mass index (BMI) before pregnancy, and cigarette 
smoking are associated with intrauterine growth restriction (Kramer, 2003). Additionally, low 
body mass index (BMI) before pregnancy, genital tract infection, incompetent cervix, and 
cigarette smoking are associated with preterm birth (Kramer, 2003). 
 Exposures to specific chemicals are increasingly associated with adverse pregnancy 
outcomes. Nitrogen dioxide (NO2) exposure as a form of air pollution has been linked to small 
for gestational age and decreased term birth weight (Stieb et al., 2016). Additionally, women 
who delivered preterm were found to have higher concentrations of selected phthalate 
metabolites in urine compared to women who delivered after 37 gestational weeks (Meeker et 
al., 2009). Furthermore, a study found that maternal plasma concentrations of polychlorinated 
biphenyls (PCBs) were inversely associated with both placenta and birth weights (Halldorsson et 
al., 2008). 
Trichloroethylene (TCE) as an environmental toxicant and potential contributor to adverse 
pregnancy outcomes 
 Trichloroethylene (TCE) is an organic solvent primarily used as a metal degreaser and in 
synthesis of other chemicals (Agency for Toxic Substances and Disease Registry, 2019). During 
manufacture, formulation, and use, TCE is released into air, soil, and surface water (Agency for 
Toxic Substances and Disease Registry, 2019). Despite the decrease of TCE release into the total 
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environment from over 57 million pounds in 1988 to 2.4 million pounds in 2010 (Chiu et al., 
2013), the legacy of TCE as a Superfund hazardous waste site pollutant and a drinking water 
contaminant remains particularly severe. Indeed, TCE has been found in 761 out of 1300 
hazardous waste sites designated by the United States Environmental Protection Agency as of 
2011 (United States Environmental Protection Agency, 2011a; Chiu et al., 2013) and has been 
estimated to be in one-third of the municipal water supplies of the United States (Jollow et al., 
2009). 
 The toxicity of TCE is well-documented. TCE negatively affects the central nervous 
system (Bale et al., 2011), kidney (Green et al., 1997a; Lash et al., 2000b), and liver (Bull, 
2000). Two case-control epidemiological studies associated TCE exposure with renal cell cancer 
(Charbotel et al., 2006; Moore et al., 2010). In mice and rats, exposure to TCE increases 
incidence of liver, kidney, lung, testes, and hematopoietic system tumors (Guha et al., 2012). 
Studies of TCE as a carcinogen led the International Agency for Research on Cancer to classify 
TCE as a Group 1 known human carcinogen in 2014 (Guha et al., 2012; International Agency for 
Research on Cancer, 2014). The United States Environmental Protection Agency (U.S. EPA) 
also determined that TCE is carcinogenic, in large part for its involvement in kidney and liver 
tumor formation (United States Environmental Protection Agency, 2011c). 
The link between TCE exposure and adverse pregnancy outcomes has been documented, 
as well. In an epidemiological study, maternal exposure to TCE in drinking water was associated 
with decreased birth weight of the offspring (Rodenbeck et al., 2000). Similarly, maternal 
inhalation of TCE was associated with adverse pregnancy outcomes such as low birth weight, 
small for gestational age, and presence of cardiac and conotruncal defects (Forand et al., 2012). 
Additional epidemiological studies at Camp Lejeune in North Carolina found that TCE exposure 
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through contaminated drinking water was associated with small for gestational age, decreased 
term birth weight (Ruckart et al., 2014), and increased presence of neural tube defects (Ruckart 
et al., 2013). A final epidemiological study has seen TCE ingestion through drinking water to be 
associated with small for gestational age, fetal eye malformations, fetal cleft lip, fetal death, and 
fetal neural tube defects (Bove et al., 2002). In the pregnant Wistar rat, maternal inhalation of 
TCE decreased fetal weight and increased incidence of skeletal ossification (Healy et al., 1982). 
TCE metabolism 
 TCE can be metabolized to a wide range of metabolites with varying degrees of toxicity 
(Figure 1.1). A first pathway by which TCE is metabolized is through the oxidative cytochrome 
P450 (CYP) pathway (Lash et al., 2014a). In this oxidation pathway, TCE is first converted to a 
transient CYP-bound intermediate, or TCE-O-CYP complex (Lash et al., 2014a), which 
spontaneously reforms into either N-(hydroxyacetyl)-aminoethanol, chloral (CHL), or TCE 
epoxide (TCE-O) (Lash et al., 2014a). TCE-O can reform into oxalate or another unstable 
compound, dichloroacetyl chloride (DCAC), which rearranges into dichloroacetic acid (DCA) 
(Lash et al., 2014a). CHL is in equilibrium with chloral hydrate (CH), which together can be 
converted to trichloroethanol (TCOH) by alcohol dehydrogenases or CYPs (Lash et al., 2014a). 
TCOH can be metabolized to its glucuronide trichloroethanol glucuronide (TCOG) by UDP-
glucuronosyltransferase (Lash et al., 2014a). The CH/CHL mixture can also be converted to 
trichloroacetic acid (TCA) by aldehyde dehydrogenases, and TCA can be converted to DCA. 
DCA undergoes multiple fates, including conversion to either monochloroacetic acid (MCA), 
glyoxylic acid, or oxalate (Lash et al., 2014a). Of all these compounds formed from CYP-
dependent oxidation of TCE, the metabolites TCOH, TCOG, TCA, DCA, MCA, and oxalate are 
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hydrophilic and recoverable in urine (Lash et al., 2014a). Additionally, it is known that CH is 
genotoxic and clastrogenic, and that TCA and DCA are liver carcinogens (Lash et al., 2000a). 
 The second pathway by which TCE is metabolized is through the glutathione (GSH) 
conjugation pathway. In this pathway, TCE is first converted to S-(1,2-dichlorovinyl)glutathione 
(DCVG) by glutathione-S-transferases (GSTs) (Lash et al., 2014a). DCVG is then metabolized 
into S-(1,2-dichlorovinyl)-L-cysteine (DCVC) in a two-part process involving γ-
glutamyltransferase (GGT) and cysteinyl-glycine dipeptidase (DP) (Lash et al., 2014a). DCVC 
can either be converted to 1,2-dichlorovinylthiol (DCVT) by cysteine conjugate β-lyase (CCBL) 
or into N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NAcDCVC) via N-acetyltransferases (Lash et 
al., 2014a). NAcDCVC can be bioactivated into its sulfoxide (NAcDCVCS) by CYP3As 
(Werner et al., 1996; Lash et al., 2014a). Additionally, DCVC can be converted into its 
sulfoxide, DCVCS, by flavin-containing monooxygenase 3 (FMO3). Both DCVT and DCVCS 
spontaneously rearrange into chlorothioketene (CTK) or chlorothionoacetyl chloride (CTAC), 
which are in equilibrium with each other (Lash et al., 2014a). Of the metabolites from the GSH 
conjugation pathway, DCVT, DCVCS, CTK, and CTAC are all unstable and reactive (Lash et 
al., 2014a). Additionally, NAcDCVCS is toxic and reduces viability in cells compared to 
NAcDCVC (Werner et al., 1996; Lash et al., 2014a). Whereas DCVT is both nephrotoxic and 
nephrocarcinogenic (Lash et al., 2000a), NAcDCVC is only nephrotoxic after it is deacetylated 
to DCVC (Wolfgang et al., 1989; Zhang and Stevens, 1989). As a whole, it is widely regarded 
that the GSH conjugation pathway of TCE metabolism is the more toxic metabolic pathway, 
leading to generation of more unstable metabolites and fewer metabolites that are recovered in 
urine compared to the CYP-dependent oxidative pathway of TCE metabolism (Lash et al., 
2014a). 
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The metabolism of TCE is highly dependent on gender, organ, and species (Lash et al., 
2000a; Lash et al., 2014a). For instance, the CYP pathway occurs mostly in the liver, and 
CYP1A1/2, CYP2B1/2, CYP2E1, and CYP2C6/11 have been documented as most active with 
TCE metabolism (Lash et al., 2000a; Lash et al., 2014a). Additionally, mice have a higher rate of 
TCE metabolism to TCA compared to rats, as depicted by blood TCA concentrations following 
oral TCE exposure (Larson and Bull, 1992). Although no direct comparisons in TCA 
concentrations were made for humans to date, findings that human liver and testes express high 
levels of CYP2E1 (Forkert et al., 2003), especially compared to human kidney (Sasso et al., 
2013), indicate potential for humans to generate CYP-pathway metabolites dependent on organ. 
Specific to pregnancy, the rate of TCE metabolism to CH has been shown to decrease almost 
two-fold in pregnancy (Nakajima et al., 1992). Regarding the glutathione conjugation pathway, 
the liver and kidney are thought to be the organs principally involved (Lash et al., 2000a). 
Moreover, rats have higher GGT activity compared to mice, and both have higher GGT activity 
compared to humans (Lash et al., 2000a). Finally, although the rate of GSH conjugation in male 
rats is greater than the rate of GSH conjugation in female rats (Green et al., 1997a; Lash et al., 
1998), literature is sparse on enzymatic activity in pregnant rats. 
Role of TCE metabolism in TCE-stimulated toxicity 
A first line of evidence that TCE metabolism is critical for its toxicity stems from 
findings that DCVC as an exposure produces adverse outcomes in several types of cells, thus 
suggesting that DCVC and/or its downstream metabolites are toxic TCE metabolites. Supporting 
evidence includes findings that DCVC induces apoptosis and mitochondrial dysfunction in 
kidney cells (Xu et al., 2008; Lash et al., 2014b). Additionally, in human cytotrophoblastic HTR-
8/SVneo cells (Graham et al., 1993), DCVC exposure generates increased reactive oxygen 
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species (ROS), pro-inflammatory response (Hassan et al., 2016), apoptosis (Elkin et al., 2018), 
mitochondrial dysfunction (Elkin et al., 2019), and altered energy metabolism (Elkin et al., 
2020a). In contrast, CYP metabolism-derived metabolites TCA and DCA do not stimulate 
toxicity in HTR-8/SVneo cells (unpublished data), suggesting GSH conjugation metabolites to 
be more important for toxicity in placenta. 
Studies have addressed how DCVC metabolism contributes to its toxicity. In kidney 
cells, the administration of aminooxyacetic acid (AOAA), which decreases CCBL activity, 
reduces DCVC-induced toxicity (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994). 
This suggests that the metabolism of DCVC to DCVT by CCBL is necessary for DCVC toxicity. 
Similarly, in human placental HTR-8/SVneo cells, it was shown that 1 mM AOAA pretreatment 
reduced interleukin-6 (IL-6) release stimulated by 20 µM DCVC (Hassan et al., 2016). 
Potential for modulation of toxicity based on modulation of TCE metabolism 
 Based on the aforementioned literature suggesting that inhibition of CCBL activity via 
AOAA administration is a mechanism to reduce DCVC toxicity (Elfarra and Anders, 1984; Lash 
et al., 1986; Lash et al., 1994), the choice of utilization of AOAA as an exposure that could 
modulate DCVC toxicity remains plausible. However, it is only known that AOAA is a CCBL 
inhibitor in kidney cells (Elfarra and Anders, 1984; Lash et al., 1986), so its effectiveness as a 
CCBL inhibitor in placental cells is unknown prior to this dissertation. Additionally, it is 
unknown if modulation of other pathways of DCVC metabolism could result in modulation of 
DCVC toxicity. Because DCVC can be N-acetylated to form NAcDCVC by N-acetyltransferases 
(Lash et al., 2014a), it is plausible that administration of chemicals that are a source of acetyl 
groups could favor DCVC metabolism towards production of NAcDCVC and its sulfoxide, 
NAcDCVCS. N-acetyl-L-cysteine (NAC) is a provider of an acetyl group (Aldini et al., 2018) 
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that could potentially modulate DCVC toxicity. Additionally, NAC is a ROS scavenger by itself 
and through its property as a GSH precursor (Aldini et al., 2018), so it could modulate DCVC 
toxicity through that means. The two potential modulators of DCVC toxicity used in this 
dissertation are NAC and AOAA. 
The placenta as a target organ for TCE 
Despite the presence of a significant amount of work on TCE in the kidney and liver, 
(Lash et al., 2000a), research into effects of TCE in the placenta is more limited. Many reasons 
exist to suspect that the placenta is a target organ for TCE. Firstly, maternal blood flow to the 
placenta at term has been estimated to be 600-700 mL/min (Wang and Zhao, 2010), meaning that 
toxicants in circulating blood encounter the placenta. Secondly, the placenta transports nutrients 
between mother and fetus, metabolizes xenobiotic agents, and secretes hormones (Prouillac and 
Lecoeur, 2010), highlighting how placenta disruption could have major consequences. Thirdly, 
placental cytotrophoblasts fuse to become multinucleated syncytiotrophoblasts that form the 
maternal-fetal interface during pregnancy (Potgens et al., 2002; Wang et al., 2014). Given this 
dynamic nature of the placental surface, lipophilic compounds known to cross membranes or 
utilize placental organic xenobiotic transporters are known to have associations with placenta-
related adverse outcomes (Leazer and Klaassen, 2003; Chao et al., 2007). Indeed, TCE is a 
lipophilic and volatile compound (Yoon et al., 2007) that has been shown to readily cross the 
placenta (Beppu, 1968; Laham, 1970), and DCVC has been detected in the amniotic fluid of 
pregnant Wistar rats (Hassan, 2015). 
The plausibility of the placenta as a target organ for TCE toxicity also stems from the fact 
that many of the enzymes needed to produce the toxic TCE metabolites are located in the 
placenta. Both CYP1A1 and GST are active in the placenta of pregnant Wistar rats (Serafini et 
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al., 1991; Wang et al., 2009). Finally, TCE-exposed and control pregnant Wistar rats have 
detectable GGT activity in the placenta, and TCE exposure significantly increases placental GST 
activity compared to control rats (Loch-Caruso et al., 2019). 
Similarities and differences between human and rat placenta 
 The human and rat placentae share similarities but also have differences in their anatomy 
and function. Among similarities between the placentae, proper levels of similar molecules such 
as nuclear factor erythroid 2-related factor-2 (Nrf2) and peroxiredoxin 6 (Prdx6) play a role in 
preventing pregnancy disorders such as hypertension and intrauterine growth restriction in both 
species (Acar et al., 2014). Despite anatomical differences in the number of cell layers between 
mother and fetus, and implantation types, rat and human placentae are both hemochorial 
(Furukawa et al., 2011). 
 A major difference between rat and human placenta concerns the quantity and type of 
hormone production. The rat placenta synthesizes significantly less estrogen and progesterone 
compared to the human placenta (Sybulski, 1969; Townsend and Ryan, 1970; Matt and 
MacDonald, 1984). Additionally, the rat placenta uses cholesterol to synthesize androgen, 
whereas the human placenta uses cholesterol to synthesize pregnenolone (Furukawa et al., 2011). 
Because of these differences, it is necessary to use caution when extrapolating endocrine-related 
endpoints in rat placenta to humans. 
The BeWo human placental trophoblast cell model 
 The BeWo cell line is a human choriocarcinoma villous cytotrophoblastic cell line 
(Pattillo and Gey, 1968). Through fusion and multinucleation, cytotrophoblasts differentiate into 
syncytiotrophoblasts as part of normal placentation, a process known as syncytialization 
(Potgens et al., 2002; Wang et al., 2014). Syncytiotrophoblasts form the outermost layer of the 
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fetal side of the placenta in contact with maternal blood, providing the maternal-fetal interface 
for nutrient, gas, and waste exchange (Potgens et al., 2002; Wang et al., 2014). The BeWo cell 
line can be induced to differentiate, or syncytialize, into syncytiotrophoblasts upon addition of 
forskolin (Wice et al., 1990; Nampoothiri et al., 2007), an adenylate cyclase activator (Daly, 
1984). This process is characterized by the increased expression of syncytin-1 and syncytin-2, 
often used as biomarkers of syncytialization (Vargas et al., 2009). These characteristics make the 
BeWo cell line a useful in vitro model for studying cytotrophoblasts, syncytiotrophoblasts, and 
the process of syncytialization. 
 BeWo cells as cytotrophoblasts, syncytiotrophoblasts, and in the process of 
syncytialization provide a model for study of signaling pathways leading to apoptosis in the 
context of syncytialization. Particularly, BeWo cells have been studied in the context of ROS 
generation, pro-inflammatory response, and apoptosis itself, which are known mechanisms of 
DCVC toxicity. Firstly, syncytialization decreases the quantity of proteins involved in apoptosis, 
such as galectin-3 (Hu et al., 2007), and apoptosis promoted by tumor necrosis factor-α (TNF-α) 
hampers syncytialization (Al-Nasiry et al., 2006). Secondly, proper control of BCL2, which is 
anti-apoptotic, is crucial to prevent excessive cell death during syncytialization (Huppertz et al., 
1998; Zheng et al., 2016). Furthermore, p38-MAPK, a protein sensitive to ROS generation, is in 
the cascade leading to increased syncytin-1 expression and subsequent syncytialization (Gupta et 
al., 2016). Moreover, proteins that may mediate antioxidant response, such as peroxiredoxin 1 
and peroxiredoxin 2, are upregulated when syncytialization occurs (Hu et al., 2007). Likewise, 
silencing expression of peroxiredoxin 2 prevents BeWo cell syncytialization (Wu et al., 2017). 
Finally, ROS generation and pro-inflammatory response are established precursors of apoptosis 
in cytotrophoblasts (Bai et al., 2009; Khera et al., 2017). Therefore, BeWo cells provide a model 
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to study ROS, pro-inflammatory response, and apoptosis endpoints that are relevant to DCVC 
toxicity. 
Apoptosis as an endpoint of interest in the placenta 
 Apoptosis is a form of programmed cell death that involves the activation of multiple 
caspases (Parrish et al., 2013). Apoptosis can proceed via an extrinsic pathway involving a 
membrane receptor or an intrinsic pathway involving the mitochondria (Parrish et al., 2013). In 
trophoblastic JEG-3 (Kohler and Bridson, 1971; Kohler et al., 1971), BeWo (Pattillo and Gey, 
1968), and Swan-71 cells (Straszewski-Chavez et al., 2009), ROS generation precedes apoptosis 
(Khera et al., 2017). Similarly, pro-inflammatory response has been linked to apoptosis in 
cytotrophoblasts (Bai et al., 2009). DCVC stimulates ROS generation, pro-inflammatory 
response, and apoptosis in human placental HTR-8/SVneo cells (Hassan et al., 2016; Elkin et al., 
2018). DCVC also stimulates apoptosis in kidney cells (Xu et al., 2008; Lash et al., 2014b) Thus, 
it is plausible that apoptosis, ROS generation, and pro-inflammatory response are endpoints 
affected by DCVC exposure across multiple cell types. However, knowledge of the cellular 
signaling pathways by which TCE or DCVC exposure lead to apoptosis in placental cells remain 
unclear or incomplete. 
Placental apoptosis is a mechanism of relevance to adverse pregnancy outcomes. For 
instance, a study found that preeclamptic placentae had altered gene expression relative to 
control placentae of RELL2, whose gene product is involved in apoptosis (Sober et al., 2015). 
Additionally, apoptosis of syncytiotrophoblasts is associated with intrauterine growth retardation 
and preeclampsia as determined by bcl-2 expression and terminal deoxynucleotidyl transferase 
dUTP nick-end labeling (Ishihara et al., 2002). The prior publications provide rationale for 
further investigation of the role of placental cell apoptosis in adverse pregnancy outcomes. 
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Study of potential mechanisms of ROS and pro-inflammatory response are supported by 
known relationships to apoptosis and adverse pregnancy outcomes. Increased ROS in maternal 
serum is associated with preeclampsia (Matsubara et al., 2010). Similarly, increased systemic IL-
6, a pro-inflammatory cytokine, has been associated with infertility, recurrent miscarriage, 
preterm birth, and preeclampsia (Prins et al., 2012). Additionally, TNF-R1, IL-6, TNF-α, IFN-γ, 
and IL-1β are all molecules that have pro-inflammatory properties (Chen and Goeddel, 2002; 
Prins et al., 2012; Turner et al., 2014), participate in regulation of apoptosis (Garcia-Lloret et al., 
2000; Chen and Goeddel, 2002; Fortunato and Menon, 2003; Al-Nasiry et al., 2006; Sun et al., 
2007; Bai et al., 2009; Saquib et al., 2013; Cao et al., 2015; Jiang et al., 2015; Maurya and 
Vinayak, 2015), and are relevant to placental health (Maymon et al., 1999; Garcia-Lloret et al., 
2000; Fortunato and Menon, 2003; Hebisch et al., 2004; Al-Nasiry et al., 2006; Sun et al., 2007; 
Bai et al., 2009; Vitoratos et al., 2010; Mulla et al., 2011; Prins et al., 2012; Saquib et al., 2013). 
Energy metabolism as an endpoint of interest during pregnancy 
 Energy metabolism is an important endpoint for DCVC toxicity and pregnancy health. 
Specifically, in HTR-8/SVneo placental cells, DCVC exposure altered some metrics of energy 
metabolism, including the increase of several amino acids, including alanine, glutamine, 
glutamate, and tryptophan, and decreased the adenosine triphosphate (ATP) to adenosine 
diphosphate (ADP) ratio (Elkin et al., 2020a). These DCVC-induced alterations suggest a role 
for energy metabolism in a mechanism of DCVC-induced toxicity in placental cells. 
Likewise, energy metabolism is critical to pregnancy health. Changes in energy 
metabolism in amniotic fluid have been associated with adverse pregnancy outcomes. These 
include decreased amino acids and carbohydrates, including alanine, glycine, proline, glutamine, 
galactose, mannose, and inositol in the amniotic fluid of preterm birth deliveries versus control 
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(Romero et al., 2010). Similarly, Virgiliou et al. found changes in metabolites, including 
decreased alanine, glutamine, creatine, ornithine, pyruvate, tyrosine, and inositol but increased 
glutamate, in amniotic fluid of preterm birth deliveries versus control (Virgiliou et al., 2017). 
Additional literature about amniotic fluid metabolomics and associations with a focus on preterm 
birth have been reviewed by Gil and Duarte (Gil and Duarte, 2018). Altered amino acids and 
energy metabolism metabolites, such as decreased aspartate and uridine monophosphate (UMP) 
and increased creatine, creatinine, and ribose 5-phosphate, were found in placenta of early-onset 
preeclampsia patients versus control (Kawasaki et al., 2019). Changes in serum metabolites 
associated with late-onset preeclampsia versus control include increased valine, glucose, citrate, 
creatine, creatinine, and pyruvate, and decreased acetamide (Bahado-Singh et al., 2013). 
In a slime mold model of multinucleation, decreases in glutathione (GSH) concentration 
and oxygen consumption rate occurred as differentiation proceeded (Allen et al., 1985). 
Similarly, D-amino oxidase activity induces differentiation in the slime mold (Allen et al., 1988). 
Furthermore, L-gamma-carboxyglutamic acid has been implicated to be important in the 
multinucleation of osteoclasts (Kahn et al., 1982). Although these prior reports suggest energy 
metabolism as critical in other systems of multinucleation, it is currently unknown if a similar 
mechanism involving energy metabolism is involved in syncytialization in BeWo cells. 
However, specific to pregnancy, provision or adequate supply of proline is critical to the 
development of the fetus (Wu et al., 2005; Wu et al., 2008). 
Overarching hypothesis and experimental design 
 Given the importance of adverse pregnancy outcomes and the potential of TCE to affect 
pregnancy through actions on the placenta, this dissertation aims to advance our understanding of  
the mechanisms by which TCE or its metabolite DCVC stimulate changes in the placenta or 
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during pregnancy that could lead to adverse pregnancy outcomes. Additionally, this dissertation 
aims to modulate TCE- or DCVC-stimulated toxicity using treatments that modify TCE 
metabolism. 
The overarching hypothesis of this dissertation is that TCE or its metabolite DCVC 
stimulates adverse outcomes of pregnancy by increasing ROS generation, increasing pro-
inflammatory response, increasing apoptosis, and decreasing supply of energy metabolites, 
with outcomes modifiable by modulation of TCE or DCVC metabolism. Experimental goals 
are indicated by thesis chapter and summarized in Figure 1.2. This dissertation uses a timed-
pregnant Wistar rat model of fetal growth restriction to investigate how TCE-stimulated 
outcomes may be modified by NAC or AOAA pre/co-treatment to TCE (Chapter 2). Using the 
same rat model, this dissertation investigates energy metabolism in male and female amniotic 
fluid samples as it is modified by maternal exposure to TCE (Chapter 3). The remaining 
dissertation data chapters use the in vitro model consisting of the BeWo cell line, a 
cytotrophoblast cell line capable of fusing to form syncytiotrophoblasts (Pattillo and Gey, 1968; 
Nampoothiri et al., 2007). This dissertation investigates how DCVC exposure could activate 
apoptosis in unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, and 
syncytialized BeWo cells (Chapter 4). Subsequently, this dissertation examines how NAC or 
AOAA pre/co-treatment with DCVC exposure could modulate DCVC-stimulated toxicity in 
BeWo cells (Chapter 5). Finally, the dissertation investigatates how energy metabolism in BeWo 
cells is altered by syncytialization and DCVC treatment during syncytialization (Chapter 6). 
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Figure 1.1. Trichloroethylene (TCE) is biotransformed by two different metabolic 
pathways. The two metabolic pathways by which TCE can be biotransformed are the 
cytochrome P450 (CYP)-dependent oxidation pathway or the glutathione (GSH) conjugation 
pathway. Unstable metabolites and metabolites recoverable in urine are depicted in brackets and 
ovals, respectively. All TCE metabolites, except for the unstable metabolites and DCVCS, are 
systemically available (Lash et al. 2014). Additional abbreviations: TCE-O, TCE-epoxide; TCE-
O-CYP, CYP-bound TCE-epoxide; DCAC, dichloroacetyl chloride; CHL, chloral; CH, chloral 
hydrate; DCA, dichloroacetic acid; TCA, trichloroacetic acid; TCOH, trichloroethanol; TCOG, 
trichloroethanol glucuronide; MCA, monochloroacetic acid; ALDH, aldehyde dehydrogenase; 
ADH, alcohol dehydrogenase; GST, glutathione S-transferase; UGT, UDP-
glucuronosyltransferase; DCVG, S-(1,2-dichlorovinyl)glutathione; DCVC, S-(1,2-dichlorovinyl)-
L-cysteine; DCVT, 1,2-dichlorovinylthiol; DCVCS, DCVC sulfoxide; NAcDCVC, N-acetyl-S-
(1,2-dichlorovinyl)-L-cysteine; NAcDCVCS, NAcDCVC sulfoxide; CTAC, chlorothionoacetyl 
chloride; CTK, chlorothioketene; GGT, γ-glutamyltransferase; DP, cysteinyl-glycine 
dipeptidase; CCBL, cysteine conjugate β-lyase; FMO, flavin-containing monooxygenase; NAT, 
N-acetyltransferase. This figure was modified from Lash et al. 2014 and Elkin et al. 2020 (Lash 
et al., 2014a; Elkin et al., 2020b). 
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Figure 1.2. Summary of Chapter 2 through Chapter 6 of this dissertation. This dissertation 
investigates responses stimulated by TCE in timed-pregnant Wistar rats and how NAC or AOAA 
pre/co-treatment to TCE could modulate responses induced by TCE (Chapter 2). For the timed-
pregnant Wistar rats, the dissertation uses a metabolomics approach to investigate how TCE 
alters the abundance of metabolites in amniotic fluid of associated male and female fetuses 
(Chapter 3). Sunsequently, the dissertation uses an in vitro BeWo human placental trophoblast 
model to examine how DCVC may stimulate toxic responses in unsyncytialized BeWo cells, 
BeWo cells undergoing syncytialization, and syncytialized BeWo cells (Chapter 4). The 
dissertation investigates how DCVC-stimulated responses in BeWo cells could be modified by 
NAC or AOAA pre/co-treatment (Chapter 5). Finally, this dissertation examines how 
metabolites in energy metabolism are altered by syncytialization and DCVC treatment during 
syncytialization (Chapter 6). Abbreviations: TCE, trichloroethylene; DCVC, S-(1,2-
dichlorovinyl)-L-cysteine; NAC, N-acetyl-L-cysteine; AOAA, aminooxyacetic acid; ROS, 
reactive oxygen species. 
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Chapter II. Differential Modulation by N-acetyl-L-cysteine and Aminooxyacetic Acid of 
Trichloroethylene Toxicity in Wistar Rats 
 
Abstract 
 
 Exposure to trichloroethylene (TCE), a colorless chlorinated organic solvent with many 
industrial purposes, has been associated with adverse pregnancy outcomes in epidemiological 
studies, decreased fetal weight in timed-pregnant rats, and increased expression of markers of 
oxidative stress in rat placenta. The toxicity of TCE can be manifest through formation of 
reactive metabolites via its glutathione (GSH) conjugation metabolic pathway. However, exact 
mechanisms of TCE toxicity during pregnancy remain incomplete or unclear. To understand the 
contribution of the GSH conjugation metabolic pathway and oxidative stress to TCE toxicity 
during pregnancy, we exposed rats orally to 480 mg TCE/kg/day from gestational day (GD) 6 to 
GD 16 with and without N-acetyl-L-cysteine (NAC) at 200 mg/kg/day or aminooxyacetic acid 
(AOAA) at 20 mg/kg/day as pre/co-treatments from GD 5 to GD 16. NAC was included as a 
scavenger of reactive oxygen species that can also modify the GSH conjugation pathway. AOAA 
was included as an inhibitor of cysteine conjugate β-lyase (CCBL), an enzyme responsible for 
metabolic activation of DCVC. TCE decreased fetal weight, and this was prevented by AOAA 
but not NAC pre/co-treatment to TCE. Although AOAA inhibited CCBL activity in maternal 
kidney, it was not an effective inhibitor of CCBL activity in maternal liver and placenta, 
suggesting that AOAA prevention of TCE-stimulated decreased fetal weight was due to CCBL 
activity inhibition in the kidneys, not in the liver or placenta. Exposure to NAC pre/co-treatment 
with TCE, relative to TCE treatment alone, altered placental morphology consistent with a 
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delayed developmental phenotype. Immunohistochemical staining revealed that the decidua 
basale, relative to basal zone and labyrinth zone, expressed the highest abundance of CCBL1, 
flavin-containing monooxygenase 3, and cleaved caspase-3. As a whole, TCE by itself produced 
modest changes to placenta. Together, the findings of the current study show that NAC and 
AOAA differentially modulated TCE-induced pregnancy outcomes and suggests additional 
approaches and future directions to protect against TCE toxicity during pregnancy. 
Introduction 
 Trichloroethylene (TCE) is a chlorinated environmental contaminant commonly used as a 
metal degreaser and in synthesis of chemicals such as refrigerants (Agency for Toxic Substances 
and Disease Registry, 2019). Exposure to TCE can occur by inhalation of contaminated air, 
ingestion of contaminated drinking water, and, to a lesser extent, ingestion of contaminated foods 
and dermal contact with contaminated consumer products (Agency for Toxic Substances and 
Disease Registry, 2019). Release of TCE into air has been widespread throughout the United 
States (United States Environmental Protection Agency, 2011b), although total environmental 
emission in any media of TCE decreased from 57.4 million pounds in 1988 to 2.18 million 
pounds in 2018 (United States Environmental Protection Agency, 2020). Relatively recent 
publications indicate continued water and other environmental media contamination by TCE 
(Jollow et al., 2009; Agency for Toxic Substances and Disease Registry, 2019). TCE is found in 
over half of current or former National Priorities List hazardous waste sites designated by the 
United States Environmental Protection Agency (Agency for Toxic Substances and Disease 
Registry, 2019), and TCE was detected in about a third of municipal water supplies in the United 
States (Jollow et al., 2009). Significantly, TCE is classified as a Group 1 known human 
carcinogen by the International Agency for Research on Cancer (Guha et al., 2012; International 
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Agency for Research on Cancer, 2014) and classified as a known human carcinogen via all 
routes of exposure by the United States Environmental Protection Agency (United States 
Environmental Protection Agency, 2011c). TCE is a suggested toxicant to multiple organs, 
including liver (Bull, 2000), kidney (Green et al., 1997a), lungs (Forkert et al., 1985; Green et 
al., 1997b), and the immune (Cooper et al., 2009), nervous (Bale et al., 2011), reproductive 
(Healy et al., 1982; Manson et al., 1984; Lamb and Hentz, 2006; Loch-Caruso et al., 2019), and 
developmental systems (Saillenfait et al., 1995). 
Of specific relevance to the present study, epidemiological studies have identified 
adverse effects of TCE on pregnancy outcomes. Rodenbeck et al. associated maternal exposure 
to TCE via contaminated water to very low birth weight offspring (Rodenbeck et al., 2000). 
Similarly, Forand et al. found an association between TCE exposure through vapor intrusion to 
low birth weight, small for gestational age, and term low birth weight (Forand et al., 2012). 
Finally, Ruckart et al. found maternal TCE exposure through drinking water to be associated 
with small for gestational age (Ruckart et al., 2014). 
 The metabolism of TCE has been extensively studied and is thought to be responsible for 
the toxicity of TCE. TCE is metabolized through two metabolic pathways: a cytochrome P450 
(CYP)-dependent oxidative pathway and a glutathione (GSH) conjugation metabolic pathway 
(Lash et al., 2014a). The CYP-dependent oxidative pathway includes formation of reactive and 
unstable epoxide intermediates that precedes formation of stable metabolites such as 
dichloroacetic acid (DCA), trichloroacetic acid (TCA), and monoacetic acid (MCA) that can be 
recovered in urine (Lash et al., 2014a). In contrast, the GSH conjugation pathway is initiated by 
TCE conjugation with GSH to form S-(1,2-dichlorovinyl)glutathione (DCVG). DCVG is 
metabolized by γ-glutamyltransferase (GGT) and cysteinyl-glycine dipeptidase (DP) to form S-
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(1,2-dichlorovinyl)-L-cysteine (DCVC) (Lash et al., 2014a). DCVC can then be metabolized 
through three different pathways, each generating at least one reactive metabolite. Firstly, DCVC 
can be metabolized by cysteine conjugate β-lyase (CCBL) to yield 1,2-dichlorovinylthiol 
(DCVT), which spontaneously rearranges to form chlorothionoacetyl chloride (CTAC) and 
chlorothioketene (CTK) (Lash et al., 2014a). Secondly, flavin-containing monooxygenase 3 
(FMO3) can metabolize DCVC into DCVC sulfoxide (DCVCS), which also spontaneously 
forms CTAC and CTK (Lash et al., 2014a). Lastly, DCVC can be metabolized by N-acetyl-
transferases (NATs) into N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (NAcDCVC), a reaction that 
can be reversed by aminoacylase III  (Uttamsingh and Anders, 1999; Uttamsingh et al., 2000; 
Lash et al., 2014a). NAcDCVC can be bioactivated by CYP3As into NAcDCVCS (Werner et 
al., 1996; Lash et al., 2014a). DCVT, DCVCS, CTAC, and CTK are all chemically unstable and 
reactive (Lash et al., 2014a). NAcDCVCS is an additional toxic metabolite (Werner et al., 1996; 
Lash et al., 2014a). Through studies of using the CCBL inhibitor aminooxyacetic acid (AOAA) 
to reduce toxicity of DCVC in kidney cells (Elfarra and Anders, 1984; Lash et al., 1986; Lash et 
al., 1994), it has been established that TCE toxicity likely results from DCVC metabolism via 
CCBL into reactive metabolites. 
Toxicological studies have contributed to the understanding of how TCE metabolism 
contributes to its toxicity. The TCE metabolite DCVC stimulates reactive oxygen species 
generation, pro-inflammatory response, and cell death in the HTR-8/SVneo human placental 
cytotrophoblast cell line (Hassan et al., 2016; Elkin et al., 2018), suggesting that the GSH 
conjugation metabolic pathway has a role in placental toxicity. Additionally, inhibiting CCBL 
activity in kidney cells via aminooxyacetic acid (AOAA) treatment reduces DCVC-stimulated 
toxicity (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994). Together, these studies 
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suggest that TCE metabolism, particularly downstream of DCVC, contributes to the toxicity of 
TCE. 
Because of the requirement of metabolism in TCE toxicity, modulation of TCE 
metabolism by pharmacological agents has the potential to modify TCE toxicity. One approach 
can be through use of N-acetyl-L-cysteine (NAC), which is commonly thought of as a scavenger 
of reactive oxygen species generation, either in part by itself or because of its function as a GSH 
precursor (Aldini et al., 2018). Importantly, NAC is cleaved into an acetyl group and cysteine by 
aminoacylase I (Uttamsingh and Anders, 1999; Uttamsingh et al., 2000). Because DCVC can be 
N-acetylated to form NAcDCVC, NAC could contribute to its formation. This could have 
toxicity manifestations because NAcDCVC is metabolized by CYP3As into NAcDCVCS, a 
toxic metabolite (Werner et al., 1996; Lash et al., 2014a). Secondly, NAC, by metabolism into 
GSH (Aldini et al., 2018), could provide substrate for glutathione S-transferases (GSTs), the 
enzyme responsible for forming DCVG as the first step of TCE GSH conjugation (Lash et al., 
2014a). 
 Another approach to modify TCE metabolism is through the use of AOAA, a CCBL 
inhibitor in kidney (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994). However, the 
contribution of AOAA as a CCBL inhibitor in other organs, such as liver and placenta, is 
currently unknown. The different composition of CCBLs as a function of organ (Lash, 2010) 
gives rise to the possibility that AOAA may be more effective as a CCBL inhibitor in some 
organs compared to others. Although the exact composition of CCBLs in placenta is currently 
unknown, the finding that AOAA decreased DCVC-stimulated increase in interleukin-6 in media 
of HTR-8/SVneo human placental cells (Hassan et al., 2016) indicates that AOAA may have a 
mechanism of action relevant to DCVC in placental cells. However, because CCBL activity was 
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not measured in the prior study, it remains unclear if this response could be attributable to CCBL 
activity. 
 Investigation of mechanisms to explain TCE-stimulated decreased fetal weight (Loch-
Caruso et al., 2019) is a goal of the present study. A mechanism by which decreased fetal weight 
could occur is through apoptosis in placenta or activation of pro-inflammatory response in 
maternal serum. As an example, it has been demonstrated that administration of L-arginine to the 
mother increased fetal weight while decreasing anti-apoptotic Bcl-2 placenta staining and 
increasing apoptotic Bax placenta staining (Shen and Hua, 2011). Additionally, intrauterine 
growth retardation is associated with the apoptosis, as verified by Bcl-2 and TUNEL staining, of 
placental syncytiotrophoblasts (Ishihara et al., 2002), a crucial cell type at the maternal-fetal 
interface (Potgens et al., 2002; Wang et al., 2014). Furthermore, decreased fetal weight is 
associated with increased maternal serum levels of high sensitive-C-reactive protein, interleukin-
6 (IL-6), and tumor necrosis factor-α (TNF-α) (Guven et al., 2009). 
Because the toxicity of TCE could be manifest via the GSH conjugation metabolic 
pathway and involves ROS generation, pro-inflammatory response, and cell death, we 
hypothesize that modifiers of metabolism could impact these TCE-stimulated responses in an in 
vivo timed-pregnant Wistar rat model. The potential modifiers of TCE toxicity we chose to use 
for this study are NAC and AOAA. In summary, the current study tests thr hypothesis that TCE-
induced fetal weight decrease is due to apoptosis, oxidative stress, and pro-inflamatory responses 
that require metabolic activation through the TCE GSH conjugation metabolic pathway, and thus 
are modifiable by NAC and AOAA. 
Materials and Methods 
Chemicals and reagents 
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Trichloroethylene (TCE), N-acetyl-L-cysteine (NAC), aminooxyacetic acid (as O-
(carboxymethyl)hydroxylamine hemihydrochloride) (AOAA), potassium phosphate dibasic 
(K2HPO4), potassium phosphate monobasic (KH2PO4, anhydrous), sucrose, potassium hydroxide 
(KOH), boric acid, and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO). 
Vanilla wafers (Nabisco) were purchased locally. S-(2-Benzothiazolyl)-L-cysteine (BTC) was 
purchased from Toronto Research Chemicals (Toronto, ON). 
Handling and treatment of rats 
Timed-pregnant Wistar rats between 60 and 90 days of age were purchased from Charles 
River Laboratories (Portage, MI) and arrived at the University of Michigan School of Public 
Health Animal Facility on gestational day (GD) 2, with GD 0 designated as day of copulation. 
Rats were individually housed in a controlled environment with a 12-hour light/dark cycle and 
provided with standard rat chow (Purina 5001) and water ad libitum. On GD 3, the rat weights 
ranged from 121 to 224 g. All procedures with the rats were approved by the University of 
Michigan Institutional Animal Care & Use Committee (IACUC) (Approval #PRO00006981). 
Rats were exposed to chemical treatments using a vanilla wafer treat developed by Seegal 
et al. (Seegal et al., 1997). Rats were placed individually in exposure cages without food for one 
hour prior to presentation with a wafer. Rats were presented with a wafer on GD 3 and GD 4 to 
train for recognition of the wafers as food. Rats were weighed daily and treatment doses were 
adjusted to rat weight. Chemicals were added directly to the vanilla wafers and immediately 
offered to the rats for consumption. NAC and AOAA were dissolved in double-distilled and 
filtered water prior to pipetting onto the wafer. TCE was pipetted undiluted onto a vanilla wafer. 
The rats typically finished eating the vanilla wafer within ten minutes of wafer presentation. 
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The treatment regimen is depicted in Figure 2.1. Pregnant rats were exposed from GD 6-
16 to 480 mg TCE/kg/day, a dose that is within one order of magnitude of the U.S. Occupational 
Safety and Health Administration Permissible Exposure Level (Agency for Toxic Substances 
and Disease Registry, 2007) and similar to TCE dosages used in other studies with rats 
(Toraason et al., 1999; Liu et al., 2010; Loch-Caruso et al., 2019). Some rats also received NAC 
or AOAA on GD 5-16 as pre/co-exposures with TCE. The NAC dosage of 200 mg/kg/day 
(Fukami et al., 2004; Chang et al., 2005; Naik et al., 2006) and AOAA dosage of 20 mg/kg/day 
(Perry and Hansen, 1978; Donoso and Banzan, 1984) are within the range of dosages used in 
vivo in past reports. The time points of treatment encompass the gestational period when fetuses 
and placentae start to exhibit rapid growth (Furukawa et al., 2011) and are similar to TCE 
exposures used in prior studies with rats (Healy et al., 1982; Fisher et al., 1989; Loch-Caruso et 
al., 2019). In total, 49 timed-pregnant Wistar rats were acquired in eight batch deliveries. Within 
each batch, at least one rat was assigned randomly to each treatment group. Details of the 
assignments of rats to treatment group and batch are included in Table S2.1. Three of the 49 rats 
were not pregnant. 
Rat tissue collection 
Rats were euthanized on GD 16 by carbon dioxide asphyxiation. Euthanasia started 
directly after completion of vanilla wafer treatment on GD 16, and dams were euthanized in 
random order. Blood was collected from the rats directly after euthanasia by cardiac puncture. 
Typically, 6-8 mL of blood was collected from each rat. Blood was allowed to coagulate by 
incubating at 37°C in 50 mL conical tubes. Subsequently, the blood was centrifuged at 2000 x g 
for 30 minutes at 4°C to separate clotted blood from serum, yielding 3-4 mL serum per dam. 
Serum samples were aliquoted into 1.5-mL microcentrifuge tubes and stored at -80°C. Placenta, 
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maternal kidney, and maternal liver were snap frozen in liquid nitrogen and stored at -80°C, with 
the exception of tissue for RNA, which was stored overnight in RNAlater (Qiagen, Germantown, 
MD) prior to RNAlater removal and sample transfer to -80°C. Maternal kidney, maternal liver, 
placenta, and fetal weights were removed by dissection and weighed individually. 
Measurement of cysteine conjugate β-lyase (CCBL) activity 
 CCBL activity was measured according to a method developed by Dohn and Anders 
using S-(2-benzothiazolyl)-L-cysteine (BTC) as the substrate and 2-mercaptobenzothiazole as 
the product produced (Dohn and Anders, 1982). Briefly, placenta, maternal kidney, or maternal 
liver were thawed on ice, and then added to a solution of 0.1 M potassium phosphate (pH 7.4) 
containing 0.25 M sucrose at a 25% (w/v) concentration. Tissues were sonicated twice at 3.5 Hz 
for five seconds (MiSonix Sonicator 3000, Misonix Inc., Farmingdale, NY) to dissociate the 
tissue for enzyme analysis. The potassium phosphate buffer (0.1 M, pH 7.4) was made from a 
mixture of potassium phosphate dibasic (K2HPO4) at 69.6 mM and potassium phosphate 
monobasic (KH2PO4, anhydrous) at 30.4 mM prior to sucrose addition. 
The substrate solution was made by suspending 10.15 mg of BTC in 4 mL ddH2O 
representing 40% of total final desired volume. The mass of BTC added corresponds to a final 
BTC concentration in substrate solution of 4 mM. Potassium hydroxide (KOH) (1 M in ddH2O) 
was added at 0.25 mL to dissolve BTC. After the BTC dissolved, 5 mL of boric acid (0.2 M in 
ddH2O) was added. The solution pH was adjusted to 8.6 using 1 M KOH, and ddH2O was then 
added to achieve 10 mL desired total volume. In aliquots, this substrate solution was added to 0.1 
M potassium borate buffer (made from KOH and boric acid) in a 1.5:1.3 (v/v) ratio and 
incubated for 4 minutes at 37°C. Subsequently, enzyme sample was added to this reaction 
mixture in a 1:14 (v/v) ratio. Incubation time with the enzyme sample was 30 minutes at 37°C. 
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After the incubation, trichloroacetic acid at a 10% (w/v) concentration in ddH2O was 
added to the reaction mixture in a 1:5 (v/v) ratio to terminate the reaction and precipitate protein. 
A negative control for each sample was made by adding 10% (w/v) trichloroacetic acid into the 
reaction mix before addition of the enzyme source. All reactions were centrifuged at 11,000 x g 
for 1.25 minutes to remove precipitated protein. Absorbance of each supernatant was measured 
at 321 nm wavelength, with a molar extinction coefficient (ε) of 21,600 M-1 cm-1 for 321 nm, 
using a SpectraMax M2e microplate reader (Molecular Devices, San Jose, CA). The absorbance 
corresponding to the negative control was subtracted from the absorbance corresponding to the 
appropriate reaction to generate a net absorbance used to convert absorbance into nmol of 
product produced/min/mL, which were converted into nmol/min/mg tissue or nmol/min/mg 
protein or nmol/min/total tissue. The protein assay used to determine protein concentration was 
the bicinchoninic acid (BCA) assay using a kit from ThermoFisher Scientific (ThermoFisher 
Scientific, Waltham, MA). 
Hematoxylin and eosin (H&E) staining 
 Placentae stored in 10% formaldehyde (Fisherbrand, Waltham, MA) were cut in half 
transversely to expose the maternal and fetal layers. Each half was placed in a biopsy cassette 
(Fisherbrand, Waltham, MA) submerged in 10% formaldehyde and transferred to the University 
of Michigan In Vivo Animal Core (IVAC). Placentae were embedded in paraffin using an 
automated tissue processor (TissueTek, Sakura) and typical histological methods at the core. 
Sections were cut to 4 µM thickness using a rotary microtome and mounted on glass slides. All 
placental sections mounted on slides were female in sex because not enough male placentae were 
collected in 10% formaldehyde at the time of dissection. Tissues were stained with hematoxylin 
and eosin using a standard hematoxylin and eosin staining protocol assisted by an automated 
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histostainer (Leica Autostainer XL, Leica Biosystems Inc., Buffalo Grove, IL). The slides were 
digitally scanned using an Aperio AT2® scanner (Leica Biosystems Inc.), allowing imaging of 
two vertical transverse sections of the whole placenta. Quantitative morphometric measurements 
with drawn annotations of placental zones were taken from these images using Aperio 
ImageScope software (Leica Biosystems Inc.). The placental zones quantified included the 
labyrinth zone area, basal layer area, total placenta area, labyrinth zone width, basal zone width, 
and decidua basale width. Decidua basale area was calculated as total placenta area minus 
labyrinth zone area minus basal layer area. Total placenta width was calculated as labyrinth zone 
width + basal area width + decidua basale width. Three different measures of width for each of 
the zones of interest were made at the center region of each zone. Because two sections were 
taken from each placenta (one from each half) for a slide, a slide for one given placenta had two 
different area measurements for each of the area metrics and six different width measurements 
for each of the width metrics. The morphometric measurements were averaged for each placenta 
prior to further analysis. In the case of the labyrinth zone, basal zone, and decidua basale, 
absolute dimensions (length and area) and relative dimensions (normalized to the total placenta 
and reported as percentages) were reported. 
Immunohistochemistry (IHC) staining of cleaved caspase-3, CCBL1, FMO3, 3-nitrotyrosine, 
and CYP3A1 
Placental tissue sections were subjected to immunohistochemistry (IHC) staining to 
detect expression of proteins important in TCE toxicity. These proteins included cysteine 
conjugate β-lyase (CCBL1) and flavin-containing monooxygenase 3 (FMO3) because of the 
importance of these enzymes for TCE metabolic activation (Lash et al., 2014a). In addition, 3-
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nitrotyosine and cleaved caspase-3 were chosen as markers of protein oxidative stress and 
apoptosis, respectively (Ahsan, 2013; Crowley and Waterhouse, 2016). 
Unstained sections were deparaffinized and rehydrated, then subject to heat-induced 
antigen retrieval with a commercial antigen retrieval solution (DIVA, Biocare Medical, Pacheco, 
CA) performed within a pressurized retrieval chamber (Decloaker, Biocare Medical). Staining 
was performed using an automated immunohistochemical stainer (Biocare Intellipath, Biocare 
Medical) with inclusion of endogenous peroxidase and non-specific blocking steps. Negative 
control slides were run concurrently using naïve mouse/rabbit serum (Polymer Universal 
negative control serum, Biocare Medical) in place of the primary antibody. Positive detection 
was performed with commercial dextran polymer-based, biotin-free reagents for mouse 
(MACH4 HRP, Biocare Medical) or rabbit (Biocare Rabbit on Rodent Poly HRP, Biocare 
Medical) with the chromogen diaminobenzidine. Hematoxylin was utilized as the nuclear 
counterstain. Slides were dehydrated and mounted with glass cover slips. Details of the primary 
antibodies, dilutions, and positive controls used are in Table S2.2. 
After IHC staining, tissue sections were digitally scanned using an Aperio AT2® scanner 
(Leica Biosystems Inc.), allowing imaging of two vertical whole sections of the placenta. For all 
IHC stains, stain quantification was performed using QuPath. Each zone of the placenta was 
traced to allow for quantification specific to each region. From QuPath, we identified a setting to 
detect all staining, regardless of localization to cytoplasm or nucleus, and a setting to detect only 
nuclear staining. All detections were based on achieving a specific color threshold. The nuclear 
only stain detection values were subtracted from the total stain detection values to derive 
quantification of cytoplasmic stain. For a given placenta, total positive count was normalized to 
total area for each placental zone. These normalized values were used in statistical analysis. 
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Detection of fragmented DNA via labeling with terminal deoxynucleotidyl transferase (Tdt) 
Unstained placental tissues were embedded in paraffin and mounted on glass slides as 
described for the H&E staining. Sections were stained for expression of the Tdt enzyme to detect 
fragmented DNA. Slides were subject to labeling with the Tdt enzyme using the FragEL™ DNA 
Fragmentation Detection Kit, Fluorescent - TdT Enzyme (Millipore Sigma, Burlington, MA). 
Paraffin-embedded tissues underwent the protocol as described by the kit manufacturer. Positive 
and negative control slides with HL-60 cells (provided by manufacturer) were stained according 
the manufacturer’s protocol. The staining protocol consisted of Tdt as stained green whereas 
nuclei as stained by 4′,6-diamidino-2-phenylindole (DAPI) in the color of blue (used to 
normalize green staining to total nuclear stain). 
An EVOS M7000 Microscope (ThermoFisher Scientific, Waltham, MA) with 
fluorescence and image stitching capabilities was used to capture images of the placenta stained 
with Tdt. Images of whole placenta were captured under the DAPI, GFP, and DAPI + GFP 
overlay channels. The magnification used to capture the images to be stitched were 100X (10 x 
10X). QuPath2.0 was used to quantify the staining on the DAPI + GFP overlay images, with 
quantification performed specific to the labyrinth zone, basal zone, and decidua basale of the 
placenta as manually annotated using QuPath2.0. A ratio of green to blue stain was obtained for 
each of the two sections for the placenta for each zone, and the average of these was used for 
statistical analysis purposes for each zone of a given placenta. 
Alizarin Red staining to detect placental calcification 
 Paraffin-embedded unstained slides of placental tissue were prepared as described for 
H&E staining. Sections were subject to Alizarin Red staining for mineral detection, using a 
commercial reagent kit according to the manufacturer recommendations (Alizarin Red C-206, 
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Rowley Biochemical, Inc, Danvers, MA). As with H&E and IHC, slides were digitally scanned 
using an Aperio AT2® scanner (Leica Biosystems Inc.), allowing imaging of two vertical whole 
sections of the placenta. The labyrinth zone, basal zone, and decidua basale were annotated using 
Aperio ImageScope software (Leica Biosystems Inc.). Digital quantitation of staining for each 
zone was performed using a commercial algorithm (Leica Aperio Color Deconvolution, v.9.1, 
Leica Biosystems Inc.). Settings were calibrated for detection of Alizarin Red slide using a test 
area on the slide per manufacturer instructions. Calibrated parameters were set as R=0.223, 
G=0.579, B=0.785 and default parameters for intensity were used (range 0-255; weak: 220, 
moderate: 175, strong: 100). For each zone of the placenta, the average from the two placental 
sections for a given placenta was used for statistical analysis purposes. The percentage of strong 
positive and total positive stains were used for statistical analysis. 
RNA extraction 
Placental samples were thawed and homogenized using a FastPrep-24 tissue and cell 
lyser (MP Biomedicals, Solon, OH) with the placenta submerged in RLT Buffer PLUS (Qiagen, 
Germantown, MD) containing 1% (v/v) 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO). 
Following homogenization, RNA was extracted using an RNeasy Plus Mini kit (Qiagen, 
Germantown, MD) according to the manufacturer’s instructions. RNA concentration and purity 
were verified using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA). RNA was stored at -80°C until further analysis. 
Placental sex determination 
 The sex of the rat placenta and associated fetus was determined by the presence or 
absence of the Sry genomic DNA (gDNA). The gDNA was isolated from rat placenta using a 
NucleoSpinTM Tissue kit (Machery-Nagel, Bethlehem, PA) according to the manufacturer’s 
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instructions. The concentration and purity of the gDNA were verified using a Nanodrop 2000 
UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and stored -20°C until 
further analysis using qRT-PCR. A subset of these placentae also were evaluated for Sry mRNA 
expression. In the case of one discrepancy between the mRNA and gDNA Sry reading (male 
classification from gDNA but female classification from mRNA), sex was assigned based on the 
gDNA result. 
Quantitative real-time polymerase chain reaction (qRT-PCR)  
 Detection of Sry gDNA and mRNA expression of Nfkb1, Bcl2, Bax, Prdx1, Lgals3, 
Kyat1, and Fmo3 was performed with qRT-PCR. Briefly, cDNA was synthesized using a Bio-
Rad iScriptTM cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA) according to the 
manufacturer’s instructions. A Bio-Rad CFX ConnectTM Real-Time System (Bio-Rad 
Laboratories, Hercules, CA) synthesized cDNA under the following protocol: (1) 25°C for 5 
minutes, (2) 42°C for 30 minutes, (3) 85°C for 5 minutes, and then (4) cool down to 4°C. The 
cDNA samples were stored at -20°C until further use. 
 Reaction mixtures of 25 µL total were prepared in SsoAdvancedTM Universal SYBR® 
Green Supermix (60% v/v; Bio-Rad Laboratories, Hercules, CA) containing 0.32 µM of each 
(forward and reverse) primer, and 40 ng of either cDNA template or 50 ng of gDNA. Primer 
sequences and sources are listed in Table S2.3. 
 Samples were run and analyzed in Hard-Shell® 96-well plates (Bio-Rad Laboratories, 
Hercules, CA) using a Bio-Rad CFX ConnectTM Real-Time System using the following protocol: 
(1) 95°C for 10 minutes, (2) 95°C  for 15 seconds, (3) 60°C  for 1 minute, (4) repeat 39 times 
steps 2 and 3, (5) 95°C for 1 minute, (6) 65°C for 2 minutes, (7) 65°C to gradual increase to 
95°C, stopping at every 0.5°C interval for 5 seconds each. Analysis was performed using the 
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ΔΔCt method (Yuan et al., 2006). All samples were run and analyzed in duplicate. B2m served 
as the reference gene. 
Detection of IL-1β, TNF-α, and IL-6 in maternal serum 
 Maternal serum samples stored at -80°C were thawed and pipetted into round-bottom 96-
well plates. Samples were then delivered to the University of Michigan Immunologic Monitoring 
Core for IL-1β, TNF-α, and IL-6 for enzyme-linked immunosorbent assay (ELISA) using Duoset 
ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer’s recommended 
protocol. 
Statistical analysis 
 Statistical analysis included mixed models analysis of variance (ANOVA), one-way 
ANOVA, or two-way ANOVA each followed by Tukey’s post-hoc comparison of means. In the 
case where two groups were compared, an unpaired two-tailed t-test was used. Mixed models 
ANOVA was performed using SPSS software (Chicago, IL) whereas one-way ANOVA, two-
way ANOVA, and t-tests were performed using GraphPad Prism (San Diego, CA). Graphs were 
generated using GraphPad Prism (San Diego, CA). A p<0.05 was considered statistically 
significant. Percentage data were converted to proportion values and arcsine transformed prior to 
statistical analysis. The ratio data from the Tdt staining analysis was also arcsine transformed 
prior to statistical analysis. 
Results 
 
Treatment effects on fetal weight 
 Fetal weight was analyzed for all fetuses and in a subset of males and females in which 
placental sex was determined by gDNA. In analysis of all fetuses, exposure to TCE during 
pregnancy decreased average fetal weight per dam on GD 16 by 12.8% (p<0.0001) (Figure 
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2.2A). TCE suppressed average fetal weight in males by 21.7% relative to control (p<0.0001) but 
no significant effect was observed in female fetuses (Figures 2.2B and 2.2C, respectively). 
Whereas NAC alone had no significant effect on average fetal weight relative to control, AOAA 
alone decreased average fetal weight relative to control by 15.1% (p<0.0001) in all fetuses 
(Figure 2.2A), and the same pattern was observed in separate analyses of male and female 
fetuses (p=0.018 and 0.001, respectively) (Figures 2.2B and C, respectively). The combined 
treatment of AOAA with TCE prevented the depressed average fetal weight elicited by treatment 
with TCE alone and AOAA alone in all fetuses and the subset of males (Figures 2.2A and 2.2B, 
respectively). In females, the combined AOAA and TCE treatment prevented depressed average 
fetal weight elicited by treatment with AOAA alone (Figure 2.2C). The combined treatment of 
NAC with TCE decreased average fetal weight relative to control in all fetuses, male fetuses, and 
female fetuses by 13.3%, 16.7%, and 15.6%, respectively (p<0.0001, p=0.003, and p=0.002, 
respectively) (Figures 2.2A, 2.2B, and 2.2C, respectively). 
Treatment effects on placental weight and efficiency  
 Investigation of placenta weight and placental efficiency revealed treatment-related 
effects. Placental efficiency is the ratio of fetal weight to placenta weight, an index used to assess 
placental function (Wilson and Ford, 2001). Although TCE alone had no significant effect on 
average placental weight (Figures 2.3A1, B1 and C1), the combination treatment of TCE with 
AOAA increased average placental weight relative to control by 8.1% (p=0.008), NAC-only 
treated by 7.5% (p=0.016), TCE-only treated by 15.2% (p=0.001), and NAC pre/co-treated with 
TCE by 12.5% (p=0.005) for analysis of all placenta (Figure 2.3A1). Moreover, the combination 
treatment of TCE + AOAA increased average placenta weight relative to TCE-only treatment by 
20.7% in males (p=0.003) (Figure 2.3B1) whereas there was no statisitically significant effect on 
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female placentae (Figure 2.3C1). There were no remarkable treatment-related effects on average 
placental efficiency (Figures 2.3A2, B2 and C2), with the sole statistically significant difference 
between AOAA treatment alone and NAC alone in all placenta (Figure 2.3A2). 
Treatment effects on maternal body weight, tissue weights, and litter size 
Treatments with TCE, NAC, or AOAA - alone or in combination - had no significant 
effects on maternal kidney weight, maternal liver weight, litter size, or maternal weight gain 
(GD3 to GD16) (Figure 2.4), indicating lack of overt treatment-related maternal toxicity. 
Treatment effects on CCBL activity in maternal tissue and placenta 
Consistent with previous literature showing AOAA as an effective CCBL inhibitor in 
kidney (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994), exposure to AOAA 
alone, or AOAA as pre/co-treatment with TCE, markedly reduced CCBL activity in maternal 
kidney (specific activity on tissue weight basis was reduced by 73.0% and 82.0%, respectively; 
p=0.0239 and 0.0006, respectively) relative to the control and TCE-only exposed groups, 
respectively (Figure 2.5A1). Similar reductions were observed for CCBL total activity 
(nmol/min) (p=0.0297 and 0.0001, respectively) (Figure 2.5A2). When CCBL specific activity 
was expressed relative to protein, the AOAA-only treated and AOAA pre/co-treatment with TCE 
group had reduced CCBL activity compared to NAC only-treated group by 77.2% and 82.5%, 
respectively (p=0.0280 and 0.0172, respectively) and the TCE only-treated group by 79.3% and 
84.1%, respectively (p=0.0110 and 0.0067, respectively) (Figure 2.5A3). In contrast to maternal 
kidney, AOAA failed to inhibit CCBL activity in maternal liver and in placenta, regardless of 
sex, irrespective of the presence or absence of TCE (Figures 2.5B1-3, 2.5C1-3, and 2.5D1-3, 
respectively). Neither NAC nor TCE, alone or in combination with each other, had an effect on 
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CCBL specific or total activity in maternal kidney, maternal liver, or placenta (Figures 2.5A1-3, 
2.5B1-3, 2.5C1-3, 2.5D1-3, respectively). 
Treatment effects on placental zone areas and widths 
 Because pregnancy progression is associated with changes in size to each zone of the rat 
placenta (Furukawa et al., 2011), we assessed treatment effects on placental morphology. A 
representative image for a placental section illustrates our method for quantification of area and 
width in hematoxylin and eosin-stained placental sections (Figure 2.6). TCE treatment alone did 
not alter absolute or relative width and area dimensions in any of the zones nor in the absolute 
width or area for total placenta (Figure 2.7). Unexpectedly, NAC pre/co-treatment with TCE 
decreased relative area and width of the labyrinth zone by 16.9% and 17.1%, respectively 
(p=0.0483 and 0.0250, respectively) (Figures 2.7A1 and 2.7E1, respectively) and increased 
relative area and width of the basal zone by 38.1% and 47.2%, respectively (p=0.0167 and 
0.0395, respectively) (Figures 2.7B1 and 2.7F1) relative to TCE treatment alone. No other 
changes in absolute or relative dimension were observed with treatments (Figure 2.7). 
Treatment effects on Alizarin Red staining 
Intensity of Alizarin Red staining for calcium disposition did not differ by treatment 
group (data not shown). A representative image with and without quantification marking is 
displayed in Figure 2.8. To understand if different placental zones vary in calcification, which 
can inform a role in toxicity (Wallingford et al., 2018), we compared Alizarin Red staining 
intensity across different zones. Alizarin Red staining intensity differed by placental zone for 
control rats (analysis only performed for this group). Specifically, in the metric of percentage of 
strong positive stain, the decidua basale of control rats was increased relative to the labyrinth 
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zone by 52.9% (p=0.0274) (Figure 2.9A). However, in the metric of total positive stain, no 
placental zones were different compared to each other (Figure 2.9B).  
Treatment effects on markers of oxidative stress, apoptosis, and pro-inflammatory response  
No treatment-related changes were detected with immunohistochemical (IHC) staining 
for markers of oxidative stress and apoptosis in placenta, including 3-nitrotyrosine and cleaved 
caspase-3 (Table S2.4; method for IHC quantification in Figure 2.10). Likewise, no treatment-
related changes were observed for mRNA expression of Prdx1, Nfkb1, Bcl2, Bax, and Lgals3 
(Table S2.5). No treatment-related changes were also observed for Tdt enzyme staining in 
placenta (quantification method shown in Figure S2.1). Moreover, we failed to detect a 
treatment-related change for 1L-1β in maternal serum (Figure S.2.2). We also attempted to 
detect TNF-α and IL-6 in maternal serum, but stopped at N=2 because one-third (4/12) of the 
samples for each endpoint had zero values (data not shown). 
Detection of proteins via IHC by placental zone in control placenta 
 Treatment-related changes were not observed for IHC detection of 3-nitrotyrosine, 
cleaved caspase-3, CCBL1, and FMO3. However, staining for these proteins varied by placental 
zone in the untreated control placenta (Figure 2.11). A pronounced difference occurred for 
CCBL1, with increased staining in the decidua basale relative to the labyrinth zone for the total 
metric, nuclear metric, and cytoplasmic metric by 87.0%, 302.8%, and 56.1%, respectively 
(p=0.0072, 0.0005, and 0.0422, respectively) (Figures 2.11A1, 2.11A2, 2.11A3, respectively). 
Some differences in staining between the different zones is specific to a particular metric (e.g., 
nuclear). For example, whereas 3-nitrotyrosine was decreased in the basal zone detection relative 
to the labyrinth zone and dedicua basale for the nuclear metric by 42.8% and 43.9%, respectively 
(p=0.0123 and 0.0093, respectively), similar reductions were not observed for the total or 
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cytoplasmic metrics (Figure 2.11B). FMO3 was also detected in lower levels for the labyrinth 
zone compared to the basal zone and decidua basale for the total and cytoplasmic metrics (for 
total metric, by 99.88% and 99.89%, respectively; p=0.0028 and 0.0027, respectively) (for 
cytoplasmic metric, by 99.93% and 99.91%, respectively; p= 0.0016 and 0.0016, respectively) 
(Figure 2.11C). Although the yolk sac expression of FMO3 was not quantified because the yolk 
sac was not present in all placenta sections, qualitative assessment of appearance suggests that 
the yolk sac expresses FMO3 at a very high level (Figure 2.10). 
Discussion 
 
 This study confirms our prior finding that trichloroethylene exposure during mid-
pregnancy decreases fetal weight, using the same exposure regimen (Loch-Caruso et al., 2019). 
New to the present study, we report that AOAA pre/co-treatment prevented the TCE-induced 
fetal weight decrease. AOAA is an inhibitor of CCBL (Elfarra and Anders, 1984; Lash et al., 
1986; Lash et al., 1994), which metabolizes the TCE glutathione pathway metabolite DCVC into 
DCVT, a toxic and reactive metabolite (Lash et al., 2014a). We suggest that this effect may be 
due to AOAA inhibition of CCBL in maternal kidney because we found that AOAA strongly 
inhibited CCBL activity in maternal kidney but not in placenta or maternal liver. Moreover, 
although NAC pre/co-treatment did not affect fetal weight relative to TCE alone, the study 
suggested that NAC pre/co-treatment with TCE could be detrimental to pregnancy because of 
alterations in placental zone dimensions relative to TCE treatment alone. 
Unexpectedly, AOAA treatment alone decreased fetal weight. We suggest that AOAA 
inhibition of CCBL may have disrupted essential physiological processes. Examples of 
potentially vulnerable CCBLs include alanine aminotransferases and mitochondrial aspartate 
aminotransferases (Cooper and Pinto, 2006). Alanine aminotransferase above 50 U/L are used in 
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clinical diagnosis of hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome 
(Vigil-De Gracia et al., 2003). Importantly, HELPP syndrome also includes the diagnosis of 
preeclampsia (Vigil-De Gracia et al., 2003). These prior studies suggest that normal alanine 
aminotransferase activity is important for a successful pregnancy. Similarly, mitochondrial 
aspartate aminotransferase is part of the malate-aspartate shuttle that is crucial to the metabolism 
of lactate in the embryo (Lane and Gardner, 2005), supporting the notion that mitochondrial 
aspartate aminotransferase is crucial to embryonic development. Together, these findings suggest 
that inhibition of aminotransferase-derived CCBL activity critical for fetal development could at 
least partially explain a detrimental effect of treatment with AOAA alone on fetal weight. 
Although AOAA treatment alone depressed fetal weight, the mean fetal weight of the 
TCE + AOAA group increased relative to the AOAA alone group to a level similar to that 
observed in untreated control. As a possible explanation, the TCE + AOAA treatment group 
would have more systemic DCVC than the AOAA alone treatment group because of the low 
ability of maternal kidney to convert DCVC to DCVT in the TCE + AOAA group and lack of 
TCE exposure in the AOAA alone group. The increased circulating DCVC in the TCE + AOAA 
group would be accompanied by inhibited generation of reactive downstream TCE metabolites 
such as DCVT, CTK, and CTAC. Although currently unstudied, the inhibited CCBL metabolism 
of DCVC could lead to build-up of DCVC that subsequently depressed activity of upstream 
enzymes such as γ-glutamyltransferase (GGT) and cysteinyl-glycine dipeptidase (DP). Inhibition 
of GGT reduces the supply of cysteine, prevents the utilization of extracellular GSH as a source 
of cysteine, and has received attention clinically (Hanigan, 2014). Indeed, the potential benefits 
of reducing systemic cysteine extends to pregnancy because total plasma cysteine is positively 
associated with preeclampsia, very low birth weight, and premature delivery (El-Khairy et al., 
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2003). Therefore, a mechanism could be that the TCE + AOAA treatment group has lower GGT 
activity and lower systemic cysteine, which is beneficial for pregnancy (El-Khairy et al., 2003), 
compared to the AOAA treatment alone group. Similarly, because the reaction catalyzed by DP 
forms cysteine and cysteine conjugates as products (Knapen et al., 1999; Hanigan, 2014), 
inhibition of DP metabolism could be beneficial for pregnancy by reducing systemic cysteine. 
Discovering the likelihood and existence of such mechanisms to explain the finding that TCE + 
AOAA treatment increased fetal weight relative to AOAA alone remain an important future 
direction with implications for pregnancy health. 
Our finding that AOAA strongly inhibits CCBL activity in maternal kidney but not in 
placenta or maternal liver is partially supported by previous studies in kidney (Elfarra and 
Anders, 1984; Lash et al., 1986; Lash et al., 1994) and is very likely attributable to the 
differences in CCBL composition as a function of organ (Lash, 2010). Whereas AOAA is a 
known CCBL inhibitor in the kidney (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 
1994), as supported by our data here, the effectiveness of AOAA as a CCBL inhibitor in liver or 
placenta had been previously unreported. It is known that kidney and liver express different 
forms of CCBL (Lash, 2010), which explains why AOAA would inhibit CCBL activity in one 
but not the other. Specific CCBLs, such as glutamine transaminase K/ kynurenine 
aminotransferase, are found in kidney but not liver, and kynureninase and mitochondrial 
aspartate aminotransferase are found in liver but not kidney (Lash, 2010). The exact forms of 
CCBL in placenta are presently unknown: however, our data suggest that the form(s) of CCBL in 
the placenta are more similar to that (those) of liver as opposed to kidney. Identification of exact 
CCBLs in placenta require further research. Finally, we observed that alteration of CCBL 
activity was specific to AOAA and not TCE or NAC. The lack of effect of TCE or NAC on 
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CCBL activity is not unexpected; in fact, TCE does not stimulate increased activity of γ-
glutamyltransferase (Loch-Caruso et al., 2019), which is upstream of CCBL in TCE metabolism. 
Mechanistic and physiological explanations exist for how AOAA could inhibit CCBL 
activity in kidney to prevent TCE-induced decreased fetal weight. DCVG and DCVC are TCE 
metabolites generated through the glutathione conjugation metabolic pathway that circulate 
systemically (Lash et al., 2014a). Thus, it is plausible that AOAA pre/co-treatment with TCE 
could thwart the ability of the kidneys to convert DCVC into reactive and toxic downstream 
metabolites (Lash et al., 2014a). This mechanism to reduce toxicity may also be manifest in the 
fetus. Although fetal kidney CCBL composition is currently unknown, the possibility exists that 
AOAA could inhibit fetal kidney CCBL to limit production of downstream metabolites (DCVT, 
CTK, and CTAC). Indeed, the existence of peptide transporters in placenta (Leazer and 
Klaassen, 2003) that could transport DCVC from mother to fetus increases the relevance and 
plausibility that AOAA pre/co-treatment could exert an effect on fetal weight via fetal kidney. 
The morphometric zonal analysis of the placenta indicated that NAC pre/co-treatment 
with TCE caused multiple effects on placenta morphology relative to TCE treatment alone in a 
manner consistent with increased toxicity. Specifically, the effects that NAC pre/co-treatment 
with TCE decreased relative labyrinth zone width and area, and increased relative basal zone 
area and width, compared to TCE treatment alone are relevant to pregnancy health. Because the 
labyrinth zone increases as pregnancy progresses in rat and nearly the opposite is true of the 
basal zone, especially around GD 16 (Furukawa et al., 2011), the changes observed in the NAC 
+ TCE treatment group are consistent with a delayed developmental phenotype compared to the 
TCE treatment alone group. Although less data variance or inclusion of additional rats might 
allow detection of statistically significant differences between the NAC + TCE group and the 
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control group for labyrinth and basal zone measurements, the present findings are important 
because they affected relative widths and areas of multiple placental zones. A worthy future 
direction could be to explore how these manifestations could impact fetal or placental weight 
after GD 16 or if the rats exposed to NAC pre/co-treatment group would give birth later than the 
other treatment groups. 
The suggestion that NAC pre/co-treatment with TCE could be toxic is consistent the 
delayed placental phenotype observation and is also consistent with our observations in our in 
vitro BeWo human placental trophoblast model in which NAC exacerbated some responses 
stimulated by DCVC (Chapter 5). The lack of treatment effects on Alizarin Red staining of the 
rat placentae indicate that enlargement of the basal zone for the NAC pre/co-treatment group was 
not attributable to placental calcification. Rather, the mechanism of altered placenta zone areas 
may be related to growth factors and cytokines that are critical for placental growth (Furukawa et 
al., 2011), although this possibility was untested in the current study. Verification of these 
mechanisms requires further investigation beyond the scope of the present study.  
Investigation into the interaction between NAC and TCE metabolism may prove critical 
for understanding how NAC exacerbated or failed to prevent TCE toxicity. In the in vitro BeWo 
cell studies, NAC enhancement of DCVC toxicity was associated with an NAC effect of 
increased CYP3A4 mRNA expression (Chapter 5), which supports the idea that NAC 
exacerbation of TCE toxicity occurs downstream of DCVC. A possible mechanism could be that 
NAC provides an acetyl group via its breakdown by aminoacylase I (Uttamsingh and Anders, 
1999; Uttamsingh et al., 2000) to generate NAcDCVC from DCVC (Lash et al., 2014a). 
NAcDCVC can be metabolized by CYP3As into NAcDCVCS, a known toxic TCE metabolite 
(Werner et al., 1996; Lash et al., 2014a). Future work could study how NAC and TCE combined 
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treatment impacts protein expression of CYP3A1, a CYP3A expressed in rat placenta and 
suggested to be a major CYP in rat placenta (Ejiri et al., 2001; Ejiri et al., 2003). Moreover, 
NAC could be metabolized to GSH (Aldini et al., 2018) to provide substrate for GSTs that 
conjugate GSH to TCE (Lash et al., 2014a). However, GSH conjugation of TCE occurs several 
steps before the formation of any reactive metabolites, so the link to toxicity via increased GSTs 
or DCVG formation is more difficult to make. The argument for an NAC effect non-specific to 
TCE is also difficult to make because we failed to observe NAC exert an effect by itself. 
Regardless, future investigation of the formation of reactive metabolites such as NAcDCVCS 
could provide insight into the effects observed with NAC and TCE combined treatment. 
Although DCVC stimulates ROS generation, pro-inflammatory cytokine release, and 
apoptosis to HTR-8/SVneo human placental cells in vitro (Hassan et al., 2016; Elkin et al., 
2018), exposure of pregnant rats to TCE failed to stimulate changes in markers of oxidative 
stress (3-nitrotyrosine) and apoptosis (cleaved caspase-3 and Tdt enzyme staining) in placental 
tissue. Additionally, there were no significant changes in placental mRNA expression of genes 
relevant to oxidative stress and apoptosis pathways (Prdx1, Bcl2, Bax, Nfkb1 or Lgals3). These 
findings suggest that TCE, NAC, and AOAA may act by mechanisms involving tissues other 
than placenta in vivo, or else their actions on the placenta may involve mechanisms other than 
oxidative stress and apoptosis. Alternative explanations include the differences in species and 
concentrations used in the studies. For example, DCVC concentrations in cell culture may not 
correspond to DCVC concentrations in tissue generated in vivo from a given TCE dose, and this 
may differ as a function of species. Furthermore, rats exhibit higher GGT and renal CCBL 
activity compared to humans (Hinchman and Ballatori, 1990; Lash et al., 1990) as examples of 
species differences that can affect detected concentrations of TCE metabolites. Another possible 
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explanation is that the in vitro work was performed on a specific cell type but the in vivo work 
was performed on placental tissue exposed in vivo. Additionally, the possibility exists that 
extravillous cytotrophoblastic cells may be especially vulnerable to TCE or DCVC toxicity 
compared to placental tissue. However, confirming these explanations would require placental 
cell isolation methodologies not used in the present study. 
Immunohistochemical staining indicated that differences in protein expression were more 
notable across different zones in placenta, rather than between treatment groups. The differences 
in zone were highlighted using placenta from the control group of rats, in which we detected 
more CCBL1 expression in the decidua basale compared to the labyrinth zone. Because CCBL1 
can potentially bioactivate DCVC to DCVT (Lash et al., 2014a), this finding suggests that the 
decidua basale may be more sensitive to DCVC toxicity. We also detected significant differences 
in FMO3 as a function of zone in the placenta. Of novelty but not quantified because of the lack 
of yolk sac in some placenta sections, FMO3 was found to be highly expressed in yolk sac. 
These examples highlight how the current work can provide information about possible zonal 
sensitivity of the placenta for certain toxicant exposures and interventions. 
 Although treatments used in this study had only nominal effects on the placenta, some 
placental changes were observed with the TCE + NAC treatment and TCE + AOAA treatment. 
The NAC pre/co-treatment with TCE could be acting by a mechanism of DCVC bioactivation to 
produce toxicity of altered placenta dimensions. TCE + AOAA could be acting in a protective 
mechanism towards pregnancy by increasing placenta weight. Because AOAA is effective as a 
CCBL inhibitor in kidney (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994), which 
would increase the DCVC/DCVT ratio in kidney and influence the corresponding metabolites in 
systemic circulation, an untested mechanism to date is that the TCE + AOAA group could have 
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increased DCVC in placenta relative to all treatment groups. The increased DCVC may inhibit 
activity of upstream enzymes, GGT and DP (Lash et al., 2014a), with the decreased GGT and 
DP activity as beneficial for pregnancy as described previously (Knapen et al., 1999; El-Khairy 
et al., 2003; Hanigan, 2014). Measurement of enzyme activity upstream of DCVC remains 
important future work. Additionally, the finding that NAC treatment alone produced higher 
placental efficiency compared to AOAA treatment alone raises the question if the difference is 
attributable to amino acid transport. This possibility is valid because NAC is a precursor of 
cysteine (Aldini et al., 2018) and AOAA inhibits renal CCBL (Elfarra and Anders, 1984; Lash et 
al., 1986; Lash et al., 1994), which includes aspartate aminotransferase (Lash, 2010). Knowledge 
on the specific transport mechanisms and the exact enzymes with CCBL activity susceptible to 
AOAA inhibition is not definitive at this point. 
 Wistar rats were selected for the present study for several reasons. They are more 
responsive to estradiol-stimulated increase in uterine weight compared to Sprague-Dawley rats 
(Diel et al., 2004), more responsive to bisphenol A-stimulated delayed vaginal opening 
compared to Sprague-Dawley rats (Tinwell et al., 2002), and are higher in hepatic CYP2D2 
content correlated with 4-hydroxylase activity compared to Dark Agouti rats (Schulz-Utermoehl 
et al., 1999). Significantly, timed-pregnant Wistar rats have been previously reported to have 
decreased fetal weight in response to TCE exposure (Loch-Caruso et al., 2019). Thus, we chose 
a rat strain more likely to be sensitive to reproductive effects. We intentionally chose a time 
point of exposure that encompassed the time point when rat fetuses and placenta exhibit rapid 
growth and included a time point before the placenta forms (Furukawa et al., 2011). 
Likewise, dosages chosen for our study reflect the previous literature. The TCE exposure 
of 480 mg/kg/day is within an order of magnitude of the Occupational Safety and Health 
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Administration Permissible Exposure Level of 100 ppm for an 8-hour workday (Agency for 
Toxic Substances and Disease Registry, 2007). Differences between inhalation and ingestion 
exposure routes, and subsequent distribution and metabolism, could influence TCE toxicity, 
however. Moreover, prior studies report effects of TCE at similar exposure levels, including 
oxidative stress and/or neurodegeneration in rats (Toraason et al., 1999; Liu et al., 2010; Loch-
Caruso et al., 2019). The NAC dosage of 200 mg/kg/day was in the effective range of studies 
using NAC in vivo (Fukami et al., 2004; Chang et al., 2005; Naik et al., 2006). In particular, 
Chang et al. found that 100 mg NAC/kg treatment twice a day rescued high blood pressure in 
timed-pregnant Sprague-Dawley rats (Chang et al., 2005). The AOAA dosage of 20 mg/kg/day 
is also within the effective in vivo range used in prior studies (Perry and Hansen, 1978; Donoso 
and Banzan, 1984). 
 In summary, this is the first report that AOAA is capable of preventing TCE-stimulated 
decreased fetal weight, using a timed-pregnant Wistar rat model. Our data suggest that the 
mechanism is related to CCBL activity because AOAA was effective in maternal kidney but 
neither in placenta nor maternal liver. We are also the first to report that NAC pre/co-treatment 
could be more detrimental to pregnancy than TCE treatment by itself. Figure 2.12 depicts our 
proposed mechanism of action of TCE on timed-pregnant Wistar rats, with modulation of TCE 
toxicity by NAC and AOAA, to explain the impact of the treatments on fetal weight. 
Importantly, this study failed to find oxidative stress in placenta as a mechanism of toxicity. 
Future studies could further investigate modulation of the GSH conjugation pathway in TCE 
metabolism to modify toxicity, including quantification of metabolite concentrations. Finally, 
because enzymes capable of metabolizing DCVC differed by placental zone, future studies could 
investigate the toxic effects of TCE or DCVC targeted to different placental cell types. 
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Figure 2.1. Treatment schedule of the timed-pregnant Wistar rats. With gestational day 
(GD) 0 designated as day of copulation, rats arrive on GD 2, are first trained to eat the vanilla 
wafer on GD 3, and are euthanized on GD 16. The following dosages of each chemical was used: 
200 mg NAC/kg/day, 20 mg AOAA/kg/day, and 480 mg TCE/kg/day. 
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Figure 2.2. Effects of trichloroethylene (TCE), in the presence and absence of N-acetyl-L-
cysteine (NAC) and aminooxyacetic acid (AOAA), on fetal weight. The effects for (A) all 
fetuses, (B) a subset of males, and (C) a subset of females are presented. The subset of males and 
females are indicated because we were only able to determine the sex for a subset of placenta. 
Individual data points correspond to average fetal weight for a given dam. Data were analyzed by 
mixed model ANOVA with treatment as the fixed variable and litter as the random variable. 
Statistically significant differences are indicated by non-overlapping letters. Error bars represent 
mean ± SEM. For (A) and (C), N=8 for each treatment group with the exception of the AOAA-
only and TCE-only treatment groups, which had N=7 each. For (B), N=8 for each treatment 
group, with the exception of the AOAA-only and TCE-only treatment groups, which had N=7 
and N=6, respectively.    
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Figure 2.3. Effects of trichloroethylene (TCE), in the presence and absence of N-acetyl-L-
cysteine (NAC) and aminooxyacetic acid (AOAA), on placental weight and placental 
efficiency. The effects for (A) all placentae, (B) a subset of male placentae, and (C) a subset of 
female placentae are presented. Placental efficiency is defined as placental weight/fetal weight. 
Individual data points correspond to average placental weight or average placental efficiency for 
a given dam. Data were analyzed by mixed model ANOVA with treatment as the fixed variable 
and litter as the random variable. Statistically significant differences are indicated by non-
overlapping letters. Error bars represent mean ± SEM. For (A) and (C), N=8 for each treatment 
group with the exception of the AOAA-only and TCE-only treatment groups, which had N=7 
each. For (B), N=8 for each treatment group, with the exception of the AOAA-only and TCE-
only treatment groups, which had N=7 and N=6, respectively.  
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Figure 2.4. Effects of TCE, in the presence and absence of NAC and AOAA, on (A) 
maternal liver weight, (B) maternal kidney weight, (C) litter size, and (D) maternal weight 
gain. Data were analyzed by one-way or two-way ANOVA followed by Tukey’s post-hoc 
comparison of means. Error bars represent mean ± SEM. N=8 for the control group, N=8 for the 
NAC group, N=7 for the AOAA group, N=7 for the TCE group, N=8 for the TCE + NAC group, 
N8 for the TCE + AOAA group.  
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Figure 2.5. Effects of AOAA, TCE and NAC on CCBL activity in (A) maternal kidney, (B) 
maternal liver, (C) male placenta, and (D) female placenta. Data were analyzed using one-
way ANOVA followed by Tukey’s post-hoc comparison of means. Statistically significant 
differences are indicated by non-overlapping letters. Error bars represent mean ± SEM. N=4 
dams per experimental group.  
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Figure 2.6. Representative image of hematoxylin and eosin (H&E) stained placental section 
indicating quantification method for placenta morphometric analysis of different placental 
zones.   
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Figure 2.7. Effects of TCE, in the presence and absence of NAC and AOAA, on placental 
zone morphology. Effects on (A) labyrinth zone area, (B) basal zone area, (C) decidua basale 
area, (D) total placenta area, (E) labyrinth zone width, (F) basal zone width, (G) decidua basale 
width, and (H) total placenta width are presented. Data were analyzed by one-way ANOVA 
followed by Tukey’s post-hoc comparison of means. Data of relative dimensions were converted 
from percent to fraction, then arcsine transformed prior to statistical analysis. N=6 for each 
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experimental group, with each placenta from a different litter. All placenta used for this figure 
are female. 
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(A) Representative Image of Alizarin Red Stain 
 
 
(B) Quantification method  
      
 
 
Figure 2.8. Representative image and quantification method for analysis of Alizarin Red 
staining. (A) Representative image of placenta stained with Alizarin Red. (B) Display of 
Alizarin Red stain in the basal zone without (left) and with (right) marking from the total positive 
stain algorithm. The green lines are derived from tracing the basal zone and decidua basale to 
mark their borders. The images from (B) come from the same placenta as (A) and are from 
placenta from the control group. 
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(A) Percent of strong Alizarin Red positive stain as a function of placenta zone 
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(B) Percent of total Alizarin Red positive stain as a function of placenta zone 
L
a
b
y
r i
n
th
B
a
s
a
l
D
e
c
id
u
a
0
5
1 0
1 5
%
 w
it
h
 a
n
y
 l
e
v
e
l 
o
f 
p
o
s
it
iv
e
 s
ta
in
 
 
Figure 2.9. Effects of Alizarin Red stain intensity as a function of placental zone in control 
placenta for (A) strong positive stain and (B) total positive stain. Percent strong positive stain 
or total positive stain were not altered by treatment group for any zone of the placenta (not 
shown). Percentage data were converted to fraction values and arcsine transformed prior to 
statistical analysis by one-way ANOVA followed by Tukey’s post-hoc comparison of means. 
N=6 for each zone and all placenta used to arrive at this figure are female and come from distinct 
litters.  
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(A) Cleaved caspase-3 
 
 
(B) Cysteine conjugate β-lyase 
1 (CCBL1) 
 
(C) Flavin-containing 
monooxygenase 3 (FMO3) 
 
(D) 3-nitrotyrosine 
 
 
  
 
(E) Quantification method used for all IHC stains – total detection reading 
        
 
(F) Quantification method used for all IHC stains – nuclear detection reading 
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Figure 2.10. Representative images for immunohistochemistry (IHC) staining for (A) 
cleaved caspase-3, (B) cysteine conjugate β-lyase 1, (C) flavin-containing monooxygenase 3, 
and (D) 3-nitrotyrosine stains. Quantification method for the (E) total detection reading, and 
the (F) nuclear detection reading. In (E) and (F), the image on the left an unannotated image 
whereas the image on the right is the equivalent image containing annotations from the 
detections. Red markings symbolize a positive detection whereas blue markings symbolize a 
negative detection. The images from (E) and (F) are all from the labyrinth zone of placenta 
stained with 3-nitrotyrosine.  
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Figure 2.11. Effects of IHC staining of (A) cysteine conjugate β-lyase 1, (B) 3-nitrotyrosine, 
(C) flavin-containing monooxygenase 3, and (D) cleaved caspase-3 as a function of 
placental zone in control placenta. Data were analyzed by one-way ANOVA followed by 
Tukey’s post-hoc comparison of means. N=6 for each zone and all placenta used to arrive at this 
figure are female and come from distinct litters. 
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Figure 2.12. Proposed mechanism of action of trichloroethylene (TCE) in the timed-
pregnant Wistar rat with modulation by N-acetyl-L-cysteine (NAC) and aminooxyacetic 
acid (AOAA). Interventions to modulate TCE toxicity are listed in blue. TCE and its metabolites 
are in rectangular boxes, and an enzyme, cysteine conjugate β-lyase (CCBL), involved in TCE 
metabolism is in a circular box. Other abbreviations: DCVC, S-(1,2-dichlorovinyl)-L-cysteine; 
DCVT, 1,2-dichlorovinylthiol. 
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Table S2.1. Assignment of rats across treatment groups and batches. 
 
Treatment Number of rats Pregnancy status 
Control 8 across 8 batches All pregnant 
NAC 8 across 8 batches All pregnant 
AOAA 9 across 8 batches Two rats non-pregnant – one from batch 3 
and one from batch 7 
TCE 8 across 8 batches One rat from batch 8 non-pregnant 
TCE + NAC 8 across 8 batches All pregnant 
TCE + AOAA 8 across 8 batches All pregnant 
 
Eight total batches of rats arrived at eight separate time points to the researchers. Within each 
batch, each treatment group was assigned at least once with assignments made in a random 
fashion. 
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Table S2.2. Details of primary antibodies used for Immunohistochemistry (IHC) staining 
and reaction conditions.  
 
Peptide/Protein 
Target 
Antigen 
Sequence 
Manufacturer 
and Catalog 
Number 
Species 
Reactivity 
Antibody 
Type 
Dilution 
Used 
Positive 
Control 
Cleaved caspase-3 Synthetic 
peptide of 
amino-
terminal 
residues 
adjacent to 
Asp175 of 
human 
caspase-3 
Cell Signaling 
Technology, 
9664 
Human, 
Mouse, Rat, 
Monkey 
Rabbit 
monoclonal 
1:500,  
30 
minutes, 
room 
temp 
Rat thymus 
Cysteine 
conjugate β-lyase 
1 (CCBL1) 
Full length 
fusion protein 
[human]  
ThermoFisher 
Scientific, 
PA5-51313 
Human, Rat Rabbit 
polyclonal 
1:500,  
1 hour, 
room 
temp 
Rat 
Liver/Kidney 
Flavin-containing 
monooxygenase 3 
(FMO3) 
Synthetic 
peptide within 
human FMO3 
on amino 
acids 300-400 
Abcam, 
ab126711 
Human, 
Rat, Mouse 
Rabbit 
monoclonal 
1:500,  
1 hour, 
room 
temp 
Rat Kidney 
3-nitrotyrosine 3-(4-Hydroxy-
3-nitrophenyl 
acetamido) 
propionic 
acid-BSA 
conjugate 
Abcam, 
ab61392 
Any  Mouse 
monoclonal 
1:500 
30 
minutes, 
room 
temp 
Rat brain 
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Table S2.3. Primer sequences used for the current study. 
 
B2m (Beta-2-microglobulin) 
Forward 5’-TCGTGCTTGCCATTCAGAAAAC-3’ 
Reverse 5’-GCAGTTGAGGAAGTTGGGCT-3’ 
Source: NCBI nucleotide database 
 
Nfkb1 (Nuclear factor kappa B subunit 1) 
Forward 5’-ACTGTCAACAGATGGCCCATACC-3’ 
Reverse 5’-TTCGCACACGTAGCGGAAT-3’ 
Source: NCBI nucleotide database 
 
Bcl2 (BCL2 apoptosis regulator) 
Forward 5’-GACTGAGTACCTGAACCGGC-3’ 
Reverse 5’-AGTTCCACAAAGGCATCCCAG-3’ 
Source: NCBI nucleotide database 
 
Bax (BCL2 associated X, apoptosis regulator) 
Forward 5’-TTGCTACAGGGTTTCATCCAGG-3’ 
Reverse 5’-CACTCGCTCAGCTTCTTGGT-3’ 
Source: NCBI nucleotide database 
 
Prdx1 (Peroxiredoxin 1) 
Forward 5’-CTGGCATGGATTAACACACCC-3’ 
Reverse 5’-AATGGTGCGCTTGGGATCTG-3’ 
Source: NCBI nucleotide database 
 
Lgals3 (Galectin-3) 
Forward 5’-CAGTGCCCTACGATATGCCC-3’ 
Reverse 5’-GAGTGATACTGTTTGCGTTGGG-3’ 
Source: NCBI nucleotide database 
 
Fmo3 (Flavin-containing monooxygenase 3) 
Forward 5’-CCTGGGGAACTCAGGTTGTG-3’ 
Reverse 5’-GGAGCTTATGATGACCTGCTGA-3’ 
Source: NCBI nucleotide database 
 
Kyat1 (Kyurenine aminotransferase 1, also codes for cysteine conjugate beta-lyase) 
Forward 5’-TGACAAACGTCCTGGCAAGT-3’ 
Reverse 5’-CATAGGCACCCACTGTCACC-3’ 
Source: NCBI nucleotide database 
 
For sex determination (listed below) 
 
Sry (Sex determining region Y) (works for both genomic DNA and cDNA input) 
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Forward 5’-AAGCGCCCCATGAATGCAT-3’ 
Reverse 5’-CGATGAGGCTGATATTTATA-3’ 
Source: (Schulte et al. 2012) 
 
B2m (Beta-2-microglobulin) (for cDNA input) – spans exon-exon junction 
Forward 5’-TCGTGCTTGCCATTCAGAAAAC-3’ 
Reverse 5’-GCAGTTGAGGAAGTTGGGCT-3’ 
Source: NCBI nucleotide database 
 
B2m (Beta-2-microglobulin) (for genomic DNA input) – does not span exon-exon junction 
Forward 5’-CCCACCCTCATGGCTACTTC-3’ 
Reverse 5’-TGGGTGATGAAAACCGCACA-3’ 
Source: NCBI nucleotide database 
 
Primers for sex determination are at the bottom of the Table. Several criteria were used for 
primer selection in the case of using the NCBI nucleotide database. Desirable characteristics of 
the primer pair included a melting point as close to 60 degrees Celsius as possible, an amplicon 
length preferably between 75 and 150 base pairs, and base pairs as close as possible to 50% GC 
in composition. Finally, the criterion of the primer spanning an exon-exon junction was selected 
as a must (except in the case of Kyat1, in which no primers could be found with the 
specification). 
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Table S2.4. Summary of mainly null immunohistochemistry (IHC) and Tdt stain findings from 
the treatment group comparisons for each individual zone of the placenta (Cleaved caspase-3, 
cysteine conjugate β-lyase 1, flavin-containing monooxygenase 3, 3-nitrotyrosine, Tdt). 
 
 p-value ranges when comparing the four different treatment groups 
via ANOVA followed by Tukey’s posthoc comparison of means 
 Labyrinth Zone Basal Zone Decidua Basale 
Cleaved caspase-3: 
Total 
0.5960 to 0.9807 0.7445 to >0.9999 0.6168 to 0.9996 
Cleaved caspase-3: 
Nuclear 
0.6483 to 0.9994 0.6666 to 0.9984 0.5028 to >0.9999 
Cleaved caspase-3: 
Cytoplasmic 
0.5913 to 0.9878 0.7186 to 0.9993 0.6561 to 0.9994 
CCBL1: Total 0.9711 to >0.9999 0.9340 to 0.9996 0.4336 to 0.9982 
CCBL1: Nuclear 0.7068 to 0.9991 0.7499 to 0.9984 0.4912 to 0.9955 
CCBL1: Cytoplasmic 0.9591 to >0.9999 0.9662 to 0.9996 0.5027 to 0.9995 
FMO3: Total 0.3556 to 0.9931 0.6706 to >0.9999 0.9334 to 0.9996 
FMO3: Nuclear 0.6536 to 0.9997 0.0384 to 0.7770 0.8619 to 0.9959 
FMO3: Cytoplasmic 0.3351 to 0.9982 0.6920 to 0.9997 0.9212 to 0.9985 
3-nitrotyrosine: Total 0.5512 to 0.9645 0.2922 to 0.9785 0.5663 to 0.9987 
3-nitrotyrosine: 
Nuclear 
0.5979 to 0.9878 0.4095 to 0.9919 0.2486 to 0.9993 
3-nitrotyrosine: 
Cytoplasmic 
0.4667 to 0.9859 0.2799 to 0.9896 0.5495 to 0.9923 
Tdt (ratio of green to 
blue) 
0.2748 to 0.9997 0.9937 to >0.9999 0.6311 to 0.9961 
 
For the IHC stains, detections were made on QuPath using an algorithm that specifically detected 
all staining regardless of cytoplasmic or nuclear and an algorithm that specifically detected only 
nuclear staining (also described in Figure 2.10). For Tdt, abundance was quantified as a ratio of 
green (Tdt enzyme) to blue (DAPI) stain (also described in Figure S2.1). Despite almost no 
differences among treatment groups, many comparisons for IHC staining among zones for 
control placenta were statistically significant (Figure 2.11). The one statistically significant p-
value of 0.0384 here corresponds to the Control versus TCE + AOAA comparison, with the TCE 
+ AOAA group having more nuclear FMO3 stain compared to the control group. N=6 for each 
zone, with all placenta as female and coming from a different litter. Abbreviations: CCBL, 
cysteine conjugate β-lyase; FMO, flavin-containing monooxygenase; Tdt, terminal 
deoxynucleotidyl transferase. 
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Table S2.5. Summary of null findings from qRT-PCR experiments (Nfkb1, Bcl2, Bax, Prdx1, 
Lgals3, Kyat1, and Fmo3 mRNA expression). 
 
Comparison of treatment groups within each sex 
 Lowest p-value in ANOVA followed by Tukey’s multiple comparison of 
means (comparison leading to the reported p-value) 
Gene Male Female 
Nfkb1 0.5017 (NAC vs. TCE + AOAA) 0.9037 (AOAA vs. TCE) 
Bcl2 0.1360 (NAC vs. TCE + AOAA) 0.7482 (AOAA vs. TCE) 
Bax 0.5979 (Control vs. TCE) 0.9975 (Control vs. TCE) 
Prdx1 0.1517 (Control vs. TCE + AOAA) 0.8321 (Control vs. AOAA) 
Lgals3 0.8337 (Control vs. TCE + NAC) 0.6297 (AOAA vs. TCE + AOAA) 
Kyat1 0.4311 (Control vs. TCE + AOAA) 0.9181 (Control vs. AOAA) 
Fmo3 0.0799 (Control vs. TCE) 0.2744 (TCE + NAC vs. TCE + AOAA) 
 
Comparison of sex within each treatment group (p-values from unpaired, two-tailed t-
test) 
Male vs. female (Control) Male vs. female (NAC) Male vs. female (AOAA) 
Gene p-value Gene p-value Gene p-value 
Nfkb1 0.2183 Nfkb1 0.3982 Nfkb1 0.3856 
Bcl2 0.1089 Bcl2 0.2046 Bcl2 0.1352 
Bax 0.1941 Bax 0.6278 Bax 0.6414 
Prdx1 0.2194 Prdx1 0.2473 Prdx1 0.623 
Lgals3 0.2348 Lgals3 0.6009 Lgals3 0.7237 
Kyat1 0.3651 Kyat1 0.3601 Kyat1 0.0386 
Fmo3 0.5854 Fmo3 0.3471 Fmo3 0.8479  
Male vs. female (TCE) Male vs. female (TCE + 
NAC) 
Male vs. female (TCE + 
AOAA) 
Gene p-value Gene p-value Gene p-value 
Nfkb1 0.8462 Nfkb1 0.7751 Nfkb1 0.4469 
Bcl2 0.1853 Bcl2 0.209 Bcl2 0.4233 
Bax 0.559 Bax 0.6149 Bax 0.6164 
Prdx1 0.8793 Prdx1 0.9976 Prdx1 0.1535 
Lgals3 0.541 Lgals3 0.9594 Lgals3 0.6371 
Kyat1 0.5879 Kyat1 0.9229 Kyat1 0.4711 
Fmo3 0.2447 Fmo3 0.1068 Fmo3 0.8953 
 
Only one significant p-value was found in the case of a male to female comparison in Kyat1 
expression within the AOAA experimental group, which has limited interpretability because it 
was not the control group. N=8, 8, 7, 6, 8, 8, respectively for the control, NAC, AOAA, TCE, 
TCE + NAC, and TCE + AOAA male experimental groups. N=8, 8, 7, 7, 8, 8, respectively, for 
the control, NAC, AOAA, TCE, TCE + NAC, and TCE + AOAA female experimental groups. 
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Representative Image of Tdt stain (green) with DAPI counterstain (blue) 
 
Quantification method to detect Tdt stain (green) (left) and DAPI (blue) (right) 
       
Verification of quantification method (quantification of green to blue ratio for positive and 
negative control) 
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Figure S2.1. Representative image and quantification method for analysis of Tdt enzyme 
staining. Quantification was performed using QuPath. Negative and positive control staining 
were performed on manufacturer-supplied slides of HL-60 cells. Generation of negative control 
was accomplished by substituting the Tdt enzyme with ddH20 in the reaction mixture as 
described in the manufacturer-supplied instructions. Generation of positive control was 
accomplished by incubating the specimen in a Tris-buffered saline (TBS) /1 mM MgSO4 
mixture, as described in the instructions provided by the manufacturer. 
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Figure S2.2. Effects of TCE, in the presence and absence of NAC and AOAA, on maternal 
serum concentrations of IL-1β. Data were analyzed by one way-ANOVA followed by Tukey’s 
post-hoc comparison of means. N=8, 8, 7, 7, 8, 8, for the control, NAC, AOAA, TCE, TCE + 
NAC, TCE + AOAA groups, respectively. Attempt was also made to detect TNF-α and IL-6 in 
maternal serum; however, 4 out 12 samples submitted for each of these analyses returned a null 
value (data not shown) and a decision was made to not proceed with TNF-α and IL-6 detection. 
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Chapter III. Trichloroethylene Modifies Energy Metabolites in the Amniotic Fluid of 
Wistar Rats 
Abstract 
 Exposure to trichloroethylene (TCE), an organic solvent with multiple industrial 
purposes, decreases fetal weight in Wistar rats and is associated with several adverse pregnancy 
outcomes in epidemiological studies. Altered metabolite abundance in amniotic fluid is also 
associated with adverse pregnancy outcomes. However, effects of TCE exposure on metabolite 
abundance in amniotic fluid has not been studied previously to our knowledge. In the current 
study, timed-pregnant Wistar rats were exposed to TCE via vanilla wafer administration or to 
vehicle (wafer) alone from gestational day (GD) 6 to 16. Amniotic fluid was collected on GD 16 
and analyzed for metabolites important in energy metabolism using a targeted metabolomics 
platform. Concentrations of the following metabolites decreased in amniotic fluid of dams 
exposed to TCE regardless of fetal sex: 6-phosphogluconate, guanosine diphosphate, adenosine 
diphosphate, adenosine triphosphate, and flavin adenine dinucleotide. TCE decreased fructose 
1,6-bisphosphate and guanosine triphosphate concentrations in amniotic fluid of male but not 
female fetuses. Moreover, TCE treatment decreased uridine diphosphate-D-glucuronate 
concentrations, and increased arginine and phosphocreatine concentrations, in amniotic fluid of 
female fetuses only. No metabolites were increased in the amniotic fluid of male fetuses. A high 
concentration of acetate compared to other short-chain fatty acids (SCFAs) was found in the 
amniotic fluid samples. Pathway analysis revealed that folate biosynthesis and the pentose 
phosphate pathway were altered by TCE treatment in both sexes. Using metabolite ratios to 
investigate changes within specific pathways, it was found that some ratio alterations, including 
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those in arginine metabolism and phenylalanine metabolism, occurred in amniotic fluid of 
female fetuses but not male fetuses. Ratio analysis also identified enzymes, such as 
gluconokinase, that may be TCE targets. Together, our data suggest that TCE caused some 
different effects in amniotic fluid based on sex that may inform mechanisms of differential 
susceptibility to TCE dependent on fetal sex. Future considerations include the detection of 
additional critical metabolites in pathways, such as folate biosynthesis, to bolster conclusions 
about specific portions of pathways and use of knowledge from the current study, such as 
changed metabolites, to inform approaches at modulating TCE toxicity. 
Introduction 
Trichloroethylene (TCE) is an environmental contaminant commonly used as a metal 
degreaser and in the synthesis of various chemicals (Agency for Toxic Substances and Disease 
Registry, 2019). Exposure to TCE is associated with several adverse pregnancy outcomes in 
women (Rodenbeck et al., 2000; Forand et al., 2012; Ruckart et al., 2014). These adverse 
pregnancy outcomes include low birth weight (LBW) (Forand et al., 2012), term low birth 
weight (TLBW) (Forand et al., 2012), small for gestational age (SGA) (Forand et al., 2012; 
Ruckart et al., 2014), decreased mean birth weight (Ruckart et al., 2014), and very low birth 
weight (VLBW) (defined as less than 1501 grams) (Rodenbeck et al., 2000). Furthermore, 
different routes of TCE exposure are associated with distinct adverse pregnancy outcomes: 
whereas TCE inhalation has been significantly associated with LBW, TLBW, and SGA (Forand 
et al., 2012), TCE ingestion via drinking contaminated water has been significantly associated 
with SGA, decreased mean birth weight, and VLBW (Rodenbeck et al., 2000; Ruckart et al., 
2014). 
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Toxicology studies are advancing our understanding of mechanisms that may underlie the 
TCE associations with adverse pregnancy outcomes. A metabolite of TCE, S-(1,2-
dichlorovinyl)-L-cysteine (DCVC), stimulates increased reactive oxygen species (ROS) 
generation (Hassan et al., 2016), pro-inflammatory response (Hassan et al., 2016), and apoptosis 
in the human placental extravillous trophoblast HTR-8/SVneo cell line (Elkin et al., 2018). 
Exposure of pregnant rats to TCE (480 mg/kg/day) decreased fetal weight at gestational day 
(GD) 16 (Loch-Caruso et al., 2019). Additionally, TCE exposure increased expression of 
oxidative stress markers in placenta of rats in the latter study (Loch-Caruso et al., 2019). 
Despite epidemiological studies associating TCE exposure with adverse pregnancy 
outcomes and toxicological findings suggesting mechanisms by which TCE may contribute to 
adverse pregnancy outcomes, understanding of the molecular mechanisms by which TCE 
exposure could lead to adverse pregnancy outcomes remains incomplete. A consideration of a 
mechanism by which TCE exposure may be toxic is through alteration of metabolites in amniotic 
fluid, the fluid that bathes the fetus during development. Metabolites in amniotic fluid have not 
been studied before in the context of TCE or other environmental exposures. However, alteration 
of amniotic fluid metabolites by environmental exposures could be relevant for pregnancy 
health. 
Ample evidence indicates that the content of amniotic fluid is critical to pregnancy 
health. Decreased abundance of multiple amino acids, including leucine, valine, methionine, 
tyrosine, and phenylalanine, were found in amniotic fluid of third trimester versus second 
trimester patients (Orczyk-Pawilowicz et al., 2016), which highlights the dynamic nature of 
amino acids in amniotic fluid as pregnancy progresses. Recent studies reported that changes in 
the concentration of energy metabolism metabolites in amniotic fluid were associated with 
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preterm birth and other adverse pregnancy outcomes. These associations include decreased 
amino acids (though increased glutamate), inositol, and pyruvate in second-trimester amniotic 
fluid in the cases of preterm delivery (Virgiliou et al., 2017). Similarly, Romero et al. found a 
decrease in several amino acids (alanine, proline, glycine, glutamine), several altered 
carbohydrates, and altered fatty acids (increased oleic acid, decreased palmitic acid, stearic acid, 
and succinic acid) in amniotic fluid from mid- to late-gestation of preterm delivery cases without 
infection (Romero et al., 2010). Likewise, Graca et al. found decreases in many amino acids, 
glucose, citrate, and α-oxoisovalerate in amniotic fluid from gestational weeks 16-22 of preterm 
birth cases (Graca et al., 2013). Additional studies using amniotic fluid from additional 
gestational time points and using biofluids not limited to amniotic fluid to explore the 
associations between biofluid metabolites and preterm birth are described in a recent review (Gil 
and Duarte, 2018). 
Changes in aforementioned energy metabolism metabolites are highly relevant to markers 
of pregnancy health, including ROS generation, pro-inflammatory response, and apoptosis, in 
placental cells. For example, oleic acid pre-exposure of placental explants decreases IL-6 
production (Melody et al., 2015). Additionally, palmitic acid stimulates IL-6 and IL-8 production 
in Swan 71 placental cells in a caspase-3 and ROS-dependent manner (Shirasuna et al., 2016). 
Furthermore, oxidative stress decreases neutral amino acid uptake in BeWo placental cells 
(Araujo et al., 2013). Importantly, in addition to DCVC as a stimulator of ROS, pro-
inflammatory (Hassan et al., 2016), and apoptotic responses in placental cells (Elkin et al., 
2018), DCVC also stimulates alterations in energy metabolism metabolites in placental cells 
(Elkin et al., 2020a). Moreover, because ROS, pro-inflammatory response, and apoptosis have 
relevance to adverse pregnancy outcomes (Al-Gubory et al., 2010; Sharp et al., 2010; 
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McCullough et al., 2017; Garcia-Flores et al., 2018) and are modifiable by DCVC (Hassan et al., 
2016; Elkin et al., 2018), increased possibility exists that changes in metabolites caused by TCE 
may be relevant to pregnancy.    
In the present study, we hypothesize that TCE exposure changes amniotic fluid 
concentrations of at least several metabolites that have relevance to pregnancy outcomes, 
focusing on specific portions of energy metabolism pathways altered by TCE. By analyzing 
metabolite concentrations in amniotic fluid in a pregnant Wistar rat model of fetal weight 
restriction, we assessed how TCE exposure alters outcomes with relevance to metabolites in 
energy metabolism and their relevance to pregnancy outcomes. 
Materials and Methods 
Timed-pregnant Wistar rats  
Timed-pregnant Wistar rats were purchased from Charles River Laboratories (Portage, 
MI) and are a subset of the rats used in Chapter 2. The rats were transported to the University of 
Michigan School of Public Health animal facility on GD 2, with GD 0 designated as day of 
copulation. Rats used in this study weighed between 140 and 222 grams on GD 3, the first day 
the rats were weighed. Rats were individually housed in a 12-hour light/dark cycle controlled 
environment and fed standard rat chow (Purina 5001) and water ad libitum.  
Exposures of timed-pregnant Wistar rats 
Rats were exposed to trichloroethylene (TCE) (480 mg/kg/day) pipetted onto a vanilla 
wafer, an exposure method developed by Seegal et al. (Seegal et al., 1997). Control rats received 
vanilla wafer alone. The TCE dosage of 480 mg/kg/day was chosen because similar dosages 
induce oxidative stress in rats, and 480 mg/kg/day is within an order of magnitude of the United 
States Occupational Safety and Health Administration Permissible Exposure Level (PEL) for 
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TCE (Agency for Toxic Substances and Disease Registry, 2007). The dosing regimen is shown 
in Figure 3.1, with GD 16 as the day of euthanasia and tissue collection. These animals were a 
subset of a larger study (Chapter 2). 
Amniotic fluid collection 
 After euthanasia, the uterine horn of a pregnant rat was excised, and the amniotic fluid 
was withdrawn using a needle and syringe. Amniotic fluid samples were snap frozen in liquid 
nitrogen immediately and stored at -80°C until delivery on dry ice to the University of Michigan 
Metabolomics Core. Amniotic fluid samples were analyzed from one male and one female fetus 
from each of four dams per treatment for a total of 16 amniotic fluid samples. 
Fetal sex determination 
 Fetal sex was determined through qRT-PCR of placental tissue for the Sry gene. Both 
genomic DNA (gDNA) and RNA were extracted from the placentae. For all samples in this 
study, fetal sex for our samples was confirmed through both messenger RNA and gDNA. For 
RNA extraction, placental tissue was stored in RNA later (Qiagen, Germantown, MD) at 4°C 
overnight, then archived at -80°C without RNA later. To extract RNA, we used the RNeasy Plus 
Mini kit (Qiagen, Germantown, MD) according to the manufacturer’s instructions coupled with 
use of a FastPrep-24 tissue and cell lyser (MP Biomedicals, Solon, OH) prior to the gDNA 
elimination step. For DNA extraction, placental tissue was snap frozen in liquid nitrogen then 
stored at -80°C. DNA was extracted using the NucleoSpinTM Tissue kit (Machery-Nagel, 
Bethlehem, PA) according to the manufacturer’s instructions. Concentration and purity of all 
nucleic acids were verified using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA). Primer sequences for sex-determining region Y (Sry) and beta-2 
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microglobulin (B2m) (used as a reference gene) are listed in Table S3.1. Reactions and 
conditions for running and analyzing qRT-PCR are previously described (Chapter 2). 
Metabolomics analysis using the tricarboxylic acid plus targeted platform: Sample 
preparation, LC-MS analysis, and data processing  
A 100-µL aliquot of amniotic fluid was transferred to a microtube, and 0.5 mL of a 
mixture of methanol, chloroform and water (8:1:1) containing isotope-labeled internal standards 
was added. The mixture was vortexed briefly. Samples were allowed to rest at 4°C for 10 
minutes, vortexed a second time, and then centrifuged at 4° C, 14,000 rpm for 10 minutes. The 
extract was transferred to autosampler vials for mass spectrometry analysis. Aliquots of 10 µL 
were pooled for each sample and treated identically to individual samples, and the pooled extract 
was analyzed along with the individual samples for quality control purposes. Calibration 
standards were prepared and analyzed along with samples to quantify metabolites. 
LC-MS analysis was performed on an Agilent system consisting of a 1260 UPLC module 
coupled with an 6520 Quadrupole-Time-of-flight  (QTOF) mass spectrometer (Agilent 
Technologies, Santa Clara, CA). Metabolites were separated on a 150 x 1 mm Luna NH2 
hydrophilic interaction chromatography column (Phenomenex, Torrance, CA) using 10 mM 
ammonium acetate in water, adjusted to pH 9.9 with ammonium hydroxide, as mobile phase A, 
and acetonitrile as mobile phase B. The flow rate was 0.075 mL/min and the gradient was linear 
20% to 100% mobile phase A over 15 minutes, followed by isocratic elution at 100% mobile 
phase A for 5 minutes. The system was returned to starting conditions (20% mobile phase A) in 
0.1 minute and held there for 10 minutes to allow for column re-equilibration before injecting 
another sample. The mass spectrometer was operated in ESI negative mode according to 
previously published conditions (Lorenz et al., 2011). 
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Data were processed using MassHunter Quantitative analysis version B.07.00. 
Metabolites in the glycolysis, tricarboxylic acid (TCA), and pentose phosphate pathways were 
normalized to the nearest isotope-labeled internal standard and quantitated using two replicated 
injections of 5 standards to create a linear calibration curve with high accuracy. These 
compounds were reported in absolute micromolar concentrations. Other compounds in the 
analysis were normalized to the nearest internal standard, and the peak areas were used for 
differential analysis between groups. These latter compounds were reported in units of relative 
response. 
Metabolomics analysis using the short chain fatty acid targeted platform: Sample preparation, 
GC-MS analysis, and data processing 
An aliquot of 50 µL of amniotic fluid was transferred to a 15x75 mm glass tube and 
diluted to 100 µL with 50 µL HPLC grade H2O. An aliquot of 200 µL of a solution of 30 mM 
hydrochloric acid plus isotopically-labeled acetate (150 µM), butyrate (10 µM), and hexanoate (2 
µM) in water was added to each sample, and then mixed on a vortex mixer for 10 seconds. An 
aliquot of 300 µL of methyl tert-butyl ether (MTBE) was added to each sample, mixed for 10 
seconds to emulsify, held at 4°C for 5 minutes, and then mixed again for 10 seconds. Samples 
were centrifuged for 1 minute to separate the solvent layers and the MTBE layer was then 
removed to an autosampler vial for gas chromatography-mass spectrometry (GC-MS) analysis. 
An aliquot of 10 µL of MTBE was removed from each sample and pooled in a separate 
autosampler vial for quality control purposes. A series of calibration standards were prepared and 
analyzed along with samples to quantify metabolites. 
GC-MS analysis was performed on an Agilent 69890N GC -5973 MS detector with the 
following parameters: a 1-µL sample was injected with a 1:10 split ratio on a ZB-WAXplus, 30 
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m x 0.25 mm x 0.25 µm (Phenomenex Cat#7HG-G013-11) GC column, with He as the carrier 
gas at a flow rate of 1.1 mL/minute. The injector temperature was 240°C, and the column 
temperature was isocratic at 310°C. 
Data were processed using MassHunter Quantitative analysis version B.07.00. SCFAs 
were normalized to the nearest isotope labeled internal standard and quantitated using two 
replicated injections of 5 standards to create a linear calibration curve with high accuracy. 
Pathway analysis 
 Pathway analysis was performed using Metaboanalyst 4.0 (Chong et al., 2018; Chong et 
al., 2019) and the Rattus Norvegicus (81) selected for the pathway library. All pathways 
analyzed are stated to be directly in the KEGG database. Additional choices made within the 
program were as follows: Pathway enrichment analysis (global test as opposed to global 
ANCOVA); and pathway topology analysis (relative between-ness centrality as opposed to out-
degree centrality). Data were generalized log-transformed prior to analysis. 
Enrichment analyses 
 Enrichment analyses for location and drug pathway were performed using Metaboanalyst 
4.0 (Chong et al., 2018; Chong et al., 2019). These analyses were not specific to a species. The 
library for the location enrichment analysis contained 73 metabolite sets pertaining to organ, 
tissue, or subcellular localization. The library for the drug pathway enrichment analysis 
contained 461 metabolite sets pertain to drug pathways. Data were generalized log-transformed 
prior to analysis. 
Statistical analysis 
 An unpaired student’s two-tailed t-test was used to assess changes in metabolite 
concentrations in response to TCE exposure for males and females. Results from this analysis 
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were most consistent with the results obtained via pathway analysis in which data were split into 
female and male prior to analysis (i.e., correlation of p-value representing degree of change of a 
particular metabolite corresponding to p-value magnitude of a particular pathway in which the 
metabolite is important). With the exception of data involving ratios (fold-change data and data 
of ratios between two metabolites), which were computed based on the processed data for 
accuracy, all processed data were generalized log-transformed prior to any analysis given the 
non-Gaussian distribution of the concentrations and relative responses from the processed data.  
Pathway and enrichment analyses were conducted using Metaboanalyst 4.0 (Chong et al., 2018; 
Chong et al., 2019) as described in previous sections. With the exception of the analysis 
performed by Metaboanalyst 4.0, which automatically computed p-values, statistical analyses 
were performed using GraphPad Prism 7.0 (GraphPad Software, Inc.; San Diego, CA, USA). For 
all analyses, a p<0.05 was considered statistically significant. P-values computed by 
Metaboanalyst 4.0 were adjusted for multiple comparisons (Chong et al., 2019) and were similar 
in magnitude to those computed by GraphPad Prism 7.0. 
Results 
Quantity of metabolites detected 
A total of eight metabolites were detected with the short chain fatty acid (SCFA) 
platform, and 71 metabolites were detected with the tricarboxylic acid (TCA) plus platform. 
Each of the following sets of metabolites was detected as an aggregate (i.e., within the set, it was 
not possible to distinguish one from the other): (1) 2-phosphoglycerate and 3-phosphoglycerate, 
(2) citrate and isocitrate, (3) fructose 6-phosphate and glucose 6-phosphate, (4) glucose (hexose, 
etc.), (5) ribose 5-phosphate and xylulose 5-phosphate. Each of these sets was considered as one 
metabolite in the calculation of total detected metabolites. Additionally, because pathway and 
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enrichment analyses could not assign such aggregated metabolites to a specific compound, the 
aforementioned sets were excluded from those analyses. Detected metabolite concentrations or 
relative responses are listed in Table S3.2. 
Metabolites in the amniotic fluid altered by TCE exposure 
 Consistent with the pathway analysis restriction to two-group comparisons, we compared 
the control and TCE-exposed amniotic fluid results separately for each fetal sex (Figures 3.2 
and 3.3). TCE exposure significantly altered the abundance of some metabolites, and statistically 
significant changes were generally associated with a high degree of fold-change (Figure 3.2). 
Most statistically significant alterations were decreases. There was some overlap in the 
metabolites decreased by TCE in amniotic fluid of male fetuses versus female fetuses, but there 
were also metabolites decreased in only one sex (Figure 3.3). Of the 79 total metabolites, seven 
were changed in males in response to TCE exposure, and all of these changes were decreases. 
For females, we detected changes in response to TCE exposure for eight of the 79 total 
metabolites, and six of the changes were decreases. There were five metabolites that were 
decreased for both males and females (Figure 3.3). The metabolite p-values and fold-change in 
response to TCE treatment are listed in Table S3.3, with metabolites altered by TCE in one or 
both sexes listed first. 
Associations between TCE-stimulated effects on male versus female amniotic fluid 
 Because some changes stimulated by TCE were detected in amniotic fluid from male 
fetuses but not amniotic fluid from female fetuses, and vice versa, we analyzed for association of 
TCE-induced changes in metabolite concentrations between male and female amniotic fluid 
samples (Figure 3.4). In comparison of fold-change of individual metabolite abundances 
stimulated by TCE in male amniotic fluid samples versus female amniotic fluid samples, a 
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significant association was observed (p=0.0427 for Spearman correlation), indicating that there 
was modest association between changes observed in males and females. As depicted in Figure 
3.4, some metabolites decreased by TCE in males and females (e.g., adenosine diphosphate 
(ADP) and adenosine triphosphate (ATP)), which appear in the lower left quadrant of the graph 
and contributed to the positive slope of the best-fit line for the data points, likely drove the 
associations. 
Analysis of pathways altered in male amniotic fluid samples 
 A total of 54 pathways were able to be analyzed by Metaboanalyst 4.0 from our input 
data, as shown in Figure 3.5. Three pathways were statistically altered by TCE treatment for 
male amniotic fluid samples (p<0.05). The three pathways were folate biosynthesis, pentose 
phosphate pathway, and riboflavin metabolism (p=0.015162, 0.019209, 0.022343, respectively). 
However, the importance of the metabolites detected in these pathways was small (pathway 
impacts of 0.08974, 0.18522, and 0, respectively), meaning that the changes were not at crucial 
portions of the pathway despite detection of statistical significance for the pathways. The lowest 
p-value seen with a pathway impact greater than 0.02 was 0.0835 in the case of the fatty acid 
elongation pathway. At the other end of the spectrum, the pathway impact associated with the 
phenylalanine, tyrosine, and tryptophan biosynthesis pathway was 1.0 with an associated p-value 
of 0.6071. 
Analysis of pathways altered in female amniotic fluid samples 
 For the female amniotic fluid samples, 54 total pathways were able to be analyzed from 
our input data as shown in Figure 3.5, similar to male amniotic fluid samples. Four out of 54 of 
the pathways were statistically altered by TCE treatment (p<0.05). Riboflavin metabolism 
(p=0.0269), pentose phosphate pathway (p=0.0310), folate biosynthesis (p=0.0410), and 
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nicotinamide metabolism (p=0.0436) were those four pathways. The pathway impacts for each of 
these four pathways were low (impacts of 0, 0.1852, 0.0897, and 0, respectively), and, in general, 
few metabolites within each of those pathways were measured. The fifth lowest p-value for a 
pathway was 0.1866, the pathway for purine metabolism, and the corresponding pathway impact 
was 0.3604. Similar to males, the phenylalanine, tyrosine, and tryptophan biosynthesis pathway 
had an associated pathway impact of 1.0 for the female amniotic fluid data, but the 
corresponding p-value was 0.38317. 
Analysis of ratios between two metabolites to infer at specific portions of pathways impacted 
 Ratios between metabolites were calculated to infer specific portions of a pathway or 
additional measures of biological importance that could be affected by TCE treatment. Ratios of 
a metabolite near the beginning of a pathway to a metabolite near the end of the pathway were 
also calculated to assess overall change (i.e., could subtleties in specific portions of a pathway 
lead to a cumulative change). Lists of the ratios measured and whether or not they were 
significantly changed by TCE treatment are shown in Tables S3.4 through S3.8, and Figures 
3.6 through 3.14 display pathways with corresponding metabolite ratios that had statistical 
significance for at least one sex. For the males, 11 out of 81 total ratios calculated were altered 
by TCE treatment (p<0.05). 
 A similar analysis of metabolite ratios that had been performed for males was also 
performed for females (also included in Tables S3.4 through S3.8). Similar to the males, 10 out 
of 81 ratios were altered by TCE treatment for females (p<0.05). Five of the ratios were common 
between the males and females: (1) arginine to creatine (Figure 3.6B), (2) phosphocreatine to 
adenosine triphosphate (ATP) (Figure 3.8B), (3) creatine to ATP (Figure 3.8C), (4) creatine to 
adenosine diphosphate (ADP) (Figure 3.8E), and (5) gluconate to 6-phosphogluconate (6PG) 
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(Figure 3.12B). Each of the TCE-altered metabolite ratios were in the same direction for both 
sexes. 
Amino acid metabolism as impacted by TCE exposure (ratio analysis) 
 Within amino acid metabolism pathways, several metabolite ratios in the arginine and 
proline metabolism pathway were altered in response to TCE treatment (Figure 3.6, Table 
S3.4). These included an increase in the arginine to creatine ratio for males and females (28.8% 
and 26.3% increase, respectively; p=0.0491 and 0.0147, respectively) (Figure 3.6B) and an 
increase in the arginine to citrulline ratio for females only (67.1% increase, p=0.0345) (Figure 
3.6C). Relevant to two amino acid pathways (Figures 3.7A and 3.7B), the phenylpyruvate to 
phenylalanine ratio was decreased in females only (10.9% decrease, p=0.0335) (Figure 3.7C, 
Table S3.4). 
 Further downstream within the arginine and proline metabolism pathway, ratio analysis 
for the phosphocreatine, ATP shuttling system (Figure 3.8, Table S3.4) indicated many more 
changes in response to TCE exposure. Ratios analyzed in regard to the phosphocreatine, ATP 
shuttling system included (1) phosphocreatine to ATP (Figure 3.8B), (2) creatine to ATP 
(Figure 3.8C), (3) phosphocreatine to ADP (Figure 3.8D), (4) creatine to ADP (Figure 3.8E) 
and (5) phosphocreatine to creatine (Figure 3.8F). For females, all five of these ratios were 
altered in response to TCE exposure, and three out of five of these ratios were altered in response 
to TCE exposure for males. The direction of alteration indicates the increase of phosphocreatine 
and creatine in comparison to ATP and ADP. The largest fold-change and smallest p-value 
observed for males came with the creatine to ADP ratio (135.2% increase and p=0.0058 in 
response to TCE) (Figure 3.8E). For the females, the smallest p-value was associated with the 
creatine to ATP ratio (121.2% increase, and p=0.0023) (Figure 3.8C) and the largest fold-
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change was associated with the phosphocreatine to ADP ratio (380.4% increase, and p=0.0234) 
(Figure 3.8D). 
Purine and pyrimidine metabolism as impacted by TCE exposure (ratio analysis) 
 Despite the TCE-induced changes observed with adenosine triphosphate (ATP), 
adenosine diphosphate (ADP), guanosine triphosphate (GTP), and guanosine diphosphate 
(GDP), only one ratio calculated with relevance to purine or pyrimidine metabolism was altered 
by TCE exposure (Figure 3.9, Table S3.5). The only ratio significantly altered by TCE was GTP 
to GDP, which was decreased 15.4% in the males (p=0.0208) (Figure 3.9B). No ratios detected 
within the purine or pyrimidine metabolic pathways were altered for the females. 
Glycolysis, tricarboxylic acid (TCA) cycle, pentose phosphate pathway, and pyruvate 
metabolism as impacted by TCE exposure (ratio analysis) 
 To understand impacts of TCE exposure on specific portions of pathways within 
glycolysis, TCA cycle, pentose phosphate pathway, and pyruvate metabolism, we calculated 
ratio of metabolites within each of those pathways (Figures 3.10, 3.11, 3.12, 3.13, and Table 
S3.6). Within the glycolysis pathway (Figure 3.10 and Table S3.6), the only significant 
alteration was a 167.0% increase in males only of the ratio of glucose 6-phosphate and fructose 
6-phosphate (early in glycolysis) to acetyl coenzyme A (late in glycolysis) (p=0.0322) (Figure 
3.10B). This ratio was used to understand if glycolysis as a whole was being affected by TCE 
treatment. 
 Relevant to the TCA cycle (Figure 3.11 and Table 3.6), TCE treatment decreased the 
acetyl coenzyme A to citrate and isocitrate ratio in males by 67.2% (p=0.0411) (Figure 3.11B). 
TCE treatment also increased the citrate and isocitrate to malate ratio, a ratio used to assess 
overall change, in females by 28.1% (p=0.0206) (Figure 3.11C). Moreover, TCE treatment 
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decreased the acetyl coenzyme A to malate ratio in males by 65.3% (p=0.0387) (Figure 3.11D), 
which also has relevance to the pyruvate metabolism pathway. 
For the pentose phosphate pathway (Figure 3.12 and Table 3.6), TCE treatment 
increased the gluconate to 6-phosphogluconate ratio in males and females by 58.4% and 73.5%, 
respectively (p=0.0047 and 0.0166, respectively) (Figure 3.12B). In addition, TCA treatment 
increased the glucose 6-phosphate and fructose 6-phosphate to 6-phosphogluconate ratio and the 
glyceraldehyde 3-phosphate to erythrose-4-phosphate ratio in males only by 81.1% and 53.7%, 
respectively (p=0.0310 and 0.0017, respectively) (Figures 3.12C and 3.12D, respectively). The 
acetyl coenzyme A to malate ratio previously discussed is also relevant to the pyruvate 
metabolism pathway (Figure 3.13 and Table 3.6). No other ratios calculated within pyruvate 
metabolism were significantly changed by TCE treatment for either sex. 
Additional metabolite ratios and pathways as impacted by TCE exposure 
 Table S3.7 contains the ratios calculated with relevance to glutathione metabolism. As 
shown in Table S3.8, some additional ratios between metabolites were calculated. However, 
none of these metabolite ratios were altered by TCE exposure for males and females. In the case 
of the folate biosynthesis pathway (Figure 3.14) that had significant p-values from 
Metaboanalyst 4.0 pathway analysis (p=0.0152 and 0.0410 for males and females, respectively), 
guanosine triphosphate (GTP) was the only metabolite detected in the pathway. GTP was 
decreased in males but not females in response to TCE treatment (by 31.6%, p=0.0344) (Figure 
3.14B). Because GTP was the only metabolite detected in the folate biosynthesis pathway, it was 
not possible to perform analysis of metabolite ratios within that pathway. 
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Short chain fatty acid (SCFA)-specific analysis  
 Given the importance of individual and total SCFAs in pregnancy (Priyadarshini et al., 
2014; Gray et al., 2017), we performed analyses specific to SCFAs. Consistent with analyses 
performed specifically for SFCAs (Demehri et al., 2016), we investigated TCE effects on total 
SCFA concentration and the contribution of each SCFA to total SCFA by experimental group 
(Figure S3.1). In our amniotic fluid samples, total SCFA concentration (consisting of the total of 
acetate, propionate, butyrate, isovalerate, valerate, hexanoate, heptanoate, and octanoate 
concentrations) was not altered by TCE treatment for either males or females. However, an 
unexpected finding was the substantial contribution of acetate to total SCFA concentration for all 
our experimental groups. Specifically, acetate contributed an average of 89.7%, 87.2%, 87.1% 
and 89.5% of SCFAs for the control male, control female, TCE male, and TCE female 
experimental groups, respectively. These values are high compared to other studies looking at 
composition of acetate relative to other SCFAs (Weaver et al., 1988; den Besten et al., 2013; den 
Besten et al., 2014; Demehri et al., 2016; Hashemi et al., 2017). 
Enrichment analysis to analyze organs, tissues, or subcellular structures affected by TCE 
exposure 
 For both male and female samples, our input data allowed for the analysis of 30 organs, 
tissues, or subcellular structures as impacted by TCE based on the TCE effects on metabolites 
(Tables S3.9 and S3.10). For males (Table S3.9), only the thyroid gland was statistically 
significant (p=0.0361); the second lowest p-value was 0.0598 in the case of endoplasmic 
reticulum. Interestingly, placenta had a p-value of 0.3220. For females (Table S3.10), only the 
gonad achieved statistical significance (p=0.0454), and the second lowest p-value was 0.0870 for 
skin. Placenta had the highest p-value (ranked 30/30) in this set at p=0.7912. 
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Enrichment analysis to analyze drug pathways altered by TCE exposure 
 Our input data of metabolites led to 352 drug pathways analyzed for statistical 
significance for both male and female samples based on the TCE effects on metabolites (Tables 
S3.11 and S3.12). For males (Table S3.11), 243 drug pathways had a p<0.05. The lowest p-
value associated with a drug pathway was 0.00014, which was for the acetaminophen 
metabolism pathway. The following eight pathways tied for the second lowest p-value (0.00019): 
codeine action pathway, etoposide action pathway, etoposide metabolism pathway, irinotecan 
action pathway, irinotecan metabolism pathway, morphine action pathway, mycophenolic acid 
metabolism pathway, and tramadol metabolism pathway. For females (Table S3.12), 244 drug 
pathways had a p<0.05. Four pathways were tied for the lowest p-value in this data set (0.0014); 
these pathways were the glibenclamide action pathway, the gliclazide action pathway, the 
nateglinide action pathway, and the repaglinide action pathway. 
Discussion 
 
 The current study, using a pregnant rat model, is the first to our knowledge to investigate 
amniotic fluid metabolomics with a known environmental exposure, trichloroethylene (TCE). 
Changes in the abundance of metabolites, including amino acids and sugars, in amniotic fluid 
have been associated with preterm birth in humans (Romero et al., 2010; Menon et al., 2014; 
Huang et al., 2017; Virgiliou et al., 2017; Gil and Duarte, 2018). Although these human studies 
provide supportive evidence that amniotic fluid metabolite composition is important to 
pregnancy, such studies are often challenged by the lack of environmental exposure data, 
requiring inferences as to potential environmental causes of the altered metabolites in amniotic 
fluid. Thus, the current study addresses a knowledge gap by investigating TCE-stimulated 
outcomes that may be relevant to pregnancy health.  
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Metabolites altered in amniotic fluid by maternal exposure to TCE 
We have shown that TCE exposure in pregnancy modified metabolite concentrations in 
the amniotic fluid of Wistar rats. The changes in amniotic fluid metabolite concentrations were 
different depending upon the sex of the placenta and fetus. Some metabolites were altered for 
female only, some were altered for male only, and some were altered in both sexes. Interestingly, 
the majority of alterations were decreases in response to TCE exposure, with only two increases 
observed in females only. Purine multi-phosphates, e.g., guanosine triphosphate (GTP), 
guanosine diphosphate (GDP), adenosine triphosphate (ATP), and adenosine diphosphate (ADP), 
were altered by TCE exposure, highlighting TCE alteration of the amniotic fluid energy supply. 
The finding that TCE decreased GDP, ATP, and ADP in both sexes and GTP in males 
only is generally consistent with other studies that investigated TCE effects on the purine multi-
phosphate metabolites. In kidney cells, a metabolite of TCE, S-(1,2-dichlorovinyl)-L-cysteine 
(DCVC), decreases ATP levels, albeit at relatively high concentrations (Lash and Anders, 1986; 
Lash and Anders, 1987). It is noteworthy that the DCVC effect in the latter study occurred 
intracellularly whereas the TCE-induced change in the present study occurred extracellularly in 
the amniotic fluid. Mapping the relevance of this extracellular change to an intracellular change 
is a worthy future direction that may be accomplished by fluxomics not limited to amniotic fluid. 
A study showed that TCE increases Rho GDP-dissociation inhibitor 1 in human L-02 liver cells 
(Liu et al., 2007), suggesting a potential upstream mechanism by which TCE exposure may 
impact purine multi-phosphates. Additional experiments beyond the scope of the present study 
will be required to advance understanding of the mechanism and relevance to pregnancy. 
Furthermore, deciphering mechanisms by which altered multi-phosphates do not impact amino 
acid abundance, which is generally observed in the current study, remain currently unknown. 
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Arginine and proline metabolism as modified by TCE exposure 
An interesting finding from the analysis of metabolite ratios was the impact of TCE on 
arginine and proline metabolism. Multiple ratios with relevance to arginine and proline 
metabolism were altered by TCE, with more alterations in the females than the males. According 
to the KEGG pathway for rats, three metabolites of arginine include citrulline, ornithine, and 
creatine (via upstream conversion to guanidinoacetic acid). Our data indicate that TCE exposure 
reduced the conversion of arginine to citrulline in the females and that the conversion of arginine 
to creatine was reduced in both sexes. Future experiments could focus on the impact of TCE on 
the enzymology in these steps or investigation of TCE exposure on guanidinoacetic acid itself. 
Another metabolite of arginine is N-(omega)-hydroxyarginine, which can be converted to nitric 
oxide. Nitric oxide is a vasodilator, and the role of L-arginine in vasodilation is the basis for its 
use as a treatment for preeclampsia (Aouache et al., 2018). By suppressing the metabolism of 
arginine into citrulline (females only) and creatine (both sexes), TCE may favor the metabolism 
of arginine into N-(omega)-hydroxyarginine. The impact of TCE on N-(omega)-hydroxyarginine 
and nitric oxide in amniotic fluid remain worthy future directions. 
Phosphocreatine shuttling as a phenomenon modified by TCE exposure 
Metabolite ratios within phosphocreatine shuttling (Meyer et al., 1984) were also 
discovered to be changed by TCE exposure. In both sexes, TCE stimulated an abundance of 
phosphocreatine and creatine relative to the adenosine multi-phosphates (ATP, ADP). The 
abundance of phosphocreatine is most pronounced in females. In regards to pregnancy, 
extracellular ATP decreases spiral artery remodeling and is known as a vasoconstrictor (Spaans 
et al., 2014a; Spaans et al., 2014b). A decreased phosphocreatine:ATP ratio, opposite to what 
occurred in both sexes seen in this study, has been investigated extensively in heart and is linked 
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to worsening energetics and lipotoxicity (Scheuermann-Freestone et al., 2003; Shivu et al., 
2010). Study of phosphocreatine shuttling also extends to many organs with high energy demand 
(e.g., brain and skeletal muscle) (Wallimann et al., 1992), similar to the demand experienced by 
a developing fetus. Prior studies on the implications to pregnancy of phosphocreatine shuttling 
mainly focus on creatine, which the placenta is capable of synthesizing (Ellery et al., 2017). For 
example, increased birthweight and birth length are associated with higher maternal urinary 
creatine (Dickinson et al., 2016). Additionally, creatine has been proposed to benefit the fetus, 
acting on multiple potential mechanisms that include acid-base balance, antioxidant defense, and 
protein synthesis (Dickinson et al., 2014). In totality, it would seem that the impact of TCE on 
the phosphocreatine shuttling system signals an adaptive response that would be beneficial for 
pregnancy. 
Glycolysis, tricarboxylic acid (TCA) cycle, pentose phosphate pathway, and pyruvate 
metabolism as altered by TCE exposure 
We detected sex-specific TCE-induced changes in the glycolysis, TCA cycle, pentose 
phosphate, and pyruvate metabolism pathways. Although few in number, several of the changes 
are notable. The overall conversion from acetyl coenzyme A to citrate and isocitrate (both 
upstream metabolites in TCA cycle) was increased in the case of males, whereas the conversion 
of citrate and isocitrate (early in TCA cycle) to malate (late in TCA cycle) was decreased in the 
case of females. Pregnancy progression is accompanied by increased production of energy via 
the TCA cycle (Lindsay et al., 2015), and our data within females suggest that hampered 
progression of the TCA cycle could partially explain the purine multi-nucleotide findings of 
decreased abundance. Whether that is manifest in abnormalities as pregnancy progresses further 
has yet to be seen. Because acetyl coenzyme A and malate are both involved in pyruvate 
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metabolism, it is plausible that other metabolites within pyruvate metabolism could be changed 
by TCE but were not detected in the current study. Examples of such metabolites include S-
acetyldihydrolipoamide-E, pyruvate, and oxaloacetate (Figure 3.13). 
The ratio of gluconate to 6-phosphogluconate was increased by TCE in both sexes, which 
is interesting because of the importance of both metabolites in the pentose phosphate pathway. 
Gluconate is converted to 6-phosphogluconate via gluconokinase (Cohen, 1951). In light of our 
finding, the effect of TCE on gluconokinase in tissues surrounding amniotic fluid (e.g., placenta 
or fetus) is a topic of worthy consideration and could be relevant to pregnancy given that 
gluconokinase activity is detected in fetal rat and sheep (Ballard and Oliver, 1964). The 
concentration of 6-phosphogluconate was decreased in amniotic fluid of both sexes, as well. The 
impact of 6-phosphogluconate has scarcely been studied in the context of pregnancy. Future 
studies beyond the scope of the present study could explore whether the TCE-induced decrease 
in 6-phosphogluconate concentrations are detrimental for pregnancy outcomes. 
Folate biosynthesis as impacted by TCE exposure 
 Within the folate biosynthesis pathway, guanosine triphosphate (GTP) was the only 
metabolite detected. Because the TCE-stimulated change in GTP was a decreased concentration 
for males (p=0.0344) and approached statistical significance for females (p=0.0539), and 
because GTP is upstream in the folate biosynthesis pathway, a worthy future direction could be 
to detect metabolites downstream of GTP to see if this decrease persists for downstream 
metabolites such as folic acid, and to determine if both sexes are affected. Such future work is 
critical because folic acid is important to pregnancy and fetal development (Higgins and Mc 
Auliffe, 2010; Laanpere et al., 2010; Ly et al., 2016; Wen et al., 2016). If folic acid were to 
decrease in amniotic fluid to a larger extent for male fetuses compared to female fetuses with 
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maternal exposure to TCE, it could be possible that folic acid could serve as a mechanism by 
which TCE could be more deleterious to males than females, such as seen in Chapter 2 with fetal 
weights. 
Effects of TCE exposure on other amino acid metabolism pathways and other metabolite 
ratios 
 An additional metabolite ratio changed within amino acid metabolism pathways is the 
phenylpyruvate to phenylalanine ratio. This ratio represents consecutive metabolites in 
phenylalanine metabolism and phenylalanine, tyrosine, and tryptophan biosynthesis (Figure 
3.7). In females, TCE decreased phenylpyruvate relative to phenylalanine, an effect not seen in 
the males and relevant to pregnancy outcomes. Because decreased phenylalanine has been 
associated with preeclampsia (Bahado-Singh et al., 2012; Bahado-Singh et al., 2015), the 
direction of change produced by TCE in the present study could indicate a protective response 
against a pregnancy adverse outcome. It remains worthy to investigate if this response could 
explain the decreased susceptibility of female fetuses to TCE-induced decreased fetal weight 
compared to male fetuses, as reported in Chapter 2 in this dissertation. Additionally, because 
phenylalanine and phenylpyruvate are consecutive metabolites in the aforementioned amino acid 
pathways, it is plausible that TCE could target D-amino acid dehydrogenase (Olsiewski et al., 
1980) or L-amino-acid oxidase (Wellner and Meister, 1960a; Wellner and Meister, 1960b), both 
of which can convert phenylalanine to phenylpyruvate. 
 Our finding that purine multi-phosphates (e.g., ATP, GTP) were changed by TCE 
exposure but that ratios involving these metabolites were largely unchanged could have several 
explanations. Firstly, this could suggest that TCE exposure does not impact the enzymes 
involved in the conversion between the different purine phosphate species (e.g., CD39, CD73, 
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and alkaline phosphatase) (Spaans et al., 2014a), but rather that the changes in purine 
multiphosphate abundance more likely result from pathways that supply ATP or GTP such as the 
TCA cycle. Consistent with the latter explanation, we observed TCE-altered metabolite ratios 
within the TCA cycle of decreased acetyl coenzyme A to malate in males and increased citrate 
and isocitrate to malate in females. As a whole, it may be that TCE exposure diminishes the 
quantity of select metabolites within purine metabolism without impacting the pathway in 
totality. Additionally, the lack of TCE-stimulated changes we observed in metabolite ratios 
within pyrimidine metabolism in conjunction with the lack of significant changes in the 
metabolites themselves (e.g., uridine diphosphate and cytidine monophosphate) may indicate that 
TCE exposure is unlikely to use pyrimidine metabolism as a mechanism of toxicity.   
Analysis of effects of TCE exposure on short chain fatty acids (SCFAs) and composition 
 In our SCFA-specific analysis, our findings make sense in light of the functions of 
SCFAs. No SCFAs individually or in totality were changed in response to TCE exposure, 
suggesting that TCE does not alter SCFAs as a mechanism of toxicity relevant to adverse 
pregnancy outcomes. A prior epidemiological study associated the abundance of SCFAs in 
maternal serum with pregnancy outcomes, including newborn weight and length (Priyadarshini 
et al., 2014), supporting the relevance of SCFAs to pregnancy. Regardless, the composition of 
SCFAs in the amniotic fluid at the time of rat euthanasia in each of our treatment groups was 
striking. Acetate contributed to nearly 90% of total SCFA composition for all experimental 
groups. Although these values are higher than previously published reports of acetate 
composition of SCFAs (Weaver et al., 1988; den Besten et al., 2013; den Besten et al., 2014; 
Demehri et al., 2016; Hashemi et al., 2017), the high percentage of acetate makes sense in the 
light of the purpose of amniotic fluid during pregnancy. Specifically, acetate is known to be 
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produced during fasting, regulates energy homeostasis, contributes to heat production, and its 
metabolism is predictive of lifespan (Shimazu et al., 2010; Schonfeld and Wojtczak, 2016). With 
respect to pregnancy, acetate provision to mother during pregnancy protects mouse offspring 
from airway disease later in life (Thorburn et al., 2015). Thus, our finding that acetate is highly 
abundant compared to other SCFAs in amniotic fluid suggests that acetate may serve an 
important function. 
Limitations and benefits of use of pathway analysis and enrichment analyses as use for 
studying TCE-stimulated changes in amniotic fluid 
 A limitation to the current study is that a few inputs into the analyses done on 
Metaboanalyst 4.0 were not able to be mapped into the pathway and enrichment analysis. This 
applied for glyceraldehyde 3-phosphate and D-sedoheptulose 7-phosphate, in which the program 
matched its KEGG ID to one of its KEGG IDs but one that was not in the pathway itself. We 
tried other alternatives, including entry by KEGG ID as opposed to metabolite name, to attempt 
to successfully get all of the metabolites to match. Using the metabolite names as entry brought 
us closest to a match for each metabolite, with glyceraldehyde 3-phosphate and D-sedoheptulose 
7-phosphate, as mentioned previously, as the only metabolites that were not matched 
successfully. Therefore, the results presented with Metabolanalyst 4.0 (Pathway Analysis and 
Enrichment Analyses) have to be interpreted as if glyceraldehyde 3-phosphate or D-
sedoheptulose 7-phosphate were not measured at all. Additionally, because aggregates of 
metabolites (e.g., citrate versus isocitrate) could not be entered into pathway or enrichment 
analyses on Metaboanalyst 4.0, the results from these analyses have to be interpreted as if we 
have no knowledge about the aggregates, as well. Hence, to partially address these issues and 
also learn if specific regions of pathways were impacted, we manually selected and calculated 
109 
 
ratios of metabolites in specific pathways. However, the ability to decipher between different 
metabolites in an aggregate (e.g., citrate versus isocitrate) would aid interpretation and may 
contribute additional insights. Increasing the quantities of metabolites detected and standardizing 
to absolute concentrations remain outstanding important work. It is also possible that an increase 
in sample size could allow detection of additional significant metabolites. Finally, we cannot rule 
out possibility of contamination of other fluids with the amniotic fluid. 
 Nevertheless, Metaboanalyst 4.0 results provided insights in line with consequences 
important in pregnancy and literature on TCE exposure. Regarding enrichment analysis, TCE-
stimulated changes in male amniotic fluid could have implications to thyroid as an organ based 
on statistical significance. Possible explanations for this latter finding include pregnancy 
susceptibility to changes in thyroid-related metabolism (Lieutaud et al., 1999) and association of 
TCE exposure with benign thyroid disease (but not thyroid cancer) (Axelson et al., 1994; Lynge 
et al., 1997; Wingren and Axelson, 1997; Wartenberg et al., 2000; Lope et al., 2009). Similarly, 
TCE has been found to be toxic to ovaries (Henschler et al., 1980; Wu and Berger, 2007; Wu 
and Berger, 2008) and testes (Kumar et al., 2001; Forkert et al., 2002), consistent with our 
enrichment analysis finding that TCE-stimulated female amniotic fluid changes could have 
implications to gonads as a structure based on statistical significance. The enrichment analysis 
featuring drug metabolism pathways allowed for initial identification and hypotheses generation 
about how drug metabolism, such as acetaminophen metabolism, could be altered by TCE during 
pregnancy. Finally, as expected, Metaboanalyst 4.0 pathway analysis resulted in the 
identification of statistically significant KEGG pathways that involve metabolites changed by 
TCE exposure, such as GTP in the case of male amniotic fluid samples. 
110 
 
Conclusion 
 In summary, although TCE exposure did not elicit many changes with known relevance 
to adverse pregnancy outcomes, our data provide insight about potential mechanisms that could 
explain TCE toxicity in pregnancy. In general, we found that TCE exposure decreased purine 
multiphosphates (e.g., ATP, GTP, GDP), highlighting the impact of TCE on direct cellular 
energy supply that is critical for pregnancy health. Several molecules or metabolite ratios that 
were altered in amniotic fluid of one fetal sex but not the other also give indication about 
potential mechanisms by which female fetuses could be more resistant to TCE toxicity compared 
to males. Figure 3.15 depicts an overall level of change TCE could have through multiple 
energy metabolism pathways and shows the region around folate biosynthesis as worthy of 
further investigation. Importantly, the current study indicates that some changes stimulated by 
TCE have relevance to adverse pregnancy outcomes such as preeclampsia. Worthy future 
directions include understanding how some changes to specific portions of the pathways are 
related to other portions of the pathways, use of the discoveries in the current study to inform 
methods of modulating TCE toxicity possibly through enzyme modulation, and application of 
such techniques to other environmental contaminants of interest to evaluate how amniotic fluid 
could be receptive to change by toxicants beyond TCE. Finally, because some of the metabolite 
changes included amino acids that could be found in diet, such as arginine, the current study 
could also be suggestive of potential specific nutritional recommendations to modulate TCE-
stimulated toxicity. 
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Figure 3.1. Treatment schedule of the timed-pregnant Wistar rats used in the current 
study. With gestational day (GD) 0 designated as day of copulation, rats arrive on GD 2, are first 
trained to eat the vanilla wafer on GD 3, and are euthanized on GD 16. The following dosage of 
TCE was used: 480 mg/kg/day. These rats are a subset of the rats used in Chapter 2 of this 
dissertation. 
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Figure 3.2. Volcano plots displaying the negative[log10(p-value)] as a function of the 
log2(fold-change) for each individual metabolite displayed as dots in the control to TCE-
treated comparison for each sex. Individual graphs correspond to the display for the effect of 
TCE on (A) males and (B) females. Individual points correspond to individual metabolites 
detected, and the gold-dashed lines correspond to the threshold of p=0.05 (approximately where 
y=1.3 on each graph). 
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Figure 3.3. Summary of specific metabolites significantly altered by trichloroethylene in 
amniotic fluid for each sex. Metabolites highlighted in blue or red indicate metabolites 
increased or decreased, respectively, in response to TCE treatment. All metabolites in smallest 
font are p<0.05 for all associated control to TCE comparisons and metabolites in larger font are 
p<0.01 for one control to TCE comparison (in the case of ADP, p<0.01 for males while p<0.05 
for females; in the case of ATP, p<0.01 for females while p<0.05 for males). 
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Figure 3.4. Scatterplot showing association between males and females of metabolite fold-
changes in response to TCE. X and Y-axes are in units of log2(fold-change), and individual 
data points represent individual metabolites detected in amniotic fluid of male and female 
fetuses. Based on the visualization and Spearman correlation p-value, there is a modest 
association between the effects seen in males and effects seen in females. 
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Figure 3.5. Pathway analysis performed by Metaboanalyst 4.0 to reveal changes in KEGG 
pathways altered by trichloroethylene treatment in (A) males and (B) females. Pathway 
analysis (specific for Rattus norvegicus) was performed by Metaboanalyst 4.0 on the processed 
data as input into analysis. Generalized log-transformation was performed on the data prior to 
analysis to achieve normal distribution. Individual circles represent different KEGG pathways. 
The circle color corresponds to significance of the pathway (white to red in order of increasing 
significance) whereas circle size corresponds to pathway impact, which is calculated as the 
matched metabolites as a cumulative percentage contributing to total pathway importance. A 
horizontal yellow dashed line is put where negative(log(p))=3, which corresponds to a p=0.05 
under the loge (or ln) scale used in this analysis. 
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Figure 3.6. Arginine and proline metabolism as modified by trichloroethylene (TCE) 
treatment in male and female amniotic fluid. (A) Simplified depiction of the purine 
metabolism KEGG pathway in Rattus norvegicus. Metabolites underlined in red correspond to 
metabolites that are part of ratio altered by TCE treatment in both males and females. 
Metabolites underlined in dark gold correspond to metabolites that are part of a ratio altered by 
TCE in females only. Metabolites underlined in blue correspond to metabolites that were 
analyzed in ratio analysis but not altered by TCE treatment in any sex. Depiction of effects TCE 
treatment in males and females on (B) the arginine to creatine ratio and (C) the arginine to 
citrulline ratio. Graphs for the phosphocreatine to creatine ratio are in Figure 3.8F. Error bars 
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represent mean ± SEM. Statistical analysis for each sex consisted of a two-tailed unpaired t-test. 
N= 4 independent experiments. 
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Figure 3.7. Phenylalanine metabolism and phenylalanine, tyrosine, and tryptophan 
biosynthesis as modified by trichloroethylene (TCE) treatment in male and female amniotic 
fluid. Simplified depiction of the (A) phenylalanine metabolism KEGG pathway and (B) 
phenylalanine, tyrosine, and tryptophan biosynthesis pathway in Rattus norvegicus. Metabolites 
underlined in dark gold correspond to metabolites that are part of a ratio altered by TCE in 
females only. Metabolites underlined in blue correspond to metabolites that were analyzed in 
ratio analysis but not altered by TCE treatment in any sex. Depiction of effects TCE treatment in 
males and females on (C) phenylpyruvate to phenylalanine ratio. In the graphs, error bars 
represent mean ± SEM. Statistical analysis for each sex consisted of a two-tailed unpaired t-test. 
N= 4 independent experiments. 
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Figure 3.8. Phosphocreatine shuttling as modified by trichloroethylene (TCE) treatment in 
male and female amniotic fluid. (A) Simplified depiction of extracellular phosphocreatine 
shuttling. Metabolites underlined in red correspond to metabolites that are part of ratio altered by 
TCE treatment in both males and females. Metabolites underlined in blue correspond to 
metabolites that were analyzed in ratio analysis but not altered by TCE treatment in any sex. 
Depiction of effects TCE treatment in males and females on (B) the phosphocreatine to ATP 
ratio, (C) the creatine to ATP ratio, (D) the phosphocreatine to ADP ratio, (E) the creatine to 
ADP ratio, and (F) the phosphocreatine to creatine ratio. (F) is also relevant to Figure 3.6. In the 
graphs, error bars represent mean ± SEM. Statistical analysis for each sex consisted of a two-
tailed unpaired t-test. N= 4 independent experiments. Abbreviations: ATP, adenosine 
triphosphate; ADP, adenosine diphosphate. 
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Figure 3.9. Purine metabolism as modified by trichloroethylene (TCE) treatment in male 
and female amniotic fluid. (A) Simplified depiction of the purine metabolism KEGG pathway 
in Rattus norvegicus. Metabolites underlined in green correspond to metabolites that are part of 
ratio altered by TCE treatment in males only. Metabolites underlined in blue correspond to 
metabolites that were analyzed in ratio analysis but not altered by TCE treatment in any sex. 
Depiction of effects TCE treatment in males and females on (B) the GTP to GDP ratio. In the 
graphs, error bars represent mean ± SEM. Statistical analysis for each sex consisted of a two-
tailed unpaired t-test. N= 4 independent experiments. Abbreviations: IMP, inosine 
monophosphate; XMP, xanthine monophosphate; AMP, adenosine monophosphate; cAMP, 
cyclic AMP; ADP, adenosine diphosphate; ATP, adenosine triphosphate; RNA, ribonucleic acid; 
GDP, guanosine diphosphate; GTP, guanosine triphosphate; GMP, guanosine monophosphate; 
cGMP, cyclic GMP. 
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Figure 3.10. Glycolysis or gluconeogenesis as modified by trichloroethylene (TCE) 
treatment in male and female amniotic fluid. (A) Simplified depiction of the glycolysis or 
gluconeogenesis metabolism KEGG pathway in Rattus norvegicus. Metabolites underlined in 
green correspond to metabolites that are part of ratio altered by TCE treatment in males only. 
Metabolites underlined in blue correspond to metabolites that were analyzed in ratio analysis but 
not altered by TCE treatment in any sex. Depiction of effects TCE treatment in males and 
females on (B) G6P and F6P to aCoA ratio, (C) the 2PG and 3PG to PEP ratio, and (D) the PEP 
to aCoA ratio. In the graphs, error bars represent mean ± SEM. Statistical analysis for each sex 
consisted of a two-tailed unpaired t-test. N= 4 independent experiments. Abbreviations: G6P, 
glucose 6-phosphate; F6P, fructose 6-phosphate; aCoA or acetyl-CoA, acetyl coenzyme A; 2PG, 
2-phosphoglycerate; 3PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate. 
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Figure 3.11. Tricarboxylic acid (TCA) cycle as modified by trichloroethylene (TCE) 
treatment in male and female amniotic fluid. (A) Simplified depiction of the TCA cycle 
KEGG pathway in Rattus norvegicus. Metabolites underlined in red correspond to metabolites 
that are part of ratio altered by TCE treatment in both males and females. Metabolites underlined 
in green correspond to metabolites that are part of ratio altered by TCE treatment in males only. 
Metabolites underlined in blue correspond to metabolites that were analyzed in ratio analysis but 
not altered by TCE treatment in any sex. Depiction of effects TCE treatment in males and 
females on (B) the aCoA to CIT and ICIT ratio, (C) the aCoA to MAL ratio, and (D) the CIT and 
ICIT to MAL ratio. The aCoA to MAL ratio is also relevant to Figure 3.13. In the graphs, error 
bars represent mean ± SEM. Statistical analysis for each sex consisted of a two-tailed unpaired t-
test. N= 4 independent experiments. Abbreviations: aCoA or acetyl-CoA, acetyl coenzyme A; 
CIT, citrate; ICIT, isocitrate; MAL, malate. 
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Figure 3.12. Pentose phosphate pathway as modified by trichloroethylene (TCE) treatment 
in male and female amniotic fluid. (A) Simplified depiction of the pentose phosphate KEGG 
pathway in Rattus norvegicus. Metabolites underlined in red correspond to metabolites that are 
part of ratio altered by TCE treatment in both males and females. Metabolites underlined in 
green correspond to metabolites that are part of ratio altered by TCE treatment in males only. 
Metabolites underlined in blue correspond to metabolites that were analyzed in ratio analysis but 
not altered by TCE treatment in any sex. Depiction of effects TCE treatment in males and 
females on (B) the gluconate to 6PG ratio, (C) the G6P and F6P to 6PG ratio, and (D) the 
glyceraldehyde3P to E4P ratio. In the graphs, error bars represent mean ± SEM. Statistical 
analysis for each sex consisted of a two-tailed unpaired t-test. N= 4 independent experiments. 
Abbreviations: 6PG, 6-phosphogluconate; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; 
glyceraldehyde3P, glyceraldehyde 3-phosphate; E4P, erythrose 4-phosphate. 
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Figure 3.13. Pyruvate metabolism as modified by trichloroethylene (TCE) treatment in 
male and female amniotic fluid. (A) Simplified depiction of the pyruvate metabolism KEGG 
pathway in Rattus norvegicus. Metabolites underlined in green correspond to metabolites that are 
part of ratio altered by TCE treatment in males only. Metabolites underlined in blue correspond 
to metabolites that were analyzed in ratio analysis but not altered by TCE treatment in any sex. 
Graphs corresponding to the aCoA to MAL ratio are already depicted in Figure 3.11C. In the 
graphs, error bars represent mean ± SEM. Statistical analysis for each sex consisted of a two-
tailed unpaired t-test. N= 4 independent experiments. Abbreviations: aCoA or acetyl-CoA, acetyl 
coenzyme A; MAL, malate. 
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Figure 3.14. Folate biosynthesis as modified by trichloroethylene (TCE) treatment in male 
and female amniotic fluid. (A) Simplified depiction of the folate biosynthesis KEGG pathway 
in Rattus norvegicus. The metabolite underlined in green (GTP) corresponds to a metabolite that 
is decreased by TCE treatment in males but not females. No other metabolites in the pathway 
were detected. Depiction of effects TCE treatment in males and females on (B) GTP 
concentration. In the graphs, error bars represent mean ± SEM. Statistical analysis for each sex 
consisted of a two-tailed unpaired t-test. N= 4 independent experiments. Abbreviations: GTP, 
guanosine triphosphate. 
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Figure 3.15. The effect of trichloroethylene treatment on a simplified depiction of 
relationships among multiple KEGG metabolism pathways. Boxes indicate individual KEGG 
pathways, and unboxed text indicates critical metabolites that connect pathways. Red indicates 
metabolites or pathways altered in both sexes. Green indicates metabolites or pathways altered in 
males only. Dark gold indicates metabolites or pathways altered in females only. Blue indicates 
metabolites or pathways unaltered in either sex. Black indicates metabolites or pathways not 
detected in the current study. Metabolite concentrations or relative responses and Metabolanalyst 
4.0 pathway analysis results were used to determine metabolite and pathway significance, 
respectively. Dashed arrows indicate multi-step processes. Abbreviations: aCoA, acetyl 
coenzyme A; OAA, oxaloacetate; D-G1P, alpha-D-glucose 1-phosphate; UDP-Glu, uridine 
diphosphate-glucose; R5P, D-ribulose 5-phosphate; PRPP, phosphoribosyl pyrophosphate; FUM, 
fumarate; CP, carbamoyl phosphate, Gly-3P, glycerate 3-phosphate; Gly-2P, glycerate 2-
phosphate; D-Glyal-3P, D-glyceraldehyde 3-phosphate; D-G6P, alpha-D-glucose 6-phosphate; 
5-PRA, 5-phosphoribosylamine; Fru-6P, fructose 6-phosphate; GTP, guanosine triphosphate. 
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Table S3.1. Primer sequences used in the current study to identify the sex of the placental and 
fetal unit associated with the amniotic fluid. 
 
SRY (for both genomic DNA and cDNA input) 
Forward 5’-AAGCGCCCCATGAATGCAT-3’ 
Reverse 5’-CGATGAGGCTGATATTTATA-3’ 
Source: (Schulte et al. 2012) 
 
B2M (for cDNA input) – spans exon-exon junction 
Forward 5’-TCGTGCTTGCCATTCAGAAAAC-3’ 
Reverse 5’-GCAGTTGAGGAAGTTGGGCT-3’ 
Source: NCBI nucleotide database 
 
B2M (for genomic DNA input) – does not span exon-exon junction 
Forward 5’-CCCACCCTCATGGCTACTTC-3’ 
Reverse 5’-TGGGTGATGAAAACCGCACA-3’ 
Source: NCBI nucleotide database 
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Table S3.2. Concentrations or relative responses of detected metabolites. 
 
I. Short chain fatty acids (data expressed as µM) 
 
Acetate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 276.271982866701 257.708408521392 295.30353838664 250.80070608729 
 203.444027693933 287.245669109964 207.621963786731 275.111842611805 
 385.548239403696 342.078676637373 323.470485854764 364.93071275932 
 289.567058405092 220.008514460553 282.985171228317 188.369480922414 
Average 288.707827092356 276.760317182321 277.345289814113 269.803185595207 
 
Propionate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 8.1004852976173 8.79096700437706 11.6756783546484 9.31552978442684 
 8.4610411811446 35.9604762615793 16.9697241536998 7.65057962966343 
 14.4586725310812 11.5227002760205 11.6581133238875 20.2642263140754 
 18.7962475475666 13.2132073983261 15.7003410830218 9.79111421357177 
Average 12.4541116393524 17.3718377350757 14.0009642288144 11.7553624854344 
 
Butyrate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 4.984101743845 6.27015242652338 5.3923125219042 6.496987708135 
 6.18056160773178 31.7769388418729 37.0619295902022 4.71449347280659 
 8.14532934481046 6.1291109682479 7.41286375984605 8.92454746730236 
 8.94359699662898 11.0655026709102 6.87621605762163 14.1797098928921 
Average 7.06339742325406 13.8104262268886 14.1858304823935 8.57893463528401 
 
Isovalerate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.470597352293445 0 0.242103915396413 0.0390399273591738 
 0.248939377279107 0.324438228002215 0.659009712247637 0.408822382538212 
 1.4604822448603 0.249340193304065 0.387029723591049 0.722459609016718 
 2.28612157502548 0.927468226507037 0.733685741785168 0.58634098092427 
Average 1.11653513736458 0.375311661953329 0.505457273255067 0.439165724959593 
 
Valerate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 1.66344873422734 2.87973314078432 2.33905429772274 3.07302260533966 
 1.62713126923251 3.36738841216542 2.97378059591539 2.00591491173539 
 5.39706024045058 1.66067042987601 1.86017249727766 4.3946278839859 
 6.38027874345318 2.68419244206085 2.67293026410768 2.21685028085844 
Average 3.76697974684090 2.64799610622165 2.46148441375587 2.92260392047985 
 
Hexanoate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 3.7952513571157 7.58889886327068 5.60791582956784 4.2839793678578 
 4.74238481184048 4.98253446716657 7.41046374647852 4.96909298086826 
 14.5091027768945 4.68510140633916 7.27523957128617 8.34806877336278 
 10.6455501576887 7.38284473326639 9.00802969034518 8.27939771916957 
Average 8.42307227588485 6.15984486751070 7.32541220941943 6.47013471031460 
 
Heptanoate (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.34381343427593 0.592521837018908 0.321873212646279 0.48777538315166 
 0.347893379421463 0.292509609799655 0.474404687838417 0.30526719946079 
 1.17722263307827 0.287864845016662 0.344799028123874 0.985571277421056 
 1.6589208776074 0.44117992052106 0.544194981587277 0.268398449673147 
Average 0.881962581095766 0.403519053089071 0.421317977548962 0.511753077426663 
 
Octanoate (µM) 
133 
 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.15973261039682 0.410879239409786 0.149367018948578 0.20468334438462 
 0.19890388139438 0.132287002446584 0.167118250150016 0.109903697680086 
 0.467972690814254 0.19404017135944 0.249064345280658 0.296850614220606 
 0.384676848570042 0.1261259902094 0.279316474005833 0.100615278136368 
Average 0.302821507793874 0.215833100856302 0.211216522096271 0.178013233605420 
     
II. Metabolites measured as absolute concentration (TCA Plus targeted platform) (Units: µM) 
 
2-phosphoglycerate and 3-phosphoglycerate (2PG & 3PG) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 2.29330843295702 3.11684671336996 3.17626750836432 2.36112099248988 
 0.736808601954684 1.68955057310398 3.01206769741076 2.55982824741445 
 3.73682090294676 2.90525601223677 3.23639578003899 3.12465932845495 
 3.16454826826009 3.99559643464801 2.89240749208831 2.66119221122097 
Average 2.48287155152964 2.92681243333968 3.07928461947560 2.67670019489506 
 
6-phosphogluconate (6PG) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.2368 0.102 0.2581 0.1254 
 0.158 0.1098 0.2211 0.0974 
 0.13636 0.0964 0.1659 0.0941 
 0.1546 0.1 0.1443 0.1017 
Average 0.17144 0.1021 0.1974 0.1047 
 
Citrate and isocitrate (CIT & ICIT) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 95.1770872998993 121.662546541458 112.122786673005 114.712786034444 
 49.5525379497319 89.2440277471424 91.6632300955912 105.717770358297 
 115.098501548023 115.145669633639 114.561448766834 125.72759454729 
 117.017983468604 123.556499788966 105.527043055531 108.842830286182 
Average 94.2115275665645 112.402185927801 105.968627147740 113.750245306553 
 
Erythrose-4-phosphate (E4P) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.468872713830582 0.224265359847 0.342235745983 0.23949779541349 
 0.450743935271831 0.424203939567595 0.617668196698293 0.38946281521071 
 0.351953089351532 0.18522652588921 0.470626485971941 0.351827766785625 
 0.37058759474029 0.328464964129802 0.302941641098863 0.722102340395411 
Average 0.410539333298559 0.290540197358402 0.433368017438024 0.425722679451309 
 
Fructose 6-phosphate & glucose 6-phosphate (F6P & G6P) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.793235839817717 0.610682811534276 0.763572008474694 0.647790012255409 
 0.277226454587975 0.478828205465435 0.434698935388669 0.469000451413139 
 0.631952455874901 0.478518159176854 0.486009139660447 0.533555743859416 
 0.442786260887891 0.750601781660329 0.681348887940588 0.301401444584332 
Average 0.536300252792121 0.579657739459223 0.591407242866099 0.487936913028074 
 
Fructose 1,6-bisphosphate (FBP) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.276975086490366 0.165726591116647 0.293620904270615 0.159966634833449 
 0.221152480519416 0.154723379337304 0.218813012820476 0.152981504336152 
 0.190638969746489 0.155596038686046 0.180029604196881 0.159126113844131 
 0.179146744479959 0.15003857412507 0.177499158096114 0.168805490707838 
Average 0.216978320309058 0.156521145816267 0.217490669846022 0.160219935930393 
 
Guanosine diphosphate (GDP) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.161935044609202 0.117021564793478 0.175888930791753 0.117678938986407 
 0.134279107767508 0.108276020650395 0.149163632182011 0.116883603802237 
 0.123801285190235 0.106976586430058 0.135491844226981 0.11043308785515 
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 0.119767162396773 0.10834458528047 0.129883848114199 0.109467128430997 
Average 0.134945649990930 0.110154689288600 0.147607063828736 0.113615689768698 
 
Glycerol 3-phosphate (Gl-OH3P) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 4.39119529281074 4.20634381522531 4.52165793334052 4.5709112390578 
 1.65415368099845 2.97033091688291 3.16393000610236 3.98213983151541 
 4.08797187194436 4.3828968145797 5.87657527403507 4.93842733957219 
 3.40931819024611 3.92320982702911 4.0830129993303 2.23327680389119 
Average 3.38565975899991 3.87069534342926 4.41129405320206 3.93118880350915 
 
Glyceraldehyde 3-phosphate (Glyceraldehyde3P) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 15.9515472989605 15.0502631574563 16.0298731470094 14.8780449349018 
 18.9786392439884 24.6118643553081 12.8718683195233 19.3077260479532 
 15.5253638979529 12.1773902399192 18.5532444760988 13.6741209287385 
 14.3041497538849 17.4967781491959 16.9510666695505 12.8338033886849 
Average 16.1899250486967 17.3340739754699 16.1015131530455 15.1734238250696 
 
Guanosine triphosphate (GTP) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.234347288577464 0.120560983548974 0.248415731451544 0.150596672595084 
 0.161154817262453 0.124301107128232 0.220052315629347 0.137728382605887 
 0.150255704833941 0.118921464215364 0.147981036725891 0.130330523608576 
 0.151304816211229 0.113163737377275 0.160225864002402 0.122070468535473 
Average 0.174265656721272 0.119236823067461 0.194168736952296 0.135181511836255 
 
Malate (MAL) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 3.035138659769 2.96838238271834 4.02235282425872 3.16714807621585 
 1.05570518636575 1.95567084470598 2.44102289380379 2.40530440172018 
 3.51563989482841 3.28557814942716 3.42606777788102 3.1059370882642 
 2.50877907212521 3.31363014460084 3.40404022677933 2.38323289049305 
Average 2.52881570327209 2.88081538036308 3.32337093068071 2.76540561417332 
 
Phosphoenolpyruvate (PEP) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 2.91922424166332 3.45591325756795 3.66987192412319 3.24416329584767 
 1.13721251302886 2.39392778754701 2.71651549514247 3.18200448005706 
 3.69757513194478 3.26191386266909 3.70525646120795 3.85200265636012 
 3.26840639861618 3.55447359178573 2.88721130252671 2.99649429550287 
Average 2.75560457131329 3.16655712489244 3.24471379575008 3.31866618194193 
 
Succinate (SUC) (µM) 
 Control (male) TCE (male) Control (female) TCE (female) 
 4.56400949655562 4.15545165034285 6.5323931810397 4.3387287410853 
 1.09112299082636 2.46660586877778 3.25465871210832 2.960926877429 
 4.39231788212427 4.71276965881976 7.85057932981988 7.87998182232565 
 3.99031951666285 5.3233454343676 3.76296429338289 2.34347506540461 
Average 3.50944247154228 4.16454315307700 5.35014887908770 4.38077812656114 
     
III. Metabolites measured as relative concentrations (TCA Plus targeted platform) (Units: Relative response) 
 
3-Phosphoserine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00502927153591151 0.00285506809483588 0.00462739050089528 0.00137192385104196 
 0.00146684709815593 0.00156814603320146 0.00301277132021785 0.00525966025163523 
 0.00476299497715687 0.00171561007307246 0.00302728418091881 0.00568673788283254 
 0.00487517780549056 0.0032082769225232 0.00588059879316144 0.00283377154890839 
Average 0.00403357285417872 0.00233677528090825 0.00413701119879835 0.00378802338360453 
 
Acetylphosphate (Relative response) 
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 Control (male) TCE (male) Control (female) TCE (female) 
 0.102272689109334 0.0910005750539508 0.113942443329736 0.0986783814118296 
 0.0370208196005331 0.0698097427526974 0.0790482378321081 0.0854337252424941 
 0.103642069179313 0.10707228988991 0.144288209051687 0.148701130187443 
 0.0983823996997104 0.122274395951951 0.0917819925350769 0.0599437912017978 
Average 0.0853294943972226 0.0975392509121273 0.1072652206871520 0.0981892570108911 
 
Arginine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 5.6837037185127 4.45289391631858 5.30885217232204 5.0551217365079 
 2.11363610405434 6.64670861316916 3.87158980882508 7.5557548038064 
 4.15349247567646 5.1134580563055 3.75071676166752 6.30280062559677 
 5.25928842682884 6.53771226666437 4.40845392721576 5.01864600070357 
Average 4.30253018126808 5.68769321311440 4.33490316750760 5.98308079165366 
 
Asparagine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 2.97918642132418 3.4204848193291 2.22269151334002 3.4832111662888 
 4.91084773905832 3.05515444321032 5.07050995818347 3.39018175101142 
 4.5101995667538 3.00145953492596 6.85380015830096 3.72564329824483 
 3.34305146059008 3.22394623155469 3.01435315333176 1.79727637619753 
Average 3.93582129693159 3.17526125725502 4.29033869578905 3.09907814793565 
 
Aspartate (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0582964299540356 0.0647763365252277 0.0902107007574525 0.0922724780581186 
 0.0404454017726727 0.0537388310965087 0.0375429766765787 0.0520336382887273 
 0.0279835981894312 0.0220495636896825 0.03539358850456 0.0522868065574622 
 0.0374650555623649 0.0756903481502986 0.0713224636934267 0.00789013727192886 
Average 0.0410476213696261 0.0540637698654294 0.0586174324080045 0.0511207650440592 
 
Citrulline (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 1.75943242890966 1.75049823148628 1.79842691879792 1.63359562294114 
 0.883573888009974 1.58812438879269 2.02639120697304 1.70315304689964 
 2.52674982763964 1.90289126406474 2.77879707798213 1.67985391717891 
 1.66418242785741 1.98533846559812 2.08067238311648 1.89955749644303 
Average 1.70848464310417 1.80671308748546 2.17107189671739 1.72904002086568 
 
Cytidine monophosphate (CMP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0238107139016127 0.0258960376777033 0.0300138133426855 0.0359058179661057 
 0.0120366872563003 0.0200315975017078 0.00954664027239051 0.0220955582508235 
 0.0227721931419426 0.00862138951657184 0.0142513979516159 0.0184930168639229 
 0.0109422007240324 0.0501890161007984 0.0316612505126822 0.00287338771061321 
Average 0.0173904487559720 0.0261845101991953 0.0213682755198435 0.0198419451978663 
 
Creatine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 3.61527400683645 2.84625965152958 3.27016978778538 3.07998639057688 
 2.26902135422181 3.87008332332548 3.02295904936944 4.40572468140206 
 3.22028591529816 2.78908618480442 3.147468895781 3.529560220109 
 3.47763788735447 3.80841981836494 3.50133192283815 3.0967231019289 
Average 3.14555479092772 3.32846224450611 3.23548241394349 3.52799859850421 
 
Creatinine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 1.00134721958411 0.951735523056672 1.17055821642664 0.826651300987152 
 0.356371789794643 0.984156677374242 0.687145994632588 1.03039113258861 
 0.926040282576031 0.915443917809827 0.839095301676743 0.935085442899104 
 0.972101528378523 1.00497125814925 1.1232159565528 0.966194047141943 
Average 0.813965205083327 0.964076844097498 0.955003867322193 0.939580480904202 
136 
 
 
Deoxyuridine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.437545991573401 0.483692119766459 0.414992350498703 0.629065514407773 
 0.0999213830356527 0.618617884321005 0.404110368446751 0.649381055091212 
 0.499757949335196 0.544106658951022 0.464204266443553 0.687984079547692 
 0.590482028955387 0.533576777934412 0.577958946772988 0.374296273479921 
Average 0.406926838224909 0.544998360243224 0.465316483040499 0.585181730631650 
 
Dihydroxy-acetone phosphate (DAP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.06816515783158 0.0364917237462659 0.0623390439508838 0.0591169577150902 
 0.0641536494530438 0.0389615503625285 0.0926463768252128 0.0463655807683666 
 0.0782415590913062 0.0570043277683071 0.0665033325010187 0.0296629602657331 
 0.0415238381790572 0.0381007031942375 0.0388573725634919 0.106666191724361 
Average 0.0630210511387468 0.0426395762678348 0.0650865314601518 0.0604529226183877 
 
Gluconate (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 7.52267676034018 7.9845985228919 10.5820408409387 8.5779493946241 
 8.19552189253673 8.40409686820758 7.764367083852 8.4032126497332 
 8.0421362380594 8.08166197129308 8.66749064109869 9.78475006160488 
 8.1157426916426 7.04172603607755 8.37771017289613 6.59619229202214 
Average 7.96901939564473 7.87802084961753 8.84790218469638 8.34052609949608 
 
Glutamate (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.307961913155044 0.402649714837443 0.417987776399223 0.522465477411086 
 0.371635593219584 0.364665666809564 0.204378305367296 0.346804271840605 
 0.276576716242478 0.135636911247062 0.241159174098423 0.332783553075544 
 0.199021326753188 0.466495432055383 0.313116237745024 0.018702404226687 
Average 0.288798887342573 0.342361931237363 0.294160373402492 0.305188926638481 
 
Glutamine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 148.45156615073 180.05260885779 132.785099913393 174.094302488731 
 130.751805673928 177.571367040976 195.752262645839 185.33524694511 
 211.171626281737 183.81153381775 226.829995093613 199.301907855555 
 174.789006234658 168.141047322105 170.642807020059 121.110374069343 
Average 166.291001085263 177.394139259655 181.502541168226 169.960457839685 
 
Glutathione disulfide (GSSG) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00930794619774362 0.0154332913073681 0.0286315869517131 0.0138583805088712 
 0.00340130488916917 0.00438147649249482  0.00534678219369634 
 0.0103265247281325 0.00143237120348074 0.00470744678487935 0.00832539966523493 
 0.00454054060280377 0.0169715869806743 0.0149500296549962 0.00191474409604791 
Average 0.00689407910446226 0.00955468149600449 0.01609635446386290 0.00736132661596259 
 
Glutathione (GSH) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00715762187768489 0.0083225337638274 0.0127099634995166 0.0137779396850745 
 0.00493605303315922 0.00530309934558272 0.00836530168936515 0.0086278993719756 
 0.00607868763057336 0.00589586624314627 0.00629048733871203 0.00925638352323385 
 0.00315840295313328 0.0113734184594304 0.0114036773620578 0.00490543765811772 
Average 0.00533269137363769 0.00772372945299670 0.00969235747241290 0.00914191505960042 
 
Hexose (glucose etc.) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 116.270990373226 104.082771202489 124.936339420717 135.182357932123 
 51.7533190453476 160.569901166951 72.6580141395736 138.622912952932 
 114.323956473361 103.040960254044 101.813368479715 148.9844114225 
137 
 
 118.037403458686 103.432732415122 135.831997098081 97.790394968478 
Average 100.096417337655 117.781591259651 108.809929784522 130.145019319008 
 
Histidine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 5.18199859497625 6.56322432954156 5.63777177740812 8.06730351274919 
 7.59706309645618 6.93416710655496 4.88627626710831 7.72510187587655 
 5.8995445198083 5.80632732086946 5.89315569947654 7.49264677532566 
 7.81522751089826 5.98326291644746 7.04011464648112 3.65471138487619 
Average 6.62345843053475 6.32174541835336 5.86432959761852 6.73494088720690 
 
Homocysteic acid (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0165534420175248 0.00885784912943457 0.00325665117859514 0.00558134969322661 
 0.00470245126480873 0.00786736624885914 0.00617036715778341 0.0116285165397493 
 0.0100403484450849 0.0141480729006386 0.00440186795399468 0.0144740210981528 
 0.012652328644841 0.00508744130147274 0.00769155873525647 0.00772898389754247 
Average 0.0109871425930649 0.00899018239510126 0.00538011125640742 0.00985321780716780 
 
Hypoxanthine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 1.28910438750246 1.62038610294412 1.35233837227273 1.5148519684768 
 1.02599655507051 1.45445174143139 1.15286478699761 1.50376110388397 
 1.68472777788512 1.52010820578561 1.5019163014639 1.66129257701654 
 1.38606573540508 1.76059273769494 1.40859636306096 1.25882174287346 
Average 1.34647361396579 1.58888469696401 1.35392895594880 1.48468184806269 
 
Inosine monophosphate (IMP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00263783013620089 0.00663475072936561 0.00223287876825929 0.00393434285553368 
 0 0.000931712975730085 0.00153295252320881 0.00567437930764282 
 0.00492560106710619 0.0054639211559046 0.0031377235260751 0.00593872171754603 
 0.0100382118978335 0.00382216464761877 0.0065451776879585 0.00251922197890681 
Average 0.00440041077528515 0.00421313737715477 0.00336218312637543 0.00451666646490734 
 
Inosine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 1.65623602504098 1.25094810845345 2.15150834694522 1.32830104004165 
 0.416283694182781 1.0951053308403 0.438842384243419 1.36481809126711 
 1.42501020065998 0.510773945890011 1.04622698051948 1.09647976538458 
 0.545348345542713 3.02661469865942 1.82896873090907 0.0917967754556645 
Average 1.01071956635661 1.47086052096080 1.36638661065430 0.970348918037251 
 
Leucine & isoleucine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 120.392156175101 126.03929692653 123.996858296221 156.554550943523 
 84.0936520190014 158.063386572106 86.2049263738705 187.474515796931 
 126.878656448281 134.99430365122 127.726994617859 205.074970942545 
 164.146315334345 148.894073518943 147.97748315866 83.2749721179156 
Average 123.877694994182 141.997765167200 121.476565611653 158.094752450229 
 
Lysine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 28.7946956488402 30.9915390624879 22.5234231633974 30.6365322390061 
 10.6828316032565 35.8257793363831 25.8709827225469 42.3645472536058 
 33.3411742330367 28.2174944873146 32.2686079560879 32.7709736423354 
 33.9788398730765 31.411086685645 33.1533640364618 24.3477123243223 
Average 26.6993853395525 31.6114748929576 28.4540944696235 32.5299413648174 
 
Methionine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 15.373062522475 14.9485492900276 14.7998422087813 17.2284709251448 
138 
 
 7.16411737615423 18.5844114330434 9.49809241757088 21.3936387492344 
 16.9830570309393 16.3215238439866 14.7921889878151 23.282780712636 
 17.6236581973945 16.877307463463 17.2092998101684 12.0092179839734 
Average 14.2859737817408 16.6829480076301 14.0748558560839 18.4785270927472 
 
N-Acetyl-glucosamine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0660358760241889 0.0546584272955955 0.0759277420956322 0.0675602385690794 
 0.0252663312388139 0.0460608624063941 0.0373681866665481 0.048534113578411 
 0.058962731215075 0.0411907496034425 0.0497543236708654 0.0599356174273915 
 0.0433492623226577 0.0666362888446834 0.0555750751203564 0.0307651891300912 
Average 0.0484035502001839 0.0521365820375289 0.0546563318883505 0.0516987896762433 
     
Oleic acid (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 3.30228190015226 3.87337011608256 4.61712954746185 4.42898260413718 
 2.29184247356761 3.30680615968643 2.73704832156423 3.81827706166149 
 3.25309137578706 2.62244359686498 2.38975217228124 3.50199696284627 
 2.78960846979286 4.12073358802994 2.81037008648587 2.48993648755509 
Average 2.90920605482495 3.48083836516598 3.13857503194830 3.55979827905001 
 
Ornithine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 1.70628755685181 1.47808031697535 1.49851739444816 1.54020746062397 
 0.676596081328696 1.84096100813614 1.07764018588357 2.19586621138424 
 1.60398971945093 1.23143035077469 1.42948495338061 1.89325694005179 
 1.46209103428039 1.17547551086638 1.49711277418818 0.994799813265531 
Average 1.36224109797796 1.43148679668814 1.37568882697513 1.65603260633138 
 
Palmitic Acid (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 8.32433531441293 9.27164784954155 11.2432200569048 10.0089215619642 
 6.14020317719046 7.53719424100165 10.4772853856549 9.98230259312304 
 9.12563893216807 11.0271271487329 7.03901122295498 12.2157037744871 
 8.12619071689764 11.7266311471852 10.0128062821848 10.8978815672703 
Average 7.92909203516728 9.89065009661533 9.69308073692487 10.7762023742112 
 
Pantothenate (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 15.9400252022871 19.9375558916484 13.6212037934301 16.6314270515212 
 49.1708150068296 26.4508573402717 28.1475500132176 24.235264558982 
 24.0587745779932 24.438947756883 26.4972301795193 27.5511324256898 
 14.1731980718376 13.5972968990489 13.5922732579102 8.52474716114498 
Average 25.8357032147369 21.1061644719630 20.4645643110193 19.2356427993345 
 
Phenylalanine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 65.4710579488895 69.6254440705336 69.9374718187747 81.4747309893265 
 39.3658390623823 86.5593410866756 45.5329515425566 93.9719115807344 
 71.8751253836729 66.4335914809522 63.9838095771308 103.271636881263 
 88.6611813830943 71.6059529982972 74.5797356022803 47.9495460525198 
Average 66.3433009445097 73.5560824091147 63.5084921351856 81.6669563759609 
 
Phenylpyruvate (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.641794475852842 0.554991097580126 0.617107662808514 0.70743195498099 
 0.490133214872309 0.774988941208173 0.477615489058907 0.800586140937473 
 0.656069180828189 0.631167177155369 0.609317984396435 0.848021537726063 
 0.797433217672889 0.670864100378659 0.732364212183068 0.432592070516086 
Average 0.646357522306557 0.658002829080582 0.609101337111731 0.697157926040153 
 
Phosphocreatine (Relative response) 
139 
 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00923126422288645 0.0118323738435359 0.0124272942900106 0.0204443067257476 
 0.00874636132840988 0.00656835272626641 0.006870499856445 0.0222706593852555 
 0.0133444324097765 0.0175739820608964 0.00648527984199975 0.0246034141864023 
 0.0112491156550662 0.00799977077461321 0.0141208581080308 0.0106806739471165 
Average 0.0106427934040348 0.0109936198513280 0.00997598302412154 0.0194997635611305 
 
Proline (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 24.4319495088047 22.0931191735174 20.9604100159154 27.2426168212099 
 15.4975861290219 27.1444717512963 19.9563425191946 31.0739226020547 
 23.2088157215199 21.9664121745276 23.4678821712094 30.2650194575506 
 27.5022914038966 25.4924771364715 25.6124770121144 17.7761605358969 
Average 22.6601606908108 24.1741200589532 22.4992779296084 26.5894298541780 
 
Serine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 2.84411094158385 3.6119121509406 2.22397294076109 3.73634912502962 
 1.87920004182018 3.07053475302572 4.05855423849056 3.14508491164355 
 3.94365982281308 2.82218040310008 5.47187110239556 3.44663141113368 
 3.42454953972271 3.05103426413128 3.20144798539712 1.81530869120788 
Average 3.02288008648495 3.13891539279942 3.73896156676108 3.03584353475368 
 
Stearic acid (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 6.91309120801016 7.53332825147143 7.93436466515582 7.78232163866481 
 4.87134316455594 4.8659058076917 7.98100307448258 7.81067494919926 
 6.63053315682201 10.8566227425942 4.99227232317821 11.6336049211439 
 6.70754701723224 10.4698212685035 8.25559960790603 10.5342609772304 
Average 6.28062863665509 8.43141951756521 7.29080991768066 9.44021562155959 
 
Taurine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 43.043378826464 46.4038091148418 55.2665878698384 38.4541217807254 
 20.0822852645387 50.3794736843447 31.3669539554034 58.9464876935046 
 59.1087334469787 57.9914822926646 51.2413176713261 41.8856552429641 
 40.7547469586846 45.966197447735 54.2264936502988 39.0150415220936 
Average 40.7472861241665 50.1852406348965 48.0253382867167 44.5753265598219 
 
Threonine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 26.5420764860022 25.3621321158205 21.6101427765488 26.1920945647155 
 15.5664068054416 28.1049357860643 25.3375902592003 30.7539180473155 
 28.5651419261022 24.4903955482921 29.80681448867 27.1990178468201 
 28.0991613174298 26.6559267395848 27.1671781975568 20.256887999177 
Average 24.6931966337440 26.1533475474404 25.9804314304940 26.1004796145070 
 
Tryptophan (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 22.929500024936 24.5483681428409 25.3767889645271 27.469370591777 
 12.7706124682438 28.3404384770958 18.4547752044255 32.4320060766087 
 25.8799870674171 23.1094969203151 21.8962128270221 31.9109356926997 
 28.4239605261903 22.7238760587342 24.910122391868 19.4735655817221 
Average 22.5010150216968 24.6805448997465 22.6594748469607 27.8214694857019 
 
Tyrosine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 24.6509762455246 23.2712737632419 26.0342016608107 29.630537202672 
 20.0021828323961 32.4001226913387 17.1165270912691 33.5005878690139 
 27.6201399435239 25.9674033312299 22.5713434235082 36.1443975997278 
 34.3982877739876 28.7289204311099 30.3339914982273 17.8693649893354 
Average 26.6678966988581 27.5919300542301 24.0140159184538 29.2862219151873 
140 
 
 
Uridine diphosphate (UDP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0033518685337579 0.0031522836087468 0.0153012826081498 0.00161097878565159 
 0.00590550981546839 0.00219599257060329 0.00415648803688101 0.00365097711451088 
 0.0145589703046561 0.00194907818723399 0.00473420871564339 0.00328549053214651 
 0.00919455711140681 0.00416900942747892 0.00167351677546891 0.00470039945334479 
Average 0.00825272644132230 0.00286659094851575 0.00646637403403578 0.00331196147141344 
 
UDP-D-glucose (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00670994037692693 0.0132905864697261 0.00814772892556413 0.0104882047204441 
 0.00516975023734205 0.0168958426173064 0.00360393773695179 0.0047731829158808 
 0.00627196530502524 0.00256552746324231 0.00591909017062665 0.00758903057646178 
 0.00867898380394269 0.0187527903745959 0.0143916361244371 0.00194074933525791 
Average 0.00670765993080923 0.0128761867312177 0.00801559823939492 0.00619779188701115 
 
UDP-D-glucuronate (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00471392646828303 0.00346694463448202 0.00408505129594013 0.00349561226252208 
 0.00274720140636131 0.0043578868241915 0.00438882473959075 0.00351604767528023 
 0.00456518116533876 0.00379733205942947 0.0046260766560671 0.00286452983453633 
 0.00459118235876267 0.00445365316820503 0.0037990716865722 0.00316218479602178 
Average 0.00415437284968644 0.00401895417157701 0.00422475609454255 0.00325959364209010 
 
UDP-N-acetyl-D-glucosamine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.017063582781425 0.0192122136908619 0.0297903679484937 0.0207281902856347 
 0.0126368466921788 0.0279656617825415 0.0102726999330243 0.0167880594052918 
 0.0163431153984168 0.00352922697109525 0.01173492173956 0.0146910827782388 
 0.0115739731504456 0.0315453985196349 0.0235893422897365 0.00181393931681517 
Average 0.0144043795056166 0.0205631252410334 0.0188468329777036 0.0135053179464951 
 
Uridine monophosphate (UMP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0368610588212438 0.0384572551611765 0.0384316837275267 0.0517829664163903 
 0.0237788500214308 0.0363185812155498 0.0147581466924772 0.0234802041629992 
 0.0260841424669152 0.0070419748487491 0.0168520318275162 0.0254934927569337 
 0.0206169961202269 0.0592558427341418 0.0501673432868343 0.0021574110721452 
Average 0.0268352618574542 0.0352684134899043 0.0300523013835886 0.0257285186021171 
 
Uridine triphosphate (UTP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0126490875078588 0.00319790805661974 0.00622141873974524 0.0200919200499327 
 0.00211590704998849 0.00262880403884767 0.00272314163280093 0.00171444653806044 
 0.00221911755798365 0.0201211011856383 0.00250441501041233 0.000999128367882522 
 0.00444034400717764 0.0247789984384867 0.0140831063636847 0.00135699107472546 
Average 0.00535611403075214 0.0126817029298981 0.00638302043666080 0.00604062150765028 
 
Valine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 49.370396422706 50.3161715704592 46.835277928922 56.1940808338651 
 25.2264030689883 56.6150828869612 33.2183617117957 65.3861835732668 
 51.0743702134923 46.3957859493568 45.400079357805 65.9606445149623 
 59.5782956247264 53.2051145759724 52.9947785349814 37.0353220080988 
Average 46.3123663324782 51.6330387456874 44.6121243833760 56.1440577325483 
 
Xanthine (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.850855968452767 0.560425862505936 1.93173951991926 1.11430761853677 
 0.356227281452005 0.458143734892495 0.407456897551187 0.404838264675126 
 0.736787256278116 0.434408759792168 0.873838590834073 0.92848925845376 
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 0.63592566631639 0.649674377706509 0.888156649337771 0.174616410967954 
Average 0.644949043124819 0.525663183724277 1.02529791441057 0.655562888158403 
 
 
Acetyl Coenzyme A (aCoA) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00230367205791236 0.00103514271900399 0.00365335863830654 0.00144201215826825 
 0.000933218924623687 0.000275611158176368 0.00125560575037268 0.000855204749019865 
 0.00181074300118018 0.000407446594157108 0.000790456346177375 0.000520154001048692 
 0.0006281626074971 0.000733071454520461 0.000627070436249632 0.00141546264663345 
Average 0.00141894914780333 0.000612817981464482 0.00158162279277656 0.00105820838874256 
 
Adenosine diphosphate (ADP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0250695558872703 0.00897293633193122 0.0334025112834971 0.0143969696005388 
 0.0201962162705393 0.0103228955992135 0.0274427353374992 0.0101199284641065 
 0.0159519736371863 0.00785313065056357 0.0189611991123682 0.00689112311275041 
 0.0161315081927367 0.0070754086986106 0.018082484181631 0.00895210651836235 
Average 0.0193373134969331 0.0085560928200797 0.0244722324787489 0.0100900319239395 
 
Adenosine monophosphate (AMP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.022937661063937 0.0263331660219209 0.0300127481701151 0.0358153928082896 
 0.0217343026523885 0.0528775504621689 0.0172054115640828 0.00970554978274255 
 0.0195139978985843 0.00683140336579784 0.0162002507945092 0.023664278998876 
 0.0244899309625638 0.0241821114459859 0.0485116198554833 0.00904909525021646 
Average 0.0221689731443684 0.0275560578239684 0.0279825075960476 0.0195585792100312 
 
Adenosine triphosphate (ATP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0180522516459992 0.00671926183990436 0.016896126867039 0.00846967787427657 
 0.0106284612540424 0.00659045698023559 0.0161845753593636 0.00784222391166403 
 0.0127466447429012 0.00785534859155683 0.0122498679213039 0.00606807910118435 
 0.0104428010047217 0.0044559081504387 0.0122722372137768 0.00579842376741688 
Average 0.0129675396619161 0.00640524389053387 0.0144007018403708 0.00704460116363546 
 
Flavin adenine dinucleotide (FAD) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.00390674695111207 0.00297182014845727 0.00506321239705208 0.00217606570718083 
 0.00293330144689455 0.00291967732047542 0.00351504698944016 0.00311747835491235 
 0.00385131662110685 0.00234733047735774 0.00350515767335303 0.00278075857592129 
 0.00356789179657924 0.00273464752741646 0.00439723555479168 0.0032719789148241 
Average 0.00356481420392318 0.00274336886842672 0.00412016315365924 0.00283657038820964 
 
Guanosine monophosphate (GMP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0220549778155518 0.0161137153404319 0.0267908371683052 0.0219804221338922 
 0.0131379142522881 0.0126432041795463 0.0108501649996937 0.00890725905059403 
 0.0114833023072668 0.00494910791393415 0.0112376289511407 0.00875986190723127 
 0.00835507758761448 0.0188458868922096 0.0183623743515446 0.000863378438572987 
Average 0.0137578179906803 0.0131379785815305 0.0168102513676711 0.0101277303825726 
 
Nicotinamide adenine dinucleotide phosphate (NADP) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0131634487544033 0.00244234325500697 0.0178761349227166 0.00236423732715881 
 0.0068291556632232 0.0036180119716935 0.0105690567941261 0.00280379042256425 
 0.00637540546516435 0.00341562081729896 0.00543222423897134 0.00233739752658422 
 0.0052977290900525  0.00450773195038907 0.00219170282335837 
Average 0.00791643474321084 0.00315865868133314 0.00959628697655078 0.00242428202491641 
 
Nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
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 0.000522216003857349  0.00215842175567091  
 0.000194430213628183 0.000526973129512696 0.00108203922503506 0.000751800335102332 
 0.000721631144197339 0.000551997455421326 0.000607063162576973 0.000286584834522448 
 0.00089610310662185  0.00025412183176231 0.000712903190261333 
Average 0.000583595117076180 0.000539485292467011 0.001025411493761310 0.000583762786628704 
 
Ribose 5-phosphate & xylulose 5-phosphate (R5P & X5P) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0148367020750656 0.0129333820807472 0.0470602976325785 0.0280443019937553 
 0.0142973189301044 0.00595517768858172  0.0145260309080153 
 0.0135073752465351 0.00957128784437392 0.00791059906467256 0.0207267889250782 
 0.00812166299756489 0.0257399176624197 0.0217021626795717 0.00114466919829366 
Average 0.0126907648123175 0.0135499413190306 0.0255576864589409 0.0161104477562856 
 
Sedoheptulose 7-phosphate (S7P) (Relative response) 
 Control (male) TCE (male) Control (female) TCE (female) 
 0.0215699092275346 0.0132299558340737 0.0267488929311904 0.0142098280524287 
 0.00300880737726382 0.00495177856461123 0.00143397974475791 0.00454492632835358 
 0.0112446588007931 0.00394995710112161 0.0100689652747451 0.0145157730902237 
 0.0064667969662319 0.0127381394729425 0.0119427057840659  
Average 0.0105725430929559 0.00871745774318726 0.0125486359336898 0.0110901758236687 
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Table S3.3. Metabolites increased or decreased in response to trichloroethylene treatment 
for male and female amniotic fluid samples. Metabolites altered in any sex are listed first and 
followed by metabolites that are not altered in any sex. The values placed in boldface correspond 
to values associated with a p<0.05. 
 
Metabolite Change in response to TCE 
exposure (Male) 
Change in response to TCE 
exposure (Female) 
 p-value Fold-change p-value Fold-change 
Adenosine diphosphate 
(ADP) 
0.0031 0.44247 0.0111 0.41231 
Adenosine triphosphate 
(ATP) 
0.0138 0.49394 0.0020 0.48918 
6-Phosphogluconate (6PG) 0.0209 0.59525  0.0133 0.53028 
Flavin adenine dinucleotide 
(FAD) 
0.0211 0.76957 0.0287 0.68846 
Fructose 1,6-bisphosphate 
(FBP) 
0.0333 0.72137 0.0792 0.73667 
Guanosine triphosphate 
(GTP) 
0.0344 0.68422 0.0539 0.69621 
Guanine diphosphate (GDP) 0.0441 0.81629 0.0174 0.76972 
Arginine 0.2228 1.3219 0.0457 1.3802 
Uridine diphosphate (UDP)-
D-glucoronate 
0.8083 0.96740 0.0066 0.77155 
Phosphocreatine 0.9001 1.0330 0.0391 1.9547 
2-phosphoglyercerate / 3-
phosphoglycerate (2PG/3PG) 
 0.5445 1.1788  0.0655  0.86926 
 
Erythrose 4-phosphate (E4P) 0.0970 0.70770 0.9323 0.98236 
Citrulline 0.6594 1.0575 0.0732  0.79640 
Dihydroxyacetone phosphate 0.0670  0.67659 0.8228 0.92881 
Homocysteic acid 0.5470 0.81825 0.0897 1.8314 
Uridine diphosphate (UDP) 0.0720 0.34735 0.3462 0.51218 
Nicotinamide adenine 
dinucleotide phosphate 
(NADP) 
0.0754  0.39900 0.0580 0.25263 
Acetate 0.8591 0.95862 0.8094 0.97281 
Propionate 0.5452 1.3949 0.3556 0.83961 
Butyrate 0.3131 1.9552 0.6450 0.60475 
Isovalerate 0.1984 0.33614 0.7273 0.86885 
Valerate 0.6197 0.70295 0.5180 1.18733 
Hexanoate 0.5989 0.73131 0.4685 0.88325 
Heptanoate 0.2075 0.45752 0.6580 1.21465 
Octanoate 0.4141 0.71274 0.5692 0.84280 
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Citrate/ isocitrate (CIT/ICIT) 0.3423 1.19308 0.2945 1.07343 
Fructose 6-phosphate / 
glucose 6-phosphate 
(F6P/G6P) 
0.7217 1.08085 0.3723 0.82504 
Glycerol 3-phosphate (Gl-
OH3P) 
0.4683 1.14326 0.5686 0.89116 
Glyceraldehyde 3-phosphate 
(Glyceraldehyde3P) 
0.8096 1.0707 0.6142 0.94236 
Malate (MAL) 0.5381 1.1392 0.2223 0.83211 
Phosphoenolpyruvate (PEP) 0.4830 1.1491 0.7881 1.0228 
Succinate (SUC) 0.5198 1.1867 0.5050 0.81881 
3-Phosphoserine 0.1241 0.57933 0.7862 0.91564 
Acetylphosphate 0.5575 1.1431 0.7119 0.91539 
Asparagine 0.1623 0.80676 0.4050 0.72234 
Aspartate 0.3622 1.3171 0.7425 0.87211 
Cytidine monophosphate 
(CMP) 
0.3861 1.5057 0.8677 0.92857 
Creatine 0.6804 1.0581 0.4204 1.0904 
Creatinine 0.3666 1.1844 0.9579 0.98385 
Deoxyuridine 0.2609 1.3393 0.2013 1.2576 
Gluconate 0.7712 0.98858 0.5771 0.94266 
Glutamate 0.5448 1.1855 0.9475 1.0375 
Glutamine 0.4750 1.0668 0.7008 0.93641 
Glutathione – oxidized 
(GSSG) 
0.5554 1.3859 0.2383 0.45733 
Glutathione – reduced (GSH) 0.1913 1.4484 0.8208 0.94321 
Hexose (glucose, etc.) 0.4263 1.1767 0.2908 1.1961 
Histidine 0.7575 0.95445 0.6331 1.1485 
Hypoxanthine 0.1574 1.1800 0.2943 1.0966 
Inosine monophosphate 
(IMP) 
0.9409 0.95744 0.4311 1.3434 
Inosine 0.5250 1.4553 0.5125 0.71016 
Leucine / Isoleucine 0.3162 1.1462 0.3680 1.3014 
Lysine 0.3909 1.1840 0.4201 1.1432 
Methionine 0.3699 1.1678 0.2252 1.3129 
N-Acetyl-glucosamine 0.7373 1.0771 0.8029 0.94589 
Oleic acid 0.2303 1.1965 0.4952 1.1342 
Ornithine 0.7584 1.0508 0.4140 1.2038 
Palmitic acid 0.1480 1.2474 0.3437 1.1117 
Pantothenate 0.7510 0.81694 0.7860 0.93995 
Phenylalanine 0.4728 1.1087 0.3042 1.2859 
Phenylpyruvate 0.8738 1.0180 0.4657 1.1446 
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Proline 0.5657 1.0668 0.3334 1.1818 
Serine 0.7065 1.0384 0.4707 0.81195 
Stearic acid 0.2540 1.3424 0.1483 1.2948 
Taurine 0.2859 1.2316 0.7092 0.92816 
Threonine 0.5886 1.0591 0.9983 1.0046 
Tryptophan 0.5059 1.0969 0.2145 1.2278 
Tyrosine 0.7434 1.0346 0.3888 1.2195 
UDP-D-glucose 0.1459 1.9196 0.5618 0.77322 
UDP-N-acetyl-D-
glucosamine 
0.3723 1.4276 0.4249 0.71658 
Uridine monophosphate 
(UMP) 
0.4839 1.3143 0.7560 0.85612 
Uridine triphosphate (UTP) 0.2849 2.3677 0.9512 0.94636 
Valine 0.4592 1.1149 0.2405 1.2585 
Xanthine 0.3687 0.81505 0.3869 0.63939 
Acetyl coenzyme A (aCoA) 0.1044 0.43188 0.5052 0.66906 
Adenosine monophosphate 
(AMP) 
0.5936 1.2430 0.4262 0.69896 
Guanine monophosphate 
(GMP) 
0.8879 0.95495 0.2903 0.60247 
Nicotinamide adenine 
dinucleotide phosphate 
hydrogen (NADPH) 
0.8627 0.92442 0.4192 0.56930 
Ribose 5-phosphate / xylulose 
5-phosphate (R5P/X5P) 
0.8574 1.0677 0.4571 0.63036 
D-sedoheptulose 7-phosphate 
(S7P) 
0.7089 0.82454 0.8385 0.88378 
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Table S3.4. Effect of trichloroethylene treatment on amino acid metabolism-relevant metabolite 
ratios in male and female amniotic fluid samples. Abbreviations: ATP, adenosine triphosphate; 
ADP, adenosine diphosphate. The values placed in boldface correspond to values associated 
with a p<0.05. 
 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
Arginine to creatine 0.0491 1.2876 0.0147 1.2629 
Arginine to citrulline 0.3209 1.2189 0.0345 1.6714 
Arginine to ornithine 0.1654 1.2923 0.2642 1.1884 
Ornithine to citrulline 0.9921 0.99812 0.1282 1.4940 
Aspartate to citrulline 0.8422 1.0716 0.9072 1.0571 
Glutamine to citrulline 0.7117 0.94061 0.2689 1.1907 
Aspartate to glutamine 0.6272 1.1751 0.6358 0.78764 
Arginine to phosphocreatine 0.3062 1.5258 0.1306 0.69773 
Glutamine to glutamate 0.8737 1.0703 0.4228 2.8765 
Asparagine to aspartate 0.3311 0.68185 0.9793 1.0160 
Glutamate to succinate 0.6104 0.69329 0.7084 1.1954 
Phenylpyruvate to 
phenylalanine 
0.2391 0.88653 0.0335 0.89082 
Phenylalanine to tyrosine 0.2898 1.0929 0.2331 1.0428 
Serine to 3-Phosphoserine 0.0637 1.7231 0.8802 1.0929 
Homocysteic acid to 
methionine 
0.2378 0.71793 0.3195 1.3212 
Phosphocreatine to ATP 0.0279 1.9634 0.0058 3.9260 
Phosphocreatine to creatine 0.9198 1.0340 0.0406 1.8175 
Phosphocreatine to ADP 0.0784 2.2797 0.0234 4.8037 
Creatine to ATP 0.0378 2.2219 0.0023 2.2125 
Creatine to ADP 0.0058 2.3524 0.0135 2.6553 
Creatinine to creatine 0.3142 0.80783 0.6015 1.0654 
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Table S3.5. Effect of trichloroethylene treatment on purine and pyrimidine metabolism-relevant 
metabolite ratios in male and female amniotic fluid samples. Abbreviations: ATP, adenosine 
triphosphate; ADP, adenosine diphosphate; AMP, adenosine monophosphate; GTP, guanosine 
triphosphate; GDP, guanosine diphosphate; GMP, guanosine monophosphate; IMP, inosine 
monophosphate. The values placed in boldface correspond to values associated with a p<0.05. 
 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
ATP to ADP* 0.4649 1.1205 0.1700 1.1947 
ADP to AMP 0.1624 0.56545 0.2783 0.64104 
ATP to AMP 0.5529 0.72759 0.5112 0.77273 
GTP to GDP 0.0208 0.84585 0.2645 0.91177 
GDP to GMP 0.9750 1.0120 0.3500 4.0025 
GTP to GMP 0.7176 0.87540 0.3647 3.4711 
IMP to GMP 0.9772 1.0242 0.2012 5.1283 
IMP to inosine 0.7910 0.77228 0.2647 3.5989 
IMP to AMP 0.5805 1.5791 0.1276 2.4870 
Inosine to hypoxanthine 0.6686 1.2219 0.3237 0.63464 
Xanthine to hypoxanthine 0.0754 0.69121 0.2782 0.56857 
UTP to UDP 0.1998 3.8760 0.8154 1.3526 
UDP to UMP 0.1151 0.36442 0.5016 2.5091 
UTP to UMP 0.3556 4.6834 0.5590 1.4557 
IMP to xanthine 0.7039 1.2645 0.1121 2.4165 
GMP to xanthine 0.8563 1.0571 0.4214 0.75786 
*denotes relevance to both purine metabolism and phosphocreatine shuttling 
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Table S3.6. Effect of trichloroethylene treatment on glycolysis, tricarboxylic acid cycle, pentose 
phosphate pathway, and pyruvate metabolism-relevant metabolite ratios in male and female 
amniotic fluid samples. The values placed in boldface correspond to values associated with a 
p<0.05. Abbreviations: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-
bisphosphate; Glyceraldehyde3P, glyceraldehyde 3-phosphate; DAP, dihydroxyacetone 
phosphate; 2PG, 2-phosphoglycerate; 3PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; 
aCoA, acetyl coenzyme A; CIT, citrate; ICIT, isocitrate; 6PG, 6-phosphogluconate; R5P, ribose 
5-phosphate; X5P, xylulose 5-phosphate; E4P, erythrose 4-phosphate; S7P, sedoheptulose 7-
phosphate. 
 
Glycolysis (aka glycolysis or gluconeogenesis) 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
G6P/F6P to FBP 0.0980 1.5002 0.6605 1.1014 
FBP to Glyceraldehyde3P* 0.0976 0.71815 0.2686 0.78329 
FBP to DAP 0.6988 1.0644 0.7398 0.90280 
Glyceraldehyde3P to DAP 0.1301 1.6005 0.7399 1.1243 
Glyceraldehyde3P to 
2PG/3PG 
0.5814 0.67570 0.5352 1.1018 
2PG/3PG to PEP 0.6768 1.0616 0.0593 0.83946 
PEP to aCoA** 0.0540 2.5567 0.6388 1.2434 
Acetate to aCoA*** 0.1423 2.4024 0.7358 1.2020 
G6P/F6P to PEP 0.5518 0.89379 0.2768 0.79725 
G6P/F6P to aCoA  0.0322 2.6695 0.9850 0.99101 
TCA cycle 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
aCoA to CIT/ICIT 0.0411 0.32849 0.4451 0.63937 
CIT/ICIT to Succinate 0.7316 0.92860 0.2638 1.4158 
Succinate to Malate 0.5955 1.0604 0.8968 0.96335 
CIT/ICIT to Malate 0.9498 1.0081 0.0206 1.2807 
aCoA to Malate**** 0.0387 0.34666 0.7377 0.85561 
Pentose phosphate pathway 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
R5P/X5P to S7P 0.7599 0.83883 0.2962 1.5125 
Glyceraldehyde3P to E4P 0.0017 1.5370 0.9159 1.0324 
FBP to E4P 0.5482 1.1396 0.4883 0.80103 
S7P to E4P 0.6138 1.2811 0.9290 1.0593 
G6P/F6P to 6PG 0.0310 1.8105 0.1164 1.4802 
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Gluconate to 6PG 0.0047 1.5841 0.0166 1.7354 
S7P to 6PG 0.3997 1.4638 0.3033 1.6523 
E4P to 6PG 0.4867 1.1485 0.1408 1.8494 
R5P/X5P to 6PG 0.2433 1.7646 0.7353 1.1914 
R5P/X5P to 
Glyceraldehyde3P 
0.8298 1.0760 0.5588 0.68535 
R5P/X5P to gluconate 0.7868 1.1205 0.5008 0.68769 
E4P to gluconate 0.1181 0.71645 0.8466 1.0857 
S7P to gluconate 0.7437 0.83688 0.8843 0.92607 
S7P to FBP 0.6856 1.1906 0.6089 1.2663 
R5P/X5P to FBP 0.3704 1.4914 0.8962 0.93566 
S7P to Glyceraldehyde3P 0.6616 0.79365 0.9895 0.99186 
Pyruvate metabolism pathway 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
Acetylphosphate to acetate 0.3736 1.2621 0.4763 0.93020 
Malate to PEP 0.8095 0.98072 0.0617 0.81347 
Malate to acetate 0.3262 1.2661 0.3394 0.88615 
 
*denotes relevance to both glycolysis and pentose phosphate pathway 
**denotes relevance to glycolysis, tricarboxylic acid cycle, and pyruvate metabolism 
***denotes relevance to both glycolysis and pyruvate metabolism 
****denotes relevance to tricarboxylic acid cycle and pyruvate metabolism 
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Table S3.7. Effect of trichloroethylene treatment on glutathione metabolism-relevant metabolite 
ratios in male and female amniotic fluid samples. Abbreviations: GSH, glutathione; GSSG, 
glutathione disulfide; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, 
nicotinamide adenine dinucleotide phosphate hydrogen. 
 
Ratio Male: response to TCE 
treatment 
Female: response to TCE 
treatment 
 p-value Fold-change p-value Fold-change 
GSH to GSSG 0.4133 1.8650 0.1888 1.8526 
GSSG to NADP 0.3219 2.8786 0.4660 1.5823 
NADP to NADPH 0.3030 0.34773 0.0882 0.44586 
GSH to NADPH 0.7516 0.81284 0.9805 0.98090 
GSH to glutamate 0.3244 1.3857 0.4136 2.5504 
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Table S3.8. Effect of trichloroethylene treatment on other important metabolite ratios in male 
and female amniotic fluid samples. Abbreviations: DAP, dihydroxyacetone phosphate; UDP, 
uridine diphosphate. 
 
Ratio Male: response to 
TCE treatment 
Female: response to 
TCE treatment 
Significance 
 p-value Fold-
change 
p-value Fold-
change 
 
DAP to glycerol 3-
phosphate 
0.1414 0.51982 0.7434 1.2260 Glycerophospholipid 
metabolism 
Stearic acid to oleic 
acid 
0.5634 1.1657 0.5393 1.1754 Fatty acid 
biosynthesis 
Stearic acid to 
palmitic acid 
0.6174 1.0503 0.0890 1.1592 Fatty acid 
biosynthesis 
Oleic acid to 
palmitic acid 
0.9019 0.98367 0.8439 1.0372 Fatty acid 
biosynthesis 
UDP-D-glucose to 
UDP-D-glucuronate 
0.1233 1.9175 0.9415 0.96671 Various pathways 
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Figure S3.1. Short chain fatty acid (SCFA)-specific analysis. (A) Regardless of treatment 
group or sex, acetate contributed to the vast majority of SCFAs in the amniotic fluid. (B) Total 
SCFA concentration was unchanged by TCE treatment for both sex groups, as assessed by a 
student’s unpaired two-tailed t-test on the data (generalized log-transformed). Each individual 
SCFA was unchanged by TCE treatment for both sexes, as well. Error bars represent mean ± 
SEM for both (A) and (B).  N=4 independent experiments. 
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Table S3.9. Enrichment analysis results of organ, tissue, and subcellular structures predicted to 
be altered by trichloroethylene treatment based on male amniotic fluid alterations. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm 
p 
FDRb 
Thyroid Gland 12 1 54.638 14.286 0.036134 1 0.57884 
Endoplasmic 
Reticulum 
53 7 26.473 14.286 0.059796 1 0.57884 
Nucleus 23 2 30.904 14.286 0.094831 1 0.57884 
Skeletal Muscle 123 15 23.062 14.286 0.11952 1 0.57884 
Peroxisome 37 5 26.829 14.286 0.13197 1 0.57884 
Golgi Apparatus 14 4 24.865 14.286 0.16007 1 0.57884 
Muscle 160 19 21.944 14.286 0.16304 1 0.57884 
Brain 122 2 24.265 14.286 0.18448 1 0.57884 
Platelet 108 5 22.281 14.286 0.19659 1 0.57884 
Prostate 267 37 18.691 14.286 0.22415 1 0.57884 
Gonad 42 1 23.403 14.286 0.22452 1 0.57884 
Bladder 87 10 18.69 14.286 0.23154 1 0.57884 
Mitochondria 98 12 19.028 14.286 0.25304 1 0.58248 
Bone Marrow 21 1 18.175 14.286 0.29221 1 0.58248 
Spleen 170 10 17.975 14.286 0.29922 1 0.58248 
Placenta 183 16 16.854 14.286 0.32203 1 0.58248 
Testes 72 4 16.551 14.286 0.33007 1 0.58248 
Intestine 251 16 15.997 14.286 0.3682 1 0.61367 
Liver 234 5 13.052 14.286 0.4101 1 0.62327 
Kidney 164 6 15.019 14.286 0.43653 1 0.62327 
Erythrocyte 34 2 10.69 14.286 0.43695 1 0.62327 
Pancreas 118 12 13.21 14.286 0.45707 1 0.62327 
Fibroblasts 183 10 11.856 14.286 0.52 1 0.67826 
Neuron 69 4 11.892 14.286 0.55754 1 0.69692 
Nervous Tissue 12 2 8.0256 14.286 0.60247 1 0.72297 
Epidermis 216 19 10.911 14.286 0.67558 1 0.77951 
Nerve Cells 35 3 5.4681 14.286 0.70714 1 0.78571 
Heart 8 1 1.1425 14.286 0.80111 1 0.82729 
Smooth Muscle 9 1 1.1425 14.286 0.80111 1 0.82729 
Skin 125 5 6.6796 14.286 0.82729 1 0.82729 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment.  
bFDR refers to false discovery rate. 
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Table S3.10. Enrichment analysis results of organ, tissue, and subcellular structures predicted to 
be altered by trichloroethylene treatment based on female amniotic fluid alterations. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm 
p 
FDRb 
Gonad 42 1 51.374 14.286 0.045424 1 0.70489 
Skin 125 5 31.686 14.286 0.08703 1 0.70489 
Bladder 87 10 24.719 14.286 0.17509 1 0.70489 
Bone Marrow 21 1 22.059 14.286 0.24031 1 0.70489 
Heart 8 1 21.381 14.286 0.24866 1 0.70489 
Smooth Muscle 9 1 21.381 14.286 0.24866 1 0.70489 
Neuron 69 4 17.371 14.286 0.30335 1 0.70489 
Muscle 160 19 16.308 14.286 0.31482 1 0.70489 
Mitochondria 98 12 16.643 14.286 0.3263 1 0.70489 
Nerve Cells 35 3 15.584 14.286 0.33211 1 0.70489 
Liver 234 5 15.507 14.286 0.33285 1 0.70489 
Endoplasmic 
Reticulum 
53 7 16.795 14.286 0.33515 1 0.70489 
Skeletal Muscle 123 15 15.213 14.286 0.34157 1 0.70489 
Intestine 251 16 14.808 14.286 0.34661 1 0.70489 
Platelet 108 5 14.675 14.286 0.35691 1 0.70489 
Erythrocyte 34 2 11.924 14.286 0.40689 1 0.70489 
Thyroid Gland 12 1 10.565 14.286 0.43212 1 0.70489 
Testes 72 4 11.336 14.286 0.4462 1 0.70489 
Fibroblasts 183 10 10.683 14.286 0.44643 1 0.70489 
Peroxisome 37 5 12.05 14.286 0.50178 1 0.72568 
Kidney 164 6 8.6464 14.286 0.56822 1 0.72568 
Nucleus 23 2 6.4037 14.286 0.58206 1 0.72568 
Epidermis 216 19 9.7735 14.286 0.59021 1 0.72568 
Prostate 267 37 9.6945 14.286 0.59838 1 0.72568 
Spleen 170 10 7.8139 14.286 0.62296 1 0.72568 
Brain 122 2 7.615 14.286 0.62892 1 0.72568 
Pancreas 118 12 7.3092 14.286 0.67052 1 0.74502 
Golgi Apparatus 14 4 7.2038 14.286 0.6977 1 0.74521 
Nervous Tissue 12 2 5.2748 14.286 0.72037 1 0.74521 
Placenta 183 16 6.1075 14.286 0.79124 1 0.79124 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment.  
bFDR refers to false discovery rate. 
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Table S3.11. Enrichment analysis results of top ten drug pathways altered by trichloroethylene 
treatment in the male amniotic fluid samples. The 10th pathway on the list, citalopram action 
pathway, was the only pathway with a raw p-value of 0.001435. 
  
Total 
Compound
s 
Hit
s 
Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Acetaminophe
n Metabolism 
Pathway 
17 5 58.661 14.286 0.000135 0.04769 0.004415 
Codeine 
Action 
Pathway 
21 4 63.58 14.286 0.000191 0.067134 0.004415 
Etoposide 
Action 
Pathway 
15 4 63.58 14.286 0.000191 0.067134 0.004415 
Etoposide 
Metabolism 
Pathway 
15 4 63.58 14.286 0.000191 0.067134 0.004415 
Irinotecan 
Action 
Pathway 
12 4 63.58 14.286 0.000191 0.067134 0.004415 
Irinotecan 
Metabolism 
Pathway 
12 4 63.58 14.286 0.000191 0.067134 0.004415 
Morphine 
Action 
Pathway 
16 4 63.58 14.286 0.000191 0.067134 0.004415 
Mycophenolic 
Acid 
Metabolism 
Pathway 
20 4 63.58 14.286 0.000191 0.067134 0.004415 
Tramadol 
Metabolism 
Pathway 
18 4 63.58 14.286 0.000191 0.067134 0.004415 
Citalopram 
Action 
Pathway 
28 3 78.238 14.286 0.001435 0.49219 0.004415 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. 
bFDR refers to false discovery rate. 
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Table S3.12. Enrichment analysis results of top 5 drug pathways altered by trichloroethylene 
treatment in the female amniotic fluid samples. The 5th pathway on the list, citalopram action 
pathway, was the only pathway with a raw p-value of 0.002027, and the next 120 pathways on 
the list had a raw p-value of 0.003382. 
  
Total 
Compound
s 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Glibenclamid
e Action 
Pathway 
5 1 84.029 14.286 0.001358 0.47789 0.009186 
Gliclazide 
Action 
Pathway 
6 1 84.029 14.286 0.001358 0.47789 0.009186 
Nateglinide 
Action 
Pathway 
5 1 84.029 14.286 0.001358 0.47789 0.009186 
Repaglinide 
Action 
Pathway 
5 1 84.029 14.286 0.001358 0.47789 0.009186 
Citalopram 
Action 
Pathway 
28 3 75.516 14.286 0.002027 0.70555 0.009186 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. 
bFDR refers to false discovery rate. 
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Chapter IV. Apoptotic Responses Stimulated by the Trichloroethylene Metabolite S-(1,2-
dichlorovinyl)-L-cysteine in BeWo Human Trophoblast Cells Depend on Cell 
Differentiation State 
 
Abstract 
During pregnancy, the placental villous cytotrophoblasts differentiate in a process 
involving cell fusion and multinucleation to create syncytiotrophoblasts, a cell type at the 
maternal-fetal interface that regulates gas, waste, and nutrient exchange between the mother and 
fetus. The human trophoblast BeWo cell line has been used as an in vitro model for this 
differentiation process, also known as syncytialization, including use as a model to study the 
impacts of toxicant exposure on placental cells. Apoptosis of syncytiotrophoblasts is associated 
with adverse pregnancy outcomes. In the current study, we exposed unsyncytialized BeWo cells, 
BeWo cells undergoing syncytialization, and syncytialized BeWo cells to S-(1,2-dichlorovinyl)-
L-cysteine (DCVC), a metabolite of trichloroethylene (TCE), an industrial chemical and 
environmental contaminant. DCVC decreased cell viability, increased cell cytotoxicity, increased 
caspase 3/7 activity, and increased nuclear condensation or fragmentation with 48 hours of 
exposure to 50 µM DCVC in BeWo cells regardless of their differentiation status. Investigating 
mechanisms of apoptosis, DCVC increased hydrogen peroxide (H2O2) abundance and decreased 
PRDX2 mRNA in all three models of BeWo cells. DCVC decreased tumor necrosis factor-
receptor 1 (TNF-R1) concentration in media and decreased NFKB1 mRNA expression in 
syncytialized BeWo cells but not in unsyncytialized BeWo cells nor in BeWo cells undergoing 
syncytialization. DCVC decreased BCL2 mRNA expression in BeWo cells undergoing 
syncytialization and syncytialized BeWo cells, but not in unsyncytialized BeWo cells. Decreased 
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LGALS3 mRNA was seen in unsyncytialized BeWo cells. These data indicate that the oxidative 
stress or pro-inflammatory mechanisms underlying apoptosis in BeWo cells depend on 
differentiation state. Future directions should elaborate on defining the different pathways 
involved in DCVC-stimulated apoptosis for different placental cell types and attempt to 
modulate the adverse outcomes based on known molecular mechanisms. 
Introduction 
 Many adverse pregnancy outcomes are attributable to abnormalities in placenta 
development (Ilekis et al., 2016). Important classes of placental cells that have been studied with 
regard to adverse pregnancy outcomes include villous cytotrophoblasts and syncytiotrophoblasts. 
Villous cytotrophoblasts are the placental cells that differentiate in vivo into syncytiotrophoblast 
in a process involving cell fusion and multinucleation, known as syncytialization (Wang et al., 
2014). The syncytiotrophoblast serves as the maternal fetal interface that regulates gas, waste, 
and nutrient exchange between the mother and the fetus (Potgens et al., 2002; Wang et al., 
2014). As such, disruption of the process of syncytialization or the resulting syncytiotrophoblasts 
could lead to adverse pregnancy outcomes. 
Apoptosis of villous cytotrophoblasts, syncytiotrophoblasts, and other cytotrophoblasts is 
important as a mechanism for disruption of placental development and function. A specific 
example is that apoptosis of syncytiotrophoblasts is associated with intrauterine growth 
retardation and preeclampsia (Ishihara et al., 2002), with further examples provided in a review 
by Sharp et al. (Sharp et al., 2010). Loss of villous cytotrophoblasts and disrupted syncytia 
formation are proposed as stimuli for syncytiotrophoblast degeneration (Fox, 1970; Panigel and 
Myers, 1972; Castellucci et al., 1990). Furthermore, apoptosis of invasive cytotrophoblasts is 
associated with preeclampsia (DiFederico et al., 1999; Genbacev et al., 1999). 
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Multiple biological processes can contribute to placental cell apoptosis. In BeWo and 
JEG-3 cells, placental cell lines representative of villous and extravillous cytotrophoblastic cells, 
respectively (Pattillo and Gey, 1968; Kohler and Bridson, 1971; Kohler et al., 1971), 
overexpression of antioxidant response with selenium decreases apoptosis (Khera et al., 2017). 
Additionally, a pro-inflammatory mechanism can contribute to apoptosis in placental cells. In 
WISH cells, IL-1β and NF-κB1 activation stimulate apoptosis (Saquib et al., 2013), and IFN-γ 
promotes apoptosis in cultured human cytotrophoblast cells and rat placenta and uterus (Sun et 
al., 2007). Finally, TNF-α increases apoptosis in both BeWo and JEG-3 cells (Al-Nasiry et al., 
2006) as well as in syncytiotrophoblasts isolated from placentae of uncomplicated pregnancies 
(Garcia-Lloret et al., 2000). 
TCE is commonly used as a metal degreaser and in the synthesis of various chemicals, 
including refrigerants (Agency for Toxic Substances and Disease Registry, 2007). S-(1,2-
Dichlorovinyl)-L-cysteine (DCVC) is a TCE metabolite generated in the TCE glutathione (GSH) 
conjugation metabolic pathway (Lash et al., 2014a) that is important for TCE toxicity. DCVC is 
toxic because it is further metabolized into unstable and reactive compounds, including 1,2-
dichlorovinylthiol (DCVT), chlorothioketene (CTK), and chlorothionoacetyl chloride (CTAC) 
(Lash et al., 2014a). Notably, DCVC stimulates apoptosis, necrosis, and mitochondrial 
dysfunction in kidney cells (Lash and Anders, 1986; Lash et al., 1986; Lash et al., 1994; Xu et 
al., 2008; Lash et al., 2014b). DCVC also stimulates ROS generation, pro-inflammatory 
response, and apoptosis in the HTR-8/SVneo extravillous cytotrophoblast cell line (Hassan et al., 
2016; Elkin et al., 2018). The relevance of DCVC to toxicity is further supported by lack of 
toxicity of CYP-dervied TCE metabolites, such as dichloroacetate (DCA) and trichloroacetate 
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(TCA) (Lash et al., 2014a), in HTR-8/SVneo cells (unpublished data). However, the impact of 
DCVC on the BeWo cell line has not been studied to our knowledge.  
BeWo cells are a cell line that is representative of first-trimester villous cytotrophoblasts 
in vitro (Pattillo and Gey, 1968; Wice et al., 1990). Cytotrophoblastic BeWo cells have been 
used to study the impact of toxicant exposure on placental cells (Zhang et al., 1995; Zhang and 
Shiverick, 1997; Le Vee et al., 2014; Wang et al., 2015). The cytotrophoblastic BeWo cells can 
be induced to fuse and multinucleate, adopting important characteristics consistent with 
syncytiotrophoblasts (Wice et al., 1990). Visual quantification of fusion and multinucleation is a 
method of assessing syncytialization (Matsuura et al., 2011; Li et al., 2015; Zheng et al., 2016). 
Another common assessment of syncytialization involves investigating syncytin-1 and syncytin-
2 as biomarkers (Vargas et al., 2009). Forskolin, an adenylate cyclase activator (Daly, 1984), is 
commonly used to stimulate BeWo cell syncytialization (Wice et al., 1990; Al-Nasiry et al., 
2006; Inadera et al., 2010). 
For the present study, we used the BeWo cell line to test the hypothesis that DCVC 
stimulates apoptosis in a manner that is dependent on the state of syncytialization such that the 
mechanism underlying apoptosis and magnitude of apoptosis differ as a consequence of the 
BeWo cell differentiation state. 
Materials and Methods 
BeWo cell line 
The BeWo human placental villous cytotrophoblast cell line (Patillo and Gey, 1968) was 
obtained from American Type Culture Collection (ATCC CCL-98), and its identity from its short 
tandem repeat (STR) profile was verified with fragment analysis (ABI 3730XL DNA Analyzer, 
Applied Biosystems, Waltham, MA) at the University of Michigan DNA Sequencing Core. The 
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cells were grown in F12-K Nutrient Mixture Kaighn’s Modification with (+) L Glutamine 
(Gibco, Grand Island, NY). DMEM/F12 Nutrient Mixture (Gibco, Grand Island, NY) without 
phenol red was used whenever BeWo cells were treated with an exposure. Treatments for the 
cells were diluted in DMEM/F12 Nutrient Mixture. All media were supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum (HI-FBS) and 1% (v/v) penicillin/streptomycin (P/S) 
(Gibco, Grand Island, NY). Cell cultures were washed three times with phosphate buffered saline 
(PBS) (Invitrogen Life Technologies, Carlsbad, CA) prior to detaching the cells with 0.25% 
trypsin-EDTA (Invitrogen Life Technologies, Carlsbad, CA) for subculture. For regular 
subculture, BeWo cells were plated at a 100,000 cells/mL in 25 mL in 175 cm2 flasks (Corning 
Inc., Corning, NY) and subcultured at 70-80% confluence. Cell cultures were maintained in a 5% 
CO2, 37°C controlled and humidified incubator. This work with human cell cultures was 
approved by the University of Michigan Institutional Biosafety Committee (IBCA00000100). 
Exposures 
DCVC was synthesized by the University of Michigan Medicinal Chemistry Core via a 
previously published method (McKinney et al., 1959), and chemical identity of DCVC was 
verified periodically through proton nuclear magnetic resonance (NMR) spectroscopy and 
determined to be 98.7% pure by high-performance liquid chromatography (HPLC). DCVC was 
dissolved in PBS as a 1 mM stock solution and stored in 1 mL aliquots at -20°C. 
The BeWo cells were plated at 100,000 cells/mL density in either 6 well or 96 well plates 
depending on the experiment and allowed 24 hours to adhere and acclimate prior to initiating 
treatment. The unsyncytialized BeWo cells were exposed to DCVC concentrations spanning 
from 1 µM to 100 µM. The effect of DCVC on forskolin-induced syncytialization of BeWo cells 
was evaluated using co-exposure to DCVC and forskolin. The cytotrophoblastic BeWo cells 
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were syncytialized by culturing the cells with 100 µM forskolin for 48 hours (Wice et al., 1990; 
Al-Nasiry et al., 2006; Inadera et al., 2010). Forskolin was dissolved in dimethyl sulfoxide 
(DMSO) (Tocris Bioscience, Bristol, UK) to create a 100 mM forskolin stock solution, which 
was diluted 1:1000 in medium to create the 100 µM forskolin treatment. Hence, the vehicle 
control used in these experiments was 0.1% (v/v) DMSO. DCVC concentrations in these 
experiments ranged from 1-50 µM.  
We also tested the effects of DCVC exposure on BeWo cells after the 48-hour forskolin-
stimulated syncytialization, hereafter referred to as syncytialized BeWo cells receiving DCVC 
exposure. The concentration range of DCVC in these experiments was also 1-50 µM. DCVC 
concentrations were chosen based on past reports of effects of DCVC at similar concentrations 
(Xu et al., 2008; Lash et al., 2014b; Hassan et al., 2016; Elkin et al., 2018). In addition, the 
DCVC concentration range includes the average concentration of the DCVC precursor DCVG 
(13.4 μM) found in the blood of women exposed by inhalation to the US Occupational Safety 
and Health Administration permissible exposure level (Lash et al., 1999; Agency for Toxic 
Substances and Disease Registry, 2007). Camptothecin (CPT) was purchased from Cayman 
Chemical (Ann Arbor, MI) and was used as a positive control in several experiments. CPT was 
dissolved in DMSO at 5.74 mM prior to administration to cell media. 
Phalloidin-FITC and 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) staining 
Cells were plated at a density of 200,000 cells/well in 2 mL/well in Corning Costar tissue 
culture-treated 6-well plates (Corning, NY; product number 3516) and allowed to adhere for 24 
hours before treatment. After the 48-hour treatment, the medium was removed, and the cells 
were washed three times with PBS. Then, 3.7% formaldehyde was added to the wells for 5 
minutes to fix the cells, and the cells were washed three times with PBS again. Next, phalloidin-
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FITC (Sigma-Aldrich, St. Louis, MO) was applied at a concentration of 3.99 µM (from a stock 
solution of 0.399 mM in DMSO diluted 1:100 in PBS) for 40 minutes at room temperature. Cells 
were washed three times with PBS, and then incubated for 5 minutes at room temperature in 300 
nM 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) (Thermo Fisher Scientific, Waltham, 
MA) (prepared from a 2.86 mM DAPI stock solution in dH2O diluted in PBS). Cells were 
washed three times in PBS again prior to imaging using an EVOS microscope with fluorescence 
capabilities (Thermo Fisher Scientific, Waltham, MA). To obtain an accurate representation of 
the well, three images at 200X magnification were captured and analyzed per well: one near the 
top, one near the middle, and one near the bottom from a top-down direction. 
 Manual scoring of the images was performed to quantify cell multi-nucleation and fusion. 
The fusion index was calculated as follows: fusion index = [(N-S)/T]*100%, as previously 
described (Matsuura et al., 2011; Li et al., 2015; Zheng et al., 2016). In the fusion index, N is the 
number of nuclei in syncytia, S is the total number of syncytia, and T is the total number of 
nuclei. As such, this index is interpreted as the number of fusion events per total nuclei. The 
range of this index is 0 to nearly 100 but not exactly 100. In the case of a fusion index of 0, no 
fusion has occurred, and in the case of nearly 100, all nuclei are within one syncytium (i.e., [(99-
1)/99]*100% = 99%). Complementing the fusion index, the percentage of nuclei in syncytia, or 
(N/T)*100%, was calculated. Unlike the fusion index, the percentage of nuclei in syncytia does 
not decrease based on the number of syncytia (S) present, so the percentage of nuclei in syncytia 
is a value that increases relative to fusion index as the number of syncytia (S) increases or nuclei 
per syncytia (N) decreases. This general property is illustrated in Table S4.1. The numerical 
quantities used in the current study were manually assessed and verified by a research assistant 
given images without knowledge of treatment group. 
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Measurement of cell viability and cytotoxicity 
 BeWo cells were plated at a density of 10,000 cells/well in 100 µL/well in Corning 
Costar tissue cultured-treated 96-well plates (Corning, NY), and allowed to adhere for 24 hours 
before treatment. Cell viability and cytotoxicity were detected sequentially using the Multitox-
Glo Multiplex Cytotoxicity Assay assessed on the Glomax Multi Plus Detection System 
(Promega, Madison, WI), as instructed by the manufacturers. For cell viability assessment, 50 
µL of cell viability assay reagent was added to detect viability via fluorescence, and then plates 
were wrapped in aluminum foil and incubated at 37°C for 45 minutes prior to reading. The 
viability assay works by the principle of cell uptake of a fluorogenic peptide substrate (GF-AFC) 
that is cleaved by live cell protease activity to produce a fluorescence signal proportional to 
number of live cells. After the viability reading, 50 µL of cell cytotoxicity assay reagent was 
added to detect cell cytotoxicity via luminescence, and then plates were wrapped in aluminum 
foil and incubated at room temperature for 15 minutes prior to reading. This cytotoxicity assay 
works by the principle of using a luminogenic peptide substrate (AAF-aminoluciferin) that is 
cleaved by dead cell (i.e., cells with compromised membranes) protease activity to release the 
aminoluciferin product that produces a luminescent signal proportional to the number of dead 
cells. Cytotoxicity data were normalized to protein mass, which was determined from a separate 
set of cells in 96-well plates. Protein was collected in Pierce RIPA Lysis and Extraction Buffer 
(Thermo Fischer Scientific, Waltham, MA) and quantified using the bicinchoninic acid assay 
(Thermo Fisher Scientific, Waltham, MA). The average of nine different protein readings from 
three independent experiments for each experimental group was used for normalization. 
Measurement of caspase 3/7 activity 
170 
 
 Cells were plated in Corning Costar tissue culture-treated 96-well white, clear-bottom 
plates (Corning, NY) at a density of 10,000 cells/well in 100 µL/well and allowed to adhere for 
24 hours before treatment. After treatment, caspase 3/7 activity was measured using a 
luminescence-based Caspase-Glo 3/7 Assay detected with the Glomax Multi Plus Detection 
System (Promega, Madison, WI) according to the manufacturer’s instructions. The assay 
consisted of adding 100 µL of Caspase-Glo substrate in Caspase-Glo buffer followed by 
incubation at 37°C for one hour wrapped in aluminum foil to protect from light. The substrate is 
engineered to be specific in amino acid sequence to caspase 3/7: DEVD. Activity was 
luminogenically detected because the cleavage of the substrate, indicative of caspase activity, 
generates aminoluciferin, which reacts with luciferase to produce light (Niles et al., 2008). 
Caspase 3/7 activity was normalized to protein mass, which was determined from a separate set 
of cells in 96-well plates in Pierce RIPA Lysis and Extraction Buffer (Thermo Fischer Scientific, 
Waltham, MA). Protein was quantified using the bicinchoninic acid assay (Thermo Fisher 
Scientific, Waltham, MA). The average of nine different mass readings from three independent 
experiments for each experimental group was used for normalization. 
Hoechst staining to detect nuclear condensation or fragmentation 
 Cells were plated in Corning Costar tissue culture-treated 6-well plates at a density of 
200,000 cells/well in 2 mL/well and allowed to adhere for 24 hours before treatment. After the 
treatment, the medium was removed, and the cells were washed three times with PBS. The cells 
were fixed with 3.7% formaldehyde for 5 minutes, and then washed three times with PBS again. 
Next, Hoechst 33342 trihydrochloride, trihydrate (Invitrogen Life Technologies, Carlsbad, CA) 
at 0.5 µg/mL (from a 10 mg/mL stock solution diluted 1:20,000 in PBS) was added individually 
to each well to cover the cells. Cells were incubated in the Hoechst solution for 15 minutes, then 
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washed three times with PBS before imaging using an EVOS microscope with fluorescence 
capabilities (Thermo Fisher Scientific, Waltham, MA). Three images were taken per well at 
400X magnification. To provide an accurate representation of the well, images were captured 
near the top, middle, and bottom of each well, going in a top-down direction. 
 Quantification consisted of using ImageJ (NIH, Bethesda, MD) set to a brightness 
threshold that highlighted nuclei sufficiently to visualize nuclear condensation. The settings were 
as follows: hue (0, 255), saturation (0, 255), brightness (165, 255). Under these settings, at least 
10% of the nucleus had to be highlighted in order for the nucleus to be considered condensed. 
Criteria used to assess nuclear fragmentation include consideration of fragmentation into 
multiple pieces, jaggedness of the nuclei, and unequal size of nuclei subsequent to fragmentation. 
Detection of hydrogen peroxide (H2O2) abundance  
 Cells were plated at a density of 10,000 cells/well in 100 µL/well in Corrning Costar 
tissue culture-treated 96-well white, clear-bottom plates (Corning, NY) and allowed to adhere for 
24 hours before treatment. Hydrogen peroxide (H2O2) was detected using the ROS-Glo™ H2O2 
assay (Promega, Madison, WI), performed according to the manufacturer’s instructions. Six 
hours before the end of treatment, 20 µL of the H2O2 substrate solution containing a derivatized 
luciferin substrate was added to each well to bring the volume to 100 µL (specific to this 
protocol, treatments had been added at 80 µL volumes each). After 6 hours, 100 µL of the 
detection solution was added to each well. The assay works by the principle of addition of a 
derivatized luciferin substrate, which produces a luciferin precursor when reacting with H2O2. 
After 6 hours, addition of the detection solution generates a luciferin product that gives off a 
light signal proportional to the amount of H2O2 present extracellularly and intracellularly. The 
H2O2 abundance was normalized to protein mass, which was determined from a separate set of 
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cells in 96-well plates in Pierce RIPA Lysis and Extraction Buffer (Thermo Fischer Scientific, 
Waltham, MA). Protein was quantified using bicinchoninic acid assay (Thermo Fisher Scientific, 
Waltham, MA). The average of nine different protein readings from three independent 
experiments for each experimental group was used for normalization. Menadione (MD) was 
purchased from Sigma-Aldrich (St. Louis, MO) and used as a positive control. MD was directly 
dissolved in a stock solution of cell medium at a 1 mM concentration. 
Detection of pro-inflammatory factors (IL-6, IFN-γ, CRP, and TNF-R1) in media 
Cells were plated at 200,000 cells/well in 2 mL/well in Corning Costar tissue culture-
treated 6-well plates (Corning, NY) and allowed to adhere for 24 hours before treatment. After 
treatment, the medium was collected and stored at -80°C until further processing. Cells were 
scraped and collected in a lysis buffer containing 0.5% (v/v) IGEPAL CA-630 (Sigma-Aldrich, 
St. Louis, MO), 250 mM NaCl (Sigma-Aldrich, St. Louis, MO), and 5% (v/v) of 1 mM Tris-HCl 
(pH 7.4) (Sigma-Aldrich, St. Louis, MO). Protein concentration from the cell lysate was 
measured using the bicinchoninic acid (BCA) assay (Thermo Fischer Scientific, Waltham, MA) 
according to the manufacturer’s protocol. Cytokine concentrations in the medium were 
normalized to the mass of protein present. Media samples were thawed and pipetted into round-
bottom 96-well plates to immediately prior to delivering the samples to the University of 
Michigan Immunologic Monitoring Core. The core performed ELISA assays using Duosets 
(R&D Systems, Minneapolis, MN) according to the manufacturer’s recommended protocol. 
RNA extraction 
Cells were plated in Corning Costar tissue culture-treated 6-well plates at a density of 
200,000 cells/well in 2 mL/well and allowed to adhere for 24 hours before treatment. After 
treatment, the medium was removed and RNA was extracted from the cells using a RNeasy 
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PLUS Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Briefly, 
1 mL of the RLT Buffer Plus reagent (Qiagen, Hilden, Germany) containing 1% (v/v) 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO) was placed in each well to generate cell lysate. 
Cell lysates were homogenized using QIA Shredders (Qiagen, Hilden, Germany) prior to 
continuation of the manufacturer protocol with gDNA elimination as the next step. 
Concentration and purity of RNA were determined using a Nanodrop 2000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA), and RNA was stored at -80°C 
until analyzed. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
To synthesize cDNA from the RNA samples, an iScriptTM cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, CA) was used according to the manufacturer’s protocol. A Bio-Rad CFX 
ConnectTM Real-Time System (Bio-Rad Laboratories, Hercules, CA) was used to carry out the 
cDNA synthesis reaction. The protocol on the Bio-Rad CFX ConnectTM Real-Time System for 
the cDNA synthesis reaction was as follows: (1) 25°C for 5 minutes, (2) 42°C for 30 minutes, (3) 
85°C for 5 minutes, and then (4) a cool down to 4°C. The cDNA was stored at -20°C until 
further use. 
 The qRT-PCR was performed using 25-µL reaction mixtures consisting of the following: 
52.5% (v/v) SsoAdvancedTM Universal SYBR® Green Supermix (Bio-Rad Laboratories, 
Hercules, CA), 0.28 µM of each (forward and reverse) primer, and 32 ng of cDNA template. 
Primer sequences are described in Table S4.2 and were custom-made by Integrated DNA 
Technologies (Coralville, IA). A Bio-Rad CFX ConnectTM Real-Time System (Bio-Rad 
Laboratories, Hercules, CA) was used to perform qRT-PCR according to the manufacturer’s 
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protocol. Analysis was performed using the ΔΔCt method (Yuan et al., 2006), and all samples 
were analyzed in duplicate. B2M served as the reference gene. 
CyQUANT™ NF cell proliferation assay to measure DNA quantity (Used for supplemental 
data) 
 To assess cellular DNA content, the CyQUANT NF Cell Proliferation Assay kit (Thermo 
Fisher Scientific, Waltham, MA) was utilized. Cells were plated in Corning Costar tissue culture-
treated 96-well white, clear-bottom plates (Corning, NY) at a density of 10,000 cells/well in 100 
µL/well and allowed to adhere for 24 hours before treatment. After treatment, the medium was 
removed from the cells, and 100 µL of dye-binding solution (ratio of 1 µL of CyQUANT® NF 
dye reagent to 0.5 mL of 1x HBSS Buffer, as directed by the manufacturer) was added per well. 
After addition of the dye binding solution, cells were incubated in the dark at 37°C for 45 
minutes prior to obtaining a fluorescence reading (excitation = 485 nm, emission = 530 nm) 
using the SpectraMax M2e Multi-Mode Microplate Reader (Molecular Devices, San Jose, CA). 
The fluorescence signal was proportional to DNA content. 
ApoLive-Glo assay to measure cell viability and caspase 3/7 activity  
 BeWo cells were plated in Corning Costar tissue culture-treated 96-well white, clear-
bottom plates at a density of 10,000 cells/well in 100 µL/well. Cells were allowed to adhere for 
24 hours before treatment. Cell viability and caspase 3/7 were detected sequentially using the 
ApoLive-Glo assay from Promega (Madison, WI), performed as instructed by the manufacturer. 
To detect viability via fluorescence, 20 µL of cell viability reagent was added and plates were 
wrapped in aluminum foil and incubated at 37°C for 45 minutes. After the viability reading, 100 
µL of Caspase-Glo substrate in Caspase-Glo buffer was added to detect caspase 3/7 activity via 
luminescence. Plates were wrapped again in aluminum foil and incubated at 37°C for one hour 
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prior to the caspase 3/7 activity reading. The scientific principles behind how the viability and 
caspase 3/7 activity measurements work on a molecular level have been described in previous 
sections in the current chapter. Luminescence was detected using the Glomax Multi Plus 
Detection System. 
Statistical analysis 
 Statistical analyses included one-way ANOVA and mixed model ANOVA with treatment 
as fixed variable and experiment day as random variable. One-way ANOVA was performed 
using GraphPad Prism 7 (GraphPad Software, San Diego, CA). Mixed model ANOVA was 
performed using SPSS Software (IBM Corporation, Chicago, IL). Percentage data were 
transformed to fractions and arcsine transformed prior to statistical analysis. All ANOVAs were 
followed with Tukey’s post-hoc comparison of means. All graphs were generated using 
GraphPad Prism 7 (GraphPad Software, San Diego, CA). A p<0.05 was considered statistically 
significant. 
Results 
Effects of forskolin and DCVC co-treatment with forskolin on syncytialization 
 To verify our model of forskolin-stimulated syncytialization of BeWo cells, we exposed 
cytotrophoblastic BeWo cells to 0, 10, 20 50 or 100 µM of forskolin for 48 hours. These cells 
were co-stained with phalloidin-FITC and DAPI to identify the nuclei and plasma membranes, 
respectively, and thereby visualize cellular fusion and multinucleation (Figure 4.1A). As seen in 
Figures 4.1B1 and 4.1B2, forskolin increased the fusion index and percentage of nuclei in 
syncytia in a concentration-dependent manner, respectively. Treatment with 100 µM forskolin 
increased the fusion index and percentage of nuclei in syncytia by 671.8% and 531.8%, 
respectively, relative to control (0.1% DMSO) (p<0.0001). Because the indices of 
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syncytialization were substantially increased by 100 µM forskolin compared with lower 
forskolin concentrations, and because forskolin treatment for 48 hours is established as effective 
by others (Wice et al., 1990; Al-Nasiry et al., 2006; Inadera et al., 2010), we used 100 µM 
forskolin exposures for 48 hours to stimulate syncytialization in BeWo cells in the remainder of 
our experiments. 
 To investigate DCVC effects on the process of syncytialization, 5 µM to 50 µM DCVC 
was added as a co-exposure with 100 µM forskolin. As expected, forskolin treatment alone 
increased indices of syncytialization relative to vehicle control, including: (1) increased fusion 
index by 625.6% (p<0.0001), (2) increased percentage of nuclei in syncytia by 510.8% 
(p<0.0001), (3) increased ERVW-1 (syncytin-1) mRNA expression by 159.6% (p=0.0276), and 
(4) increased ERVFRD-1 (syncytin-2) mRNA expression by 2241.2% (p=0.0130) (Figures 
4.1C1, 4.1C2, 4.1C3, 4.1C4, respectively). However, treatment with DCVC did not significantly 
alter responses compared with forskolin-only treatment (Figures 4.1C1-4.1C4). The apparent 
reduction of forskolin-stimulated ERVFRD-1 mRNA expression by co-treatment with 50 µM 
DCVC was not statistically significant (p=0.1714) (Figure 4.1C4). 
Responses relevant to syncytialization were also measured in unsyncytialized BeWo cells 
exposed to 5-50 µM DCVC for 48 hours in the absence of forskolin. DCVC treatment at 5, 10, 
20, or 50 µM for 48 hours did not stimulate an increase in the fusion index or an increase in the 
percentage of nuclei in syncytia relative to control (0 µM DCVC) (Figures 4.1D1 and 4.1D2, 
respectively). Furthermore, those DCVC treatments did not stimulate an increase in ERVW-1 or 
ERVFRD-1 mRNA expression relative to control (0 µM DCVC) (Figures 4.1D3 and 4.1D4, 
respectively). 
Effects of DCVC on cell viability and cytotoxicity 
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 Treatment for 48 hours with 50 µM but not lower concentrations of DCVC decreased cell 
viability by 28.4% in unsyncytialized cytotrophoblastic BeWo cells relative to control (0 µM 
DCVC exposure) (p<0.0001) (Figure 4.2A1). Cytotoxicity, which was used as a proxy for dead 
cells, increased in unsyncytialized cytotrophoblastic BeWo cells exposed for 48 and 72 hours to 
50 µM DCVC but not lower concentrations of DCVC, relative to control (0 µM DCVC) (84.8%  
and 191.6% increase, respectively; p<0.0001 for both) (Figures 4.2A2 and 4.2B2, respectively). 
After exposure for 72 hours on unsyncytialized BeWo cells, 10, 20 and 50 µM DCVC treatment 
significantly reduced cell viability relative to control (0 µM DCVC) by 12.2% (p=0.023), 27.8% 
(p<0.0001) and 57.4% (p<0.0001), respectively (Figure 4.2B1). 
 In BeWo cells undergoing forskolin-stimulated syncytialization, 50 µM DCVC decreased 
cell viability relative to forskolin-only treatment by 42.6% (p<0.0001), whereas 1, 5, 10, and 20 
µM DCVC did not (Figure 4.2C1). Although treatment with 20 µM DCVC modestly decreased 
viability of cells undergoing forskolin-stimulated syncytialization compared with vehicle control 
(without DCVC or forskolin) and lower concentrations of DCVC, this decrease was not 
statistically different compared with the forskolin-only treatment (Figure 4.2C1). In this 
experiment, the exposure duration was 48 hours to match the exposure duration used for 
forskolin stimulation of syncytialization. Treatment with forskolin alone did not alter cell 
viability relative to vehicle control. In BeWo cells undergoing forskolin-stimulated 
syncytialization, exposure to both 20 and 50 µM DCVC increased cytotoxicity by 35.5% and 
153.4%, respectively, relative to forskolin-only treatment (p=0.001 and <0.0001, respectively), 
whereas lower concentrations of DCVC had no significant effects on cytotoxicity (Figure 
4.2C2). Interestingly, forskolin only treatment increased cytotoxicity by 76.3% relative to 
vehicle control (0.1% DMSO) (p<0.0001) (Figure 4.2C2). 
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A similar pattern was observed in BeWo cells exposed to DCVC after a 48-hour 
syncytialization with forskolin. Exposure for 48 hours to 50 µM DCVC decreased cell viability 
by 45.2% (p<0.0001) relative to control (0 µM DCVC), but 1, 2, 5, 10, or 20 µM DCVC had no 
significant effects (Figure 4.2D1). In syncytialized BeWo cells, 50 µM but not 1, 2, 5, 10, or 20 
µM DCVC treatment for 48 hours increased cytotoxicity relative to control (0 µM DCVC) 
(151.5%; p<0.0001) (Figure 4.2D2). 
Effects of DCVC on caspase 3/7 activity  
 Treatment of unsyncytialized cytotrophoblastic BeWo cells with 50 µM DCVC for 48 
and 72 hours increased caspase 3/7 activity by 57.8% and 230.6%, respectively, relative to 
control (0 µM DCVC) (p<0.0001) (Figures 4.3A and 4.3B, respectively). Exposure to 100 µM 
DCVC for 72 hours increased caspase 3/7 activity by 145.2% relative to control (p<0.0001), 
reduced from the peak activation observed with 50 µM DCVC (Figure 4.3B). Exposure to 1, 2, 
5, 10, or 20 µM DCVC did not increase caspase 3/7 activity at either 48 or 72 hours. 
 When DCVC exposure was concurrent with forskolin-stimulated cell syncytialization, 50 
µM DCVC, but not 1, 5, 10, or 20 µM DCVC, increased caspase 3/7 activity relative to 
forskolin-only treatment (85.4%; p<0.0001) (Figure 4.3C). In BeWo cells that had been 
syncytialized, 48-hour exposure to 50 µM DCVC but not lower DCVC concentrations also 
increased caspase 3/7 activity relative to control (0 µM DCVC) (102.0% increase, p<0.0001) 
(Figure 4.3D). Forskolin treatment by itself did not change caspase 3/7 activity relative to 
vehicle control (0.1% DMSO) under any of the experimental conditions tested. 
Effects of DCVC on nuclear condensation or fragmentation 
 Unsyncytialized cells exposed for 48 hours to 50 µM DCVC but not 5, 10 or 20 µM 
DCVC exhibited significantly increased percent of nuclei that were condensed or fragmented 
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compared to control (0 µM DCVC) (291.7% increase, p=0.0475) (Figure 4.4B1). Similarly, in 
BeWo cells undergoing forskolin-stimulated syncytialization, 50 µM DCVC significantly 
increased the percent of condensed or fragmented nuclei compared with forskolin alone (208.0% 
increase, p=0.0065) (Figure 4.4B2). Forskolin by itself did not increase nuclear condensation or 
fragmentation relative to control. Furthermore, 24- and 48-hour DCVC exposures of 
syncytialized BeWo cells significantly increased nuclear condensation or fragmentation at 50 
µM DCVC but not lower DCVC concentrations (101.5% and 273.8% increase, respectively; 
p=0.0214 and 0.0256, respectively) (Figures 4.4B3 and 4.4B4, respectively). We performed the 
CyQuant assay for DNA quantity to evaluate the contribution of cell division to nuclear 
condensation. We observed no change in CyQuant detection of DNA quantity under any of the 
experimental conditions for assessment of nuclear condensation and fragmentation (Figures 
S4.1A, S4.1C, and S4.1D). At the 72-hour time point of exposure in unsyncytialized BeWo 
cells, however, 50 and 100 µM DCVC exposure decreased DNA quantity relative to control (0 
µM DCVC) by 49.8% and 66.1%, respectively (p<0.0001) (Figure S4.1B). 
Effects of DCVC on biomarkers of oxidative stress 
 In unsyncytialized BeWo cells, DCVC exposure increased generation of hydrogen 
peroxide (H2O2) after 48 hours of exposure to 20 and 50 µM DCVC by 47.1% and 259.3%, 
respectively, relative to control (0 µM DCVC) (p= 0.046 and <0.0001, respectively) (Figure 
4.5A1). The hydrogen peroxide stimulation in unsyncytialized cells was accompanied by 
decreased PRDX2 mRNA expression at 10, 20 and 50 µM DCVC relative to control (0 µM 
DCVC) by 20.5%, 23.9%, and 44.6%, respectively (p= 0.0202, 0.0057, and <0.0001, 
respectively) (Figure 4.5A2). However, PRDX1 mRNA expression was unchanged by DCVC in 
unsyncytialized cells (Figure 4.5A3). 
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 In BeWo cells undergoing forskolin-stimulated syncytialization, 50 µM DCVC increased 
generation of H2O2 by 148.3% relative to forskolin-only treatment (p<0.0001) (Figure 4.5B1). 
Interestingly, syncytialization by itself decreased H2O2 generation by 51.5% relative to vehicle 
control (p<0.0001) (Figure 4.5B1). Similar to unsyncytialized cells, 50 µM DCVC decreased 
PRDX2 mRNA expression in BeWo cells undergoing syncytialization (62.9% decrease relative 
to forskolin-only treatment, p=0.0091) (Figure 4.5B2). No differences in PRDX1 mRNA 
expression were found for DCVC effects on BeWo cells undergoing syncytialization (Figure 
4.5B3). 
 After 24 hours of DCVC exposure, syncytialized BeWo cells exhibited decreased mRNA 
expression of PRDX1 and PRDX2 relative to control (0 µM DCVC). The PRDX1 mRNA 
expression was significantly decreased by 10, 20, and 50 µM DCVC (50.6%, 39.6%, and 44.1% 
decrease, respectively; p=0.0067, 0.0427, and 0.0202, respectively), and the PRDX2 mRNA 
expression was decreased by 20 and 50 µM DCVC (33.0% and 38.6% decrease, respectively; 
p=0.0223 and 0.0064, respectively) (Figures 4.5C1 and 4.5C2, respectively). In syncytialized 
BeWo cells, 50 µM DCVC increased H2O2 by 174.3% relative to control (0 µM DCVC) after a 
48-hour exposure (p<0.0001) (Figure 4.5D1), with no significant changes observed at lower 
DCVC concentrations. After 48 hours, DCVC exposure had no significant effect on PRDX1 and 
PRDX2 mRNA in syncytialized BeWo cells (Figures 4.5D2 and 4.5D3, respectively). 
Effects of DCVC on pro-inflammatory responses  
 To assess pro-inflammatory responses, interleukin-6 (IL-6), C-reactive protein (CRP), 
interferon-γ (IFN- γ), and tumor necrosis factor-receptor 1 (TNF-R1) were measured in cell 
culture media. In addition, changes in NFKB1 mRNA expression were assessed. In 
unsyncytialized BeWo cells, DCVC exposures ranging from 5-50 µM had no significant effects 
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on NFKB1 mRNA expression or on TNF-R1 and IL-6 media concentrations relative to control (0 
µM DCVC) (Figures 4.6A1, 4.6A2, and 4.6A3, respectively). Equivalent DCVC exposures on 
unsyncytialized BeWo cells also had no significant effects on IFN-γ and CRP media 
concentrations relative to control (0 µM DCVC) (Figures S4.2A1 and 4.2A2, respectively). 
Similarly, DCVC had no significant effects on NFKB1 mRNA, TNF-R1, or IL-6 responses in 
BeWo cells undergoing forskolin-stimulated syncytialization compared to forskolin-only 
treatment (Figures 4.6B1, 4.6B2, and 4.6B3, respectively). Negative results were also observed 
for CRP or IFN-γ media concentrations (Figures S4.2B1 and S4.2B2, respectively). 
Interestingly, syncytialization stimulated IL-6 release into media (91.0% increase comparing 
forskolin-only treatment to vehicle control; p=0.0028) (Figure 4.6B3). 
  In syncytialized cells, decreased NFKB1 mRNA expression was significantly depressed 
after 24 hours of exposure to 5, 20, and 50 µM DCVC relative to control (44.8%, 45.1%, and 
49.5% decrease, respectively; p= 0.0367, 0.0351, and 0.0181, respectively) (Figure 4.6C1). 
After 48 hours of exposure, NFKB1 mRNA expression was significantly decreased only with the 
10 µM DCVC exposure relative to control (47.8% decrease, p=0.0247) (Figure 4.6C2). In 
syncytialized cells, 48-hour treatment with 50 µM DCVC decreased TNF-R1 in cell media by 
48.4% after 48 hours of exposure, compared with controls (p=0.0140) (Figure 4.6C3), but had 
no significant effect on IL-6 concentrations in cell media (Figure 4.6C4). In addition, DCVC 
had no significant effects on CRP or IFN-γ concentrations in media (Figure S4.2C1 and 
S4.2C2, respectively). Cell media concentrations of TNF-R1, IL-6, CRP, or IFN-γ were not 
measured for syncytialized BeWo cells at the 24-hour time point of DCVC exposure. 
Effects of DCVC on expression of apoptotic pathway genes 
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 We evaluated changes in mRNA expression of apoptotic pathway genes including BCL2 
(codes for B-cell lymphoma 2, apoptosis regulator), BAK1 (codes for BCL2 antagonist/killer 1), 
and LGALS3 (codes for Galectin-3). In unsyncytialized cells, DCVC had no statistically 
significant effects on BCL2 and BAK1 mRNA expression compared with controls (Figures 
4.7A1 and 4.7A2, respectively), but LGALS3 mRNA expression was significantly decreased 
relative to control at 20 µM DCVC (38.3% decrease, p=0.0066) (Figure 4.7A3). In cells 
undergoing syncytialization, forskolin treatment alone increased BCL2 mRNA expression 
relative to its control (0.1% DMSO) (441.2% increase, p=0.0030) (Figure 4.7B1). Exposure to 
20 µM and 50 µM DCVC depressed the forskolin-stimulated BCL2 mRNA increase by 60.0% 
and 74.1%, respectively (p=0.0364 and 0.0073, respectively) (Figure 4.7B1). BAK1 and 
LGALS3 and mRNA expression were unchanged by syncytialization or DCVC co-treatment 
during syncytialization (Figures 4.7B2 and 4.7B3, respectively). 
 Similarly, syncytialized BeWo cells exhibited decreased BCL2 mRNA expression 
following exposure to 20 and 50 µM DCVC for 24 hours relative to control (50.7% and 60.8% 
decrease, respectively; p= 0.0156 and 0.0037, respectively) (Figure 4.7C1). BCL2 mRNA 
expression also decreased with 5, 10, and 20 µM DCVC treatments for 48 hours relative to 
control (0 µM DCVC) (65.5%, 74.7%, and 66.7% decrease, respectively; p=0.0004, 0.0002, and 
0.0004, respectively) (Figure 4.7D1). LGALS3 mRNA expression was unchanged by DCVC 
treatment in syncytialized BeWo after 24 and 48 hours of exposure (Figures 4.7C2 and 4.7D2, 
respectively). In experiments involving 48-hour DCVC exposure of syncytialized BeWo cells, 
the RNA yield for the 50 µM DCVC concentration was insufficient (Figures 4.7D1 and 4.7D2); 
therefore, no mRNA expression data could be obtained with the 50 µM DCVC concentration 
group. 
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Discussion 
 This study compares mechanisms by which unsyncytialized BeWo cells, BeWo cells 
undergoing syncytialization, and syncytialized BeWo cells undergo apoptosis in response to the 
trichloroethylene metabolite DCVC. DCVC was more effective at stimulating cell death 
observed in syncytialized BeWo cells compared to the two other BeWo models. The data suggest 
that DCVC-stimulated mechanisms of cell death had numerous similarities in unsyncytialzed 
BeWo cells and BeWo cells undergoing syncytialization but differed compared with the 
syncytialized BeWo cells. A prominent distinction is that decreased TNF-R1 media 
concentration and NFKB1 mRNA expression were observed in the syncytialized BeWo cells but 
not in BeWo cells undergoing syncytialization or in unsyncytialized BeWo cells. 
 We observed that DCVC-induced cell death in the BeWo cells was consistent with 
apoptosis, regardless of whether the cells were unsyncytialized, undergoing syncytialization, or 
syncytialized at the time of DCVC exposure. Many of the responses occurred at similar 
concentrations in the three different BeWo models. For all three types of BeWo cells at 48 hours 
of DCVC exposure, increased cytotoxicity, increased caspase 3/7 activity, increased nuclear 
condensation or fragmentation was observed at 50 µM DCVC concentration relative to the 
respective controls. The corresponding decreased viability in all three cell types regardless of 
differentiation state adds validity to our results. The measurements of viability, which is a proxy 
for quantity of viable cells, and cytotoxicity, which was a proxy for number of dead cells, tested 
if the amount of viable cell decrease was coupled with an increase in dead cells normalized to 
total protein content. The normalization to protein accounts for the fact that lower protein 
quantity by itself hampers production of the aminoluciferase dead cell signal and is already 
reflected in a viability reading. Therefore, our results are consistent with DCVC stimulation of 
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deleterious downstream outcomes (cytotoxicity, caspase 3/7, percentage of nuclei condensed or 
fragmented) and suppression of viability. Additionally, our results revealed that 50 µM DCVC 
was almost always the lowest DCVC concentration necessary to elicit downstream effects in 
BeWo cells regardless of differentiation status. 
Explanations exist for the similar effects of DCVC on caspase 3/7 activity and nuclear 
condensation or fragmentation regardless of BeWo differentiation status. Because caspase-3 is an 
executioner caspase downstream in apoptosis pathways at a point in which the intrinsic and 
extrinsic pathways of apoptosis converge (Parrish et al., 2013), it is plausible that DCVC 
stimulates apoptosis. In addition, nuclear condensation and fragmentation are hallmarks of 
apoptosis (Matassov et al., 2004; Errami et al., 2013; Crowley et al., 2016). Neither 
condensation nor fragmentation alone is sufficient for apoptosis, and apoptosis can happen in the 
presence of only one but not the other (Zhang et al., 2001). Percentage of condensed or 
fragmented nuclei was chosen as an index that would capture most apoptotic nucleic while 
minimizing the chance of overlooking some apoptotic nuclei. Therefore, the increased 
percentage of nuclear condensation or fragmentation validates our observation that DCVC 
increased caspase 3/7 activity and increased percentage of nuclear condensation or 
fragmentation. Although it is possibile that some nuclei counted as positive were undergoing cell 
division, we suggest that the changes in percentage of nuclei condensed or fragmented most 
likely reflect apoptosis because we only observed DCVC-stimulated changes to DNA quantity 
after 72 hours but not at earlier time points in unsyncytialized BeWo cells (Figure S4.1). 
DCVC stimulated larger changes in viability, cytotoxicity, and caspase 3/7 activity for 
syncytialized BeWo cells and BeWo cells undergoing syncytialization compared to 
unsyncytialized BeWo cells. A particularly important note is the larger DCVC-stimulated 
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increases in cytotoxicity and caspase 3/7 activity for syncytialized BeWo cells and BeWo cells 
undergoing syncytialization compared to unsyncytialized BeWo cells at the 48-hour time point. 
Because the DCVC-stimulated caspase 3/7 findings are similar in magnitude for a given BeWo 
model to the respective DCVC-stimulated cytotoxicity result, with the magnitudes associated 
with unsyncytialized BeWo cells as smallest, we suggest that increased cytotoxicity is at least 
partly driven by caspase 3/7. Together, the findings suggest that syncytialized BeWo cells and 
BeWo cells undergoing syncytialization may be most sensitive to DCVC-stimulated toxicity. 
In contrast to the responses downstream in apoptotic signaling pathways and cellular 
responses, responses upstream in the apoptotic pathway were stimulated at lower concentrations 
of DCVC exposure for all three models of BeWo cells. These include transcriptional changes, 
such as DCVC-stimulated decreases in mRNA expression of PRDX2 and BCL2, with BCL2-
decreases most notable in BeWo cells undergoing syncytialization and syncytialized BeWo cells. 
In the unsyncytialized BeWo cells, a lower concentration, 10 µM DCVC, decreased PRDX2 
mRNA expression after 48 hours of exposure, but decreased viability was not observed until the 
72-hour time point. Similarly, in syncytialized BeWo cells, 20 and 50 µM DCVC decreased 
PRDX2 mRNA expression at 24 hours of exposure whereas decreased viability, increased 
cytotoxicity, and increased caspase 3/7 activity from 50 µM DCVC exposure were not observed 
until the 48-hour time point. Together, these findings suggest that transcriptional changes led to 
the more downstream changes of viability, cytotoxicity, caspase 3/7 activity, and nuclear 
condensation/fragmentation. Possible future work to confirm a sequence of events include 
knock-out or pharmacological inhibition experiments that are beyond the scope of the current 
study. 
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The DCVC-stimulated decreases in PRDX1 and PRDX2 observed in the current study 
could be relevant to placental health. Both peroxidredoxin proteins are reduced if 
syncytialization is inhibited in BeWo cells through hypoxia compared to normal syncytialization 
(Hu et al., 2007). Moreover, BeWo cells with PRDX2 knocked down are unable to syncytialize 
(Wu et al., 2017). Both peroxiredoxin genes are highly expressed in the placenta (Fagerberg et 
al., 2014). However, PRDX1 is expressed at roughly twice the level of PRDX2 (Fagerberg et al., 
2014). A possible explanation for our finding that DCVC decreased PRDX2 to a greater extent 
than PRDX1 is that PRDX1 may be more essential to cytotrophoblasts and syncytiotrophoblasts 
than PRDX2. Both peroxiredoxin 1 and 2 scavenge hydrogen peroxide (H2O2), reduce other 
enzymes such as thioredoxins, and are anti-apoptotic through similar mechanisms (Ishii et al., 
2012). Whereas the anti-apoptotic mechanism for peroxiredoxin 1 involves ASK1 and JNK 
suppression, that for peroxiredoxin 2 involves ASK1 suppression (Ishii et al., 2012). Both 
peroxiredoxins could also prevent apoptosis in a Bcl-2-dependent manner (Jin et al., 2017; Lu et 
al., 2019; Lu et al., 2020; Yang et al., 2020). Peroxiredoxin 1 could also activate inflammation 
and apoptosis via toll-like receptor-4 in the context of ischemia-reperfusion injury (Liu and 
Zhang, 2019). Therefore, whereas we found PRDX1 and PRDX2 responses to be relevant to 
H2O2 and BCL2 responses, the impact of DCVC on ASK1 and JNK remain worthy 
considerations in investigating DCVC-stimulated cell death. Additionally, the role of 
peroxiredoxin 1 and 2 in relation to ROS and apoptotic outcomes, especially in relation to 
placenta, are worthy of future work. 
BCL2 and LGALS3 are critical in apoptosis and were modified by DCVC dependent on 
BeWo cell differentiation state. BCL2 and LGALS3 code for Bcl-2 and Galectin-3, respectively, 
proteins important with anti-apoptotic functions and capable of heterodimerization to inhibit 
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apoptosis (Yang et al., 1996; Yang et al., 2008; Newlaczyl and Yu, 2011). Interestingly, both 
Galectin-3 and Bcl-2 family proteins have a NWGR (Asp-Trp-Gly-Arg) motif in their 
carbohydrate recognition domains that is thought to contribute to their anti-apoptotic activity 
(Yang et al., 1996; Akahani et al., 1997; Colnot et al., 1998). In unsyncytialized BeWo cells, 
DCVC decreased LGALS3 mRNA expression at 20 µM DCVC whereas DCVC at various 
concentrations decreased BCL2 mRNA expression in BeWo cells undergoing syncytialization 
and in syncytialized BeWo cells. In syncytialized BeWo cells or BeWo cells undergoing 
syncytialization, the decrease of either BCL2 or LGALS3 mRNA expression could be sufficient 
to allow apoptosis to occur because the protein products are structurally and functionally similar 
(Yang et al., 1996; Akahani et al., 1997; Colnot et al., 1998; Yang et al., 2008; Newlaczyl and 
Yu, 2011). Similarly, in unsyncytialized BeWo cells, a balance between BCL2 and LGALS3 may 
regulate apoptosis. 
 Interactions between NF-κB and ROS provide insight into the mechanism of action of 
DCVC towards apoptosis. Firstly, NF-κB reduces ROS by interacting with ferritin heavy chain 
or manganese superoxide dismutase (Papa et al., 2005; Bubici et al., 2006). Alternatively, in 
response to ROS, TNF-R1 becomes activated (Papa et al., 2005), which increases NF-κB and its 
transcription (Bubici et al., 2006; Wajant and Scheurich, 2011; Annibaldi and Meier, 2018). The 
ability of NF-κB to reduce ROS in the first mechanism may also be a way by which NF-κB 
compensates for the increased ROS in the second mechanism. In the case of DCVC exposure of 
syncytialized BeWo cells, the mechanism of NF-κB seems to favor a mechanism in which NF-
κB reduces ROS (Papa et al., 2005; Bubici et al., 2006) with DCVC-stimulated suppression of 
NFKB1. Indeed, DCVC decreased NFKB1 mRNA expression, increased H2O2 generation, and 
increased apoptosis, suggesting that NFKB1 may activate a mechanism to reduce ROS in the 
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syncytialized BeWo cells (Papa et al., 2005; Bubici et al., 2006) as part of an anti-apoptotic 
response. Because TNF-R1 is a positive regulator of NFKB transcription (Bubici et al., 2006; 
Wajant and Scheurich, 2011; Annibaldi and Meier, 2018), our data of decreased TNF-R1 and 
decreased NFKB1 mRNA expression suggest that NFKB1 may be regulated by TNF-R1 in 
syncytialized BeWo cells, as well. However, the extent to which TNF-R1 may respond to ROS 
in the context of DCVC exposure is currently unknown. The interaction among DCVC and 
ferritin heavy chain and manganese superoxide dismutase also remain unknown. These remain 
directions worthy of future investigation in order to understand mechanisms of DCVC-
stimulated ROS more completely. 
 BeWo cell models have limitations as well as strengths. Forskolin stimulates 
unsyncytialized BeWo cells to adopt characteristics that are consistent with in vivo 
syncytialization and syncytiotrophoblasts, including increased cell fusion and multinucleation 
(Wice et al., 1990; Wang et al., 2014). Forskolin is more effective than other agents for 
stimulating cell fusion and other characteristics in BeWo cells that are consistent with normal 
syncytialization, including increased synthesis and secretion of human chorionic gonadotrophin 
(hCG) (Wice et al., 1990). However, syncytiotrophoblasts in primary cell culture exhibit some 
different characterististics from BeWo b30 cells (a specific clone of BeWo cells) that have been 
syncytialized (Wice et al., 1990). These include differing levels of expression of placental 
alkaline phosphatase, human placental lactogen, and Schwangerschafts protein 1 (Wice et al., 
1990). It has been proposed that syncytriotrophoblasts obtained from differentiating BeWo cells 
are biochemically representative of an early placenta stage near 10 weeks gestation age (Wice et 
al., 1990). 
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We report here some novel findings in regard to syncytialization that contribute to our 
understanding of the relevance of in vitro syncytialization to in vivo syncytialization. We found 
that syncytialization decreased hydrogen peroxide generation, which has not been previously 
reported. This is consistent with literature indicating the importance in syncytialization of 
peroxiredoxin 1 and peroxiredoxin 2, which scavenge H2O2 (Hu et al., 2007; Wu et al., 2017). 
We also found that syncytialization increased interleukin-6 (IL-6) release, which has not been 
previously reported nor suggested to have a role in syncytialization, suggesting a noteworthy 
future direction. Our finding of increased BCL2 mRNA expression with syncytialization is 
consistent with a prior report that syncytialization increases BCL2 mRNA expression in BeWo 
cells and human primary cytotrophoblasts (Zheng et al., 2016). Bcl-2 is anti-apoptotic, is thought 
to control excessive apoptosis during syncytialization (Huppertz et al., 1998), and may account 
for why we did not observe syncytialization to increase caspase-3. In contrast, our finding of 
increased cytotoxicity with forskolin stimulation, which activates adenylate cyclase and 
increases cAMP (Daly, 1984), is consistent with a previous report showing that elevated levels of 
cAMP stimulate apoptosis for proper lymphocyte development and homeostasis (McConkey et 
al., 1990). Follow-up of these findings would provide important information concerning the 
relevance of the BeWo in vitro syncytialization cell model for studies of human placental cell 
responses. 
 The DCVC concentrations used in the current study are relevant with respect to human 
occupational exposures and prior studies of DCVC toxicity. Firstly, women exposed by 
inhalation to 100 ppm TCE, which is the United States Occupational Safety and Health 
Administration permissible exposure level (Agency for Toxic Substances and Disease Registry, 
2007), had an average of 13.4 µM of DCVG in their blood serum (Lash et al., 1999). Because 
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DCVG is the TCE metabolic precursor to DCVC in a 1:1 stoichiometric ratio (Lash et al., 
2014a), the concentration range of 1-50 µM used in the present study encompasses blood 
concentrations relevant for occupational exposures to TCE. In comparison of DCVC to other 
TCE metabolites, we have observed that the TCE metabolites dichloroacetic acid (DCA) and 
trichloroacetic acid (TCA) (Lash et al., 2014a) elicit very modest effects in unsyncytialized 
BeWo cells (Figure S4.3). 
Secondly, the DCVC concentrations used in the present study have relevance to prior 
studies using DCVC. DCVC induces significant effects on cell apoptosis, mitochondrial 
dysfunction, and energy metabolism in HTR-8/SVneo placental cells, a cell line representative of 
extravillous cytotrophoblasts, with DCVC concentrations ranging from 5-100 µM, (Elkin et al., 
2018; Elkin et al., 2019; Elkin et al., 2020). These findings in HTR-8/SVneo cells are consistent 
with our findings of apoptosis in BeWo cells, although the impact of DCVC in BeWo cells on 
mitochondrial dysfunction and energy metabolism remain to be investigated. Because a prior 
study reported significant stimulation of apoptosis in HTR-8/SVneo cells following 24-hour 
exposure to 20 µM DCVC (Elkin et al., 2018), whereas 48-hour exposure to 50 µM DCVC was 
required for significant stimulation of apoptosis in the BeWo cells, the HTR-8/SVneo cells may 
be more sensitive to DCVC compared to BeWo cells. Moreover, incubation with 10 µM DCVC 
for 4 hours or 5 µM DCVC for 24 hours blocked lipoteichoic acid (LTA)-stimulated release of 
tumor necrosis factor-α (TNF-α) from extraplacental membranes in culture (Boldenow et al., 
2015), highlighting the effectiveness of acute and low-concentration DCVC exposure in a related 
model. In kidney cells, DCVC stimulates significant apoptosis from concentrations ranging from 
10-200 µM DCVC with 4- and 24-hour exposure durations. Decreased cellular respiration was 
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observed in human proximal tubular (hPT) kidney cells exposed to DCVC concentrations 
ranging from 10-500 µM DCVC at the 1, 4, 24, and 48 hour time points (Xu et al., 2008). 
Our findings of DCVC toxicity as dependent on particular cell type is consistent with a 
prior report. Looking at differences in DCVC-stimulated responses across passage generation in 
hPT kidney cells, Lash et al. found that cells at passage 4 exhibit greater DCVC-stimulated 
apoptosis compared to earlier passage cells especially at the 25 and 50 µM DCVC concentrations 
(Lash et al., 2014b). This finding highlights that DCVC toxicity depends on the status of a cell 
type, whether it is differentiation state or passage number. Because of these differences in 
response to DCVC and because TCE is toxic to various organs, including kidney (Green et al., 
1997a; Xu et al., 2008; Lash et al., 2014b), liver (Bull, 2000), and lungs (Forkert et al., 1985; 
Green et al., 1997b), future studies should aim to characterize levels of DCVC toxicity in other 
cell types from other organs to further inform sensitive cell populations to DCVC exposure. 
 Particularly for the unsyncytialized BeWo cells, exposures were performed at 48 hours in 
duration or longer. Whereas this is consistent with time points for BeWo cells to achieve 
syncytialization, studies at earlier time points are informative. Similar to effects at 48 hours, 
DCVC increased the percentage of condensed or fragmented nuclei at the 24-hour time point of 
exposure in unsyncytialized BeWo cells (Figure S4.4). As such, unsyncytialized BeWo cells 
may serve as a good model for short-term exposures, as well. The relationship and mechanisms 
between short-term exposures and long-term exposures are currently unknown and worthy of 
future study. This is particularly true for transcriptional mechanisms that may initiate additional 
mechanisms. 
 In summary, the current study provides new information comparing DCVC-stimulated 
apoptotic responses in BeWo cells in three different states of differentiation: unsyncytialized 
192 
 
BeWo cells, BeWo cells undergoing syncytialization, and syncytialized BeWo cells. These 
responses were observed primarily at the 50 µM DCVC concentration for 48 hours of exposure, 
although decreased cell viability occurred with DCVC concentrations as low as 10 µM when 
exposure time was extended to 72 hours. Some responses, including increased H2O2 abundance, 
decreased PRDX2 mRNA expression, and decreased BCL2 mRNA expression, occurred at lower 
concentrations of DCVC and equivalent or shorter exposure durations, supporting potential roles 
for stimulating apoptosis. These findings can inform future studies of possible interventions for 
reducing TCE- and DCVC-stimulated toxicity in placental cells, as well as expand upon the 
sequence of events leading to apoptosis in BeWo cells. Importantly, the current study suggests 
that syncytiotrophoblasts may be more sensitive to DCVC than villous cytotrophoblasts, 
evidenced by differences in responses of syncytialized BeWo cells compared to unsyncytialized 
BeWo cells. Notably, the mechanisms proposed by which DCVC-stimulated apoptosis may 
occur differ by differentiation state of the BeWo cells (Figures 4.8, 4.9, and 4.10). Whereas the 
proposed mechanism involves PRDX2 and H2O2 alterations in unsyncytialized BeWo cells 
(Figure 4.8) and BeWo cells undergoing syncytialization (Figure 4.9), the mechanism proposed 
in syncytialized BeWo cells (Figure 4.10) involves TNF-R1 and NFKB1, in addition to PRDX2 
and H2O2. As a whole, this study informs differing mechanisms of toxicity based on placental 
cell type, which can be used to understand differences in susceptibility to DCVC toxicity. Future 
studies can use these findings as a guideline for duration and concentrations of DCVC exposure 
likely to yield effects for additional cell types representing different organs to understand 
additional susceptible tissues. 
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(A) Visualization of forskolin-stimulated syncytialization 
Vehicle (0.1% DMSO) 
 
10 µM Forskolin  
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50 µM Forskolin 
 
100 µM Forskolin 
 
 
(B) Quantification of concentration-dependent response of forskolin-stimulated 
syncytialization 
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(C) DCVC effect on syncytialization 
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(D) DCVC exposure on unsyncytialized BeWo cells do not lead to any evidence of 
syncytialization 
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Figure 4.1. Concentration-dependent effects of forskolin on syncytialization with and 
without DCVC co-exposure. (A) Visualization of BeWo cell syncytialization. The green stain is 
a phalloidin-FITC membrane stain, and the blue stain corresponds to a 4',6-diamidino-2-
phenylindole, dihydrochloride (DAPI) nuclear stain. (B) Quantification of staining assessment of 
syncytialization using the fusion index and percentage of nuclei in syncytia. N=4 independent 
experiments. (C) DCVC effects on forskolin-stimulated syncytialization. N=5 independent 
experiments. (D) DCVC effects on syncytialization metrics in the absence of forskolin. N=5 
independent experiments. Statistical analysis was performed using one-way ANOVA followed 
by Tukey’s post-hoc multiple comparisons of means. Statistical significance is indicated by non-
overlapping letters. Error bars represent mean ± SEM. 
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Figure 4.2. Concentration-dependent effects of DCVC on cell viability and cytotoxicity. (A) 
Unsyncytialized BeWo cells exposed to DCVC for 48 hours. (B) Unsyncytialized BeWo cells 
exposed to DCVC for 72 hours. (C) BeWo cells co-exposed to DCVC while undergoing 
forskolin-stimulated syncytialization for 48 hours. (D) Syncytialized BeWo cells exposed to 
DCVC for 48 hours. Statistical analysis was performed using mixed models ANOVA followed 
by Tukey’s post-hoc comparison of means. Statistical significance is denoted by non-overlapping 
letters. N=3 independent experiments with triplicate wells for each experiment. Cell viability was 
measured as relative fluorescence units (RFU) and cytotoxicity was measured as relative 
luminescence units (RLU)/mg protein. Camptothecin (CPT) was included as a positive control. 
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(B) Unsyncytialized BeWo cells (72-hour 
exposure) 
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(C) BeWo cells undergoing syncytialization 
(48-hour exposure)
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(D) Syncytialized BeWo cells (48-hour 
exposure) 
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Figure 4.3. Effects of DCVC on caspase 3/7 activity. (A) Unsyncytialized BeWo cells exposed 
to DCVC for 48 hours. (B) Unsyncytialized BeWo cells exposed to DCVC for 72 hours. (C) 
BeWo cells co-exposed to DCVC while undergoing forskolin-stimulated syncytialization for 48 
hours. (D) Syncytialized BeWo cells exposed to DCVC for 48 hours. Statistical analysis was 
performed using mixed models ANOVA followed by Tukey’s post-hoc comparison of means. 
Statistical significance is denoted by non-overlapping letters. N=4 independent experiments for 
(A) and N=3 independent experiments for (B-D), performed in triplicate for each experiment. 
Camptothecin (CPT) was included as a positive control. 
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(A) Representative images of Hoechst staining to detect nuclear condensation or fragmentation 
(48-h exposures on unsyncytialized BeWo cells) 
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(B) Quantification results of Hoechst staining 
(B1) Unsyncytialized BeWo cells (48-h 
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(B2) Process of syncytialization (48-h 
exposure) 
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(B3) Syncytialized BeWo cells (24-h 
exposure) 
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(B4) Syncytialized BeWo cells (48-h 
exposure) 
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Figure 4.4. Effects of DCVC on nuclear condensation or fragmentation in BeWo cells. (A) 
Representative images of Hoechst 33342 staining to visualize nuclear condensation or 
fragmentation in unsyncytialized BeWo cells following 48-hour exposure to DCVC. (B) 
Quantification of DCVC effects on nuclear condensation or fragmentation in (B1) 
unsyncytialized BeWo cells exposed to DCVC for 48 hours, (B2) BeWo cells undergoing 
syncytialization for 48 hours, (B3) syncytialized BeWo cells exposed to DCVC for 24 hours, and 
(B4) syncytialized BeWo cells exposed to DCVC for 48 hours. Statistical analysis was 
performed using one-way ANOVA. Statistically significant differences are indicated by non-
overlapping letters. Error bars represent mean ± SEM. N=4-5 independent experiments. 
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(A) Unsyncytialized BeWo cells (48-hour exposure) 
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(B) Process of syncytialization (48-hour exposure) 
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(C) Syncytialized BeWo cells (24-hour exposure) 
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(D) Syncytialized BeWo cells (48-hour exposure) 
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Figure 4.5. DCVC effects on H2O2 abundance, PRDX1 mRNA expression, and PRDX2 
mRNA expression as biomarkers of oxidative stress. (A) Unsyncytialized BeWo cells exposed 
to DCVC for 48 hours. (B) BeWo cells co-treated with DCVC while undergoing forskolin-
201 
 
stimulated syncytialization. (C) Syncytialized BeWo cells exposed to DCVC for 24 hours. (D) 
Syncytialized BeWo cells exposed to DCVC for 48 hours. For the mRNA expression data, 
statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc 
comparison of means, with N=4-5 independent experiments. For the H2O2 abundance data, 
statistical analysis was performed using mixed models ANOVA followed by Tukey’s post-hoc 
comparison of means, with N=3 independent experiments performed in triplicate. Statistically 
significant differences are indicated by non-overlapping letters. Error bars for all graphs 
represent mean ± SEM. Menadione (MD) was included as a positive control for the experiments 
involving measurement of H2O2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
202 
 
(A) Unsyncytialized BeWo cells (48-hour exposure) 
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(B) BeWo cells undergoing syncytialization (48-hour exposure) 
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(C) Syncytialized BeWo cells 
(C1) NFBK1 mRNA expression (24-h 
exposure) 
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(C2) NFKB1 mRNA expression (48-h 
exposure) 
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(C3) TNF-R1 (48-h exposure) 
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(C4) IL-6 (48-h exposure) 
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Figure 4.6. DCVC effects on NFKB1 mRNA expression and cell media concentrations of 
TNF-R1 and IL-6 as biomarkers of pro-inflammatory response. (A) Unsyncytialized BeWo 
cells exposed to DCVC for 48 hours. (B) BeWo cells co-treated with DCVC while undergoing 
forskolin-stimulated syncytialization for 48 hours. (C1) Syncytialized BeWo cells exposed to 
DCVC for 24 hours. (C2-C4) Syncytialized BeWo cells exposed to DCVC for 48 hours. Data 
were analyzed using one-way ANOVA followed by Tukey’s post-hoc comparison of means. 
Statistically significant differences are indicated by non-overlapping letters. For the TNF-R1 and 
IL-6 data, N=3, 5, and 3 independent experiments for unsyncytialized BeWo cells, BeWo cells 
undergoing syncytialization, and syncytialized BeWo cells, respectively. For the NFKB1 mRNA 
expression data, N=5 independent experiments for all except N=4 for exposures on syncytialized 
cells for 48-hour duration. Error bars represent mean ± SEM. 
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(A) Unsyncytialized BeWo cells (48-hour exposure) 
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(B) BeWo cells undergoing syncytialization (48-hour exposure) 
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(C) Syncytialized BeWo cells (24-hour exposure) 
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(D) Syncytialized BeWo cells (48-hour exposure) 
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Figure 4.7. Effects of DCVC on apoptotic pathway genes BCL2, BAK1, and LGALS3. (A) 
Unsyncytialized BeWo cells exposed to DCVC for 48 hours. (B) BeWo cells co-treated with 
DCVC while undergoing forskolin-stimulated syncytialization for 48 hours. (C) Syncytialized 
BeWo cells exposed to DCVC for 24 hours. (D) Syncytialized BeWo cells exposed to DCVC for 
48 hours. Data were analyzed using one-way ANOVA followed by Tukey’s post-hoc 
comparison of means. Statistical significance is indicated by non-overlapping letters. Error bars 
represent mean ± SEM. N=5 independent experiments for the experiments in (A) and (B). N=4 
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independent experiments for the experiments in (C). N=3 and N=4 independent experiments for 
the BCL2 and LGALS3 outcomes, respectively, in Panel (D). 
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Figure 4.8. Simplified mechanism of apoptosis stimulated by DCVC in unsyncytialized 
BeWo cells. Solid arrows represent relationships observed and dashed arrows represent inferred 
relationships based on prior reports (not necessarily in placental cells). All endpoints were 
measured after 48 hours of exposure, with the exception of cytotoxicity and caspase 3/7 activity, 
which were measured at both the 48-hour and 72-hour time points. 
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Figure 4.9. Simplified mechanism of apoptosis stimulated by DCVC in BeWo cells 
undergoing syncytialization. Solid arrows represent relationships observed and dashed arrows 
represent inferred relationships based on prior reports (not necessarily in placental cells). All 
endpoints were measured after 48 hours of exposure. 
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Figure 4.10. Simplified mechanism of apoptosis stimulated by DCVC in syncytialized 
BeWo cells. Solid arrows represent relationships observed and dashed arrows represent inferred 
relationships based on prior reports (not necessarily in placental cells). DCVC-stimulated 
alterations in the directions as depicted in the above endpoints occurred with the following 
exposures: PRDX1, 24 hours; PRDX2, 24 hours; TNF-R1, 48 hours; NFKB1, 24 and 48 hours; 
H2O2, 48 hours; BCL2, 24 and 48 hours; caspase 3/7 activity, 48 hours; cytotoxicity, 48 hours; 
nuclear fragmentation or condensation, 24 and 48 hours. 
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Table S4.1. Relationship between fusion index and percentage of nuclei in syncytia to 
characteristic of syncytialization.  
 
 Low fusion index High fusion index 
Low percentage of nuclei in 
syncytia 
Low syncytialization Syncytialization favoring 
many nuclei per syncytia 
High percentage of nuclei in 
syncytia 
Syncytialization favoring low 
(e.g., two) nuclei per syncytia 
High overall syncytialization  
 
As depicted, high fusion index and percentage of nuclei in syncytia is indicative of high degree 
of syncytialization. Low fusion index and percentage of nuclei in syncytia is indicative of low 
degree of syncytialization. In the case of high fusion index but low percent of nuclei in syncytia, 
syncytialization is occurring in a manner favoring many nuclei per syncytia. In the case of low 
fusion index but high percentage of nuclei in syncytia, syncytialization is occurring in a manner 
favoring not many nuclei per syncytia. 
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Table S4.2. Primer sequences used for the current study. In the case of using the NCBI 
database, primers were selected to have as close to 60 degrees Celsius melting point for each 
primer as possible, have an amplicon size preferably between 75 and 150 base pairs, and be as 
close to 50% GC pairs in sequence as possible. Also, the criteria of the primer spanning an exon-
exon junction was selected as a must. 
 
B2M (Beta-2-microglobulin) 
Forward 5’-TGCCGTGTGAACCATGTG-3’ 
Reverse 5’-GCGGCATCTTCAAACCTC-3’ 
Source Vreeburg, R.A.M, Bastiaan-Net, S., and Mes, J.J. (2011). Normalization 
genes for quantitative RT-PCR in differentiated Caco-2 cells used for 
food exposure studies. Food Funct. 2, 124-129.  
 
PRDX1 (Peroxiredoxin 1)  
Forward 5’-AACCTGGTTGAACCCCAAGC-3’ 
Reverse 5’-TATTTTCCTTTGTAGTCAGACAGGC-3’ 
Source NCBI Nucleotide Database 
 
PRDX2 (Peroxiredoxin 2) 
Forward 5’-AGACGAGCATGGGGAAGTTTG-3’ 
Reverse 5’-TGTCATCCACGTTGGGCTTA-3’ 
Source NCBI Nucleotide Database 
 
ERVFRD-1 (Syncytin-2) 
Forward 5’-GCTGTCCCTGGTGTTTCAGT-3’ 
Reverse 5’-CCTTCACTAGCAGCCTACCG-3’ 
Source Vargas, A., Moreau, J., Landry, S, et al. (2009). Syncytin-2 plays an 
important role in the fusion of human trophoblast cells. J. Mol. Biol. 
392, 301-318. 
 
ERVW-1 (Syncytin-1) 
Forward 5’-GATATTTGGCTAAGGAGGTGATGTC-3’ 
Reverse 5’-GAAGGCCCTTCATACCAATGA-3’ 
Source Vargas, A., Moreau, J., Landry, S, et al. (2009). Syncytin-2 plays an 
important role in the fusion of human trophoblast cells. J. Mol. Biol. 
392, 301-318. 
 
LGALS3 (Galectin-3) 
Forward 5’-GTGAAGCCCAATGCAAACAGA-3’ 
Reverse 5’-AGCGTGGGTTAAAGTGGAAGG-3’ 
Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 294345474c2 
 
NFKB1 (Nuclear factor kappa B subunit 1) 
Forward 5’-AACAGAGAGGATTTCGTTTCCG-3’ 
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Reverse 5’-TTTGACCTGAGGGTAAGACTTCT-3’ 
Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 259155300c1 
 
BCL2 (BCL2, B-cell lymphoma 2, apoptosis regulator) 
Forward 5’-CATGCTGGGGCCGTACAG-3’ 
Reverse 5’-GAACCGGCACCTGCACAC-3’ 
Source Wyrębska, A., Szymański, J., Gach, K., et al. (2013). Apoptosis-
mediated cytotoxic effects of parthenolide and the new synthetic analog 
MZ-6 on two breast cancer cell lines. Mol. Biol. Rep. 40, 1655-1663. 
 
BAK1 (BCL2 antagonist/killer 1) 
Forward 5’-ATGGTCACCTTACCTCTGCAA-3’ 
Reverse 5’-TCATAGCGTCGGTTGATGTCG-3’ 
Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 109698605c2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
212 
 
DNA Quantity as measured by CyQuant 
(A) Unsyncytialized BeWo cells (48-h 
exposure) 
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(B) Unsyncytialized BeWo cells (72-h 
exposure)
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(C) BeWo cells undergoing syncytialization 
(48-h exposure) 
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(D) Syncytialized BeWo cells (48-h 
exposure) 
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Figure S4.1. Effects of DCVC on DNA quantity. (A) Unsyncytialized BeWo cells exposed to 
DCVC for 48 hours. (B) Unsyncytialized BeWo cells exposed to DCVC for 72 hours. (C) BeWo 
cells co-treated with DCVC while undergoing forskolin-stimulated syncytialization for 48 hours. 
(D) Syncytialized BeWo cells exposed to DCVC for 48 hours. DCVC only decreases DNA 
quantity in unsyncytialized BeWo cells for the 72-hour time point. Statistical analysis was 
performed using mixed models ANOVA followed by Tukey’s post-hoc comparison of means. 
Statistical significance is denoted by non-overlapping letters. N=3 independent experiments with 
triplicate wells for each experiment. Camptothecin (CPT) was included as a positive control. 
 
213 
 
 IFN-γ (pg/mg protein) CRP (pg/mg protein) 
(A) 
Unsyncytialized 
BeWo cells (48-h 
exposure) 
(A1) 
0
 
M
 D
C
V
C
5
 
M
 D
C
V
C
1
0
 
M
 D
C
V
C
2
0
 
M
 D
C
V
C
5
0
 
M
 D
C
V
C
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
IF
N
-
 (
p
g
/m
g
 p
r
o
te
in
)
0 5 10 20 50
D C V C  C o n c e n tra t io n  ( )
 
(A2) 
0
 
M
 D
C
V
C
5
 
M
 D
C
V
C
1
0
 
M
 D
C
V
C
2
0
 
M
 D
C
V
C
5
0
 
M
 D
C
V
C
0
2 0 0
4 0 0
6 0 0
D C V C  C o n c e n tra t io n  ( )
C
R
P
 (
p
g
/m
g
 p
r
o
te
in
)
0 5 10 20 50
 
(B) BeWo cells 
undergoing 
syncytialization 
(48-h exposure) 
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(C) Syncytialized 
BeWo cells (48-h 
exposure) 
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Figure S4.2. DCVC effects on pro-inflammatory endpoints in cell media IFN-γ and CRP 
unchanged in unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, and 
syncytialized BeWo cells. (A) Unsyncytialized BeWo cells exposed to DCVC for 48 hours. (B) 
BeWo cells co-exposed to DCVC while undergoing forskolin-stimulated syncytialization for 48 
hours. (C) Syncytialized BeWo cells exposed to DCVC for 48 hours. Data were analyzed using 
one-way ANOVA followed by Tukey’s post-hoc comparison of means. Error bars represent 
mean ± SEM. N=3, 5, and 3 independent experiments for unsyncytialized BeWo cells, BeWo 
cells undergoing syncytialization, and syncytialized BeWo cells, respectively. As a few values 
for CRP on syncytialized BeWo cells were at or very close to zero, we are only including the 
graph for completion purposes and do not think the data is particularly reliable. 
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(A) Effects of dichloroacetic acid (DCA) 24-hour exposure on unsyncytialized BeWo cells 
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(B) Effects of trichloroacetic acid (TCA) 24-hour exposure on unsyncytialized BeWo cells 
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Figure S4.3. Effects of (A) dichloroacetic acid (DCA) and (B) trichloroacetic acid (TCA) on 
unsyncytialized BeWo cells at the 24-hour time point. Time was chosen to be consistent with 
that of previous studies looking at DCA and TCA exposure on other placental cells (unpublished 
data). Statistical analysis was performed using mixed models ANOVA followed by Tukey’s 
post-hoc comparison of means with treatment as the fixed variable and experiment as the random 
variable. Statistical significance is denoted by non-overlapping letters. Error bars represent mean 
± SEM. N=3 independent experiments performed in triplicate. RFU and RLU stand for relative 
fluorescence units and relative luminescence units, respectively. Camptothecin (CPT) was 
included as a positive control. 
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Nuclear Condensation or Fragmentation: 
24-hour exposures on unsyncytialized BeWo cells 
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Figure S4.4. Effects on DCVC exposure on nuclear condensation or fragmentation at the 
24-hour time point for unsyncytialized BeWo cells. The percentage data were converted to 
fractions and arcsine transformed prior to statistical analysis. One-way ANOVA followed by 
Tukey’s post-hoc comparison of means was used to statistically analyze the data. Statistically 
significant differences are indicated by non-overlapping letters. Error bars represent mean ± 
SEM. N=4 independent experiments. 
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Chapter V. Toxicity of the Trichloroethylene Metabolite S-(1,2-dichlorovinyl)-L-cysteine in 
Human Placental Villous Trophoblast BeWo cells is Differentially Modulated by N-acetyl-
L-cysteine and Aminooxyacetic Acid 
 
Abstract 
 Trichloroethylene (TCE) is a known human carcinogen with toxicity primarily attributed 
to its metabolism to reactive metabolites. TCE metabolism by the glutathione (GSH) conjugation 
metabolic pathway is important for its toxicity. S-(1,2-Dichlorovinyl)-L-cysteine (DCVC) is a 
metabolite of TCE formed from the GSH conjugation pathway and is upstream of several toxic 
TCE metabolites. Despite knowledge that exposure to DCVC is toxic to placental cells via 
reactive oxygen species generation (ROS), pro-inflammatory response, and apoptosis, the 
contribution of DCVC metabolism modulation has not been reported previously as a means to 
modify DCVC toxicity in placental cells. The current study used N-acetyl-L-cysteine (NAC) and 
aminooxyacetic acid (AOAA) as pharmacological modifiers of DCVC metabolism to investigate 
DCVC toxicity in the human placental trophoblast BeWo cell model. DCVC-stimulated 
responses of unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, and 
syncytialized BeWo cells were compared in order to ascertain BeWo syncytialization impacts on 
DCVC toxicity. NAC pre/co-treatment with DCVC either failed to inhibit or exacerbated 
DCVC-stimulated hydrogen peroxide (H2O2) abundance, PRDX2 mRNA expression, and BCL2 
mRNA expression. Because the findings that NAC exacerbated or failed to modify DCVC 
outcomes might be due to increased expression of CYP3A4 mRNA, which could favor the 
formation of the toxic N-acetyl-DCVC sulfoxide (NAcDCVCS), we used ketoconazole (KTZ) to 
inhibit CYP3A4 activity. However, KTZ inhibition of CYP3A4 failed to prevent DCVC or 
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DCVC/NAC-stimulated toxicity. The KTZ data suggest that interventions additional to CYP3A4 
inhibition would be required to prevent DCVC or DCVC/NAC-stimulated toxicity. Moreover, 
AOAA was ineffective as an inhibitor of cysteine conjugate β-lyase (CCBL) and did not affect 
the percentage of nuclei condensed or fragmented, a measure of apoptosis, in unsyncytialized 
BeWo cells, BeWo cells undergoing syncytialization, and syncytialized BeWo cells. Because 
CCBL converts DCVC to 1,2-dichlorovinylthiol (DCVT), a toxic metabolite, the lack of ability 
of AOAA to impact CCBL would hamper its ability to prevent DCVC-stimulated toxicity. We 
found that syncytialized BeWo cells exhibit higher CCBL activity than unsyncytialized BeWo 
cells, indicating that syncytialized BeWo cells may be more sensitive to DCVC toxicity. 
Together, our data show that neither NAC nor AOAA mitigated DCVC toxicity. In addition, we 
noted differences across BeWo differentiation state in CCBL activity and in response to NAC 
pre/co-treatment. Future directions could investigate developing alternate methods of enzyme 
inhibition to reduce DCVC toxicity, improvement in availability of methodologies to detect 
reactive metabolites of TCE, and further definition of sensitive cell populations to DCVC 
toxicity to increase understanding of DCVC toxicity modulation. 
Introduction 
 Trichloroethylene (TCE) is a common volatile organic solvent found in over half of 
Superfund Hazardous Waste Sites designated by the United States Environmental Protection 
Agency (U.S. EPA) (United States Environmental Protection Agency, 2011a). Uses of TCE 
include metal degreasing, synthesis of various chemicals, and the manufacture of adhesives 
(Agency for Toxic Substances and Disease Registry, 2019). Significantly, TCE is classified as a 
Group 1 known human carcinogen by the International Agency for Research on Cancer (IARC) 
and concluded to be a human carcinogen by the U.S. EPA (United States Environmental 
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Protection Agency, 2011b; Guha et al., 2012; International Agency for Research on Cancer, 
2014). TCE has been found to act in part via an oxidative stress mechanism in rat kidneys 
(Siddiqi et al., 2015) and increases oxidative stress markers in rat placenta (Loch-Caruso et al., 
2019). In epidemiological studies, TCE exposure has been associated with adverse pregnancy 
outcomes. These include associations with small for gestational age (SGA) via contaminated 
drinking water exposure (Ruckart et al., 2014), low birth weight, SGA, and low term birth 
weight via inhalation (Forand et al., 2012), and very low birth weight via contaminated drinking 
water exposure (Rodenbeck et al., 2000). The TCE metabolite S-(1,2-dichlorovinyl)-L-cysteine 
(DCVC) is formed through the TCE glutathione (GSH) conjugation metabolic pathway (Lash et 
al., 2014a). Further metabolism of DCVC produces transient reactive species such as 1,2-
dichlorovinylthiol (DCVT), chlorothioketene (CTK), and chlorothionoacetyl chloride (CTAC) 
(Lash et al., 2014a). 
 The toxicity of DCVC has been investigated in limited placental cell types. DCVC 
stimulates reactive oxygen species (ROS) generation and pro-inflammatory response in HTR-
8/SVneo cells (Hassan et al., 2016), a first-trimester human extravillous cytotrophoblastic cell 
line (Graham et al., 1993). DCVC stimulates apoptotic responses that are associated with lipid 
peroxidation in the HTR-8/SVneo cell line, as well (Elkin et al., 2018). DCVC also stimulates 
apoptosis and ROS generation in BeWo cells (Chapter 4), a cell line representing human villous 
cytotrophoblasts (Pattillo and Gey, 1968). In contrast, metabolites from the cytochrome P450-
dependent oxidative pathway of TCE metabolism, dichloroacetic acid (DCA) and trichloroacetic 
acid (TCA), do not produce toxicity in HTR-8/SVneo cells (unpublished data) and exhibit 
markedly less toxicity in BeWo cells compared to DCVC (Chapter 4). Furthermore, DCVC 
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decreases lipoteichoic acid-stimulated increase of tumor necrosis factor-α (TNF-α) in media and 
mRNA expression in extraplacental membranes (Boldenow et al., 2015).  
 Apoptosis is a mechanism critical to placental health regarding villous trophoblastic 
BeWo cells. BeWo cells can be cultured as cytotrophoblasts and can also be stimulated by 
forskolin to differentiate in vitro to form syncytiotrophoblastic cells (Wice et al., 1990; Al-
Nasiry et al., 2006; Inadera et al., 2010; Wang et al., 2014). This differentiation process, known 
as syncytialization, requires the fusion and mutinucleation of cytotrophoblasts (Potgens et al., 
2002; Wang et al., 2014). The process of syncytialization is characterized by some signs of 
apoptosis (Hu et al., 2007) (Chapter 4). In human studies, apoptosis of syncytiotrophoblasts is 
associated with intrauterine growth retardation (IUGR) and preeclampsia (Ishihara et al., 2002). 
Moreover, apoptosis developed more rapidly in a rat model of preeclampsia versus control rats 
(Mei et al., 2020). Additional studies linking placental cell apoptosis and disease are summarized 
in a review by Sharp et al. (Sharp et al., 2010). Together, these prior reports suggest that 
apoptosis of syncytiotrophoblasts has critical implications to placental health. 
 Molecular mechanisms underlying apoptosis in placental cells include ROS generation 
and pro-inflammatory response. In syncytiotrophoblasts, release of TNF-α was shown to 
contribute to apoptosis (Garcia-Lloret et al., 2000; Chan and Guilbert, 2006). Similarly, the role 
of TNF-α and IFN-γ in promoting programmed cell death in syncytiotrophoblasts was 
demonstrated in another study (Garcia-Lloret et al., 1996). ROS generation is a contributor to 
apoptosis in syncytiotrophoblasts, as well. Hydrogen peroxide exposure increased apoptosis in 
syncytiotrophoblasts (Moll et al., 2007). Similarly, a ROS-dependent mechanism was proposed 
to explain hypoxia and reoxygenation-induced apoptosis in syncytiotrophoblasts (Belkacemi et 
al., 2007). Adverse pregnancy outcomes are attributable to a ROS-dependent mechanism, as 
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well. For example, silencing of the peroxiredoxin 2 (Prdx2) gene, which codes for a ROS 
scavenger, prevents syncytialization from occurring and another publication shows that 
peroxiredoxin 1 (Prdx1) and Prdx2 are decreased in abnormal syncytialization occurring during 
hypoxia versus normal syncytialization (Hu et al., 2007; Wu et al., 2017). Additionally, 
hydrogen peroxide was increased in placenta or serum of preeclamptic patients compared with 
normal patients (Aris et al., 2009; Li et al., 2019).  
 N-acetyl-L-cysteine (NAC) is a chemical most notable for its antioxidant and ROS-
scavenging properties, commonly attributable to its property as a precursor of reduced 
glutathione (GSH) (Aldini et al., 2018). Because of ROS roles in DCVC toxicity and 
syncytialization, NAC pre/co-treatment may potentially modify DCVC toxicity or 
syncytialization. Additionally, NAC likely modulates metabolism downstream of DCVC in the 
GSH conjugation metabolic pathway of TCE. Specifically, NAC is cleaved by aminoacylase I 
into cysteine and an acetyl group (Uttamsingh and Anders, 1999; Uttamsingh et al., 2000; Aldini 
et al., 2018). The acetyl group contributes to metabolism of DCVC into N-acetyl-S-(1,2-
dichlorovinyl)-L-cysteine (NAcDCVC) (Lash et al., 2014a). However, NAC is not expected to 
impact the conversion of NAcDCVC back into DCVC because the enzyme responsible for 
cleaving NAC (aminoacylase I) is different from the enzyme responsible for cleaving 
NAcDCVC into DCVC (aminoacylase III) (Uttamsingh and Anders, 1999; Uttamsingh et al., 
2000; Lash et al., 2014a). NAcDCVC is further converted by CYP3As into NAcDCVC sulfoxide 
(NAcDCVCS), which is toxic (Werner et al., 1996; Lash et al., 2014a). Thus, CYP3As are of 
particular interest in toxicity because these enzymes directly convert a non-toxic TCE metabolite 
(NAcDCVC) into the toxic metabolite NAcDCVCS (Werner et al., 1996; Lash et al., 2014a). 
Upstream, NAC serves as a precursor to GSH (Aldini et al., 2018), which is used by glutathione 
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S-transferases (GSTs) (Allocati et al., 2018) to initiate TCE metabolism by the GSH conjugation 
pathway (Lash et al., 2014a).  
 Another modulator of DCVC toxicity is aminooxyacetic acid (AOAA). AOAA is an 
inhibitor of cysteine conjugate β-lyase (CCBL) in kidney (Elfarra and Anders, 1984; Lash et al., 
1986; Lash et al., 1994), the enzyme responsible for converting DCVC into DCVT, a highly 
reactive and toxic species (Lash et al., 2014a). There are many isoforms of enzymes capable of 
performing the CCBL reaction (Cooper and Pinto, 2006; Lash, 2010), and it is not currently 
known which enzymes are most susceptible to AOAA inhibition. It is also currently not known 
which CCBL-related enzymes are most relevant in placenta. 
In the present study, we hypothesize that NAC and AOAA will modulate DCVC 
metabolism and toxicity. We hypothesize that NAC contribution to DCVC acetylation will 
outweigh the role of NAC as a ROS scavenger. We also hypothesize that AOAA will reduce 
DCVC-stimulated toxicity if AOAA is an effective CCBL inhibitor in BeWo cells. The results 
from this current study provide new knowledge on limitations of NAC and AOAA pre/co-
treatment for differential modulation of DCVC-stimulated toxicity. 
Materials and Methods 
 
Materials and reagents 
N-acetyl-L-cysteine (NAC) and aminooxyacetic acid (as O-
(carboxymethyl)hydroxylamine hemihydrochloride) (AOAA), potassium phosphate dibasic 
(K2HPO4), potassium phosphate monobasic (KH2PO4, anhydrous), sucrose, potassium hydroxide 
(KOH), boric acid, and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO). 
S-(2-Benzothiazolyl)-L-cysteine (BTC) was purchased from Toronto Research Chemicals 
(Toronto, ON). Ketoconazole (KTZ), an inhibitor of CYP3A4 (Gibbs et al., 2000; Lopez-
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Barcons et al., 2017; Yang et al., 2017), was purchased from Sigma-Aldrich (St. Louis, MO). 
Dimethyl sulfoxide (DMSO) was purchased from Tocris Bioscience (Tocris Bioscience, Bristol, 
UK). DCVC was synthesized by the University of Michigan Medicinal Chemistry Core using a 
previously published method (McKinney et al., 1959). The identity of DCVC was verified using 
proton nuclear magnetic resonance (NMR) spectroscopy and the purity of DCVC stock solution 
was verified periodically by high-performance liquid chromatograph (HPLC) to be at least 
98.7% pure. DCVC was dissolved in phosphate buffered saline (PBS) as a 1 mM stock solution 
and stored in 1 mL aliquots at -20°C. Camptothecin (CPT) was purchased from Cayman 
Chemical (Ann Arbor, MI) and was used as a positive control in several experiments. CPT was 
dissolved in DMSO at 5.74 mM prior to addition to cell media. Menadione (MD) was purchased 
from Sigma-Aldrich (St. Louis, MO) and included as a positive control for the experiments 
involving H2O2 detection. MD was directly dissolved in a stock solution of cell medium at a 1 
mM concentration.  
The BeWo cell line 
 The present study used the human villous trophoblast BeWo cell line, a cell line of male 
sex and representative of a first-trimester villous trophoblastic cell (Pattillo and Gey, 1968). 
BeWo cells were obtained from American Type Culture Collection (ATCC CCL-98). Identity of 
the BeWo cells was periodically verified through its short tandem repeat (STR) profile that was 
confirmed via fragment analysis on the ABI 3730XL DNA Analyzer from Applied Biosystems 
(Waltham, MA) at the University of Michigan DNA Sequencing Core. BeWo cells were grown, 
passaged, and plated with 1X F12-K Nutrient Mixture Kaighn’s Modification with (+) L 
Glutamine (Gibco, Grand Island, NY). Chemical treatments were first diluted in 1X DMEM/F12 
Nutrient Mixture (Gibco, Grand Island, NY), referred to as the treatment media, used for its 
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absence of phenol red. All media were supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (HI-FBS) and 1% (v/v) penicillin/streptomycin (P/S) (Gibco, Grand Island, NY). 
Three washes of phosphate buffered saline (PBS) (Invitrogen Life Technologies, Carlsbad, CA) 
were performed prior to detaching the cells with 0.25% trypsin-EDTA (1X) (Invitrogen Life 
Technologies, Carlsbad, CA) for subculture. For regular subculture, cells were plated at 100,000 
cells/mL in 25 mL in 175 cm2 flasks (Corning Inc., Corning, NY) and allowed to grow to 70-
80% confluence. Cell cultures were maintained in a 5% CO2, 37°C controlled and humidified 
incubator. This work with human cell cultures was approved by the University of Michigan 
Institutional Biosafety Committee (IBCA00000100).   
Exposures 
 Experimental exposures began after allowing 24 hours for the BeWo cells to adhere and 
acclimate to the plate(s) used for experiments. To the unsyncytialized BeWo cells, the TCE 
metabolite S-(1,2-dichlorovinyl)-L-cysteine (DCVC) was applied at concentrations ranging from 
5 µM to 50 µM. These concentrations were chosen based on past reports that similar DCVC 
concentrations elicited effects in placental and kidney cells (Xu et al., 2008; Lash et al., 2014b; 
Hassan et al., 2016; Elkin et al., 2018). Additionally, this concentration range includes an 
average concentration of DCVG (13.4 μM) found in the blood of women exposed by inhalation 
to the permissible exposure limit of the U.S. Occupational Health and Safety Administration 
(Lash et al., 1999; Agency for Toxic Substances and Disease Registry, 2007). Although DCVC 
was not measured in the aforementioned study, DCVG is the precursor to DCVC in a 1:1 
stoichiometric ratio (Lash et al., 2014a). 
 BeWo cells were syncytialized using 100 µM forskolin treatment for 48 hours based on 
previous reports (Wice et al., 1990; Al-Nasiry et al., 2006; Inadera et al., 2010) and verified as 
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maximally effective in our prior studies (Chapter 4). To test DCVC impacts on syncytialization, 
DCVC was applied from 10–50 µM concentrations as a co-treatment with forskolin. Because 
forskolin was dissolved in DMSO, cells in the vehicle control group were treated with 0.1% (v/v) 
DMSO, the final DMSO concentration in the DCVC exposure media. 
 Additional experiments tested the effect of DCVC on BeWo cells after they have been 
syncytialized using DCVC concentrations ranging from 5-50 µM. Because we observed in pilot 
experiments that the syncytialized BeWo cells approach reduced viability by 48 hours, 48 hours 
was the longest time of exposure of DCVC on these cells.     
 Cell cultures were exposed to NAC, AOAA or KTZ as pre/co-treatments to DCVC, with 
pre-treatments lasting 30 minutes. The NAC pre/co-treatment was applied at 5 mM 
concentration, a concentration shown previously to produce an ROS-dependent effect in BeWo 
cells (Inadera et al., 2010) and other cells (Chen et al., 2008; Sato et al., 2009). The AOAA 
concentration of 1 mM was used because it reduces CCBL activity and DCVC-stimulated 
toxicity in kidney cells (Lash et al., 1994). Likewise, KTZ was only applied at 1 µM 
concentration, a concentration previously reported to be nontoxic in various cell types (Lopez-
Barcons et al., 2017) and exceeds previously reported IC50s of KTZ to CYP3A4 (Gibbs et al., 
2000; Yang et al., 2018). 
Hoechst staining to detect nuclear condensation or fragmentation 
Cells were plated in Corning Costar tissue culture-treated 6-well plates (Corning, NY) at 
a density of 200,000 cells/well in 2 mL/well and allowed to adhere for 24 hours before treatment. 
After treatment, medium was removed, and the cells were washed three times with PBS. 
Formaldehyde (3.7%, v/v) was applied for 5 minutes to fix the cells, and the cells were washed 
three times with PBS again. Following this, 0.5 µg/mL Hoechst 33342 trihydrochloride, 
230 
 
trihydrate, prepared from a 10 mg/mL stock solution (Invitrogen Life Technologies, Carlsbad, 
CA) and diluted 1:20,000 in PBS, was added to each well. Plates were incubated with the 
Hoechst solution for 15 minutes, then washed three times with PBS before imaging using an 
EVOS microscope with fluorescence capabilities (Thermo Fisher Scientific, Waltham, MA). 
Going in a top-down direction, three images (one near the top, one near the middle, and one near 
the bottom) were captured per well at 400X magnification, to provide an accurate representation 
of the well, and analyzed.  
 Quantification consisted of using ImageJ (NIH, Bethesda, MD) set to a brightness 
threshold that would highlight nuclei that the authors considered sufficiently bright to be 
considered condensed. The settings were as follows: hue (0, 255), saturation (0, 255), brightness 
(165, 255). Under these settings, at least 10% of the nucleus had to be highlighted in order for 
the nucleus to be considered condensed. Criteria used to assess nuclear fragmentation included 
fragmentation into multiple pieces, jaggedness of the nucleic acid, and unequal size of nuclei 
subsequent to fragmentation. 
Detection of hydrogen peroxide (H2O2) abundance  
Cells were plated at a density of 10,000 cells/well in 80 µL/well on Corrning Costar 
tissue culture-treated 96-well white, clear-bottom plates (Corning, NY; product number 3610) 
and allowed to adhere for 24 hours before treatment. Treatment volumes were 80 µL. Hydrogen 
peroxide (H2O2) was detected using the ROS-Glo™ H2O2 assay system (Promega, Madison, WI) 
according to the manufacturer’s instructions. Six hours before the end of treatment, 20 µL of the 
H2O2 substrate solution containing a derivatized luciferin substrate was added to each well to 
bring the volume of each well to 100 µL. After a 6-hour incubation with the luciferin substrate, 
100 µL of the detection solution was added to each well to achieve 200 µL total per well. The 
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assay works by principle of a luciferin precursor that reacts with H2O2. Addition of the detection 
solution 6 hours later generates a luciferin product that gives off a light signal that is proportional 
to the amount of H2O2 present extracellularly and intracellularly in the well. H2O2 abundance 
was normalized to protein mass, which was determined from a separate set of cells in 96-well 
plates. Protein was isolated in Pierce RIPA Lysis and Extraction Buffer (Thermo Fischer 
Scientific, Waltham, MA), and then quantified using bicinchoninic acid assay (Thermo Fisher 
Scientific, Waltham, MA). The average of nine different protein readings from three independent 
experiments for each experimental group was used for normalization. 
RNA extraction 
Cells were plated in Corning Costar tissue culture-treated 6-well plates at a density of 
200,000 cells/well in 2 mL/well and allowed to adhere for 24 hours before treatment. After 
treatment, the medium was removed and RNA was extracted from the cells using a RNeasy 
PLUS Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Cells 
were first homogenized as previously described (Chapter 4). Briefly, 1 mL of the RLT Buffer 
Plus reagent (Qiagen, Hilden, Germany) containing 1% (v/v) 2-mercaptoethanol (Sigma-Aldrich, 
St. Louis, MO) was added to each well with medium removed. The cell lysates were 
homogenized using QIA Shredders (Qiagen, Hilden, Germany) prior to continuation with the 
manufacturer protocol, with subsequent gDNA elimination. Concentration and purity of RNA 
were determined using a Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA), and the RNA samples were stored at -80°C until further assayed. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
To synthesize cDNA from the RNA samples, an iScriptTM cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, CA) was used according to the manufacturer’s protocol. A Bio-Rad CFX 
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ConnectTM Real-Time System (Bio-Rad Laboratories, Hercules, CA) was used to carry out the 
cDNA synthesis reaction. The protocol on the Bio-Rad CFX ConnectTM Real-Time System for 
the cDNA synthesis reaction was as follows: (1) 25°C for 5 minutes, (2) 42°C for 30 minutes, (3) 
85°C for 5 minutes, and then (4) a cool down to 4°C. The cDNA was stored at -20°C until 
further use. 
 qRT-PCR was performed using 25-µL reaction mixtures consisting of the following: 
52.5% (v/v) SsoAdvancedTM Universal SYBR® Green Supermix (Bio-Rad Laboratories, 
Hercules, CA), 0.28 µM of each primer (forward and reverse), and 32 ng of cDNA template. 
Primer sequences are described in Table S5.1 and were custom made by Integrated DNA 
Technologies (Coralville, IA). A Bio-Rad CFX ConnectTM Real-Time System was used to 
perform qRT-PCR according to the manufacturer’s protocol. Analysis was performed using the 
ΔΔCt method (Yuan et al., 2006), and all samples were analyzed in duplicate. B2M served as the 
reference gene. 
Measurement of cell viability and cytotoxicity 
BeWo cells were plated in Corning Costar tissue culture-treated 96-well plates (Corning, 
NY) at a density of 10,000 cells/well in 100 µL/well and allowed to adhere for 24 hours before 
treatment. Cell viability and cytotoxicity were detected using the Multitox-Glo Multiplex 
Cytotoxicity Assay (Promega, Madison, WI), performed as instructed by the manufacturers. This 
assay works by the principle of using a fluorogenic peptide substrate (GF-AFC) that enters intact 
cells and is cleaved by live cell proteases to release a fluorescent molecule (AFC) and produce a 
fluorescence signal that is proportional to number of live cells. After treatment, 50 µL of cell 
viability assay reagent was added and plates were wrapped in aluminum foil and incubated at 
37°C. Cell viability was detected via fluorescence reading 45 minutes after reagent application. 
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After the viability reading, cytotoxicity was assayed via a luminescence assay. The cytotoxicity 
assay works by the principle of using a luminogenic peptide substrate (AAF-aminoluciferin) that 
is cleaved by proteases that have leaked out of dead cells (i.e., cells without intact membrane) to 
release the aminoluciferin product that produces a luminescence signal proportional to number of 
dead cells. For the asaay, 50 µL cytotoxicity assay reagent was added to each well, then plates 
were wrapped in aluminum foil and incubated at room temperature for 15 minutes before 
luminescence was detected using the Glomax Multi Plus Detection System (Promega, Madison, 
WI). Cytotoxicity readings were normalized to protein mass, which was determined from a 
separate set of cells in 96-well plates. Protein was isolated in Pierce RIPA Lysis and Extraction 
Buffer (Thermo Fischer Scientific, Waltham, MA), and then quantified using bicinchoninic acid 
assay (Thermo Fisher Scientific, Waltham, MA). The average of nine different mass readings 
from three independent experiments for each experimental group was used for normalization. 
Measurement of cysteine conjugate β-lyase (CCBL) activity 
BeWo cells were plated in Corning Costar tissue culture-treated 6-well plates at a density 
of 200,000 cells/well in 2 mL/well and allowed to adhere for 24 hours before treatment. After 
treatment, cells were incubated in 200 µL of 0.1 M potassium phosphate buffer (pH 7.4) 
containing 0.25 M sucrose for 5 minutes before cells were scraped off the plate using a cell 
scraper (Fisher Scientific, Hampton, NH). The cell samples became the enzyme source and were 
frozen at -80°C until assayed. Potassium phosphate buffer (0.1 M, pH 7.4) consisted of 
potassium phosphate dibasic (K2HPO4) at 69.6 mM and potassium phosphate monobasic 
(KH2PO4, anhydrous) at 30.4 mM prior to addition of sucrose. 
To perform the assay, cell samples were thawed, and then sonicated at 3.5 Hz twice for 
five seconds using a sonicator (MiSonix Sonicator 3000, Misonix Inc., Farmingdale, NY). The 
234 
 
assay followed the method of Dohn and Anders (1982) using BTC as substrate and a protocol 
previously described (Dohn and Anders, 1982) (Chapter 2). The substrate solution was made by 
suspending 10.15 mg of BTC in 4 mL ddH2O. The mass of BTC added corresponds to a final 
BTC concentration in substrate solution of 4 mM. Potassium hydroxide (KOH) (1 M in ddH2O) 
was added at 0.25 mL to dissolve BTC. After the BTC dissolved, 5 mL of boric acid (0.2 M in 
ddH2O) was added. The solution pH was adjusted to 8.6 using 1 M KOH, and ddH2O was then 
added to achieve 10 mL desired total volume. In aliquots, this substrate solution was added to 0.1 
M potassium borate buffer (made from KOH and boric acid) in a 1.5:1.3 (v/v) ratio and 
incubated for 4 minutes at 37°C. Enzyme sample was added to this reaction mixture in a 1:14 
(v/v) ratio. Incubation time with the enzyme sample was 30 minutes at 37°C. 
After incubation, trichloroacetic acid at a 10% (w/v) concentration in ddH2O was added 
to the reaction mixture in a 1:5 (v/v) ratio to terminate the reaction and precipitate protein. A 
negative control for each sample was made by adding 10% (w/v) trichloroacetic acid into the 
reaction mix before addition of the enzyme source (i.e., the cells). All samples were centrifuged 
at 11,000 x g for 1.25 minutes to remove precipitated protein. Absorbance of supernatant was 
measured at 321 nm wavelength with a molar extinction coefficient (ε) of 21,600 M-1 cm-1 for 
321 nm using a SpectraMax M2e microplate reader (Molecular Devices, San Jose, CA). The 
absorbance corresponding to the negative control was subtracted from the absorbance 
corresponding to the appropriate reaction to generate a net absorbance used to convert 
absorbance into nmol of product produced/min/mL, which were converted into nmol/min/mg 
protein. Protein was assayed with bicinchoninic acid (BCA) using a kit from Thermo Fisher 
Scientific. 
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Statistical analysis 
 Statistical analyses included unpaired two-tailed t-tests, one-way ANOVA, and two-way 
ANOVA performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA). Mixed 
models ANOVA was performed with treatment as fixed variable and experimental day as 
random variable using SPSS Software (IBM Corporation, Chicago, IL). In the case of percentage 
data, percentages were transformed to fractions and arcsine transformed prior to statistical 
analysis. All ANOVAs were followed with Tukey’s post-hoc comparison of means. All graphs 
were generated using GraphPad Prism 7 (GraphPad Software, San Diego, CA). For all tests, a 
p<0.05 was considered as statistically significant. 
Results 
Effects of DCVC with and without NAC pre/co-treatment on nuclear condensation or 
fragmentation  
 Representative images of DCVC-induced nuclear condensation or fragmentation in 
unsyncytialized BeWo cells are shown in Figure 5.1A. In unsyncytialized BeWo cells at the 48-
hour time point, 20 µM DCVC increased the percentage of condensed or fragmented nuclei by 
438.3% relative to nontreated control (absence of NAC or DCVC) (p= 0.0355), and NAC pre/co-
treatment did not significantly modify this DCVC-induced response (Figure 5.1B). For BeWo 
cells undergoing forskolin-stimulated syncytialization, NAC treatment with forskolin only and 
NAC treatment with forskolin + DCVC elevated nuclear condensation or fragmentation by 
624.5% and 601.3%, respectively, relative to vehicle control (0.1% DMSO only) (p=0.0026 and 
0.0038, respectively) (Figure 5.1C). In syncytialized BeWo cells, NAC with 10 µM DCVC or 
20 µM DCVC increased nuclear condensation or fragmentation by 75.9% and 97.8%, 
respectively, relative to nontreated control (absence of NAC or DCVC) (p=0.0293 and 0.0036, 
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respectively), but not in comparison to NAC treatment alone (Figure 5.1D). Thus, with 
exception of a few treatments done in combination, NAC did not modify DCVC-stimulated 
nuclear condensation or fragmentation. 
Effects of DCVC with and without NAC pre/co-treatment on biomarkers of oxidative stress  
 Because NAC is a ROS scavenger either by itself or through its property as a GSH 
precursor (Aldini et al., 2018), we measured abundance of hydrogen peroxide (H2O2). In 
unsyncytialized BeWo cells at 48 hours of exposure, 50 µM DCVC increased H2O2 abundance 
relative to control (absence of DCVC or NAC) by 83.9% (p<0.0001), and NAC plus 50 µM 
DCVC elicited even greater H2O2 abundance, increased by 80.5% compared to treatment with 50 
µM DCVC without NAC (p<0.0001) (Figure 5.2A1). NAC alone did not significantly change 
H2O2 abundance.  
A similar pattern was observed in BeWo cells undergoing syncytialization. In cells 
treated with forskolin to induce syncytialization, 50 µM DCVC increased H2O2 abundance by 
61.4% relative to controls exposed to forskolin alone (p=0.037) (Figure 5.2B1). Cells exposed to 
NAC plus 50 µM DCVC (as well as forskolin) exhibited further increased H2O2 abundance 
relative to cells undergoing syncytialization in the presence of 50 µM DCVC alone (increased by 
92.7%, p<0.0001) (Figure 5.2B1). NAC by itself or as pre/co-treatment to forskolin did not alter 
H2O2 abundance relative to respective controls (cells receiving only 0.1% DMSO or only 
forskolin, respectively) (Figure 5.2B1). 
In cells already syncytialized, 48-hour exposures to NAC by itself decreased H2O2 
abundance relative to control (absence of DCVC or NAC) by 31.4% (p=0.014). Treatment at 50 
µM DCVC increased H2O2 abundance relative to control (absence of DCVC or NAC) by 55.6% 
(p<0.0001), similar to unsyncytialized cells and cells undergoing syncytialization. However, the 
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combination treatment of NAC with 50 µM DCVC did not alter H2O2 abundance relative to 50 
µM DCVC treatment alone (Figure 5.2C1), in contrast to unsyncytialized cells and cells 
undergoing syncytialization. There were no significant changes with NAC treatment on PRDX2 
mRNA expression in unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, or 
syncytialized BeWo cells (Figures 5.2A2, 5.2B2, and 5.2C2, respectively). 
Effects of DCVC with and without NAC pre/co-treatment on apoptotic pathway genes 
 NAC alone had no significant effect on DCVC-stimulated decrease of BCL2 mRNA 
expression in unsyncytialized BeWo cells (48-hour exposure), in BeWo cells undergoing 
syncytialization (48-hour exposure), and in syncytialized BeWo cells (24-hour exposure) 
(Figures 5.3A1, 5.3B1, 5.3C1, respectively). In contrast to findings with nuclear 
condensation/fragmentation and H2O2 abundance, the combination treatment of NAC and DCVC 
did not significantly alter the BCL2 response compared with exposure to DCVC without NAC in 
all three differentiate states of BeWo cells (Figures 5.3A1, 5.3B1, and 5.3C1). LGALS3 is 
another gene linked to cellular anti-apoptotic response (Yang et al., 1996; Newlaczyl and Yu, 
2011). Whereas the 50 µM DCVC effect was significant for LGALS3 mRNA expression in two-
way ANOVA in unsyncytialized BeWo cells (p=0.0188, in the direction of decrease), the effect 
of NAC was not significant (Figure 5.3A2). Neither NAC nor DCVC had an effect on LGALS3 
mRNA expression in BeWo cells undergoing syncytialization (48-hour exposures) or in 
syncytialized BeWo cells (24-hour exposures) (Figures 5.3B2 and 5.3C2, respectively). No 
significant effects were observed for NFKB1 mRNA expression for the same experimental 
treatments on BeWo cells undergoing syncytialization or syncytialized BeWo cells (Figure 
S5.1).  
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Effects of DCVC with and without NAC pre/co-treatment on CYP3A4 mRNA expression  
 Because NAC failed to prevent or reverse a DCVC-stimulated response, even in the case 
of ROS-relevant outcomes such as hydrogen peroxide (H2O2), we measured CYP3A4 mRNA 
expression because of its potential role in the formation of a toxic metabolite NAcDCVCS due to 
potential increased acetylation of DCVC in the presence of NAC. In unsyncytialized BeWo cells 
exposed for 48 hours and syncytialized BeWo cells exposed for 24 hours, the NAC effect from 
two-way ANOVA for CYP3A4 mRNA was significant in the direction of increased CYP3A4 
mRNA expression (p=0.0275 and p=0.0344, respectively) (Figures 5.4A and 5.4C, 
respectively). In BeWo cells undergoing syncytialization, syncytialization by itself increased 
CYP3A4 mRNA expression by 1150% (p=0.0265), but no changes in CYP3A4 mRNA 
expression were elicited by treatment with DCVC or NAC (Figure 5.4B).   
Effects of NAC and KTZ on DCVC-stimulated cell viability and cytotoxicity  
 We used ketoconazole (KTZ) as a CYP3A4 inhibitor to further investigate the potential 
role of CYP3A4 in DCVC and NAC toxicity. We performed these experiments with 
unsyncytialized cells and syncytialized cells, but not with cells undergoing syncytialization, 
because CYP3A4 mRNA expression increased with syncytialization in the absence of other 
treatments (Figure 5.4B). In unsyncytialized BeWo cells receiving 48-hour treatments, neither 
KTZ, NAC, nor the combination of KTZ and NAC as pre/co-treatments to 50 µM DCVC 
prevented the 50 µM DCVC-stimulated decrease in cell viability and increase in cytotoxicity 
(Figures 5.5A1 and 5.5A2, respectively). Similarly, in syncytialized BeWo cells receiving 48-
hour treatments, neither the KTZ, NAC, nor the combination of KTZ and NAC as pre/co-
treatments to 50 µM DCVC prevented the 50 µM DCVC-stimulated decrease in cell viability 
(Figure 5.5B1). Cytotoxicity in syncytialized BeWo cells was reduced by KTZ and NAC alone 
239 
 
or in combination relative to control (absence of KTZ, NAC, or DCVC) by 52.9%, 33.9%, and 
49.0%, respectively (p<0.0001) (Figure 5.5B2). Combined exposure to 50 µM DCVC with KTZ 
and NAC treatment, alone or in combination, also reduced cytotoxicity relative to treatment with 
50 µM DCVC without KTZ or NAC by 47.8%, 49.7%, and 51.6%, respectively (p<0.0001) 
(Figure 5.5B2).  
Effects of DCVC with and without AOAA pre/co-treatment on nuclear condensation or 
fragmentation  
 Exposure to 20 µM DCVC by itself did not statistically increase nuclear condensation or 
fragmentation in unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, or 
syncytialized BeWo cells, although the direction for each was towards an increase (Figures 
5.6A, 5.6B, and 5.6C, respectively). Moreover, AOAA did not significantly alter DCVC-
induced nuclear condensation or fragmentation, regardless of BeWo cell differentiation state 
(Figures 5.6A, 5.6B, and 5.6C). Relative to vehicle control (0.1% DMSO), AOAA pre/co-
treatment with forskolin increased nuclear condensation or fragmentation by 402.4% (p=0.0041) 
(Figure 5.6B). Treatment with 20 µM DCVC and forskolin in the absence of AOAA increased 
nuclear condensation or fragmentation by 280.4% relative to vehicle control (0.1% DMSO) 
(p=0.0355) (Figure 5.6B).  
Effects of DCVC with and without AOAA pre/co-treatment on CCBL activity  
BeWo cells exhibited CCBL activity regardless of differentiation state at 48-hour 
exposure time points. However, the CCBL activity in all three cases was unaltered by AOAA, 
DCVC, or AOAA pre/co-treatment with DCVC (Figures 5.7A, 5.7B, and 5.7C). Additionally, 
when comparing the control group (absence of DCVC or AOAA) for unsyncytialized BeWo 
cells to the control group (absence of DCVC or AOAA) for syncytialized BeWo cells, 
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syncytialized BeWo cells were found to have more CCBL activity than unsyncytialized BeWo 
cells by 54.8% (p=0.0319) (Figure 5.7D). 
Effects of DCVC on KYAT1 mRNA expression 
 We investigated how CCBL activity results compare to mRNA expression of KYAT1, 
which codes for a specific CCBL, CCBL1. Similar to the finding that syncytialized BeWo cells 
have greater CCBL activity compared to unsyncytialized BeWo cells (Figure 5.7D), KYAT1 
mRNA expression was increased by forskolin-stimulated syncytialization by 123.8% 
(p=0.0034). Relative to forskolin treatment alone, DCVC co-treatments at 20 µM and 50 µM 
reduced KYAT1 mRNA expression by 38.5% and 64.1%, respectively (p=0.0338 and 0.0011, 
respectively) (Figure 5.8B). KYAT1 mRNA expression was not changed by DCVC exposure in 
unsyncytialized BeWo cells for 48 hours or syncytialized BeWo cells for 24 hours (Figures 5.8A 
and 5.8C, respectively). 
Effects of DCVC on FMO3 and CYP2E1 mRNA expression 
We investigated the relevance of the BeWo cells in genes for other pathways of DCVC 
metabolism and TCE metabolism. In unsyncytialized BeWo cells with treatment lasting for 48 
hours, FMO3 mRNA expression was decreased by 53.6% (p=0.0121) with 50 µM DCVC 
exposure relative to control (0 µM DCVC) (Figure 5.9A1). DCVC exposure during 
syncytialization for 48 hours or on syncytialized BeWo cells for 24 hours had no significant 
effect on FMO3 mRNA expression (Figures 5.9A2 and 5.9A3, respectively). DCVC exposure 
on unsyncytialized BeWo cells for 48 hours or during syncytialization for 48 hours did not 
change CYP2E1 mRNA expression (Figures 5.9B1 and 5.9B2, respectively). However, 50 µM 
DCVC exposure for 24 hours decreased CYP2E1 mRNA expression by 56.6% relative to control 
(0 µM DCVC) in syncytialized BeWo cells (p=0.0124) (Figure 5.9B3).   
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Discussion 
 The current study is the first to our knowledge to use NAC and AOAA to modulate 
metabolism of the TCE metabolite, DCVC, and affect toxicity in BeWo cells. The TCE 
metabolite, DCVC, stimulated toxic responses in unsyncytialized BeWo cells, BeWo cells 
undergoing syncytialization, and syncytialized BeWo cells (Chapter 4). DCVC toxicity is 
attributable to its metabolism, which is supported by work utilizing the CCBL inhibitor, AOAA, 
to decrease DCVC-stimulated toxicity in kidney cells (Elfarra and Anders, 1984; Lash et al., 
1986; Lash et al., 1994) and suppress DCVC-stimulated increase of interleukin-6 (IL-6) in HTR-
8/SVneo cells (Hassan et al., 2016). Mechanisms by which DCVC is toxic to BeWo cells and 
another placental cell line, the HTR-8/SVneo cells, involve ROS generation, pro-inflammatory 
response, and apoptosis (Hassan et al., 2016; Elkin et al., 2018) (Chapter 4). With respect to 
BeWo cells, DCVC increased nuclear condensation or fragmentation, a metric that quantifies 
apoptosis (Matassov et al., 2004; Errami et al., 2013; Crowley et al., 2016). A pathway of 
DCVC metabolism is acetylation (Lash et al., 2014a), and NAC is a provider of an acetyl group 
(Aldini et al., 2018). As such, we investigated the ability of NAC and AOAA to modify 
numerous DCVC-stimulated responses. 
 Nuclear condensation or fragmentation results from this study indicate that neither NAC 
nor AOAA were effective at preventing a DCVC-stimulated response. This was true for any 
differentiation state of the BeWo cells. Although DCVC concentrations in the present study did 
not always increase nuclear condensation or fragmentation, the data nonetheless suggest that 
neither NAC nor AOAA would likely prevent a DCVC effect even if DCVC concentrations or 
sample sizes were increased. If anything, the trend suggested that NAC pre/co-treatment would 
exacerbate the DCVC response in syncytialized BeWo cells. Regardless, our prior finding 
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(Chapter 4) that DCVC did not alter DNA quantity under exposure conditions similar to those 
that produced changes in nuclear condensation or fragmentation increases the likelihood that 
nuclear condensation or fragmentation reflected apoptosis and not cell proliferation. 
The nuclear condensation or fragmentation data also indicate that NAC or AOAA 
exposure could be detrimental during syncytialization. Exposure to NAC or AOAA with 
forskolin-stimulated syncytialization increased nuclear condensation or fragmentation relative to 
control. Because our primary interest was DCVC toxicity, we did not further investigate the 
mechanisms involved in responses to NAC or AOAA during forskolin-stimulated 
syncytialization. However, numerous mechanisms exist that could possibly explain an effect 
resulting from the combination of NAC and forskolin or the combination of AOAA and 
forskolin. Forskolin is a known adenylate cyclase activator (Daly, 1984) that increases 
intracellular cyclic adenosine monophosphate (cAMP) (Cooper, 2003) that is necessary for 
syncytialization (Gupta et al., 2016). In rat retinal pigmented epithelial (RPE-J) cells cultured in 
the presence of L-cysteine, AOAA decreases cAMP relative to the absence of AOAA (Njie-
Mbye et al., 2012). Similarly, NAC at 0.5 mM decreases Aβ(25–35)-stimulated adenylate 
cyclase activity in the ventral hippocampus and frontal cortex in rats (Soomets et al., 1999). 
Therefore, NAC or AOAA could have interfered with the forskolin-stimulated cAMP response 
necessary for normal syncytialization and thereby produced a toxic effect. Syncytialization is 
also likely associated with altered antioxidant activity because cAMP decrease has been 
associated with lower antioxidant activity (Saha et al., 2008; Boyadjieva and Sarkar, 2013). 
However, NAC and AOAA differ in regard to antioxidant properties. NAC is commonly thought 
of as an antioxidant (Aldini et al., 2018; Ezerina et al., 2018). In contrast, AOAA has been 
reported to further increase palmitate-stimulated ROS augmentation in HepG2 cells (Sarna et al., 
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2016) and exacerbate oxaliplatin-stimulated ROS production and apoptosis in HCT116 and 
HT29 cells (Yue et al., 2020). Therefore, these differences are not as likely to explain a common 
mechanism of action for interaction with forskolin. Further investigation of these mechanisms 
requires additional experiments beyond the scope of the present thesis to explain why exposure 
of NAC or AOAA during syncytialization could be deleterious.  
 Our data on measures of ROS indicated that NAC exacerbated a DCVC-stimulated 
response. This is particularly notable for the hydrogen peroxide (H2O2) abundance data in 
unsyncytialized BeWo cells and BeWo cells undergoing syncytialization, in which DCVC-
stimulated increase in H2O2 was augmented by NAC pre/co-treatment. Although NAC is a 
scavenger of ROS (Aldini et al., 2018), the possibility exists that NAC and DCVC metabolism 
could interact to increase production of deleterious DCVC metabolites. NAC is metabolized to 
an acetyl group (Aldini et al., 2018), which could be used to biotransform DCVC into 
NAcDCVC via N-acetyl-transferases (Lash et al., 2014a). NAcDCVC itself is not toxic, but is 
metabolized to its sulfoxide, NAcDCVCS, which is toxic (Werner et al., 1996; Lash et al., 
2014a). Our findings of increased toxicity stimulated by NAC pre/co-treatment with DCVC are 
consistent with the notion that NAC administration shifted DCVC metabolism towards increased 
production of toxic metabolites. The findings of no alterations provided by NAC pre/co-
treatment relative to DCVC treatment alone likewise are consistent with the notion that NAC-
stimulated changes to DCVC metabolism could counter anti-oxidant protective effects of NAC 
(Aldini et al., 2018) as pre/co-treatment with DCVC. The effect of NAC on CYP3A4 mRNA 
expression would favor formation of NAcDCVCS. Worthy future directions include studies that 
directly measure formation of NAcDCVCS or measurement of CYP3A4 activity to bolster the 
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conclusion that increased formation of NAcDCVCS is a mechanism of NAC exacerbation of 
DCVC-stimulated toxicity. 
 Notably, nearly all NAC-stimulated effects differed by the differentiation stage of the 
BeWo cells and by endpoint. For syncytialized but not unsyncytialized BeWo cells, NAC by 
itself exerted effects even in the absence of DCVC, as evidenced by changes in H2O2 abundance, 
cytotoxicity, and BCL2 mRNA expression. This highlights that syncytialized BeWo cells are 
more susceptible than unsyncytialized BeWo cells to NAC. Additionally, the results from this 
study indicate that H2O2 abundance is an endpoint modifiable by DCVC and NAC pre/co-
treatment more than PRDX2 mRNA expression. Similarly, we saw that DCVC treatment or NAC 
pre/co-treatment had a greater effect on BCL2 mRNA expression than on LGALS3 mRNA 
expression. These findings show that DCVC and NAC acted on specific components within the 
oxidative stress response and apoptosis pathways, and that exact mechanisms depended on the 
differentiation state of the BeWo cells. As such, it is difficult to claim NAC as strictly an 
antioxidant or prooxidant in the BeWo cells, particularly the syncytialized cells. 
 We investigated the potential role of CYP3A4 on DCVC-stimulated toxicity using 
pharmacological inhibitors. These experiments were only performed on unsyncytialized and 
syncytialized BeWo cells because we found that CYP3A4 mRNA was increased by 
syncytialization. We used KTZ as a CYP3A4 inhibitor at 1.0 µM concentration, which is 
consistent with other reports (Gibbs et al., 2000; Lopez-Barcons et al., 2017; Yang et al., 2018) 
and higher than previously reported IC50 values to CYP3A4 of 0.3 or 0.4 µM in Caco-2 cells 
(Gibbs et al., 2000) and 0.618 µM in human liver microsomes (Yang et al., 2018). Neither KTZ, 
NAC, nor the combination of KTZ and NAC were toxic to the BeWo cells. We found that KTZ 
did not prevent DCVC or DCVC + NAC-stimulated toxicity in unsyncytialized BeWo cells. For 
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syncytialized BeWo cells, KTZ, NAC, and KTZ + NAC treatments with DCVC decreased 
cytotoxicity relative to DCVC-only treatment. However, this latter finding could be explained by 
the finding that KTZ, NAC, KTZ + NAC treatments in the absence of DCVC also lowered 
cytotoxicity relative to control (absence of DCVC, KTZ, or NAC). The inability of NAC to 
prevent DCVC-stimulated toxicity in syncytialized BeWo cells hampers a conclusion that KTZ, 
NAC, or KTZ + NAC pre/co-treatment prevents DCVC-stimulated cytotoxicity. It remains 
unclear how KTZ, NAC, or KTZ + NAC treatments could reduce cytotoxicity relative to control 
in syncytialized BeWo cells. Although we saw no indication that CYP3A4 inhibition prevented 
DCVC- or DCVC/NAC-stimulated toxicity, the possibility that NAC pre/co-treatment 
exacerbation of DCVC toxicity could depend on CYP3A4 is still valid in light of our CYP3A4 
mRNA data displaying a significant NAC effect of increased CYP3A4. 
Although CYP3A4 may have a role in DCVC toxicity, inhibition with KTZ was 
insufficient to prevent toxicity. It is plausible that CYP3A4 inhibition alone failed to prevent 
DCVC toxicity because the cells had no mechanism to prevent the regeneration of DCVC from 
NAcDCVC. Indeed, whereas CYP3A4 inhibition by KTZ can result in less NAcDCVCS 
formation from NAcDCVC, the cells could still use aminoacylase III to convert NAcDCVC back 
into DCVC (Uttamsingh and Anders, 1999; Uttamsingh et al., 2000; Lash et al., 2014a), which 
could form reactive metabolites such as DCVT, CTK, and CTAC (Lash et al., 2014a). Therefore, 
an alternative approach to reduce DCVC-stimulated toxicity would be to inhibit both CYP3A4 
and aminoacylase III, which would theoretically “trap” the innocuous NAcDCVC metabolite. 
Ebselen seems to be a particularly good candidate for aminoacylase III inhibition (Tsirulnikov et 
al., 2012; Hanavan et al., 2015; Tan et al., 2015). The proposed mechanism of inhibiting 
CYP3A4 and aminoaceylase III to reduce DCVC-stimulated toxicity is illustrated in Figure 
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5.10. Although reports suggest that CYP3A4 is a relevant CYP in BeWo cells (Pavek et al., 
2007; Suksawat et al., 2019), the possibility exists that inhibition of other CYP3As may be more 
effective interventions for DCVC-stimulated toxicity. Finally, another possibility is that KTZ 
may not be an effective CYP3A4 inhibitor in BeWo cells. Validation of the role of metabolic 
inhibition of CYP3A on DCVC toxicity requires additional investigation that is beyond the scope 
of the current study. 
 AOAA was ineffective as a CCBL inhibitor in BeWo cells regardless of differentiation 
status. This is consistent with our finding that AOAA is ineffective as a CCBL inhibitor in rat 
placenta (Chapter 2), but differs from prior reports that AOAA inhibits CCBL in kidney (Elfarra 
and Anders, 1984; Lash et al., 1986; Lash et al., 1994). Nonetheless, the differences in response 
to AOAA are supported by previous findings that CCBL composition differs by organ (Cooper 
and Pinto, 2006; Lash, 2010). It is possible that BeWo cells and placenta contain CCBLs that are 
different than those of kidney, which confers the BeWo and placental cell resistance to AOAA as 
a CCBL inhibitor. Identifying the exact CCBLs in placenta remains important future work. 
Although DCVC did not change CCBL activity (regardless of differentiation status), 
CCBL activity was higher in syncytialized BeWo cells compared with unsyncytialized BeWo 
cells. Our finding that the process of syncytialization increased mRNA expression of KYAT1, 
which codes for CCBL1, supports the notion that syncytialized cells have more CCBL activity 
than unsyncytialized cells. Because CCBL activity generates the toxic DCVT metabolite from 
DCVC, these findings help explain our prior finding that syncytialized BeWo cells were more 
susceptible than unsyncytialized BeWo cells to DCVC toxicity (Chapter 4). It remains unknown, 
however, how changes in CCBL activity correspond with multinucleation and cell fusion 
processes in other systems, such as slime molds and striated muscle cells (Potgens et al., 2002). 
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Future experiments looking at such phenomena may inform basic biology questions of cell 
fusion and multinucleation, and define sensitive cell populations.  
To our knowledge, we provide the first evidence that DCVC exposure altered mRNA 
expression of enzymes relevant to TCE metabolism in BeWo cells. A notable finding was that 
DCVC decreased FMO3 mRNA expression in unsyncytialized BeWo cells while not affecting 
KYAT1 mRNA expression. If these findings translate to the level of protein activity, this raises 
the possibility that unsyncytialized BeWo cells exposed to DCVC have less induction of FMO3 
activity relative to CCBL activity. This could mean that the DCVC to 1,2-dichlorovinylthiol 
(DCVT) conversion via CCBL would be more relevant to these cells than the DCVC to DCVC 
sulfoxide (DCVCS) conversion via FMO3 (Lash et al., 2014a). In syncytialized BeWo cells, 
DCVC exposure decreased CYP2E1 but not KYAT1 mRNA expression. Because CYP2E1 is a 
major CYP that metabolizes TCE in its initial step in the CYP-dependent oxidative pathway 
(Lash et al., 2014a), this finding raises the possibility that DCVC exposure in syncytialized 
BeWo cells decreased the relevance of the CYP-dependent oxidative pathway in these cells. 
Additionally, based on observation of Cq values, it seems that BeWo cells have higher levels of 
KYAT1 mRNA compared to FMO3 or CYP2E1 mRNA regardless of differentiation state (data 
not shown). Interestingly, we observed KYAT1 but not FMO3 or CYP2E1 mRNA expression 
changed by syncytialization. Future experiments can measure activities of multiple enzymes 
involved in TCE metabolism across different cell types or tissues. Together, these experiments 
can inform which metabolites could be in highest abundance following TCE or DCVC exposure.  
In summary, NAC and AOAA differentially modulated DCVC-stimulated toxicity. 
Figure 5.11 summarizes the knowledge of NAC and AOAA on DCVC metabolism modulation 
highlighting contributions of the current study. We have shown for the first time that NAC 
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increased DCVC toxicity relative to DCVC treatment alone. The mechanism of NAC 
exacerbation of DCVC cytotoxicity could be attributable to increased metabolism towards the 
toxic NAcDCVCS metabolite. Consistent with in vivo data showing the ineffectiveness of 
AOAA for CCBL activity inhibition in rat placenta (Chapter 2), AOAA was an ineffective 
CCBL inhibitor in BeWo cells regardless of differentiation status. This could mean that AOAA 
was unable to block the CCBL-catalyzed conversion of DCVC into the toxic DCVT. A key 
finding from the CCBL experiments was the discovery that syncytialized BeWo cells had higher 
CCBL activity compared to unsyncytialized BeWo cells. This discovery offers an explanation 
for our prior finding that syncytialized BeWo cells were more susceptible to DCVC toxicity 
(Chapter 4). Future directions could measure concentrations of TCE metabolites, such as DCVT 
and NAcDCVCS, to verify that changes in enzyme activity or mRNA expression correlate with 
changes in metabolite abundance. Additional noteworthy considerations include the need to 
define mechanisms explaining the different sensitives among placental and other cell populations 
to DCVC exposure, investigate mechanisms of co-exposure toxicity or reduction in toxicity, and 
use of tissue-specific enzyme activity to inform alternate methods of enzyme inhibition.  
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(A) Hoechst staining in unsyncytialized BeWo cells  
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(B) Quantification in 
unsyncytialized BeWo cells 
(48-hour exposure) 
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(C) Quantification in BeWo 
cells undergoing 
syncytialization (48-hour 
exposure) 
V
e
h
ic
le
 (
0
.1
%
 D
M
S
O
)
F
o
rs
k
o
li
n
 (
1
0
0
 
M
)
F
o
rs
k
o
li
n
 (
1
0
0
 
M
) 
+
 D
2
0
0
2 0
4 0
6 0
8 0
%
 o
f 
n
u
c
le
i
c
o
n
d
e
n
s
e
d
 o
r
 f
r
a
g
m
e
n
te
d
( - )  5  m M  N A C
(+ ) 5  m M  N A C
F o rs k o lin  (M )
D C V C  (M )
1 0 0
0
1 0 0
2 0
b
b
0
0
a
a b
a b a b
 
(D) Quantification in 
syncytialized BeWo cells 
(48-hour exposure) 
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Figure 5.1. Effects of DCVC with and without NAC pre/co-treatment on nuclear 
condensation or fragmentation. (A) Representative images of Hoechst staining to detect 
nuclear condensation or fragmentation. (B) Unsyncytialized BeWo cells received treatment(s) 
for 48 hours. (C) BeWo cells received treatment(s) for 48 hours while undergoing forskolin-
stimulated syncytialization. (D) Syncytialized BeWo cells received treatment(s) for 48 hours. 
Statistical analysis was performed using two-way ANOVA followed by Tukey’s post-hoc 
comparison of means. Statistical significance is indicated by non-overlapping letters. Error bars 
represent mean ± SEM. N=6 independent experiments. 
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(A) Unsyncytialized BeWo cells (48-hour exposure) 
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(B) BeWo cells undergoing syncytialization (48-hour exposure) 
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(C) Syncytialized BeWo cells 
(C1) (48-hour exposure) 
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(C2) (24-hour exposure) 
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Figure 5.2. Effects of DCVC with and without NAC pre/co-treatment on H2O2 abundance 
and PRDX2 mRNA expression as biomarkers of oxidative stress. (A) Unsyncytialized BeWo 
cells received treatment(s) for 48 hours. (B) BeWo cells received treatment(s) while undergoing 
forskolin-stimulated syncytialization for 48 hours. (C) Syncytialized BeWo cells received 
treatment(s) for (C1) 48 hours and (C2) 24 hours. For the PRDX2 mRNA expression data, data 
were analyzed by two-way ANOVA followed by Tukey’s post-hoc comparison of means, with 
N=3 independent experiments. For the H2O2 abundance data, statistical analysis was performed 
using mixed models ANOVA followed by Tukey’s post-hoc comparison of means, with N=3 
independent experiments performed in triplicate. Non-overlapping letters signify statistically 
significant differences. Error bars represent mean ± SEM. Menadione (MD) was included as a 
positive control for the H2O2 experiments. 
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(B) BeWo cells undergoing syncytialization (48-hour exposure) 
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(C) Syncytialized BeWo cells (24-hour exposure) 
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Figure 5.3. Effects of DCVC with and without NAC pre/co-treatment on apoptotic pathway 
genes BCL2 and LGALS3. (A) Unsyncytialized BeWo cells received treatment(s) for 48 hours. 
(B) BeWo cells received treatment(s) while undergoing forskolin-stimulated syncytialization for 
48 hours. (C) Syncytialized BeWo cells received treatment(s) for 24 hours. For the LGALS3 data 
in unsyncytialized BeWo cells, LGALS3 is unchanged by NAC for BeWo cells, however, 
p=0.0188 for the DCVC effect. Data were analyzed by two-way ANOVA followed by Tukey’s 
post-hoc comparison of means. Non-overlapping letters signify statistically significant 
differences. Error bars represent mean ± SEM. N=3 independent experiments.  
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Figure 5.4. Effects of DCVC with and without NAC pre/co-treatment on CYP3A4 mRNA 
expression. (A) Unsyncytialized BeWo cells received treatment(s) for 48 hours. (B) BeWo cells 
received treatment(s) while undergoing forskolin-stimulated syncytialization for 48 hours. (C) 
Syncytialized BeWo cells received treatment(s) for 24 hours. Data were analyzed by two-way 
ANOVA followed by Tukey’s post-hoc comparison of means. Error bars represent mean ± SEM. 
Non-overlapping letters signify statistically significant differences. Independent experiments 
with unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, and syncytialized 
BeWo cells were repeated five, three, and three times, respectively.  
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(A) Unsyncytialized BeWo cells (48-hour exposure) 
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(B) Syncytialized BeWo cells (48-hour exposure) 
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Figure 5.5. Effects of NAC and KTZ on DCVC-stimulated cell viability and cytotoxicity. 
Effects are shown for (A) unsyncytialized BeWo cells receiving treatment(s) for 48 hours and 
(B) syncytialized BeWo cells receiving treatment(s) for 48 hours. Statistical analysis was 
performed using mixed models ANOVA followed by Tukey’s post-hoc comparison of means. 
Statistically significant differences are indicated by non-overlapping letters. Error bars represent 
mean ± SEM. N=3 independent experiments with each experiment performed in triplicate. Cell 
viability was measured as relative fluorescence units (RFU) and cytotoxicity was measured as 
relative luminescence units (RLU)/mg protein. Camptothecin (CPT) was included as a positive 
control. 
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Figure 5.6. Effects of DCVC with and without AOAA pre/co-treatment on nuclear 
condensation or fragmentation. (A) Unsyncytialized BeWo cells received treatment(s) for 48 
hours. (B) BeWo cells received treatment(s) while undergoing forskolin-stimulated 
syncytialization for 48 hours. (C) Syncytialized BeWo cells received treatment(s) for 48 hours. 
Statistical analysis was performed using two-way ANOVA followed by Tukey’s post-hoc 
comparison of means. Statistical significance is indicated by non-overlapping letters. N=3 
independent experiments.  
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(D) Comparison of 
unsyncytialized BeWo 
cells to syncytialized 
BeWo cells 
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Figure 5.7. Effects of DCVC with and without AOAA pre/co-treatment on CCBL activity. 
(A) Unsyncytialized BeWo cells received treatment(s) for 48 hours. (B) BeWo cells received 
treatment(s) while undergoing forskolin-stimulated syncytialization for 48 hours. (C) 
Syncytialized BeWo cells received treatment(s) for 48 hours. (D) Comparison of CCBL activity 
in unsyncytialized BeWo cells versus syncytialized BeWo cells. Groups in (D) were taken from 
the respective groups in (A) and (C). For the comparisons within unsyncytialized BeWo cells, 
within BeWo cells undergoing syncytialization, and within syncytialized BeWo cells (A, B, and 
C), statistical analysis was performed using two-way ANOVA followed by Tukey’s post-hoc 
comparison of means. For the comparison between the control unsyncytialized BeWo cells and 
the control syncytialized BeWo cells (D), statistical analysis was performed using a two-tailed 
unpaired t-test. Error bars represent mean ± SEM. N=3 independent experiments.   
 
 
 
 
 
 
 
 
 
 
 
256 
 
(A) Unsyncytialized BeWo 
cells (48-hour exposure) 
(B) BeWo cells undergoing 
syncytialization (48-hour 
exposure) 
(C) Syncytialized BeWo 
cells (24-hour exposure) 
D
0
D
5
D
1
0
D
2
0
D
5
0
0 .0
0 .5
1 .0
1 .5
2 .0
D C V C  C o n c e n tra t io n  (M )
K
Y
A
T
1
 r
e
la
ti
v
e
 m
R
N
A
 e
x
p
r
e
s
s
io
n
(f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
0 5 0 0 0
 
V
C F
F
+
D
1
0
F
+
D
2
0
F
+
D
5
0
0
1
2
3
K
Y
A
T
1
 m
R
N
A
 e
x
p
r
e
s
s
io
n
(f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
F o rsk o lin  (M )
D C V C  (M )
1 0 0
0
1 0 0
1 0
1 0 0
2 0 5 0
1 0 0
0
0
a
c b c
a b
a
 
D
0
D
5
D
1
0
D
2
0
D
5
0
0 .0
0 .5
1 .0
1 .5
D C V C  C o n c e n tra t io n  (M )
K
Y
A
T
1
 r
e
la
ti
v
e
 m
R
N
A
 e
x
p
r
e
s
s
io
n
(f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
0 5 0 0 0
 
 
Figure 5.8. Effects of DCVC on KYAT1 mRNA expression. (A) Unsyncytialized BeWo cells 
exposed to DCVC for 48 hours. (B) BeWo cells exposed to DCVC while undergoing forskolin-
stimulated syncytialization for 48 hours. (C) Syncytialized BeWo cells exposed to DCVC for 24 
hours. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc 
comparison of means. Non-overlapping letters indicate statistical significance. Error bars 
represent mean ± SEM. N=3 independent experiments.  
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(A) Unsyncytialized BeWo cells (48-hour exposure) 
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(B) BeWo cells undergoing syncytialization (48-hour exposure) 
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(C) Syncytialized BeWo cells (24-hour exposure) 
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Figure 5.9. Effects of DCVC on FMO3 and CYP2E1 mRNA expression. (A) Unsyncytialized 
BeWo cells exposed to DCVC for 48 hours. (B) BeWo cells exposed to DCVC while undergoing 
forskolin-stimulated syncytialization for 48 hours. (C) Syncytialized BeWo cells exposed to 
DCVC for 24 hours. Statistical analysis was performed using one-way ANOVA followed by 
Tukey’s post-hoc comparison of means. Statistical significance is indicated by non-overlapping 
letters. Error bars represent mean ± SEM. N=3 independent experiments.  
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Figure 5.10. Proposed model for targeting S-(1,2-dichlorovinyl)-L-cysteine (DCVC) 
metabolism to reduce toxicity. The current study suggests that CYP3A4 inhibition alone is not 
sufficient to reduce DCVC-stimulated toxicity, even in the presence of N-acetyl-L-cysteine 
(NAC). A strategy to reduce DCVC toxicity proposed is the administration of CYP3A inhibition 
and aminoacylase III inhibition to prevent N-acetyl-DCVC (NAcDCVC) from being metabolized 
to either DCVC or NAcDCVC sulfoxide (NAcDCVCS), as shown above. NAcDCVCS itself is 
toxic, and DCVC can be metabolized to toxic metabolites via cysteine conjugate β-lyase (CCBL) 
or flavin-containing monooxygenase 3 (FMO3). Whereas unstable metabolites appear in 
brackets, metabolites known to be toxic appear in red. Enzymes are depicted by placement 
within arrows between metabolites. The dashed symbol with ebselen indicates a method 
uninvestigated in the current study but suggested for future studies. Other abbreviations: DCVT, 
1,2-dichlorovinylthiol; DCVCS, DCVC sulfoxide; CTAC, chlorothionoacetyl chloride; CTK, 
chlorothioketene; NAT, N-acetyltransferase; CYP, cytochrome P450. This figure was modified 
from a figure by Lash et al. 2014 (Lash et al., 2014). 
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Figure 5.11. Proposed mechanism of action of aminooxyacetic acid (AOAA) and N-acetyl-
L-cysteine (NAC) on S-(1,2-dichlorovinyl)-L-cysteine (DCVC) metabolism in BeWo cells. In 
the placental BeWo cells, AOAA was ineffective as a cysteine conjugate β-lyase (CCBL) 
inhibitor. It is proposed that NAC can increase N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine 
sulfoxide (NAcDCVCS) production. Supporting evidence from the current study is that NAC has 
a significant effect on CYP3A4 mRNA expression in the direction of increase. Ultimately, 
because of the toxicity of NAcDCVCS and the ability of AOAA to inhibit CCBL in BeWo cells, 
NAC and AOAA were unable to prevent DCVC-stimulated toxicity. Unstable metabolites appear 
in brackets, metabolites known to be toxic appear in red, and metabolites recoverable in urine are 
circled. Enzymes are depicted by placement within arrows between metabolites. Other 
Abbreviations: DCVT, 1,2-dichlorovinylthiol; DCVCS, DCVC sulfoxide; NAcDCVC, N-acetyl-
S-(1,2-dichlorovinyl)-L-cysteine; CTAC, chlorothionoacetyl chloride; CTK, chlorothioketene; 
FMO, flavin-containing monooxygenase; NAT, N-acetyltransferase; CYP, cytochrome P450. 
This figure was based in part from Lash et al. 2014 (Lash et al., 2014). 
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Table S5.1. Primer sequences used for the current study. In the case of using the NCBI 
database, primers were selected to have as close to 60 degrees Celsius melting point for each 
primer as possible, have an amplicon size preferably between 75 and 150 base pairs, and be as 
close to 50% GC pairs in sequence as possible. An absolute criterion of the primer was inclusion 
of an exon-exon junction.  
 
B2M (Beta-2-microglobulin) 
Forward 5’-TGCCGTGTGAACCATGTG-3’ 
Reverse 5’-GCGGCATCTTCAAACCTC-3’ 
Source Vreeburg, R.A.M, Bastiaan-Net, S., and Mes, J.J. (2011). Normalization 
genes for quantitative RT-PCR in differentiated Caco-2 cells used for 
food exposure studies. Food Funct. 2, 124-129. 
 
PRDX2 (Peroxiredoxin 2) 
Forward 5’-AGACGAGCATGGGGAAGTTTG-3’ 
Reverse 5’-TGTCATCCACGTTGGGCTTA-3’ 
Source NCBI Nucleotide Database 
 
BCL2 (BCL2, B-cell lymphoma 2, apoptosis regulator) 
Forward 5’-CATGCTGGGGCCGTACAG-3’ 
Reverse 5’-GAACCGGCACCTGCACAC-3’ 
Source Wyrębska, A., Szymański, J., Gach, K., et al. (2013). Apoptosis-
mediated cytotoxic effects of parthenolide and the new synthetic analog 
MZ-6 on two breast cancer cell lines. Mol. Biol. Rep. 40, 1655-1663. 
 
LGALS3 (Galectin-3) 
Forward 5’-GTGAAGCCCAATGCAAACAGA-3’ 
Reverse 5’-AGCGTGGGTTAAAGTGGAAGG-3’ 
Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 294345474c2 
 
NFKB1 (Nuclear factor kappa B subunit 1) 
Forward 5’-AACAGAGAGGATTTCGTTTCCG-3’ 
Reverse 5’-TTTGACCTGAGGGTAAGACTTCT-3’ 
Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 259155300c1 
 
FMO3 (Flavin-containing monooxygenase 3) 
Forward 5’-AAGAACGGGTTACCATGGGG-3’ 
Reverse 5’-TGTAAATGCTAGCCCTGCCC-3’ 
Source NCBI Nucleotide Database 
 
KYAT1 (Kynurenine aminotransferase 1) 
Forward 5’-CCAGTGGATGGTCTACGACG-3’ 
Reverse 5’-CTCCCGTTCAAAGCTCTCG-3’ 
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Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 95147550c1 
 
CYP2E1 (Cytochrome P450, family 2, subfamily E, polypeptide 1) 
Forward 5’-GGGAAACAGGGCAATGAGAG-3’ 
Reverse 5’-GGAAGGTGGGGTCGAAAGG-3’ 
Source PrimerBank: (https://pga.mgh.harvard.edu/primerbank/) 
PrimerBank ID: 75709190c3 
 
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) 
Forward 5’-TGCACATAGCCCAGCAAAGA-3’ 
Reverse 5’-TGGGTTCCATATAGATAGAGGAGCA-3’ 
Source NCBI Nucleotide Database 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
262 
 
(A) BeWo cells undergoing syncytialization 
(48-hour exposure) 
(B) Syncytialized BeWo cells (48-hour 
exposure) 
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Figure S5.1. Effects of DCVC with and without NAC pre/co-treatment on NFKB1 mRNA 
expression. Effects are shown for (A) BeWo cells undergoing syncytialization and (B) 
syncytialized BeWo cells. Data were analyzed by two-way ANOVA followed by Tukey’s post-
hoc comparison of means. N=3 independent experiments. Analysis was not performed on 
unsyncytialized BeWo cells for NFKB1 mRNA expression because DCVC by itself did not 
change NFKB1 mRNA expression in those cells (Figure 4.6). 
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Chapter VI. Alterations in Energy Metabolism Stimulated by the Trichloroethylene 
Metabolite S-(1,2-dichlorovinyl)-L-cysteine in the BeWo Human Placental Trophoblast 
Model During Syncytialization 
Abstract 
 Syncytialization is a crucial event of placentation that forms the syncytiotrophoblasts 
comprising the maternal-fetal interface. The process is characterized by changes in amino acid 
and energy metabolism. Exposure to the trichloroethylene (TCE) metabolite S-(1,2-
dichlorovinyl)-L-cysteine (DCVC) stimulates changes in energy metabolism in HTR-8/SVneo 
placental cells. In the current study, we exposed human villous trophoblastic BeWo cells to 
forskolin at 100 µM for 48 hours to stimulate syncytialization and investigated how DCVC 
treatment at 10 and 20 µM during syncytialization altered metabolites involved in energy 
metabolism using a metabolomics platform. Notable changes stimulated by syncytialization in 
the absence of DCVC included increased adenosine monophosphate (AMP) and guanosine 
monophosphate (GMP) and decreased aspartate and glutamate. In contrast, DCVC treatment 
during syncytialization decreased oleic acid, aspartate, proline, uridine diphosphate (UDP), 
UDP-D-glucose, uridine monophosphate (UMP), and cytidine monophosphate (CMP) relative to 
forskolin treatment alone, but did not increase any measured metabolites. Pathway analysis 
revealed multiple pathways in amino acid metabolism and sugar metabolism that were altered 
with forskolin-stimulated syncytialization alone and DCVC treatment during syncytialization 
(p<0.05). Analysis of ratios of metabolites within the pathways revealed that DCVC during 
syncytialization changed metabolite ratios in the same or different direction of syncytialization 
alone, indicating the complex nature of the relationship between syncytialization and DCVC 
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treatment. Together, the metabolic changes stimulated by DCVC treatment during 
syncytialization suggest energy metabolism and amino acid abundance as potential mechanisms 
by which DCVC could impact syncytialization and pregnancy. Future work could explore the 
relevance of the findings to TCE reproductive toxicity, including the detection of additional 
metabolites or assessment of the enzymes in the metabolic pathways that may be targets of TCE 
or DCVC.   
Introduction 
In the placenta, the differentiation of cytotrophoblasts into syncytiotrophoblasts is a 
process known as syncytialization and is crucial for a healthy pregnancy (Wice et al., 1990; 
Potgens et al., 2002; Wang et al., 2014). Multinucleation and cell fusion occur as 
cytotrophoblasts differentiate into syncytiotrophoblasts (Wang et al., 2014), which become the 
outermost layer of the villous tree of the fetal side of the placenta and hence the maternal-fetal 
interface (Cantle et al., 1987; Robbins et al., 2010; Wang et al., 2014). These 
syncytiotrophoblasts are the cells responsible for the transport of nutrients, gas, and waste 
between mother and fetus (Potgens et al., 2002; Wang et al., 2014). As such, abnormalities of 
syncytialization or syncytiotrophoblast function could impair fetal growth and development. 
Apoptosis of villous cytotrophoblasts, syncytiotrophoblasts, and other trophoblasts is 
associated with adverse pregnancy outcomes such as preeclampsia and intrauterine growth 
restriction, as reviewed by Sharp et al. (Sharp et al., 2010). A pattern of apoptosis of 
syncytiotrophoblasts, in particular, has been described in which apoptosis initiates locally and 
then expands to encompass the entire syncytium (Longtine et al., 2012). Mechanisms by which 
syncytiotrophoblast apoptosis are executed include decreased Bcl-2, which is associated with 
both preeclampsia and intrauterine growth retardation (Ishihara et al., 2002). Caspase-3 
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activation is downstream in the mechanism by which apoptosis in villous cytotrophoblasts is 
carried out, and is associated with intrauterine growth restriction (Endo et al., 2005; Huppertz et 
al., 2006). Thus, there is a clear link between syncytiotrophoblast apoptosis and adverse 
pregnancy outcomes. 
The BeWo human placental trophoblast cell line is a popular in vitro model for studying 
syncytialization (Pattillo and Gey, 1968). BeWo cells are villous trophoblasts that can be 
stimulated to syncytialize by forskolin (Daly, 1984; Wice et al., 1990), producing a cell 
phenotype that is similar to syncytialization as it occurs in vivo (Wice et al., 1990). An 
appropriate condition used to syncytialize the cytotrophoblastic BeWo cells is administration of 
100 µM forskolin for 48 hours (Wice et al., 1990; Al-Nasiry et al., 2006; Inadera et al., 2010) 
(Chapter 4). 
 Studies characterizing the molecular effects of forskolin-stimulated syncytialization of 
BeWo cells indicate a role for cellular redox regulation. These include findings that hypoxia 
inhibits syncytialization and alters the proteome of BeWo cells stimulated with forskolin (Hu et 
al., 2007). Additional findings from the prior study include alterations in proteins with relevance 
to oxidative stress (peroxiredoxin 1, peroxiredoxin 2), among others (Hu et al., 2007). Another 
study reported that peroxiredoxin 2 knockdown prevents BeWo cell syncytialization in response 
to forskolin (Wu et al., 2017), which suggests that syncytialization involves reactive oxygen 
species (ROS) regulation. Furthermore, syncytin-1, a biomarker of syncytialization (Vargas et 
al., 2009), is regulated by redox-sensitive proteins such as p38 and protein kinase A (Gupta et 
al., 2016). Moreover, forskolin reduces cell viability and proliferation in BeWo cells (Al-Nasiry 
et al., 2006) and reduced cell viability is associated with increased ROS in BeWo cells (Chapter 
4). 
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Environmental exposures have the potential to disrupt syncytialization, especially 
because numerous toxicants disrupt cellular ROS regulation (Jones and Sies, 2015). For this 
study, we focused on a common environmental contaminant, trichloroethylene (TCE), a 
chemical used as a metal degreaser and in the synthesis of various chemicals (Agency for Toxic 
Substances and Disease Registry, 2019). In epidemiological studies, TCE exposure has been 
associated with adverse pregnancy outcomes, including low birth weight and small for 
gestational age (Rodenbeck et al., 2000; Forand et al., 2012; Ruckart et al., 2014). In addition, 
TCE modifies oxidative stress markers in a pregnant Wistar rat model of fetal growth restriction 
(Loch-Caruso et al., 2019). S-(1,2-Dichlorovinyl)-L-cystine (DCVC) is a metabolite of TCE 
through its glutathione conjugation pathway (Lash et al., 2014). In vitro studies using DCVC 
exposure to HTR-8/SVneo extravillous placental cells (Graham et al., 1993) demonstrated that 
DCVC stimulates apoptosis, ROS generation, and pro-inflammatory response (Hassan et al., 
2016; Elkin et al., 2018). Thus, there is overlap between the mechanism of DCVC toxicity and 
the mechanism of syncytialization in regard to ROS, suggesting that DCVC may disrupt 
syncytialization. Importantly, TCE metabolites from its cytochrome P450-dependent oxidative 
pathway, trichloroacetic acid and dichloroacetic acid (Lash et al., 2014), are non-toxic to HTR-
8/SVneo cells (unpublished data).     
 Another possibile mechanism through which DCVC could disrupt syncytialization is 
through alteration of energy metabolism metabolites. Energy metabolites, particularly amino 
acids, are altered by DCVC treatment of HTR-8/SVneo placental cells (Elkin et al., 2020). 
DCVC also targets intracellular signaling relevant to the mitochondria (Elkin et al., 2019), where 
generation of energy metabolites such as adenosine triphosphate (ATP), crucial for pregnancy, 
takes place (Spaans et al., 2014; Sferruzzi-Perri et al., 2019). With respect to syncytialization, a 
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recent study discovered that syncytialization alters amino acid phosphorylation and collagen 
metabolic process in BeWo cells (Zheng et al., 2016). In addition, slime mold multinucleation 
involves energy utilization and amino acid turnover (Wright and Anderson, 1959; Liddel and 
Wright, 1961). Thus, we hypothesize that syncytialization and DCVC exposure during 
syncytialization will alter energy utilization and amino acid turnover in manners consistent with 
important pregnancy outcomes. The present study investigates modifications to energy 
metabolism stimulated by exposure to the TCE metabolite DCVC during syncytialization using a 
targeted metabolomics approach. 
Materials and Methods 
The BeWo cell line 
The BeWo human placental villous cytotrophoblast cell line (Pattillo and Gey, 1968) was 
used for the present study. BeWo cells were obtained through the American Type Culture 
Collection (ATCC CCL-98) and their identity was verified by short tandem repeat profile with 
fragment analysis on the ABI 3730XL DNA Analyzer from Applied Biosystems (Waltham, MA) 
at the University of Michigan DNA Sequencing Core. The cells were maintained in F12-K 
Nutrient Mixture Kaighn’s Modification medium with (+) L Glutamine (Gibco, Grand Island, 
NY). For cell treatments, DMEM/F12 Nutrient Mixture medium (Gibco, Grand Island, NY) was 
used so that the exposure media were without phenol red. All media were supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (HI-FBS) and 1% (v/v) penicillin/streptomycin 
(P/S) (Gibco, Grand Island, NY). Three washes of phosphate buffered saline (PBS) (Invitrogen 
Life Technologies, Carlsbad, CA) were performed prior to detaching the cells with 0.25% 
trypsin-EDTA (Invitrogen Life Technologies, Carlsbad, CA) during subculture. All cells were 
kept in a 5% CO2, 37°C controlled and humidified incubator. For regular subculture, cells were 
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plated at a 100,000 cells/mL concentration in 25 mL in 175 cm2 flasks (Corning Inc., Corning, 
NY) and passaged at about 70-80% confluence. This work with human cell cultures was 
approved by the University of Michigan Institutional Biosafety Committee (IBCA00000100).  
Exposures 
We applied 100 µM forskolin exposure for 48 hours to promote BeWo cell 
syncytialization, consistent with prior reports (Wice et al., 1990; Al-Nasiry et al., 2006; Inadera 
et al., 2010) and verified by us (Chapter 4). The vehicle control for any experiments using 
forskolin was 0.1% dimethyl sulfoxide (DMSO) (Tocris Bioscience, Bristol, UK). The TCE 
metabolite S-(1,2-dichlorovinyl)-L-cysteine (DCVC) was synthesized by the University of 
Michigan Medicinal Chemistry Core via published methods (McKinney et al., 1959). The 
chemical identity of DCVC was verified through proton nuclear magnetic resonance (NMR) 
spectroscopy and determined to be 98.7% pure by high-performance liquid chromatography 
(HPLC). DCVC was added to cultures at 10 and 20 µM concentrations. These DCVC 
concentrations were chosen based on prior findings of efficacy for elicitation of metabolic 
changes (Elkin et al., 2020). Moreover, the DCVC concentration range is similar to the average 
concentration of DCVG (13.4 μM), a precursor of DCVC (Lash et al., 2014), found in the blood 
of women exposed to occupationally relevant doses TCE (Lash et al., 1999; Agency for Toxic 
Substances and Disease Registry, 2007). DCVC was applied as a co-treatment with forskolin to 
investigate the effect of DCVC on syncytialization. To prepare for the experiment, cells were 
plated in 10-cm tissue culture dishes (Corning Inc., product 430167) at a density of 800,000 cells 
per dish in 8 mL volume. After 24 hours, the cells were treated according to the experimental 
groups in Figure 6.1. 
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Sample preparation for metabolomics analysis 
After the 48-hour treatment duration, medium was removed from the cells, and a gentle, 
quick wash with 150 mM ammonium acetate was performed. Following the ammonium acetate 
wash, liquid nitrogen was poured over the cells and allowed to evaporate from the dishes. Cell 
dishes were then stored at -80°C until delivery to the University of Michigan Metabolomics Core 
on dry ice for analysis. The targeted platform used at the University of Michigan Metabolomics 
Core for these plates was the Tricarboxylic acid (TCA) Plus Platform. Metabolites detected 
through the TCA plus platform include metabolites in energy utilization (e.g., metabolites in 
glycolysis, TCA cycle, pentose phosphate pathway) and amino acids. At the Core, cell culture 
dishes were removed from -80°C storage and maintained on wet ice throughout processing. To 
each 10-cm dish, a 1.5-mL mixture of methanol, chloroform and water (8:1:1) containing 
isotope-labeled internal standards was added. Dishes were gently agitated to release cells and 
then scraped to homogenize the cells. The resulting cell mixtures were transferred to microtubes. 
Microtubes were mixed on a vortex mixer and allowed to incubate at 4°C for 10 minutes to 
complete metabolite extraction. Samples were mixed a second time, and then centrifuged at 
14,000 RPM for 10 minutes at 4°C. From each sample, an aliquot of 100 µL of the extraction 
solvent was transferred to an autosampler vial for liquid chromatography-mass spectrometry 
(LC-MS) analysis. A volume of 10 µL of each sample was removed and pooled in a separate 
autosampler vial for a separate run for quality control purposes. 
Liquid chromatography-mass spectrometry (LC-MS) analysis  
Glycolysis, tricarboxylic acid, pentose phosphate pathway, and additional analyses were 
performed on an Agilent system consisting of a 1290 UPLC coupled with a 6520 Quadrupole-
Time-of-flight (QTOF) mass spectrometer (Agilent Technologies, Santa Clara, CA). Metabolites 
275 
 
were separated on a 150 x 1 mm Luna NH2 Hilic column (Phenomenex, Torrance, CA) using 10 
mM ammonium acetate in water, adjusted to pH 9.9 with ammonium hydroxide, as mobile phase 
A. Acetonitrile was used as mobile phase B. The flow rate was 0.075 mL/minute and the 
gradient was linear from 20% to 100% mobile phase A over 15 minutes, followed by isocratic 
elution at 100% mobile phase A for 5 minutes. The system was returned to starting conditions 
(20% mobile phase A) and held there for 10 minutes to allow for column re-equilibration before 
injecting another sample. The mass spectrometer was operated in ESI negative mode according 
to previously published conditions (Lorenz et al., 2011). 
Data processing 
Data were processed using MassHunter Quantitative analysis version B.07.00. 
Metabolites in the glycolysis, tricarboxylic acid, and pentose phosphate pathways were 
normalized to the nearest isotope-labeled internal standard and quantitated using two replicated 
injections of five standards to create a linear calibration curve with high accuracy for each 
standard. The locally estimated scatterplot smoothing (LOESS) method (Dunn et al., 2011; 
Thonusin et al., 2017) was used as a signal and drift correction method using Metabodrift 
(Thonusin et al., 2017). Because of the presence of internal standards, quantities arising from this 
method are reported in absolute concentrations. These absolute concentrations were normalized 
to protein mass to arrive at a reporting unit of pmol metabolite per µg protein and used in data 
analyses. Other compounds in the analysis were normalized to the nearest internal standard, and 
the peak areas were used for differential analysis between groups. The LOESS method using 
Metabodrift (Dunn et al., 2011; Thonusin et al., 2017) was also utilized as a signal and drift 
correction method for these data. Data from this method of processing were reported in the unit 
of relative responses (RR) and were used in data analyses.  
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Some metabolites were detected more than once. Guanosine monophosphate (GMP) and 
phosphoenolpyruvate (PEP) were detected as both absolute concentrations and relative 
responses: in both cases, the values from the absolute concentrations were used because of 
decreased total variance (for each metabolite, defined as the aggregate of the variance from each 
experimental group). Also, 3-phosphoserine was detected twice using the method with relative 
response with similar values within each treatment group: the second set of values, which had 
lower variance within each treatment group, was used in the current study. 
Pathway analysis 
Pathway analysis was performed using Metaboanalyst 4.0 (Chong et al., 2018; Chong et 
al., 2019) and selecting Homo sapiens (KEGG) within the pathway library. Because pathway 
analysis could only be performed for comparison of two groups, four sets of comparisons were 
made: (1) Vehicle control (0.1% DMSO) versus forskolin, (2) forskolin versus forskolin + 10 
µM DCVC, (3) forskolin versus forskolin + 20 µM DCVC, and (4) forskolin + 10 µM DCVC 
versus forskolin + 20 µM DCVC. Because of the non-Gaussian distribution of the processed 
data, data were generalized log-transformed prior to analysis. Other choices made within the 
program include: Pathway enrichment analysis (global test as opposed to global ANCOVA); and 
pathway topology analysis (relative between-ness centrality as opposed to out-degree centrality).  
Detection of MMP-1, MMP-2, MMP-3, and MMP-9 in media 
BeWo cells were plated at a 200,000 cells/well density in 2 mL/well of 6-well tissue 
culture plates (Corning, Corning, NY) and allowed to adhere for 24 hours before treatment. 
Upon completion of treatment, medium was collected and stored at -80°C until further 
processing. Protein was collected in a lysis buffer featuring 0.5% (v/v) IGEPAL CA-630 (Sigma-
Aldrich, St. Louis, MO), 250 mM NaCl (Sigma-Aldrich, St. Louis, MO), and 5% (v/v) of Tris-
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HCl (1 M, pH 7.4). Protein concentration was measured using the Pierce bicinchoninic acid 
(BCA) protein assay kit (Thermo Fischer Scientific, Waltham, MA) according to the 
manufacturer’s protocol, to allow for analyte concentration normalization to mass of protein. 
Directly prior to delivery, the media samples were thawed and pipetted into round-bottom 96-
well plates, and then submitted to the University of Michigan Immunologic Monitoring Core. 
The Immunologic Monitoring Core performed enzyme-linked immunosorbent assays to detect 
the analytes of interest using Duosets (R&D Systems, Minneapolis, MN) according to the 
manufacturer’s recommended protocol. 
Enrichment analyses 
 Enrichment analyses for location and drug pathway were performed using Metaboanalyst 
4.0 (Chong et al., 2018; Chong et al., 2019). The library for the location enrichment analysis 
contained 73 metabolite sets pertaining to organ, tissue, or subcellular localization. The library 
for the drug pathway enrichment analysis contained 461 metabolite sets pertaining to drug 
pathways. All enrichment analyses were done using the same types of comparisons as in 
pathway analysis and performed on the processed data that subsequently underwent generalized 
log-transformation. 
Statistical analysis 
 The sample size from all experiments in the current study is five independent replicates. 
To analyze up- or down-regulated individual metabolites, statistical analysis was conducted 
using unpaired two-tailed t-tests in the case of the forskolin treatment to vehicle (0.1% v/v 
DMSO) comparison to investigate the impact of syncytialization. In the case of the comparison 
of the forskolin alone, forskolin + 10 µM DCVC, and forskolin + 20 µM DCVC treatment 
groups, statistical analysis was conducted using one-way analysis of variance (ANOVA) 
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followed by Tukey’s post-hoc comparison of means. The data from the same forskolin group 
was used in all analyses. All processed metabolomics data were generalized log-transformed 
prior to statistical analysis because of non-Gaussian distribution, with the exception of ratio data, 
which used the processed but not generalized log-transformed data in order to obtain accurate 
ratios. Pathway and enrichment analyses were conducted using Metaboanalyst 4.0 (Chong et al., 
2018; Chong et al., 2019) with the settings described in the respective previous sections, and also 
consisted of generalized log-transformation of the processed data for comparison of two 
treatment groups at a time. Statistical analyses were performed using GraphPad Prism 7 
(GraphPad Software Inc.; San Diego, CA, USA), with the exception of the analyses from 
Metaboanalyst 4.0, which automatically computed p-values. P-values computed by 
Metaboanalyst 4.0 were adjusted for multiple comparisons (Chong et al., 2019) and were similar 
in magnitude to those computed by GraphPad Prism 7.0, whether from t-tests for one-way 
ANOVA. 
Results 
Quantity of metabolites measured 
 A total of 54 metabolites were measured from the BeWo cells using the TCA plus 
metabolomics platform, and concentrations or relative responses are listed in Table S6.1. Each 
of the following sets of metabolites was detected as an aggregate (i.e., within the set, it was not 
possible to distinguish one from the other): (1) citrate and isocitrate, (2) fructose 6-phosphate and 
glucose 6-phosphate, (3) ribose 5-phosphate and xylulose 5-phosphate, (4) leucine and 
isoleucine, and (5) hexose (glucose etc.). Each of these sets was considered as one metabolite in 
the counting of total. Additionally, the aforementioned sets were excluded from pathway and 
enrichment analyses because those analyses could not assign an aggregate of metabolites to a 
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specific compound. Three metabolites were counted more than once, as further discussed in the 
methods section along with what set of values were used; these metabolites were not double-
counted in the total number (54) of detected metabolites. 
Metabolites altered by forskolin-stimulated syncytialization  
 The effect of forskolin-stimulated syncytialization on metabolites was assessed by 
comparing forskolin-only treatment to vehicle control (Figure 6.2A). Forskolin treatment altered 
nine of the 54 detected metabolites (Figure 6.3; Table S6.2). Five out of the nine alterations 
were decreases, and four of the nine alterations were increases. Interestingly, two of the increases 
were monophosphate products: adenosine monophosphate and guanine monophosphate. 
Analysis of fold-change versus p-value in response to forskolin treatment revealed that 32 
metabolites had a fold-change less than one but that eight metabolites had a fold-change greater 
than 2. 
Metabolites altered by DCVC treatment during forskolin-stimulated syncytialization 
 To investigate if DCVC exposure could alter metabolites during forskolin-stimulated 
syncytialization, treatment with 10 or 20 µM DCVC was compared with forskolin-only 
treatment. Exposure to 10 µM DCVC during forskolin-stimulated syncytialization decreased two 
metabolites. Analysis of fold-change versus p-value indicates that 37 of the 54 metabolites had a 
fold-change less than one in the same comparison (Figure 6.2B; Table S6.2). Exposure to 20 
µM DCVC during forskolin-stimulated syncytialization decreased seven metabolites. In this 
comparison, 37 of the 54 metabolites had a fold-change less than one (Figure 6.2C; Table S6.2). 
Concentration-dependent changes in metabolites were observed for DCVC exposure during 
forskolin-stimulated syncytialization: comparison of the 20 µM DCVC group to the 10 µM 
DCVC group revealed that 20 µM DCVC decreased two metabolites. In this comparison, 20 out 
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of 54 metabolites had a fold-change less than one (Figure 6.2D; Table S6.2). Whereas both 
metabolites changed by 10 µM DCVC were also within the seven metabolites changed by 20 µM 
DCVC relative to forskolin-only treatment, one of the metabolites changed in the 20 µM DCVC 
versus 10 µM DCVC comparison was not included in the seven metabolites changed in the 20 
µM DCVC to forskolin-only treatment comparison (Table S6.2). 
Associations of metabolites changed by syncytialization versus metabolites changed by DCVC 
treatment during syncytialization 
 Among the metabolites significantly altered by syncytialization (comparing forskolin-
only and vehicle control groups), three metabolites (oleic acid, aspartate, and uridine diphosphate 
D-glucose) were also significantly altered by DCVC treatment during syncytialization (Figure 
6.3). Oleic acid decreased by 40.5% with 20 µM DCVC (p=0.0344), whereas a 69.2% increase 
was seen with syncytialization (forskolin-only treatment) (p=0.0152). In the case of aspartate and 
uridine diphosphate D-glucose, 20 µM DCVC further decreased (by 40.2% and 44.2%, 
respectively; p=0.0310 and 0.0255, respectively) concentrations seen with syncytialization 
(forskolin-only treatment) (by 38.5% and 57.3%, respectively; p=0.0068 and 0.0060, 
respectively). We next visualized associations between metabolite fold-changes across different 
comparisons to assess changes associated with syncytialization versus changes associated with 
DCVC treatment during syncytialization. Comparison of fold change of 10 µM DCVC co-
treatment versus 20 µM DCVC co-treatment led to statistically significant association (p<0.0001 
for Spearman correlation), indicating that changes stimulated by 10 µM DCVC co-treatment are 
similar to changes stimulated by 20 µM DCVC co-treatment (Figure 6.4A). Neither comparison 
of 10 or 20 µM DCVC treatment to syncytialization by itself were statistically significant 
(p=0.1182 and 0.9893 for Spearman correlation, respectively) (Figures 6.4B and 6.4C).  
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KEGG pathway analysis 
 Our data input identified 47 pathways that were able to be analyzed by Metaboanalyst 4.0 
(Figure 6.5A). Of these, 13 pathways were statistically altered in response to forskolin treatment 
to induce syncytialization (p<0.05). Four of these 13 pathways had a corresponding pathway 
impact above 0.1, indicating that measured metabolites had relevance to those pathways. 
Impacted pathways included histidine metabolism (p=0.0038; pathway impact=0.2213), 
ascorbate and aldarate metabolism (p=0.0120; pathway impact=0.5), pentose and glucuronate 
interconversions (p=0.0120; pathway impact=0.2031), and amino sugar and nucleotide sugar 
metabolism (p=0.0120; pathway impact=0.1031). Six of the 13 statistically altered pathways had 
a corresponding pathway impact of 0, which indicates that very few, if any, of the important 
metabolites in the pathway were detected. 
 Because Metaboanalyst limited pathway analysis to comparison of two groups, three 
comparisons were undertaken to assess alterations by DCVC treatment during syncytialization. 
Exposure to 10 µM DCVC significantly increased one pathway, arginine and proline 
metabolism, relative to forskolin-only treatment (p=0.0262, pathway impact=0.2744). Three 
additional pathways (starch and sucrose metabolism, galactose metabolism, and pyrimidine 
metabolism) had p-values between 0.05 and 0.06 (Figure 6.5B). 
 Following treatment with 20 µM DCVC during syncytialization, 16 pathways were 
statistically significantly altered in comparison with forskolin-only treatment. Eight out of the 16 
pathways had a pathway impact above 0.1: (1) pyrimidine metabolism (p=0.000015; pathway 
impact=0.1305), (2) arginine and proline metabolism (p=0.0006; pathway impact=0.2744), (3) 
ascorbate and aldarate metabolism (p=0.0029; pathway impact=0.5), (4) pentose and glucuronate 
interconversions (p=0.0029; pathway impact=0.2031), (5) amino sugar and nucleotide sugar 
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metabolism (p=0.0029; pathway impact=0.1031), (6) alanine, aspartate and glutamate 
metabolism (p=0.0055; pathway impact=0.5345), (7) arginine biosynthesis (p=0.0184; pathway 
impact=0.1777), and (8) histidine metabolism (p=0.0202; pathway impact=0.2213). Five of the 
16 identified pathways had a pathway impact of 0 (metabolites analyzed in the pathway were 
few and/or unimportant). For the third comparison of 10 µM DCVC versus 20 µM DCVC during 
syncytialization, none of the 54 pathways achieved statistical significance. The lowest p-value 
for that comparison was 0.05904 in the case of fatty acid biosynthesis (pathway impact=0), and 
the next lowest was for pyrimidine metabolism (p=0.0650; pathway impact=0.1305). 
Analysis of metabolite ratios within pathways 
 To distinguish specific points within metabolic pathways, ratios between known 
consecutive metabolites of a pathway were analyzed. Additionally, ratios of biological 
importance, such as ratios of metabolites near the beginning and end of a pathway, were 
assessed. The totality of metabolite ratios analyzed are listed in Tables S6.3 through S6.7 along 
with their treatment-dependent fold changes and p-values. Details within specific pathways are 
presented in subsequent sections. In totality of analysis, forskolin-stimulated syncytialization 
(forskolin-only treatment) significantly changed 16 of 48 ratios analyzed (p<0.05). Treatment 
with 20 µM DCVC during syncytialization significantly changed 18 of the 48 ratios (p<0.05). 
Both 10 and 20 µM µM DCVC changed 5 of the 18 ratios relative to forskolin-only treatment. 
Comparison of 20 µM DCVC treatment versus 10 µM DCVC treatment during syncytialization 
identified 8 of the 18 ratios significantly altered with one additional change that was not 
observed in the 20 µM DCVC treatment comparison to forskolin-only treatment. Of the ratios 
changed by forskolin or any comparison within DCVC co-treatment, nine (adenosine 
triphosphate (ATP) to adenosine diphosphate (ADP), ADP to adenosine monophosphate (AMP), 
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citrate and isocitrate to succinate, phosphoenolpyruvate to succinate, ornithine to proline, 
histidine to aspartate, phenylalanine to succinate, oleic acid to palmitic acid, and uridine 
diphosphate (UDP)-D-glucose to uridine monophosphate (UMP)) were in common to each other. 
In the case of citrate and isocitrate to succinate, phosphoenolpyruvate to succinate, histidine to 
aspartate, phenylalanine to succinate, and ornithine to proline, DCVC treatment during 
syncytialization served to further a change in the same direction as that produced by 
syncytialization. However, in the case of ATP to ADP, ADP to AMP, UDP-D-glucose to UMP, 
and oleic acid to palmitic acid, DCVC treatment during syncytialization made changes in the 
opposite direction as the change with syncytialization. 
Analysis of metabolite ratios within the purine and pyrimidine metabolism pathway 
 Metabolite ratios altered within the purine and pyrimidine metabolism pathways are 
shown in Figures 6.6 and 6.7, and in Table S6.3. Forskolin-stimulated syncytialization 
(forskolin-only treatment) altered the following ratios: ATP to ADP (56.6% decrease, p=0.0410), 
ADP to AMP (50.8% decrease, p=0.0051), GDP to GMP (57.0% decrease, p=0.0096), and UDP 
to CMP (42.1% decrease, p=0.0218) (Figures 6.6B, 6.6C, 6.6E, and 6.7C, respectively).  
Treatment with 20 µM DCVC during syncytialization altered the following ratios relative to 
forskolin-only treatment: ATP to ADP (51.4% increase, p=0.0142), ADP to AMP (72.8% 
increase, p=0.0049), ATP to AMP (166.7% increase, p=0.0086), UMP to cytidine 
monophosphate (CMP) (42.6% decrease, p<0.0001), and glutamine to UMP (243.1% increase, 
p<0.0001) (Figures 6.6B, 6.6C, 6.6D, 6.7B, and 6.7D, respectively). Metabolite ratio analysis 
comparing 20 µM DCVC versus 10 µM DCVC treatment during syncytialization revealed the 
following differences: ADP to AMP (65.8% increase, p=0.0074), ATP to AMP (117.4% 
increase, p=0.0209), UMP to CMP (31.3% decrease, p<0.0001), glutamine to UMP (136.6% 
284 
 
increase; p=0.0001), and inosine to hypoxanthine (55.6% decrease, p=0.0484) (Figures 6.6C, 
6.6D, 6.7B, 6.7D, and 6.6F, respectively). DCVC treatment at 10 µM during syncytialization 
altered the UMP to CMP ratio relative to forskolin only treatment (16.5% decrease, p=0.0010) 
(Figure 6.7B).  
Analysis of metabolite ratios within the glycolysis, tricarboxylic acid (TCA) cycle, and pentose 
phosphate pathways 
 Ratios analyzed within glycolysis, the TCA cycle, and pentose phosphate pathway are in 
Figures 6.8, 6.9, 6.10, and Table S6.4. Metabolite ratios specific to glycolysis that were 
changed only included a decrease in the fructose 1,6-bisphosphate to phosphoenolpyruvate ratio 
in the case of forskolin-stimulated syncytialization (forskolin-only treatment) relative to its 
control (0.1% DMSO) (48.7% decrease, p=0.0024) (Figure 6.8B). Although a change in 
response to forskolin treatment occurred within a specific portion of the glycolysis pathway, to 
understand if glycolysis as a whole was impacted, the ratio of glucose 6-phosphate and fructose 
6-phosphate (early in glycolysis) to phosphoenolpyruvate (late in glycolysis) for each sample 
was analyzed. This ratio was not changed in response to forskolin exposure (p=0.4974) (Table 
S6.4). Relative to forskolin-only treatment, no DCVC treatment during syncytialization changed 
this ratio (lowest p-value was 0.8680 in the case of the 10 µM DCVC versus 20 µM DCVC 
treatment during syncytialization comparison) (Table S6.4). 
 Within the TCA cycle, the citrate and isocitrate to succinate ratio was decreased in 
response to forskolin treatment (54.1% decrease, p=0.0061) and when 10 µM DCVC treatment 
during syncytialization and 20 µM DCVC treatment during syncytialization were each compared 
to syncytialization alone (49.3% and 47.1% decrease, respectively; p=0.0011 and p=0.0015, 
respectively) (Figure 6.9B). The phosphoenolpyruvate to succinate ratio was decreased by 
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forskolin treatment (50.2% decrease, p=0.0007) and 20 µM DCVC treatment during 
syncytialization compared to forskolin-only treatment (55.8% decrease, p=0.0103) (Figure 
6.9C). Forskolin treatment did not change any of the ratios we calculated for the pentose 
phosphate pathway. However, two of the ratios for the pentose phosphate pathway, ribose 5-
phosphate and xylulose 5-phosphate to 6-phosphogluconate and ribose 5-phosphate and xylulose 
5-phosphate to sedoheptulose 7-phosphate, were decreased for the 20 µM DCVC treatment 
during syncytialization to forskolin-only treatment comparison (75.1% and 68.7% decrease, 
respectively; p=0.0455 and 0.0090, respectively) (Figures 6.10B and 6.10C, respectively). 
Analysis of metabolite ratios within amino acid metabolism pathways 
 Analysis of amino acid metabolism pathways are included in Figures 6.11, 6.12, 6.13, 
6.14, and Table S6.5. Forskolin-stimulated syncytialization (forskolin-only treatment) changed 
the following three metabolite ratios: Glutamate to succinate (73.6% decrease, p=0.0029), 
histidine to aspartate (63.1% increase, p=0.0046), ornithine to proline (42.6% increase, 
p=0.0030), phenylalanine to succinate (68.8% decrease, p=0.0053), and taurine to alanine 
(34.4% decrease, p=0.0138) (Figures 6.11C, 6.12C, 6.13B, 6.14B, and Table S6.5, 
respectively). The asparagine to aspartate ratio was increased in the 20 µM DCVC treatment 
during syncytialization group compared to the forskolin-only treatment and the 10 µM DCVC 
treatment during syncytialization groups (61.7% and 63.5% increase, respectively; p=0.0366 and 
0.0335, respectively) (Figure 6.11B). The ornithine to proline ratio was increased in the 10 µM 
DCVC and 20 µM DCVC treatments during syncytialization groups relative to the forskolin-
only treatment group (65.1% and 109.6% increase, respectively; p=0.0091 and 0.0001, 
respectively) (Figure 6.13B). The histidine to aspartate ratio was increased in the 20 µM DCVC 
treatment during syncytialization group comparison to the forskolin-only treatment and the 10 
286 
 
µM DCVC treatment during syncytialization groups (61.4% and 51.1% increase, respectively; 
p=0.0195 and 0.0369, respectively) (Figure 6.12C). The phenylalanine to succinate ratio was 
decreased in the 10 µM DCVC and 20 µM DCVC treatments during syncytialization groups 
relative to the forskolin-only treatment group (54.3% and 63.7% decrease, respectively; 
p=0.0152 and 0.0054, respectively) (Figure 6.14B). 
Analysis of metabolite ratios within glutathione metabolism 
 Analysis of glutathione metabolism is included in Figure 6.15 and Table S6.6. Only one 
calculated ratio for glutathione (GSH) metabolism was altered: Glutathione disulfide to 
nicotinamide adenine dinucleotide phosphate. This ratio was decreased with forskolin-stimulated 
syncytialization (forskolin-only treatment) (57.9% decrease, p=0.0487), and none of the 
comparisons with DCVC treatment during syncytialization altered this ratio (Figure 6.15B). 
Analysis of other metabolite ratios of interest 
 Additional analysis of metabolites ratios as they relate to pathways is included in Figure 
6.16 and Table S6.7. Other metabolite ratios altered by forskolin-stimulated syncytialization 
(forskolin-only treatment) included the following: Oleic acid to palmitic acid (99.8% increase, 
p=0.0104), UDP-D-glucose to UDP-D-glucuronate (31.7% decrease, p=0.0272), and UDP-D-
glucose to UMP (58.1% decrease, p=0.0266) (Table S6.7). A few other metabolite ratios were 
altered in comparisons involving DCVC treatment during syncytialization. DCVC treatment at 
20 µM during syncytialization altered the following ratios relative to forksolin-only treatment: 
Phosphocreatine to ATP (82.4% decrease, p=0.0074) (Figure 6.16B), phosphocreatine to ADP 
(72.0% decrease, p=0.00126) (Figure 6.16C), stearic acid to oleic acid (116.9% increase, 
p=0.0072) (Table S6.7), oleic acid to palmitic acid (53.5% decrease, p=0.0148) (Table S6.7), 
and UDP-D-glucose to UMP (100.6% increase, p=0.0091) (Table S6.7). DCVC treatment at 10 
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µM during syncytialization decreased the phosphocreatine to ATP ratio relative to forksolin only 
treatment (59.7% decrease, p=0.0465) (Figure 6.16B). DCVC treatment at 20 µM during 
syncytialization altered the following ratios relative to DCVC treatment at 10 µM during 
syncytialization: Stearic acid to oleic acid (72.0% increase, p=0.0324) and UDP-D-glucose to 
UMP (84.1% increase, p=0.0163) (Table S6.7). It is noteworthy that both of the ratios consisting 
of phosphocreatine were only altered when performing the comparisons involving DCVC 
treatment compared to forskolin-only treatment and not when investigating forskolin-only 
treatment compared to vehicle (0.1% DMSO). 
Effects of syncytialization and DCVC during syncytialization on concentrations of matrix 
metalloproteinases (MMP)-1, MMP-2, MMP-3, and MMP-9 in media 
 Changes in media concentrations of the matrix metalloproteinases MMP-1, MMP-2, 
MMP-3, and MMP-9 due to syncytialization and DCVC treatment are shown in Figure 6.17. 
Forskolin-stimulated syncytialization (forskolin-only treatment) increased MMP-2 379.6% 
(p=0.0001), an effect that was reduced by DCVC treatment at 20 and 50 µM during 
syncytialization relative to forskolin-only treatment (44.2% and 68.6% decrease, respectively; 
p=0.0351 and 0.0007, respectively) (Figure 6.17B). Treatment with 50 µM DCVC during 
syncytialization increased MMP-1 relative to control (forskolin-only treatment) by 340.5% 
(p=0.0299) (Figure 6.17A). Neither syncytialization nor DCVC treatment during 
syncytialization significantly changed MMP-3 or MMP-9 (Figures 6.17C and 6.17D, 
respectively). 
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Enrichment analysis identifying organs, tissues, or subcellular structures altered by 
syncytialization 
 Our input data of metabolites led to the corresponding analysis of 28 organs, tissues, or 
subcellular structures that could be associated with the effects of forskolin-stimulated 
syncytialization on detected metabolites (Table S6.8). Out of these 28, eight were statistically 
significant (p<0.05) in the comparison of forskolin-only treatment to vehicle control (0.1% 
DMSO). The top five were liver (p=0.0062), endoplasmic reticulum (p=0.0069), peroxisome 
(p=0.0078), Golgi apparatus (p=0.0120), and heart (p=0.0233). 
Enrichment analysis identifying organs, tissues, or subcellular structures altered by DCVC 
during syncytialization 
 The same comparison groups used in the corresponding pathway analysis section were 
used here to assess impacts of DCVC exposure during syncytialization (Tables S6.9, S6.10, and 
S6.11). Comparison of the 10 µM DCVC treatment during forskolin-stimulated syncytialization 
with the forskolin-only treatment comparison revealed only one out of 28 organs, tissues, or 
subcellular structures that was significantly altered (thyroid gland; p=0.0161) (Table S6.9). For 
the 20 µM DCVC treatment during syncytialization versus forskolin-only treatment comparison, 
13 out of the 28 structures were significantly altered – the top five were placenta (p=0.000065), 
skin (p=0.00093), Golgi apparatus (p=0.0029), thyroid gland (p=0.0031), and mitochondria 
(p=0.0040) (Table S6.10). For the 20 µM DCVC treatment versus 10 µM DCVC treatment 
during syncytialization comparison, two out of the 28 were significantly altered. The top two 
were kidney (p=0.0290) and erythrocyte (p= 0.0474) (Table S6.11). The p-values corresponding 
to placenta for the first and third-mentioned comparisons were 0.2248 and 0.1391, respectively. 
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Enrichment analysis identifying drug pathways altered by syncytialization 
 There were 357 drug pathways analyzed for association with forskolin-stimulated 
syncytialization from our input data of metabolites. Of these 357 drug pathways, 13 appeared as 
significantly altered by forskolin treatment. The lowest p-value from this set was 0.0277, and 
eleven pathways shared this p-value. The names of these pathways are reported in Table S6.12. 
Enrichment analysis identifying drug pathways altered by DCVC during syncytialization 
 The set of three comparisons mentioned previously in this results section is relevant here, 
as well, for analysis of drug pathways as associated with DCVC treatment during 
syncytialization (Tables S6.13, S6.14, and S6.15). For the 10 µM DCVC treatment during 
syncytialization versus forskolin-only treatment comparison, four out of the 357 drug pathways 
were significantly altered: these included morphine metabolism pathway (p=0.0274), sorafenib 
metabolism pathway (p=0.0274), celecoxib metabolism pathway (p=0.0356), and ibuprofen 
metabolism pathway (p=0.0356) (Table S6.13). For the 20 µM DCVC treatment during 
syncytialization versus forskolin-only treatment comparison, 52 out of the 357 drug pathways 
were significantly altered (Table S6.14): the lowest p-value from this set was 0.00038, which 30 
pathways shared. For the 20 µM DCVC treatment versus 10 µM DCVC treatment during 
syncytialization comparison, none of the 357 drug pathways were significantly altered. The 
lowest p-value from this set was 0.1526, which four pathways shared (Table S6.15). 
Discussion 
This study provides novel information regarding metabolic changes during placental cell 
syncytialization and the impact of DCVC, a metabolite of TCE, on energy metabolism during 
syncytialization. The major changes in energy metabolism observed in the present study are 
summarized in Figure 6.18, which provides a proposed model of how DCVC treatment during 
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syncytialization impacts energy metabolism. Figure 6.18 also highlights multiple KEGG 
pathway regions that could be deserving of further investigation, such as arginine biosynthesis. 
DCVC treatment during syncytialization affected multiple endpoints that were affected by 
syncytialization by itself, especially with regard to the pathway and metabolite ratio analyses.  
Metabolites altered 
Our findings of altered metabolites with forskolin-stimulated syncytialization (forskolin-
only treatment) and DCVC treatment during syncytialization provides insight into specific 
metabolites and classes of metabolites in energy metabolism changed by syncytialization and 
DCVC. Thematically, forskolin-stimulated syncytialization decreased abundance of cellular 
acidic amino acids (e.g., glutamate and aspartate) and increased abundance of purine 
monophosphates (adenosine monophosphate (AMP) and guanosine monophosphate (GMP)). On 
the other hand, DCVC treatment during syncytialization decreased pyrimidine phosphates 
(uridine diphosphate (UDP), uridine monophosphate (UMP), and cytidine monophosphate 
(CMP)) and altered the abundance of other metabolites not part of a specific energy metabolite 
group. Similar to our findings, forskolin does not affect amino acid system transporter A (SysA), 
which mediates the transport of neutral amino acids (Novak et al., 2006). Changes in energy 
metabolites in BeWo cells undergoing syncytialization is consistent with energy utilization and 
protein turnover previously observed in slime molds multinucleation (Wright and Anderson, 
1959; Liddel and Wright, 1961). Likewise, our results support findings that DCVC modifies 
energy metabolism outcomes in HTR-8/SVneo placental cells (Elkin et al., 2020). However, the 
impact of forskolin on transport of acidic and basic amino acids has not been investigated 
previously, and our data suggest that acidic amino acids could be a target for forskolin-
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stimulation. Investigations of transport and mechanisms surrounding this could be a worthy 
future direction.  
From prior studies, it is known that forskolin activates adenylate cyclase to increase 
intracellular cyclic AMP (cAMP) (Daly, 1984). Although we did not measure cAMP directly, it 
is plausible that our data on increased AMP is a consequence of the increased cAMP breakdown 
by cyclic nucleotide phosphodiesterase (Nair, 1966; Fischer and Amrhein, 1974) into AMP. 
Whether phosphodiesterase activity increases more than other enzymes stimulated by cAMP is 
not presently clear, however. Our data showing increased GMP following syncytialization could 
be a consequence of increased phosphodiesterase activity, perhaps by cAMP stimulation, in 
converting cyclic GMP (cGMP) to GMP. However, the role of forskolin on GMP or cGMP has 
not been previously studied in BeWo cells. 
The impact of DCVC treatment on energy metabolites during forskolin-stimulated 
syncytialization is generally consistent with prior reports of DCVC effects on placental cells, 
while contributing new information about possible mechanisms of action. The finding that 
DCVC altered pyrimidine phosphates (UDP, UMP and CMP) has not been previously reported. 
Because oleic acid is protective against apoptosis in syncytiotrophoblasts (Colvin et al., 2017), 
the oleic acid decrease we observed might have a role in the DCVC-stimulated apoptosis in 
HTR-8/SVneo placental cells (Elkin et al., 2018) and BeWo cells (Chapter 4). Additionally, 
proline and aspartate, both decreased by DCVC treatment during syncytialization, have 
important roles in pregnancy. Proline is crucial for polyamine synthesis during pregnancy and 
has been suggested to ameliorate intrauterine growth restriction (Wu et al., 2005; Wu et al., 
2008). Aspartate is also decreased in cases of early-onset preeclampsia (Kawasaki et al., 2019) 
292 
 
and, in addition to glutamate, preferentially locates in placenta as opposed to maternal or fetal 
circulation (Hoeltzli et al., 1990).  
Of three metabolites altered by both forskolin treatment and DCVC treatment during 
syncytialization, the change produced by DCVC treatment further decreased the response to 
forskolin treatment for two metabolites (aspartate and UDP-D-glucose) and suppressed an 
increased response to forskolin treatment for one metabolite (oleic acid). These findings 
highlight that DCVC exposure during syncytialization failed to elicit many changes in 
metabolites altered by syncytialization, and that the direction of change could either be 
exacerbation or reversal of the syncytialization effect. Furthermore, changes stimulated by 
syncytialization did not correlate well with changes stimulated by DCVC treatment during 
syncytialization. The conclusion is also consistent with our finding that of 14 metabolites altered 
by forskolin-stimulated syncytialization or any comparison involving DCVC treatment during 
syncytialization, eight metabolites were altered by DCVC treatment, nine metabolites were 
altered by forskolin treatment, and three metabolites were altered in both cases. In contrast, 
changes stimulated by different concentrations of DCVC correlated well with each other. 
Purine and pyrimidine metabolism 
 Ratio analysis within the purine metabolism pathway revealed that forskolin-stimulated 
syncytialization increased the formation of ATP relative to ADP, which was increased relative to 
AMP. DCVC treatment during syncytialization reversed all those forskolin-stimulated changes. 
Although the increased AMP relative to ADP stimulated by syncytialization was not unexpected 
given the role of forskolin as increasing cAMP (Daly, 1984; Wice et al., 1990), the finding that 
DCVC treatment during syncytialization reversed this hallmark of forksolin-stimulated 
syncytialization is novel. Because extracellular ATP is known to be vasoconstrictive and pro-
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inflammatory during pregnancy (Spaans et al., 2014) and causes albuminuria with pro-
inflammatory response in rats (Faas et al., 2010), it is plausible that the DCVC-stimulated effect 
would be detrimental for pregnancy. Future directions can serve to further characterize 
pregnancy-related outcomes resulting from DCVC exposure during pregnancy, understand how 
extracellular ATP is manifest in intracellular ATP, and investigate the relationship between 
DCVC and enzymes involved in conversion between the adenosine phosphates, such as CD39, 
CD73, and alkaline phosphatase (Spaans et al., 2014). Interestingly, syncytialization also 
increased GMP relative to GDP, showing that guanosine phosphates may also be as relevant to 
syncytialization. The mechanism linking changes in adenosine phosphates with changes in 
guanosine phosphates remain unknown in the context of syncytialization.  
 Ratios analyzed within the pyrimidine metabolism pathway revealed that forskolin-
stimulated syncytialization favored the formation of CMP relative to UDP whereas DCVC 
treatment during syncytialization favored the formation of CMP and glutamine relative to UMP. 
We suggest these changes in pyrimidine metabolism stimulated by DCVC during 
syncytialization, especially regarding glutamine, could be an adaptive response to improve 
pregnancy outcome. In support of this, glutamine has been proposed to improve pregnancy 
outcomes in mice and other mammals (Ren et al., 2013; Wu et al., 2015), reduces alcohol-
stimulated maternal hypercapnia during pregnancy (Sawant et al., 2014), and appropriate levels 
prevent hypoglycemia during pregnancy (Metzger et al., 1971). However, the roles of UMP, 
UDP, or CMP in pregnancy remain outstanding questions and their understanding would be 
needed to further place these findings in context. 
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Glycolysis, tricarboxylic acid (TCA) cycle, and pentose phosphate pathways 
Despite the inability of forskolin-stimulated syncytialization or DCVC treatment during 
syncytialization to affect glycolysis or gluconeogenesis in pathway analysis by Metaboanalyst 
(p>0.05), forskolin treatment altered a portion of glycolysis. Specifically, the ratio of fructose 
1,6-bisphosphate to phosphoenolpyruvate was decreased by forskolin treatment. Although these 
are not consecutive metabolites in glycolysis, the possibility exists that syncytialization 
preferentially shifted glycolysis overall to favor the late portion of glycolysis (e.g., 
phosphoenolpyruvate) as opposed to the earlier portion of glycolysis (e.g., fructose 1,6-
bisphosphate). Investigation of additional metabolites in glycolysis would address that 
possibility. Additionally, the change in metabolite ratio could be attributable to a substrate that 
feeds into phosphoenolpyruvate but not fructose 1,6-bisphosphate, such as oxaloacetate and 2-
phospho-D-glycerate (Holt and Wold, 1961; Chang and Lane, 1966; Bar-Even et al., 2012), 
which were not measured in the current study. 
For the TCA cycle, ratio analysis indicated that both forskolin-stimulated syncytialization 
and DCVC treatment during syncytialization favored the production of succinate relative to 
phosphoenolpyruvate and citrate and isocitrate. Whereas succinate is a direct precursor of 
succinyl coenzyme A (Hager, 1962), isocitrate can be converted to 2-oxoglutarate (Plaut and 
Sung, 1954), which can be converted to succinyl coenzyme A (Kerscher and Oesterhelt, 1981a; 
Kerscher and Oesterhelt, 1981b). Succinyl coenzyme A was not measured in the current study, 
and its measurement would be needed to further conclusions about the impact of DCVC on the 
TCA cycle. The pentose phosphate pathway was a pathway in which DCVC treatment during 
syncytialization favored production of 6-phosphogluconate and sedoheptulose 7-phosphate 
relative to ribose 5-phosphate and xylulose 5-phosphate. Future analysis can consider the role of 
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6-phosphogluconate dehydrogenase, which converts 6-phosphogluconate into 6-ribulose 5-
phosphate (Dickens and Glock, 1951; Yoon et al., 1989), which can be converted to D-xylulose 
5-phosphate by an epimerase (Dickens and Williamson, 1956). Identification of the relationship 
between DCVC and these enzymes can help inform the mechanism of action of DCVC. 
Amino acid and glutathione metabolism 
 Forskolin-stimulated syncytialization favored the abundance of (1) histidine relative to 
aspartate, (2) succinate relative to glutamate, (3) nicotinamide adenine dinucleotide phosphate 
(NADP) relative to glutathione disulfide (GSSG), (4) succinate relative to phenylalanine, and (5) 
ornithine relative to proline. In contrast, DCVC treatment during syncytialization favored 
abundance of (1) asparagine relative to aspartate, (2) histidine relative to aspartate, (3) succinate 
relative to phenylalanine, and (4) ornithine relative to proline. With regard to the ornithine to 
proline ratio that is within the arginine metabolism pathway, the direction of change by both 
syncytialization and DCVC treatment during syncytialization was towards the direction of 
increased arginine and nitric acid as opposed to proline. Because arginine has been suggested to 
promote embryonic survival (Zeng et al., 2008) and is a treatment for preeclampsia because of 
its role as a precursor of the vasodilator nitric oxide (Aouache et al., 2018), the current study 
would have benefitted from actual detection of arginine or other metabolites that are located 
closer to nitric oxide in the arginine metabolism pathway. These detections could further 
knowledge about the relationship of syncytialization or DCVC treatment to vasodilation or 
vasoconstriction during pregnancy.  
 The finding that DCVC treatment during syncytialization increased aspartate relative to 
asparagine may be relevant to pregnancy. Asparagine has been implicated to be important in rat 
fetal growth (Newburg and Fillios, 1979), so it may be possible that the increase in the 
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asparagine to aspartate ratio stimulated by DCVC treatment during syncytialization could be a 
compensatory change in amino acid supply. Additional metabolite ratios in amino acid 
metabolism altered in the current study have implications for adverse pregnancy outcomes. 
These include decreased succinate as associated with preeclampsia (Bahado-Singh et al., 2012; 
Bahado-Singh et al., 2015) and decreased phenylalanine as also associated with preeclampsia 
(Bahado-Singh et al., 2012; Bahado-Singh et al., 2015). Additionally, the finding that DCVC 
treatment during syncytialization altered three ratios (histidine to aspartate, succinate to 
phenylalanine, and ornithine to proline) in the same direction as syncytialization and no ratios 
the other way around was notable. This suggests that on the level of amino acid metabolism, 
DCVC treatment during syncytialization could more likely be further promoting syncytialization 
as opposed to opposing syncytialization. 
 The finding that forskolin-stimulated syncytialization increased the NADP to GSSG ratio 
but did not alter the glutathione (GSH) to GSSG ratio is contrary to findings in slime mold, in 
which multinucleation is accompanied by decreased GSH (Allen et al., 1985). Possible 
explanations for the different findings include the different methods used to stimulate 
multinucleation (i.e., a specific differentiation media, not forskolin, was used to stimulate 
multinucleation of the slime molds (Allen et al., 1985)) and differences in methodology used to 
detect GSH. Nevertheless, the finding of the increased NADP to GSSG ratio by syncytialization 
raises considerations. The first is whether NADP may have a greater impact than GSH in 
regulating glutathione reductase, which generates GSSG from GSH and NADP (Worthington 
and Rosemeyer, 1976; Bohme et al., 2000). The second is whether syncytialization is 
accompanied by glutathione reductase inhibition.  
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Oleic acid and matrix metalloproteinases 
 Because oleic acid was increased by forskolin-stimulated syncytialization and decreased 
by DCVC treatment during syncytialization in our current study, we investigated manifestations 
of the effects on oleic acid with a focus on matrix metalloproteinases (MMPs). Consistent with 
prior reports that oleic acid positively correlates with multiple matrix metalloproteinases 
(MMPs) (Yamaguchi et al., 2002; Soto-Guzman et al., 2010), we found that DCVC treatment 
during syncytialization decreased MMP-2 and oleic acid. MMP-2 and oleic acid were increased 
by syncytialization. Increased extracellular MMP-2 is suggested to have relevance to adverse 
pregnancy outcomes (Palei et al., 2012; Nissi et al., 2013) as well as hold importance to 
syncytialization (Sawicki et al., 2000; Xu et al., 2002). Interestingly, although MMP-1 increased 
with DCVC treatment during syncytialization, MMP-3 and MMP-9 were unchanged by 
syncytialization or DCVC treatment during syncytialization. Figure 6.17E shows a model by 
which syncytialization and DCVC treatment during syncytialization could impact MMPs and 
oleic acid. Although MMP-1 and MMP-2 are classified as a collagenase and a gelatinase, 
respectively, and cleave different substrates (Li et al., 2020), the meaning of these differences, as 
well as other differences among MMPs, remain unclear in the context of syncytialization. 
However, our data still suggest that selective regulation of MMPs, possibly attributable to oleic 
acid, would be plausible mechanisms for regulation of syncytialization or execution of the effects 
of DCVC treatment during syncytialization. Additional future directions could consider the 
extent by which alternative mechanisms, including AMP-activated protein kinase that enchances 
MMP-1 and MMP-2 production (Um et al., 2017), could be responsible for a MMP effect.  
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Enrichment analyses and other considerations 
Enrichment analysis identified syncytialization-associated changes that did not 
necessarily translate to placenta effects. As one plausible explanation, cell fusion and 
multinucleation are events that are not limited to placental cells, but also occur in muscle cells, 
slime molds, and osteoclasts (Potgens et al., 2002). It is also unknown if the enrichment analysis 
specifically considers syncytialization events and if so, the contribution of syncytialization as a 
placenta-specific pathway. Because we observed placenta as the most associated organ with 20 
µM DCVC treatment during syncytialization relative to forskolin only treatment, we suggest that 
BeWo cells are capable of responding in a manner that is specific to placenta. Further, this 
finding may indicate that BeWo cells have the ability to respond to DCVC in a placenta-specific 
manner that is not reflective of responses in other organs. Drug pathway enrichment analysis 
revealed that none of the top 13 drug pathways associated with syncytialization were in the top 
30 pathways associated with the 20 µM DCVC treatment during syncytialization versus 
syncytialization alone comparison. This suggests there is a difference between syncytialization 
and DCVC treatment during syncytialization. Nevertheless, these results can be used to generate 
hypotheses about alterations in drug metabolism with DCVC exposure and pregnancy. 
An overall limitation in the current study lies with the limited number of metabolites able 
to be quantified and the different methods for quantification (e.g., relative versus absolute 
processed and reported values) in the metabolomics analysis. Overcoming these limitations 
would allow for more specific inferences to pathways and adverse pregnancy outcomes. 
Additionally, the cells used in the study have limitations. Although forskolin-stimuation of 
BeWo cells produces features consistent with normal syncytialization (Wice et al., 1990), results 
may differ for placental cells in vivo. Nevertheless, forskolin presents benefits compared to other 
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agents that have been proposed to stimulate syncytialization. The other candidates that could 
stimulate syncytialization included theophylline, cholera toxin, 8-Br-cAMP, and dibutyryl-
cAMP, of which the last two require up to 1 mM to induce cell fusion (Wice et al., 1990). 
Conclusion 
 In summary, both forskolin-stimulated syncytialization and DCVC treatment during 
forskolin-stimulated syncytialization elicited effects on metabolites involved in energy 
metabolism. Notable and novel findings indicate that syncytialization and DCVC treatment 
during syncytialization provide opposing effects on metabolite ratios involving ATP, ADP, and 
AMP, suggesting that DCVC effects on adenosine phosphates may contribute a mechanism to 
oppose syncytialization. In contrast, histidine to aspartate, succinate to phenylalanine, and 
ornithine to proline ratios are examples of same direction of change promoted by syncytialization 
and DCVC treatment during syncytialization. Additionally, acidic amino acids, glutamate and 
aspartate, and nucleotide monophosphates may be likely targets of DCVC because these classes 
of metabolites were altered by DCVC. Furthermore, DCVC failed to increase the abundance of 
any measured metabolite. Finally, our work identified a potential role for MMPs in the 
mechanism of syncytialization that is modifiable by DCVC treatment during syncytialization. 
The notion of DCVC treatment as not simply a positive or negative regulator of syncytialization 
is consistent with the idea that syncytialization is a complex process (Gupta et al., 2016). 
Important future directions include understanding how changes in specific portions of the 
pathways have relation to other pathway portions and use of the discoveries in the current study 
to inform approaches at DCVC toxicity modulation possibly through targeting specific enzymes.  
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Figure 6.1. Summary and purposes of treatment groups used in the metabolomics study 
design. Comparison of the first two treatment groups, groups 1 and 2, test the effect of 
syncytialization on metabolomics outcomes. Comparison of groups 2, 3, and 4, investigate the 
effect of DCVC treatment on forskolin-stimulated syncytialization. Group 1 is the vehicle 
control group exposed to 0.1% (v/v) dimethyl sulfoxide (DMSO).  
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Figure 6.2. Volcano plots displaying the negative[log10(p-value)] as a function of the 
log2(fold-change) for each individual metabolite comparison. Graphs show four different 
comparisons, corresponding to the effect of: (A) syncytialization, comparing forskolin-only 
treatment to vehicle control; (B) 10 µM DCVC during syncytialization, comparing 10 µM 
DCVC treatment during syncytialization to forkskolin-only treatment; (C) 20 µM DCVC during 
syncytialization, comparing 20 µM DCVC treatment during syncytialization to forskolin-only 
treatment, and (D) DCVC concentration response, comparing 20 µM DCVC during 
syncytialization versus 10 µM DCVC during syncytialization. Individual points correspond to 
individual metabolites detected. The dashed gold lines correspond to the threshold of p=0.05 
(approximately where y=1.3 on each graph). Axes ranges differ among the graphs to clearly 
show metabolites. 
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Figure 6.3. Summary of specific metabolites altered by syncytialization or DCVC treatment 
during syncytialization. Metabolites highlighted in blue or red indicate metabolites increased or 
decreased, respectively, in response to forskolin-stimulated syncytialization and/or DCVC co-
treatment. The metabolites in smallest, moderate, and largest text sizes were significantly 
different at p<0.05, p<0.01, and p<0.001, respectively. In the case of DCVC effect during 
syncytialization, a metabolite was listed if it changed with at least 20 µM DCVC treatment, with 
the exception of inosine (marked with an asterisk), which was decreased in the 20 µM DCVC 
group compared to the 10 µM DCVC group.  
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Figure 6.4. Scatterplots showing associations between metabolite fold-changes across 
different comparisons to visualize changes associated with syncytialization versus changes 
associated with DCVC treatment during syncytialization. Comparisons displayed correspond 
to (A) the 20 µM DCVC treatment during syncytialization versus 10 µM DCVC treatment 
during syncytialization comparison, (B) the 10 µM DCVC treatment during syncytialization 
versus syncytialization alone comparison, and (C) the 20 µM DCVC treatment during 
syncytialization versus syncytialization alone comparison. X and Y axes are in units of log2(fold-
change), and individual data points represent individual metabolites detected in the cells.  
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Figure 6.5. KEGG pathways altered by forskolin-stimulated syncytialization or DCVC 
treatment during syncytialization. Individual figures represent the effect of (A) 
syncytialization, comparing forskolin-only treatment to vehicle control; (B) 10 µM DCVC 
during syncytialization, comparing 10 µM DCVC treatment during syncytialization to 
forkskolin-only treatment; (C) 20 µM DCVC during syncytialization, comparing 20 µM DCVC 
treatment during syncytialization to forskolin-only treatment, and (D) DCVC concentration 
response, comparing 20 µM DCVC during syncytialization versus 10 µM DCVC during 
syncytialization. Pathway analysis (specific for Homo sapiens) was performed by Metaboanalyst 
4.0 on the data (generalized log-transformed). The circle color corresponds to significance of the 
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pathway (white to red in order of increasing significance) whereas circle size corresponds to 
pathway impact, which is calculated as the matched metabolites as a cumulative percentage 
contributing to total pathway importance. A horizontal yellow dashed line indicates 
negative(log(p))=3, which corresponds to a p=0.05 under the loge (or ln) scale used in this 
analysis. Axes ranges differ among the graphs to clearly label pathways. 
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Figure 6.6. Purine metabolism as modified by syncytialization and DCVC treatment during 
syncytialization. (A) Simplified depiction of the purine metabolism KEGG pathway in Homo 
sapiens. Metabolites underlined in red correspond to metabolites that are part of a ratio altered by 
both syncytialization and DCVC treatment, compared to forskolin-only treatment. Metabolites 
underlined in green correspond to metabolites that are part of a ratio altered by syncytialization 
only. Metabolites underlined in blue correspond to metabolites that were analyzed in ratio 
analysis but not altered by syncytialization nor DCVC treatment, compared to forskolin-only 
treatment. Specific metabolite ratios changed by syncytialization or DCVC treatment during 
syncytialization are shown for: (B) the ATP to ADP ratio; (C) the ADP to AMP ratio; (D) the 
ATP to AMP ratio; (E) the GDP to GMP ratio; and (F) the inosine to hypoxanthine ratio. The 
inosine to hypoxanthine ratio was indicated as nonsignifiant in (A) because of lack of statistical 
significance compared to control (forskolin-only treatment). In the graphs, error bars represent 
mean ± SEM. N= 5 independent experiments. Abbreviations: ATP, adenosine triphosphate; 
ADP, adenosine diphosphate; AMP, adenosine monophosphate; cAMP, cyclic AMP; GTP, 
guanosine triphosphate; GDP, guanosine diphosphate; GMP, guanosine monophosphate; cGMP, 
cyclic GMP; IMP, inosine monophosphate.  
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Figure 6.7. Pyrimidine metabolism as modified by syncytialization and DCVC treatment 
during syncytialization. (A) Simplified depiction of the pyrimidine metabolism KEGG pathway 
in Homo sapiens. Metabolites underlined in red correspond to metabolites that are part of a ratio 
altered by both syncytialization and DCVC treatment, compared to forskolin-only treatment. 
Metabolites underlined in green correspond to metabolites that are part of a ratio altered by 
syncytialization only. Metabolites underlined in dark gold correspond to metabolites that are part 
of a ratio altered by DCVC treatment only. Metabolites underlined in blue correspond to 
metabolites that were analyzed in ratio analysis but not altered by syncytialization nor DCVC 
treatment, compared to forskolin-only treatment. Specific metabolite ratios changed by 
syncytialization or DCVC treatment during syncytialization are shown for: (B) the UMP to CMP 
ratio; (C) the UDP to CMP ratio; and (D) the glutamine to UMP ratio. In the graphs, error bars 
represent mean ± SEM. N= 5 independent experiments. Abbreviations: CTP, cytidine 
triphosphate; CDP, cytidine diphosphate; CMP, cytidine monophosphate; UTP, uracil 
triphosphate; UDP, uracil diphosphate; UMP, uracil monophosphate. 
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Figure 6.8. Glycolysis or gluconeogenesis as modified by syncytialization and DCVC 
treatment during syncytialization. (A) Simplified depiction of the glycolysis or 
gluconeogenesis KEGG pathway in Homo sapiens. Metabolites underlined in green correspond 
to metabolites that are part of a ratio altered by syncytialization only. Metabolites underlined in 
blue correspond to metabolites that were analyzed in ratio analysis but not altered by 
syncytialization nor DCVC treatment, compared to forskolin-only treatment. Specific metabolite 
ratios changed by syncytialization or DCVC treatment during syncytialization are shown for: (B) 
the FBP to PEP ratio. In the graphs, error bars represent mean ± SEM. N= 5 independent 
experiments. Abbreviations: FBP, fructose 1,6-bisphosphate; PEP, phosphoenolpyruvate. 
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Figure 6.9.  Tricarboxylic acid (TCA) cycle as modified by syncytialization and DCVC 
treatment during syncytialization. (A) Simplified depiction of the TCA cycle KEGG pathway 
in Homo sapiens. Metabolites underlined in red correspond to metabolites that are part of a ratio 
altered by both syncytialization and DCVC treatment, compared to forskolin-only treatment. 
Metabolites underlined in blue correspond to metabolites that were analyzed in ratio analysis but 
not altered by syncytialization nor DCVC treatment, compared to forskolin-only treatment. 
Specific metabolite ratios changed by syncytialization or DCVC treatment during 
syncytialization are shown for: (B) the CIT and ICIT to succinate ratio; and (C) the PEP to 
succinate ratio. In the graphs, error bars represent mean ± SEM. N= 5 independent experiments. 
Abbreviations: CIT, citrate; ICIT, isocitrate; PEP, phosphoenolpyruvate. 
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Figure 6.10. Pentose phosphate pathway as modified by syncytialization and DCVC 
treatment during syncytialization. (A) Simplified depiction of the pentose phosphate KEGG 
pathway in Homo sapiens. Metabolites underlined in dark gold correspond to metabolites that are 
part of a ratio altered by DCVC treatment only. Metabolites underlined in blue correspond to 
metabolites that were analyzed in ratio analysis but not altered by syncytialization nor DCVC 
treatment, compared to forskolin-only treatment. Specific metabolite ratios changed by 
syncytialization or DCVC treatment during syncytialization are shown for: (B) the R5P and X5P 
to 6PG ratio; and (C) the R5P and X5P to S7P ratio. In the graphs, error bars represent mean ± 
SEM. N= 5 independent experiments. Abbreviations: R5P, ribose 5-phosphate; X5P, xylulose 5-
phosphate; 6PG, 6-phosphogluconate; S7P, sedoheptulose 7-phosphate. 
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Figure 6.11. Alanine, aspartate, and glutamate metabolism as modified by syncytialization 
and DCVC treatment during syncytialization. (A) Simplified depiction of two portions of 
alanine, aspartate, and glutamate metabolism KEGG pathway in Homo sapiens. Metabolites 
underlined in green correspond to metabolites that are part of a ratio altered by syncytialization 
only. Metabolites underlined in dark gold correspond to metabolites that are part of a ratio 
altered by DCVC treatment only. Metabolites underlined in blue correspond to metabolites that 
were analyzed in ratio analysis but not altered by syncytialization nor DCVC treatment, 
compared to forskolin-only treatment. Specific metabolite ratios changed by syncytialization or 
DCVC treatment during syncytialization are shown for: (B) the Asn to Asp ratio; and (C) the Glu 
to succinate ratio. In the graphs, error bars represent mean ± SEM. N= 5 independent 
experiments. Abbreviations: Asn, Asparagine; Asp, Aspartate; Glu, Glutamate. 
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Figure 6.12. Beta-alanine metabolism and histidine metabolism as modified by 
syncytialization and DCVC treatment during syncytialization. Simplified depiction of the 
(A) the beta-alanine metabolism and (B) histidine metabolism KEGG pathways in Homo 
sapiens. Metabolites underlined in red correspond to metabolites that are part of a ratio altered by 
both syncytialization and DCVC treatment, compared to forskolin-only treatment. Metabolites 
underlined in blue correspond to metabolites that were analyzed in ratio analysis but not altered 
by syncytialization nor DCVC treatment, compared to forskolin-only treatment. Specific 
metabolite ratios changed by syncytialization or DCVC treatment during syncytialization are 
shown for: (B) the His to Asp ratio; and (C) the His to Glu ratio. In the graphs, error bars 
represent mean ± SEM. N= 5 independent experiments. Abbreviations: His, Histidine; Asp, 
Aspartate; Glu, Glutamate. 
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Figure 6.13. Arginine and proline metabolism as modified by syncytialization and DCVC 
treatment during syncytialization. (A) Simplified depiction of the arginine and proline 
metabolism KEGG pathway in Homo sapiens. Metabolites underlined in red correspond to 
metabolites that are part of a ratio altered by both syncytialization and DCVC treatment, 
compared to forskolin-only treatment. Metabolites underlined in blue correspond to metabolites 
that were analyzed in ratio analysis but not altered by syncytialization nor DCVC treatment, 
compared to forskolin-only treatment. Specific metabolite ratios changed by syncytialization or 
DCVC treatment during syncytialization are shown for: (B) the ornithine to Pro ratio. In the 
graphs, error bars represent mean ± SEM. N= 5 independent experiments. Abbreviation: Pro, 
proline. 
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Figure 6.14. Phenylalanine metabolism as modified by syncytialization and DCVC 
treatment during syncytialization. (A) Simplified depiction of the phenylalanine metabolism 
KEGG pathway in Homo sapiens. Metabolites underlined in red correspond to metabolites that 
are part of a ratio altered by both syncytialization and DCVC treatment, compared to forskolin-
only treatment. Metabolites underlined in blue correspond to metabolites that were analyzed in 
ratio analysis but not altered by syncytialization nor DCVC treatment, compared to forskolin-
only treatment. Specific metabolite ratios changed by syncytialization or DCVC treatment during 
syncytialization are shown for: (B) the Phe to succinate ratio. In the graphs, error bars represent 
mean ± SEM. N= 5 independent experiments. Abbreviation: Phe, phenylalanine. 
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Figure 6.15. Glutathione (GSH) metabolism as modified by syncytialization or DCVC 
treatment during syncytialization. (A) Simplified depiction of the glutathione metabolism 
KEGG pathway in Homo sapiens. Metabolites underlined in green correspond to metabolites that 
are part of a ratio altered by syncytialization only. Metabolites underlined in blue correspond to 
metabolites that were analyzed in ratio analysis but not altered by syncytialization nor DCVC 
treatment, compared to forskolin-only treatment. Specific metabolite ratios changed by 
syncytialization or DCVC treatment during syncytialization are shown for: (B) the GSSG to 
NADP ratio. In the graphs, error bars represent mean ± SEM. N= 5 independent experiments. 
Other abbreviations: GSSG, glutathione disulfide; NADP, nicotinamide adenine dinucleotide 
phosphate; NADPH, nicotinamide adenine dinucleotide phosphate hydrogen. 
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Figure 6.16. Phosphocreatine shuttling as modified by syncytialization and DCVC 
treatment during syncytialization. (A) Depiction of phosphocreatine shuttling. Metabolites 
underlined in red correspond to metabolites that are part of a ratio altered by both 
syncytialization and DCVC treatment, compared to forskolin-only treatment. Metabolites 
underlined in dark gold correspond to metabolites that are part of a ratio altered by DCVC 
treatment only. Specific metabolite ratios changed by syncytialization or DCVC treatment during 
syncytialization are shown for: (B) the phosphocreatine to ATP ratio and (C) the 
phosphocreatine to ADP ratio. A graph corresponding to the ATP to ADP ratio had already been 
shown in Figure 6.6B. In the graphs, error bars represent mean ± SEM. N= 5 independent 
experiments. Abbreviations: ATP, adenosine triphosphate; ADP, adenosine diphosphate.  
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Figure 6.17. Effect of syncytialization and DCVC treatment during syncytialization on 
matrix metalloproteinase (MMP) concentrations in BeWo cell media. Effect on (A) MMP-1, 
(B) MMP-2, (C) MMP-3, and (D) MMP-9. Statistical significance is denoted by non-overlapping 
letters. Error bars represent mean ± SEM. N=5 independent experiments. (E) Proposed 
mechanism by which DCVC co-treatment may act to stimulate adverse pregnancy outcomes 
involving oleic acid and MMPs. Solid lines indicate relationships confirmed by current study to 
date. Dotted lines indicate relationships inferred by previous literature. Dotted lines with a 
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question mark above indicate relationships untested previously. High likelihood exists that the 
relationships are also mediated by tissue inhibitors of metalloproteinases (TIMPs) and a 
disintegrin and metalloproteinases (ADAMs). 
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Figure 6.18. The effect of syncytialization or DCVC treatment during syncytialization on a 
simplified depiction portraying relationships among KEGG metabolism pathways. Boxed 
names are individual KEGG pathways, and unboxed names are critical metabolites that connect 
the pathways. Red names indicate metabolites or pathways altered in both syncytialization and 
DCVC treatment during syncytialization. Green names indicate metabolites or pathways altered 
in syncytialization only. Dark gold names indicate metabolites or pathways altered by DCVC 
treatment during syncytialization only. Blue names indicate metabolites or pathways unaltered 
by neither syncytialization nor DCVC treatment during syncytialization, compared to forskolin-
only treatment. Black names indicate metabolites or pathways not detected in the current study. 
Metabolite concentrations or relative responses and Metaboanalyst 4.0 pathway analysis results 
were used in determining metabolite and pathway significance, respectively. Dashed arrows 
indicate multi-step processes. Abbreviations: aCoA, acetyl coenzyme A; OAA, oxaloacetate; D-
G1P, alpha-D-glucose 1-phosphate; UDP-Glu, uridine diphosphate-glucose; R5P, D-ribulose 5-
phosphate; PRPP, phosphoribosyl pyrophosphate; FUM, fumarate; CP, carbamoyl phosphate, 
Gly-3P, glycerate 3-phosphate; Gly-2P, glycerate 2-phosphate; D-Glyal-3P, D-glyceraldehyde 3-
phosphate; D-G6P, alpha-D-glucose 6-phosphate; 5-PRA, 5-phosphoribosylamine; Fru-6P, 
fructose 6-phosphate; GTP, guanosine triphosphate. 
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Table S6.1. Concentrations or relative responses of detected metabolites.  
 
I. Metabolites measured as relative concentrations (Units: Relative response (RR)) 
 
Stearic Acid (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 8983063.51130517 3577837.32705119 5431447.91171993 5596887.95485907 
 5309191.82737296 4970376.93938718 4555250.233188 3689164.71627745 
 2316491.86649554 3955183.14662995 4221499.02388262 6932041.9166587 
 5952094.30303425 5883524.81876735 5779520.33984377 8184450.2131122 
 5903087.30347712 4743309.14831395 5142683.13674597 6085090.48027335 
Average 5692785.76233701 4626046.27602992 5026080.12907606 6097527.05623615 
 
Oleic Acid (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1080628.7038924 2469380.74722079 2597896.95143052 1100786.69353322 
 1634979.19089547 1850275.3172575 3021027.28454472 1366968.94107996 
 1151241.59875212 2076607.73829589 3055181.68577114 1486500.1225454 
 1300022.32983317 2928630.99824654 1314864.35304729 2184215.7507185 
 2325587.1253798 3348756.51462918 2006869.7928271 1403874.40248789 
Average 1498491.78975059 2534730.26312998 2399168.01352415 1508469.18207299 
 
Palmitic Acid (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 6808559.7598119 2643544.24796784 4221843.74678367 3782355.21897362 
 4226931.12878125 3621361.50290839 3572248.14937695 2965763.03767177 
 2205836.73832168 3502112.10792534 3336952.18620769 5000208.09952605 
 4436110.22027933 4070100.36120745 4482519.35830523 6190033.73623017 
 4673870.68947895 3506856.88492195 3596481.19482056 4354955.74273263 
Average 4470261.70733462 3468795.02098619 3842008.92709882 4458663.16702685 
 
Hexose (glucose, etc.) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 5103597.09754602 3236554.83207516 2624231.87819794 3068304.84111315 
 3562483.66006332 3271849.91222307 2413077.00625465 2256955.40781663 
 2696991.31249283 3941753.28921425 1326403.17785934 3537069.76059081 
 3077305.92642198 5006211.2079981 2995553.93221561 2635258.95097011 
 5310893.73056186 3539723.23792435 3926256.25510115 3467773.37614554 
Average 3950254.34541720 3799218.49588699 2657104.44992574 2993072.46732725 
 
Hypoxanthine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 701843.204092439 412361.312438637 445150.040148062 736871.929020986 
 316348.270692475 276694.687377403 362304.453406435 280665.348952527 
 373662.72878256 389438.649146639 208190.872017565 390254.729447692 
 423512.514897494 754888.292820714 426661.683034317 368544.364462013 
 453634.391719787 403352.761139326 398850.450338736 360260.500438105 
Average 453800.222036951 447347.140584544 368231.499789023 427319.374464264 
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Gluconate (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1174019.21649567 1750110.34386574 2505808.61216436 4686597.69396932 
 989449.199527297 2264130.59324959 2361972.44666252 1491445.40192058 
 668630.841360544 1243439.68713348 553218.637550705 1260908.34596076 
 1454140.92606625 3471006.37472047 1776220.85938873 1412845.59411985 
 1410192.97895479 972137.022021575 1680767.73738885 995264.705119501 
Average 1139286.63248091 1940164.80419817 1775597.65863103 1969412.34821800 
 
Glutamate (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 10196860.6384147 6657977.13275369 10476261.2873121 5349117.87845842 
 11066260.5969455 7826781.92650512 9878505.93224222 11084413.2448821 
 9803838.60082761 8669008.41356904 6800052.84766124 12266120.0710548 
 9031997.83100949 7763643.07617403 10107909.2765198 11477316.7015036 
 11591719.1258661 9160111.38198923 8748392.2489722 10253004.7676401 
Average 10338135.3586127 8015504.38619822 9202224.31854151 10085994.5327078 
 
Aspartate (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2298719.23327588 1171271.67868016 1408887.06810831 683939.718936933 
 2404797.0408211 1299069.37398625 1031865.5261527 641757.272000444 
 2134695.24981922 1582802.43195329 963776.054962218 1276084.04734685 
 3253270.97557796 2326734.8402766 1841762.09408527 1219084.63716756 
 2783007.1919358 1537316.45847726 1134262.43855932 916358.344019551 
Average 2574897.93828599 1583438.95667471 1276110.63637356 947444.803894268 
 
Glutathione (GSH) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2574666.109163 1285849.40637094 1254483.51606688 1478818.67530848 
 2927994.16493215 1602271.82557549 1276637.17257534 1069787.35073975 
 1910890.29904556 1014690.19270616 1553677.20230736 904679.966742162 
 2071224.15968098 3313869.00354071 1496296.93124825 1437571.34604358 
 775544.877295789 1219651.34066514 1021975.90568927 740217.653758553 
Average 2052063.92202350 1687266.35377169 1320614.14557742 1126214.99851850 
 
Phosphocreatine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 454551.85697831 204145.607313613 170327.276045687 166500.194239367 
 331298.315353717 229572.247003832 118184.314470439 79845.1898154739 
 327141.221602214 392386.471035413 56773.3791944169 162681.548258016 
 225983.170758931 142106.168398271 170606.813829002 136937.291475438 
 735899.770019573 254872.974355581 159090.696530966 108539.658896785 
Average 414974.866942549 244616.693621342 134996.496014102 130900.776537016 
 
Uridine diphosphate (UDP) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
324 
 
 645917.427355274 685432.235277347 436125.045207122 418813.65094107 
 708233.487450085 415523.832544218 240783.787879113 149322.836801892 
 687704.267413249 738559.7411582 126486.345980097 228260.125587615 
 622884.198806184 637076.097748023 226058.655670003 198968.80097381 
 2243486.70168367 385204.353116313 364186.855151468 190509.666703531 
Average 981645.216541692 572359.251968820 278728.137977561 237175.016201584 
 
UDP-N-acetyl-D-glucosamine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1782091.14925734 623398.03069108 1053190.40632734 980826.99666882 
 1389152.1717686 840427.278962086 1006461.05855669 925033.71417051 
 1385336.5941752 1108560.53518808 459082.750381614 1334937.78073005 
 1406524.11354646 824793.293644988 813160.978492501 903923.213684079 
 2841716.48009302 1191122.61079255 936267.416660438 1345672.19231531 
Average 1760964.10176812 917660.34985576 853632.52208372 1098078.77951375 
 
UDP-D-glucose (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1610529.88578895 562057.932063174 716843.058101649 423761.325061167 
 1153370.52970799 603653.583800584 411361.31671166 257849.105844303 
 1323388.77217408 877137.445441189 216649.958037673 460385.335574967 
 965530.681537843 620664.959285628 505202.612512754 435340.78231225 
 2982747.36867778 764352.265866518 406015.18419757 335618.145122503 
Average 1607113.44757733 685573.23729142 451214.42591226 382590.93878304 
 
N-Acetyl-glucosamine-1-phosphate (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 43060.1555538728 28792.6430909685 44353.3760728178 28383.926971332 
 40381.6049585973 25506.0935043795 33120.413095387 21967.6488991945 
 32464.622344282 28573.6052892275 16864.0613345608 32436.429164985 
 39668.0370959446 51546.8241798381 32571.277467623 34611.8056822476 
 78406.5822631106 34306.757902136 20952.1543814387 30724.9733272983 
Average 46796.2004431615 33745.1847933099 29572.2564703655 29624.9568090115 
 
Uridine monophosphate (UMP) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 387164.713937517 746068.767065474 954965.645731668 147057.19856209 
 624199.533063653 508739.353949539 404353.744112558 178483.972039197 
 783958.841280369 862223.558524544 242437.757393647 234030.291084895 
 332907.394128567 500941.662747765 254134.091538829 217688.176473857 
 2105823.44642235 919099.419671158 490000.716821029 187427.58654357 
Average 846810.785766491 707414.552391696 469178.391119546 192937.444940722 
 
Glutathione disulfide (GSSG) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 5157060.43478775 2452228.71313292 5313680.17179217 3878517.90734591 
 3868058.76340793 1415574.1478066 3564541.30930056 3633697.98898544 
 4574057.8957487 3268557.94742999 865149.438860533 4758626.4367129 
 4171230.95663982 2490552.45481477 3471727.4877796 3813336.61022054 
325 
 
 13992628.2236502 2931170.8827408 3310475.47992373 4080398.0202422 
Average 6352607.25484688 2511616.82918502 3305114.77753132 4032915.39270140 
 
Cytidine monophosphate (CMP) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 93645.9812971805 194089.470130283 294246.610610406 68998.9077829792 
 152481.987441027 153345.031417315 143133.82641875 91401.6516727605 
 189727.163031354 241678.549275991 72217.4414239354 110767.095373784 
 94116.9844755483 136250.797325772 90480.1163943396 101522.091896064 
 442310.976824141 242427.506718835 165384.849112367 89424.0586510191 
Average 194456.618613850 193558.270973639 153092.568791960 92422.7610753214 
 
UDP-D-glucuronate (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 152791.862043021 121821.670320996 115555.027263174 122394.180426833 
 153263.124950914 103049.920759709 98464.1991803553 64913.9129158291 
 164183.400601146 153548.657752835 43037.407327095 92689.6512297803 
 169462.156677757 158869.940931369 92412.7096221748 75730.4630910972 
 396535.481284785 112905.051441851 123696.35645341 95170.5916234926 
Average 207247.205111525 130039.048241352 94633.1399692418 90179.7598574064 
 
Guanosine diphosphate (GDP) (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 138855.665416501 180817.019995708 239851.50791973 457088.139898694 
 160097.828763909 144789.276503541 249079.154962596 193156.756887486 
 109043.985677624 185935.782753223 88134.427533928 297822.845243087 
 180183.403948 278208.138602849 221139.568898053 231263.003427751 
 479676.477920829 146679.770442953 287446.560007494 276865.218885692 
Average 213571.472345373 187285.997659655 217130.243864360 291239.192868542 
 
Leucine & isoleucine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 11343654.5307601 9912566.24124498 6715326.94664157 9168638.37367567 
 8834100.50444693 10406711.9940073 6464509.41503418 6008179.73080259 
 6647467.13467104 9345839.59034407 2769562.35416773 8837845.86698693 
 7632107.83816127 10797693.8615505 7467129.59109134 6874405.70560619 
 18096763.2415142 7599536.25529325 11576347.9934083 8521944.86953362 
Average 10510818.6499107 9612469.58848802 6998575.26006862 7882202.90932100 
 
Valine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 41863997.0013018 59415334.1512695 44711418.6221319 58227676.2257195 
 40947500.1817221 72867101.330966 36796509.1816118 37151100.417638 
 41302326.797836 53635102.1823053 52018076.0333312 50271208.2448146 
 48083692.0590495 73936154.6525552 44321870.8356226 45032381.5195939 
 77549463.0793953 42177430.2994955 61587925.6476063 37445448.0374934 
Average 49949395.8238609 60406224.5233183 47887160.0640608 45625562.8890519 
 
Alanine (Relative response) 
326 
 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1251761.77259576 1156696.88229286 1640231.91714714 1061674.71952721 
 1199734.83264185 1003110.99653245 1260390.19749639 1041966.79796466 
 1044063.47284301 1590270.49164745 525921.754890769 1675263.60767559 
 662383.09602826 984716.455139082 1026112.96163433 969155.672613549 
 1097776.87606626 1622019.5604579 1261055.5765126 1400777.76733933 
Average 1051144.01003503 1271362.87721395 1142742.48153625 1229767.71302407 
 
Phenylalanine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 4242006.26355555 3147478.1964243 2403584.9887673 3175526.17366259 
 3219119.14634314 3164968.73743551 2299841.20428549 1998914.92635796 
 2387673.93396912 3204109.27716673 881279.736587924 2868154.59127969 
 2602605.48387078 4001978.15664152 2514593.65235578 2353168.08829021 
 5287830.31731118 2672339.65484187 3775387.07067325 2810842.62246749 
Average 3547847.02900995 3238174.80450199 2374937.33053395 2641321.28041159 
 
Proline (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 4410509.14315248 3212930.91963301 1509874.37547466 1630644.43907842 
 4383537.44288163 3984053.9780354 1216813.66058772 908547.193515211 
 4023562.95024057 2799667.31269328 580835.943408454 1519074.29202187 
 3227231.97099285 3279498.85463706 1142787.40283567 1051955.99256528 
 9450002.84262297 2731683.65740384 3692704.79519709 1315197.72733954 
Average 5098968.86997810 3201566.94448052 1628603.23550072 1285083.92890406 
 
Tyrosine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2408423.93067313 1658435.64947996 1669482.34893131 1427875.31954282 
 2258255.00289601 1682948.63917859 1558202.79137452 1545613.54309392 
 1728680.32768422 1969713.10178216 916205.174969534 1938657.30475188 
 1705017.07104411 2340243.17295009 1681970.0762979 1583296.34815492 
 2467920.48007969 1855176.56981293 1950341.75944492 1618402.95096117 
Average 2113659.36247543 1901303.42664075 1555240.43020364 1622769.09330094 
 
Inosine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 0 575868.640851873 1063134.59321198 140366.597238706 
 419830.468932748 387624.726164021 886815.244877786 304905.560332782 
 254146.296299846 346438.13593634 656595.524612478 272311.383914118 
 482408.070402302 905047.384387647 552377.193066114 585622.820080736 
 260596.492745321 1011862.633655 435906.987860136 374280.836612713 
Average 283396.265676043 645368.304198976 718965.908725699 335497.439635811 
 
Taurine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 34832116.7998706 22087965.9626573 36718502.277578 22568531.8347089 
 37175004.244683 20423154.2509749 24250668.8701759 23197132.1593347 
327 
 
 33959463.3280719 30696726.7625361 15479791.9381939 31278122.9072844 
 28325168.2069816 24156553.1910148 24500870.9051007 24855195.7896179 
 25101322.9693925 31859201.1741884 27757953.2438995 23240257.1151208 
Average 31878615.1097999 25844720.2682743 25741557.4469896 25027847.9612133 
 
Threonine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1164192.6125416 1118774.44172737 703292.191779367 1151171.71986693 
 1216930.32449122 1344506.14018676 716758.251996643 667721.77963068 
 871606.507158474 1117090.64442412 405109.392504064 1050846.38976126 
 922920.811346582 1906531.83579642 725747.459244199 770551.640353699 
 0 902359.916186898 1735056.19408761 909668.447427323 
Average 835130.051107575 1277852.59566431 857192.697922377 909991.995407978 
 
Ornithine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 804030.731589232 711888.477623132 486108.936173583 681677.792198983 
 623789.299996837 737260.128653208 476929.423049256 430887.119421208 
 474636.187931985 672819.584103773 211225.678164372 634166.237526866 
 546844.64217889 764019.639681086 556043.319400091 504811.559963168 
 1362557.22626383 542315.657116506 799644.431607857 618591.440049595 
Average 762371.617592155 685660.697435541 505990.357679032 574026.829831964 
 
Glutamine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 11945289.8254137 9164974.33853216 10199986.2175945 9689465.67942537 
 12500063.1523097 9340994.43741836 9906358.61657095 9374614.04771588 
 9149185.65110307 12259097.8300695 4770369.69419618 13003653.0748484 
 9177487.68623987 13452335.4094325 10838604.0826682 11276585.9144576 
 0 9551327.32152035 10551850.5325479 10478556.7482073 
Average 8554405.26301327 10753745.8673946 9253433.82871555 10764575.0929309 
 
Methionine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 592505.248066773 444152.393732023 331688.121731243 436233.022518756 
 445223.95873605 474945.791698838 308923.914637661 284287.681428199 
 328083.189185964 425541.776217965 128986.105409223 420456.768371393 
 390539.490487559 652239.056046085 356234.734328076 353377.738612674 
 0 392273.467466704 534796.959338014 407941.937534404 
Average 351270.377295269 477830.497032323 332125.967088843 380459.429693085 
 
Asparagine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 306056.6941342 228639.496465658 212044.475228957 242705.024835956 
 359386.823685761 186611.913832089 195594.16750488 181320.447802217 
 318863.709890896 262044.821493868 80833.8104264451 265266.819919936 
 247776.730653648 292094.761533788 216117.399992834 229229.888016946 
 0 248159.245229985 274135.692067005 226041.032888935 
Average 246416.791672901 243510.047711078 195745.109044024 228912.642692798 
328 
 
 
Serine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 246259.44751448 324428.726300696 170511.016591597 423002.177011066 
 245650.830649712 255943.296805446 147604.040966249 132050.745107001 
 219143.616103128 215763.528855643 50365.0829176607 233445.770317545 
 274516.871459558 577445.576718414 175765.873216621 195787.535363497 
 400440.106802223 185499.539191126 437980.505213508 195357.79921253 
Average 277202.174505820 311816.133574265 196445.303781127 235928.805402328 
 
Tryptophan (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1372489.99556618 788253.357168473 807663.450518481 707500.337736937 
 1122413.58558275 744813.10258015 796412.159224484 732620.047209912 
 811610.599075742 987077.993122173 331562.185094567 970198.786332832 
 886507.715688728 1014820.75406683 899130.718260305 843168.405478302 
 894436.610484804 902871.864936989 848175.018914986 931141.99393615 
Average 1017491.70127964 887567.414374923 736588.706402565 836925.914138827 
 
Xanthine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 590302.025695044 467280.828151001 346876.017340094 585424.330320352 
 429574.316314556 378796.636209808 340223.360533151 274446.065267453 
 326287.69464977 460049.938823525 166785.67639351 396812.068176301 
 378514.029267081 623034.958457026 354938.3140946 335840.492600153 
 731990.70120991 393795.523118429 546182.976562623 454210.344558645 
Average 491333.753427272 464591.576951958 351001.268984796 409346.660184581 
 
Histidine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1222968.71443757 991340.787979862 877146.502956747 982289.915234937 
 1140411.22547602 787305.208083144 913436.455259294 822834.123185479 
 972879.63173437 1139109.7616317 539851.830364185 985104.37370831 
 941914.087402447 1296302.68374535 1086350.35380326 1036712.12575555 
 926139.168189361 1031204.23800577 1105872.45669494 1051859.80743311 
Average 1040862.56544795 1049052.53588917 904531.519815685 975760.069063477 
 
3-Phosphoserine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1231661.63905574 634376.645931474 1182163.28667798 570145.549100882 
 1241235.29558227 655299.28593687 992071.998687401 848327.533902546 
 999435.318337713 997897.056163873 78881.2516908852 1131279.32765401 
 787271.6560686 597550.772362055 926644.983570854 966135.731032963 
 1732476.1656398 1123991.05779469 647889.107274331 918188.265246278 
Average 1198416.01493682 801822.963637793 765530.125580290 886815.281387336 
 
Lysine (Relative response) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
329 
 
 1256660.88109214 869652.757308284 513744.969548776 792030.761590202 
 866169.423880891 987418.493356993 520138.043973971 396896.167617712 
 601703.364818574 986460.986097304 112876.465891973 693665.024904138 
 818777.215685111 0 587092.413430996 474528.919345792 
 0 683212.88399536 993865.980145295 742747.518808663 
Average 708662.177095343 705349.024151588 545543.574598202 619973.678453301 
     
II. Metabolites measured as absolute concentration and normalized to protein (Units: pmol/µg protein) 
 
Nicotinamide adenine dinucleotide (NAD) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2.512408041 2.106652992 3.148497671 3.625955015 
 2.385852219 2.174842643 2.542743101 2.984764575 
 1.053241991 2.428894436 0.638498238 2.589431237 
 1.495720425 5.85646457 1.908604939 3.083416378 
 3.240356039 2.76192841 7.625911006 2.450495068 
Average 2.137515743 3.06575661 3.172850991 2.946812455 
 
Succinate (SUC) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1.703093977 2.543016556 8.330499233 16.10042428 
 2.170219945 3.518507554 6.491699533 9.996673157 
 0.770305684 4.241699003 1.660184916 10.01823461 
 1.240298284 9.107839054 4.316164187 9.458343242 
 1.246777346 3.110622096 23.89671458 4.767429293 
Average 1.426139047 4.504336853 8.93905249 10.06822092 
 
Ribose 5-phosphate & xylulose 5-phosphate (R5P & X5P) (pmol/µg protein) 
Units: pmol/µg protein Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 0.227773237 0.387335443 1.408464282 0.169374061 
 0.325449587 0.345835944 0.547649001 0.174126778 
 0.232593052 0.439961997 0.084493685 0.477933432 
 0.192264922 2.014695697 0.166168137 0.203293387 
 0.266245396 0.447900557 0.733925725 0 
Average 0.248865239 0.727145928 0.588140166 0.204945532 
 
Flavin adenine dinucleotide (FAD) (pmol/µg protein) 
Units: pmol/µg protein Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 0.151034716 0.052364344 0.240234386 0.080859811 
 0.166830931 0.087093666 0.16795638 0.106806589 
 0.075879083 0.12080502 0.055173856 0.164451934 
 0.063842232 0.144817552 0.093240837 0.167232668 
 0.138567877 0.18579586 0.212334377 0.058236056 
Average 0.119230968 0.118175288 0.153787967 0.115517412 
 
Erythrose 4-Phosphate (E4P) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 8.157250779 2.272840201 16.17954389 6.010695038 
 4.262950786 8.053224475 7.728650957 5.409879586 
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 1.277958761 3.112437343 1.438108088 9.898652169 
 3.649866932 30.83773592 5.065637725 7.999987735 
 2.226808455 4.14130445 6.752652229 2.048201957 
Average 3.914967143 9.683508478 7.432918578 6.273483297 
 
Fructose 6-phosphate & glucose 6-phosphate (F6P & G6P) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2.583601509 3.230561626 5.718755308 5.267814328 
 3.423073182 2.634837937 4.268601975 4.302948439 
 1.324955227 3.462942036 0.895104763 4.31558929 
 3.159625941 14.20994424 3.603083419 5.518673139 
 2.617617752 3.356595921 7.163270019 3.214738886 
Average 2.621774722 5.378976352 4.329763097 4.523952816 
 
Sedoheptulose 7-phosphate (S7P) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1.282433373 1.206156524 3.879572892 1.140541295 
 1.377359714 0.93584822 2.745851084 2.802180569 
 0.677253421 1.389225017 0.890338996 2.170419633 
 0.894199895 4.75938268 1.574069718 2.809401472 
 1.149949479 2.54091571 3.039774417 0.928822 
Average 1.076239176 2.16630563 2.425921421 1.970272994 
 
Adenosine monophosphate (AMP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2.22928311 7.371546416 17.73390332 9.653842529 
 4.603465593 6.408469763 10.02720341 11.54446467 
 2.473878321 10.03555051 2.638267844 9.877139135 
 3.844682004 31.95891773 8.594408619 14.89845906 
 5.132023061 8.23585817 29.36664694 5.278488174 
Average 3.656666418 12.80206852 13.67208603 10.25047871 
 
Guanosine monophosphate (GMP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 0.949893578 1.511727141 5.020870595 1.758213781 
 1.374913923 1.550151515 3.826359918 3.704769784 
 0.610545073 2.014445056 0.924762436 3.043790399 
 0.803849684 5.446565642 2.535953908 3.956753765 
 1.714677648 2.954046664 6.943680508 2.541494849 
Average 1.090775981 2.695387204 3.850325473 3.001004516 
 
Citrate & isocitrate (CIT & ICIT) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 20.04101895 14.30240541 20.10824349 24.9039243 
 17.01766637 12.38034457 14.90018721 25.26417531 
 7.517133919 19.76033261 3.558957003 24.51030888 
 9.117503625 40.26148274 15.55888752 26.39417839 
 19.22439186 17.82976091 40.14712529 15.96465496 
Average 14.58354294 20.90686525 18.8546801 23.40744837 
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6-Phosphogluconate (6PG) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 2.020133516 1.448090138 2.979943897 3.243144935 
 1.9545711 1.762767551 2.834339765 3.784738496 
 0.709157845 2.008384684 1.067303955 2.909222086 
 1.869742905 6.307301655 3.576043789 4.788333532 
 1.275495911 2.010306158 3.786650067 1.824198111 
Average 1.565820255 2.707370037 2.848856295 3.309927432 
 
Nicotinamide adenine dinucleotide phosphate (NADP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1.297819561 0.411018751 1.499869221 0.4098734 
 1.007640977 0.456413968 1.155227254 1.386243727 
 0.44201914 0.749275374 0.425134206 1.388148311 
 0.405539277 1.057745671 0.987346851 2.173351976 
 0.995808022 1.403090958 0.966933153 0.539382955 
Average 0.829765395 0.815508944 1.006902137 1.179400074 
 
Phosphoenolpyruvate (PEP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1.019389633 0.649581738 0.968538835 0.767341594 
 0.810402955 0.690770367 0.762620802 1.156927533 
 0.320494431 0.864017084 0.462691584 0.905175333 
 0.55310764 2.045845707 0.816773572 1.447928874 
 0.661787143 0.922327987 1.455742652 0.542422661 
Average 0.67303636 1.034508577 0.893273489 0.963959199 
 
Adenosine diphosphate (ADP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 10.82866734 11.1895863 20.73431637 35.84161726 
 14.04707046 13.03137309 18.13796142 29.43924233 
 7.054577274 17.36894386 3.755229213 31.03713965 
 15.69843466 59.66881479 22.47673919 32.33186504 
 12.47546768 11.06170632 53.92549153 16.35991426 
Average 12.02084348 22.46408487 23.80594754 29.00195571 
 
Fructose 1,6-bisphosphate (FBP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 6.411887221 2.035235111 2.62573712 3.719698462 
 4.948563162 1.995760456 2.31012425 5.285969706 
 2.64081915 3.914514461 0.905751308 5.467536175 
 3.340991079 3.079679175 4.364336339 5.381722253 
 3.873956722 4.261802064 7.718745803 2.662456246 
Average 4.243243467 3.057398253 3.584938964 4.503476568 
 
Adenosine triphosphate (ATP) (pmol/µg protein) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
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 47.44641598 9.915070784 20.0525312 74.16448978 
 33.4240421 14.3123025 22.79260526 44.74719708 
 11.09888575 14.49837465 4.232818336 52.29192421 
 40.74059774 78.94727219 35.40194012 41.06983018 
 14.51043606 12.25325486 55.57974082 22.93466603 
Average 29.44407553 25.985255 27.61192715 47.04162146 
 
Below are duplicate measurements that were not used 
 
3-phosphoserine (duplicate – not used) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 1223296.39988493 627148.784327659 1176312.35607987 559025.790770423 
 1231713.04090067 627093.870703473 987111.344850652 839817.753864484 
 993249.806328151 992505.285573434 70000.0502570201 1118503.27091267 
 782968.607180161 586031.409551877 916121.460926119 957469.131058504 
 4593396.11423264 1115261.7167805 643939.977080099 906985.015732987 
Average 1764924.79370531 789608.213387389 758697.037838752 876360.192467814 
     
GMP (duplicate – not used) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 69384.7592724389 213436.04574124 454617.558156657 170032.612251211 
 134224.542787707 157768.149707528 390376.801374495 207002.805322597 
 12560.9952014022 222141.732494345 156672.582708375 229168.665241053 
 118408.618062833 323295.13708953 230421.949411317 231436.207627368 
 462817.288684281 312985.566448983 325150.657251106 267859.293315077 
Average 159479.240801732 245925.326296325 311447.909780390 221099.916751461 
     
Phosphoenolpyruvate (duplicate – not used) 
 Vehicle (0.1% 
DMSO) 
Forskolin Forskolin + DCVC 
(10 µM) 
Forskolin + DCVC 
(20 µM) 
 22801.1838297166 18168.6794515709 8533.18931296423  
 13409.5244461231 10293.8671749891 9538.90343508598 6088.89611069714 
 13573.3515877345 17223.0967455805 2694.80728955237 11720.8744565169 
 25451.0619327432 29368.7773587766 17752.6958296976 12016.3356277916 
 52158.967571701 10634.7104696581 4843.0216406369 11094.9077533408 
Average 25478.8178736037 17137.8262401150 8672.52350158742 10230.2534870866 
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Table S6.2. Metabolites increased or decreased in response to forskolin-stimulated 
syncytialization and DCVC treatment during syncytialization. Metabolites altered by any 
scenario are listed first and followed by metabolites that are not altered in any scenario. The 
values placed in boldface correspond to values associated with a p<0.05. In the case of DCVC-
stimulated responses, the first values for p-value and fold-change correspond to the 10 µM 
DCVC to syncytialization comparison. The second and third values correspond to the 20 µM 
DCVC to syncytialization comparison and the 20 µM DCVC to 10 µM DCVC comparison, 
respectively.  
 
Metabolite Change in response to 
syncytialization (forskolin-
only treatment) 
Change in response to DCVC 
treatment during syncytialization 
(10 µM, 20 µM, 20 vs. 10 µM)  
 p-value Fold-
change 
p-value Fold-change 
Succinate 0.0047 3.1584 0.5705, 0.1592, 
0.6224 
1.9845, 2.2352, 
1.1263 
Uridine diphosphate 
(UDP)-D-glucose 
0.0060 0.42659 0.0729, 0.0255, 
0.8247 
0.65816, 0.55806, 
0.84791  
Glutamate 0.0065 0.77533 0.6483, 0.4017, 
0.9016 
1.1481, 1.2583, 
1.0960 
Aspartate 0.0068 0.61495 0.4704, 0.0310, 
0.2350 
0.80591, 0.59835, 
0.74245  
UDP-N-acetyl-D-
glucosamine 
0.0079 0.52111 0.8714, 0.5298, 
0.2805 
0.93023, 1.1966, 
1.2864 
Adenosine 
monophosphate 
(AMP) 
0.0110 3.5010 >0.9999, 0.9839, 
0.9862 
1.0680, 0.80069, 
0.74974 
Oleic acid 0.0152 1.6915 
 
0.9056, 0.0344, 
0.0726 
0.94652, 0.59512, 
0.62875   
Glutathione – 
oxidized (GSSG) 
0.0167 0.39537 0.8314, 0.2113, 
0.4667 
1.3159, 1.6057, 
1.2202 
Guanine 
monophosphate 
(GMP) 
0.0278 2.4711 0.6785, 0.8657, 
0.9391 
1.4285, 1.1134, 
0.77942  
Proline 0.0732 0.62789  0.0187, 0.0114, 
0.9583  
0.50869, 0.40139, 
0.78907  
Uridine diphosphate 
(UDP) 
0.1629 0.58306 0.0241, 0.0088, 
0.8426 
0.48698, 0.41438, 
0.85092 
Inosine 0.2649 2.2773 0.8667, 0.0962, 
0.0395 
1.1140, 0.51985, 
0.46664  
Cytidine 
monophosphate 
(CMP) 
0.6423 0.99538 0.3577, 0.0218, 
0.2435 
 
0.79094, 0.47749, 
0.60371 
Uridine 
monophosphate 
(UMP) 
0.9445 0.83539 0.1232, 0.0005, 
0.0190 
0.66323, 0.27274, 
0.41122    
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Stearic acid 0.5836 0.81262 0.7896, 0.1923, 
0.4757 
1.0865, 1.3181, 
1.2132 
Palmitic acid 0.3306 0.77597 0.6858, 0.2008, 
0.5957 
1.1076, 1.2854, 
1.1605 
Hexose (glucose etc.) 0.9214 0.96177 0.0938, 0.3873, 
0.6290 
0.69938, 0.78781, 
1.1264 
Hypoxanthine 0.8798 0.98578 0.7155, 0.9751, 
0.8348 
0.82314, 0.95523, 
1.1605 
Gluconate 0.1142 1.7030 0.9540, 0.9856, 
0.9906 
0.91518, 1.0151, 
1.1092 
3-Phosphoserine 0.0605 0.66907 0.7414, 0.9644, 
0.5888 
0.95474, 1.1060, 
1.1584 
Glutathione – 
reduced (GSH) 
0.5356 0.82223 0.7323, 0.2687, 
0.6657 
0.78269, 0.66748, 
0.85280 
Phosphocreatine 0.0867 0.58947 0.0664, 0.0699, 
0.9995 
0.55187, 0.53513, 
0.96966 
N-Acetyl-
glucosamine-1-
phosphate 
0.1470 0.72111 0.6822, 0.8292, 
0.9637 
0.87634, 0.87790, 
1.0018 
UDP-D-glucuronate 0.0813 0.62746 0.1790, 0.1640, 
0.9983 
0.72773, 0.69348, 
0.95294 
Guanine diphosphate 
(GDP) 
0.9706 0.87692 0.8940, 0.1939, 
0.3703 
1.1594, 1.5551, 
1.3413 
Leucine/isoleucine 0.8756 0.91453 0.1651, 0.6001, 
0.6062 
0.72807, 0.82000, 
1.1263 
Valine 0.2435 1.2093 0.2359, 0.1325, 
0.9280 
0.79275, 0.75531, 
0.95277 
Alanine 0.2628 1.2095 0.7446, 0.9863, 
0.8319 
0.89883, 0.96728, 
1.0762 
Phenylalanine 0.7446 0.91272 0.1897, 0.6059, 
0.6534 
0.73342, 0.81568, 
1.1122   
Tyrosine 0.3523 0.89953 0.2146, 0.4497, 
0.8524 
0.81799, 0.85350, 
1.0434 
Taurine 0.0972 0.81072 0.9826, 0.9849, 
>0.9999 
0.99601, 0.96839, 
0.97227 
Threonine 0.3199 1.5301 0.1326, 0.3660, 
0.7773 
0.67081, 0.71213, 
1.0616 
Ornithine 0.8484 0.89938 0.1724, 0.6295, 
0.5931 
0.73796, 0.83719, 
1.1345 
Glutamine 0.3464 1.2571 0.4826, 0.9988, 
0.4574 
0.86048, 1.0010, 
1.1633 
Methionine 0.3320 1.3603 0.1372, 0.5625, 
0.5753 
0.69507, 0.79622, 
1.1455 
Asparagine 0.3892 0.98820 0.3323, 0.9490, 
0.4891 
0.80385, 0.94005, 
1.1694 
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Serine 0.8122 1.1249 0.2607, 0.7395, 
0.6459 
0.63000, 0.75663, 
1.2010 
Tryptophan 0.3037 0.87231 0.3679, 0.9342, 
0.5582  
0.82990, 0.94294, 
1.1362 
Xanthine 0.8768 0.94557 0.2655, 0.7593, 
0.6328 
0.75551, 0.88109, 
1.1662 
Histidine 0.9937 1.0079 0.4392, 0.8816, 
0.7182 
0.86224, 0.93013, 
1.0787 
Lysine 0.9971 0.99532 0.6325, 0.5586, 
0.9915  
0.77344, 0.87896, 
1.1364 
Nicotinamide 
adenine dinucleotide 
(NAD) 
0.2436 1.4343 0.9317, 0.9965, 
0.9001 
1.0349, 0.96120, 
0.92876  
Ribose 5-phosphate / 
Xylulose 5-
phosphate 
(R5P/X5P) 
0.1297 2.9218 
 
 
0.9317, 0.2515, 
0.4100 
0.80883, 0.28185, 
0.34846 
Flavin adenine 
dinucleotide (FAD) 
0.9729 0.99115 0.6403, 0.9974, 
0.5993 
1.3014, 0.97751, 
0.75115 
Erythrose 4-
phosphate (E4P) 
0.3179 2.4735 0.9986, 0.9912, 
0.9968 
0.76759, 0.64785, 
0.84401 
Fructose 6-phosphate 
/ glucose 6-
phosphate (F6P/G6P) 
0.1677 2.0517 0.9140, 0.9949, 
0.8719 
0.80494, 0.84104, 
1.0449 
D-sedoheptulose 7-
phosphate (S7P) 
0.1331 2.0128 0.8884, 0.9987, 
0.8661 
1.1198, 0.90951, 
0.81218 
Citrate / Isocitrate 
(CIT/ICIT) 
0.2674 1.4336 0.7618, 0.8656, 
0.4613 
0.90184, 1.1196, 
1.2415 
6-phosphogluconate 
(6PG) 
0.2111 1.7290 0.9088, 0.5949, 
0.8359 
1.0523, 1.2226, 
1.1618 
Adenosine 
diphosphate (ADP) 
0.2645 1.8688 0.9999, 0.5678, 
0.5773 
1.0597, 1.2910, 
1.2183 
Nicotinamide 
adenine dinucleotide 
phosphate (NADP) 
0.9447 0.98282 0.8065, 0.6204, 
0.9454 
1.2347, 1.4462, 
1.1713 
Phosphoenolpyruvate 
(PEP) 
0.2174 1.5371 0.9001, 0.9881, 
0.9545 
0.86348, 0.93180, 
1.0791 
Fructose 1,6-
bisphosphate (FBP) 
0.1759 0.72053 0.9998, 0.4592, 
0.4684 
1.1725, 1.4730, 
1.2562 
Adenosine 
triphosphate (ATP) 
0.5045 0.88253 0.9616, 0.2145, 
0.3155  
1.0626, 1.8103, 
1.7037 
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Table S6.3. Metabolite ratios with relevance to purine and pyrimidine metabolism analyzed and 
degree of change. Abbreviations: ATP, adenosine triphosphate; ADP, adenosine diphosphate; 
AMP, adenosine monophosphate; GDP, guanosine diphosphate, GMP, guanosine 
monophosphate; UDP, uridine diphosphate; UMP, uridine monophosphate; CMP, cytidine 
monophosphate. In the case of DCVC-stimulated responses, the first values for p-value and fold-
change correspond to the 10 µM DCVC to syncytialization comparison. The second and third 
values correspond to the 20 µM DCVC to syncytialization comparison and the 20 µM DCVC to 
10 µM DCVC comparison, respectively. 
 
Metabolite Ratio Change in response to 
syncytialization (forskolin-
only treatment) 
Change in response to DCVC 
treatment during syncytialization (10 
µM, 20 µM, 20 vs. 10 µM)  
 p-value Fold-
change 
p-value Fold-change 
ATP to ADP 0.0410 0.43414 0.6599, 0.0142, 
0.0682 
1.1346, 1.5136, 
1.3340  
ADP to AMP 0.0051 0.49161 0.9709, 0.0049, 
0.0074 
1.0425, 1.7280, 
1.6576 
ATP to AMP 0.0518 0.19333 0.8737, 0.0086, 
0.0209 
1.2270, 2.6672, 
2.1737 
GDP to GMP 0.0096 0.42963 0.9125, 0.5837, 
0.3614 
0.82939, 1.4219, 
1.7144 
UDP to UMP 0.0805 0.64730 0.8035, 0.3894, 
0.1546 
0.74871, 1.5388, 
2.0552 
UMP to CMP 0.0515 0.88087 0.0010, <0.0001, 
<0.0001 
0.83525, 0.57356, 
0.68669 
UDP to CMP 0.0218 0.57943 0.3373, 0.9068, 
0.5611 
0.61794, 0.89029, 
1.4407 
Glutamine to UMP 0.8060 0.91114 0.3768, <0.0001, 
0.0001 
1.4498, 3.4306, 
2.3663 
Inosine to 
hypoxanthine 
0.0751 1.9874 0.3776, 0.4223, 
0.0484 
1.4034, 0.62243, 
0.44352 
Xanthine to 
hypoxanthine 
0.9198 0.98308 0.5036, 0.7171, 
0.9308 
0.86063, 0.90447, 
1.0509 
Inosine to xanthine 0.0956 2.0760 0.2211, 0.6683, 
0.0526 
1.7014, 0.65494, 
0.38493 
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Table S6.4. Metabolite ratios with relevance to glycolysis, tricarboxylic acid-cycle and pentose 
phosphate pathway analyzed and degree of change. The values placed in boldface correspond to 
values associated with a p<0.05. Abbreviations: G6P, glucose 6-phosphate; F6P, fructose 6-
phosphate; FBP, fructose 1,6-bisphosphate; PEP, phosphoenolpyruvate; CIT, citrate; ICIT, 
isocitrate; 6PG, 6-phosphogluconate; R5P, ribose 5-phosphate; X5P, xylulose 5-phosphate; S7P, 
sedoheptulose 7-phosphate; E4P, erythrose 4-phosphate. In the case of DCVC-stimulated 
responses, the first values for p-value and fold-change correspond to the 10 µM DCVC to 
syncytialization comparison. The second and third values correspond to the 20 µM DCVC to 
syncytialization comparison and the 20 µM DCVC to 10 µM DCVC comparison, respectively. 
 
Glycolysis (aka glycolysis or gluconeogenesis) 
Ratio Change in response to 
syncytialization (forskolin-
only treatment) 
Change in response to DCVC 
treatment during syncytialization (10 
µM, 20 µM, 20 vs. 10 µM)  
 p-value Fold-change p-value Fold-change 
G6P/F6P to FBP 0.1331 2.8572 0.7265, 0.4459, 
0.8810 
0.73610, 0.57130, 
0.77611 
FBP to PEP 0.0024 0.51272 0.9096, 0.1950, 
0.3546  
1.0998, 1.4439, 
1.3128 
G6P/F6P to PEP 0.4974 1.1372 0.9901, 0.9257, 
0.8680 
0.97382, 1.0731, 
1.1020 
Tricarboxylic acid cycle 
Ratio Change in response to 
syncytialization (forskolin-
only treatment) 
Change in response to DCVC 
treatment during syncytialization (10 
µM, 20 µM, 20 vs. 10 µM)  
 p-value Fold-change p-value Fold-change 
PEP to CIT/ICIT 0.6561 1.0477 0.5989, 0.8068, 
0.2766 
1.2854, 0.81772, 
0.63616 
CIT/ICIT to 
succinate 
0.0061 0.45943 0.0011, 0.0015, 
0.9750 
0.50671, 0.52851, 
1.0430 
PEP to succinate 0.0007 0.49755 0.1044, 0.0103, 
0.4169 
0.64814, 0.44247, 
0.68268 
Pentose Phosphate Pathway 
Ratio Change in response to 
syncytialization (forskolin-
only treatment) 
Change in response to DCVC 
treatment during syncytialization (10 
µM, 20 µM, 20 vs. 10 µM)  
 p-value Fold-change p-value Fold-change 
6PG to gluconate 0.9256 1.0229 0.7979, 0.2845, 
0.6204  
1.2080, 1.5140, 
1.2533 
R5P/X5P to 6PG 0.2227 1.3332 0.7630, 0.0455, 
0.1516 
0.80437, 0.24897, 
0.30952 
R5P/X5P to S7P 0.1423 1.3348 0.1594, 0.0090, 
0.2645 
0.62503, 0.31314, 
0.50100 
S7P to E4P 0.8894 1.0505 0.9771, 0.9705, 
0.9002  
1.0612, 0.93043, 
0.87676 
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Gluconate to E4P 0.8582 0.93114 0.8672, 0.9974, 
0.8331 
0.80353, 1.0263, 
1.2773 
R5P/X5P to 
gluconate 
0.2283 1.4843 0.8584, 0.1590, 
0.3467  
0.83484, 0.38202, 
0.45760 
Gluconate to S7P 0.8405 1.0737 0.7997, 0.9561, 
0.6333 
0.64806, 1.1564, 
1.7845 
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Table S6.5. Metabolite ratios with relevance to amino acid metabolism analyzed and degree of 
change. The values placed in boldface correspond to values associated with a p<0.05. In the case 
of DCVC-stimulated responses, the first values for p-value and fold-change correspond to the 10 
µM DCVC to syncytialization comparison. The second and third values correspond to the 20 µM 
DCVC to syncytialization comparison and the 20 µM DCVC to 10 µM DCVC comparison, 
respectively. 
 
Ratio Change in response to 
syncytialization 
(forskolin-only treatment) 
Change in response to DCVC 
treatment during syncytialization (10 
µM, 20 µM, 20 vs. 10 µM) 
 p-value Fold-
change 
p-value Fold-change 
Phenylalanine to 
tyrosine 
0.7075 1.0387 0.4324, 0.9370, 
0.6296 
0.85421, 0.96073, 
1.1247 
Glutamine to 
glutamate 
0.0755 1.5904 0.1582, 0.5076, 
0.6847 
0.73324, 0.84647, 
1.1544 
Asparagine to 
aspartate 
0.1053 1.5575 0.9987, 0.0366, 
0.0335 
0.98936, 1.6174, 
1.6348 
Glutamate to 
succinate 
0.0029 0.26449 0.9365, 0.3419, 
0.5221 
0.89701, 0.56437, 
0.62917 
Aspartate to alanine 0.0663 0.49607 0.9616, 0.2276, 
0.3330  
0.93815, 0.59482, 
0.63404 
Ornithine to proline 0.0030 1.4261 0.0091, 0.0001, 
0.0704 
1.6512, 2.0956, 
1.2692 
Taurine to alanine 0.0138 0.65575 0.3854, 0.9883, 
0.4616 
1.1362, 1.0145, 
0.89293 
Serine to tryptophan 0.4513 1.2263 0.6033, 0.8348, 
0.9153 
0.72084, 0.83554, 
1.1591 
Serine to 3-
phosphoserine 
 0.1869 1.8794 0.8686, 0.6976, 
0.9479 
0.79890, 0.67539, 
0.84540 
Histidine to 
glutamate 
0.0532 1.3042 0.2492, 0.4337, 
0.9117 
0.74113, 0.80417, 
1.0851 
Histidine to aspartate 0.0046 1.6313 0.9328, 0.0195, 
0.0369 
1.0685, 1.6143, 
1.5109 
Phenylalanine to 
succinate 
0.0053 0.31246 0.0152, 0.0054, 
0.8358 
0.45674, 0.36312, 
0.79503 
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Table S6.6. Metabolite ratios with relevance to glutathione metabolism analyzed and degree of 
change. The values placed in boldface correspond to values associated with a p<0.05. 
Abbreviations: GSH, glutathione; GSSG, glutathione disulfide; NADP, nicotinamide adenine 
dinucleotide phosphate. In the case of DCVC-stimulated responses, the first values for p-value 
and fold-change correspond to the 10 µM DCVC to syncytialization comparison. The second and 
third values correspond to the 20 µM DCVC to syncytialization comparison and the 20 µM 
DCVC to 10 µM DCVC comparison, respectively. 
 
Ratio Change in response to 
syncytialization (forskolin-
only treatment) 
Change in response to DCVC 
treatment during syncytialization (10 
µM, 20 µM, 20 vs. 10 µM) 
 p-value Fold-change p-value Fold-change 
GSH to GSSG  0.2391 1.6682 0.9178, 0.3024, 
0.4994 
0.84285, 0.38353, 
0.45505 
GSSG to NADP  0.0487 0.42058 0.9422, 0.5852, 
0.4019 
0.87297, 1.3893, 
1.5914 
GSH to NADP 0.5302 0.79446 0.5888, 0.4257, 
0.9551 
0.68096, 0.58899, 
0.86494 
GSH to glutamate 0.8451 1.0661 0.5005, 0.3270, 
0.9383 
0.69059, 0.59930, 
0.86780 
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Table S6.7. Other important metabolite ratios analyzed and degree of change. The values placed 
in boldface correspond to values associated with a p<0.05. Abbreviations: ATP, adenosine 
triphosphate; ADP, adenosine diphosphate; UDP, uracil diphosphate; UMP, uracil 
monophosphate; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine 
dinucleotide phosphate. In the case of DCVC-stimulated responses, the first values for p-value 
and fold-change correspond to the 10 µM DCVC to syncytialization comparison. The second and 
third values correspond to the 20 µM DCVC to syncytialization comparison and the 20 µM 
DCVC to 10 µM DCVC comparison, respectively. 
 
Ratio Change in response 
to syncytialization 
(forskolin-only 
treatment) 
Change in response to 
DCVC treatment during 
syncytialization (10 µM, 20 
µM, 20 vs. 10 µM) 
Significance 
 p-value Fold-
change 
p-value Fold-change  
Phosphocreatine to 
ATP 
0.7008 0.82006  0.0465, 
0.0074, 
0.5736 
0.40296, 
0.17623, 
0.43732 
Phosphocreatine 
shuttling 
Phosphocreatine to 
ADP 
0.0513 0.45260 0.0698, 
0.0126, 
0.6124 
0.48155, 
0.27981, 
0.58106 
Phosphocreatine 
shuttling 
Stearic acid to oleic 
acid 
0.0873 0.45750 0.6871, 
0.0072, 
0.0324  
1.2613, 
2.1688, 
1.7195 
Fatty acid 
biosynthesis 
Stearic acid to 
palmitic acid 
 0.2863 1.0679 0.9311, 
0.8271, 
0.6189  
0.98386, 
1.0265, 
1.0433 
Fatty acid 
biosynthesis 
Oleic acid to 
palmitic acid 
 0.0104 1.9980 0.7006, 
0.0148, 
0.0634 
0.86949, 
0.46450, 
0.53423 
Fatty acid 
biosynthesis 
UDP-D-glucose to 
UDP-D-
glucuronate 
0.0272 0.68268 0.7184, 
0.3205, 
0.7537 
0.89962, 
0.80699, 
0.89704 
Multiple 
pathways 
NAD to NADP 0.0943 1.5143 0.8058, 
0.9718, 
0.9147 
0.75697, 
0.91227, 
1.2052 
Source of co-
factor 
UDP-D-glucose to 
UMP 
0.0266 0.41856 0.9446, 
0.0091,  
0.0163 
1.0896, 
2.0056, 
1.8408 
Peripheral to 
pyrimidine 
metabolism 
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Table S6.8. Enrichment analysis of organ, tissue, and subcellular structures predicted to be 
altered by forksolin-stimulated syncytialization (comparison of vehicle control versus forskolin-
only treatment) based on the metabolite alterations. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Liver 234 6 32.1 11.111 0.006218 0.1741 0.073087 
Endoplasmic 
Reticulum 
53 6 38.092 11.111 0.006938 0.18732 0.073087 
Peroxisome 37 4 43.102 11.111 0.007831 0.2036 0.073087 
Golgi 
Apparatus 
14 2 53.164 11.111 0.011962 0.29905 0.083733 
Heart 8 1 49.452 11.111 0.023283 0.5588 0.093133 
Neuron 69 1 49.452 11.111 0.023283 0.5588 0.093133 
Smooth 
Muscle 
9 1 49.452 11.111 0.023283 0.5588 0.093133 
Skin 125 4 26.934 11.111 0.027756 0.58287 0.097145 
Nervous 
Tissue 
12 1 30.59 11.111 0.097248 1 0.30255 
Bladder 87 4 22.083 11.111 0.1123 1 0.31443 
Thyroid Gland 12 1 22.79 11.111 0.16293 1 0.36422 
Adrenal Gland 30 1 17.116 11.111 0.23464 1 0.36422 
Platelet 108 4 14.983 11.111 0.26751 1 0.36422 
Nerve Cells 35 3 14.977 11.111 0.26826 1 0.36422 
Testes 72 3 14.548 11.111 0.27639 1 0.36422 
Brain 122 2 14.502 11.111 0.27713 1 0.36422 
Kidney 164 3 14.441 11.111 0.27844 1 0.36422 
Erythrocyte 34 2 14.386 11.111 0.2793 1 0.36422 
Skeletal 
Muscle 
123 12 12.375 11.111 0.31758 1 0.36422 
Epidermis 216 14 12.187 11.111 0.32181 1 0.36422 
Muscle 160 11 11.831 11.111 0.33004 1 0.36422 
Mitochondria 98 7 11.822 11.111 0.33026 1 0.36422 
Placenta 183 10 13.253 11.111 0.33512 1 0.36422 
Pancreas 118 9 12.755 11.111 0.33533 1 0.36422 
Fibroblasts 183 9 13.181 11.111 0.34035 1 0.36422 
Spleen 170 6 12.554 11.111 0.34221 1 0.36422 
Intestine 251 10 12.764 11.111 0.35121 1 0.36422 
Prostate 267 29 9.0146 11.111 0.45264 1 0.45264 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.9. Enrichment analysis results of organ, tissue, and subcellular structures predicted to 
be altered when comparing DCVC treatment at 10 µM during syncytialization to forskolin-
stimulated syncytialization alone based on the metabolite alterations. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Thyroid Gland 12 1 53.59 11.111 0.016078 0.4502 0.4502 
Golgi 
Apparatus 
14 2 33.777 11.111 0.066095 1 0.62222 
Skin 125 4 28.271 11.111 0.066666 1 0.62222 
Mitochondria 98 7 15.672 11.111 0.22163 1 0.78474 
Placenta 183 10 15.057 11.111 0.22477 1 0.78474 
Liver 234 6 12.903 11.111 0.30323 1 0.78474 
Spleen 170 6 11.661 11.111 0.35455 1 0.78474 
Endoplasmic 
Reticulum 
53 6 11.361 11.111 0.35655 1 0.78474 
Kidney 164 3 12.541 11.111 0.35672 1 0.78474 
Skeletal Muscle 123 12 10.766 11.111 0.37972 1 0.78474 
Muscle 160 11 10.423 11.111 0.39358 1 0.78474 
Prostate 267 29 9.0028 11.111 0.41274 1 0.78474 
Peroxisome 37 4 9.0204 11.111 0.4254 1 0.78474 
Fibroblasts 183 9 8.3702 11.111 0.49732 1 0.78474 
Heart 8 1 5.3025 11.111 0.52215 1 0.78474 
Neuron 69 1 5.3025 11.111 0.52215 1 0.78474 
Smooth Muscle 9 1 5.3025 11.111 0.52215 1 0.78474 
Testes 72 3 7.139 11.111 0.54698 1 0.78474 
Nerve Cells 35 3 6.3932 11.111 0.60335 1 0.78474 
Bladder 87 4 4.6333 11.111 0.60681 1 0.78474 
Pancreas 118 9 6.3886 11.111 0.62376 1 0.78474 
Epidermis 216 14 5.5766 11.111 0.6784 1 0.78474 
Adrenal Gland 30 1 1.9487 11.111 0.70052 1 0.78474 
Erythrocyte 34 2 4.2407 11.111 0.70788 1 0.78474 
Intestine 251 10 4.8927 11.111 0.71356 1 0.78474 
Platelet 108 4 3.8162 11.111 0.72868 1 0.78474 
Brain 122 2 2.4227 11.111 0.82338 1 0.85388 
Nervous Tissue 12 1 0.30018 11.111 0.88051 1 0.88051 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.10. Enrichment analysis results of organ, tissue, and subcellular structures predicted to 
be altered when comparing DCVC treatment at 20 µM during syncytialization to forskolin-
stimulated syncytialization alone based on the metabolite alterations. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Placenta 183 10 44.6 11.111 6.46E-05 0.00181 0.00181 
Skin 125 4 46.463 11.111 0.000931 0.025139 0.013035 
Golgi 
Apparatus 
14 2 62.119 11.111 0.002943 0.076512 0.022037 
Thyroid 
Gland 
12 1 68.427 11.111 0.003148 0.078704 0.022037 
Mitochondria 98 7 33.69 11.111 0.004033 0.096802 0.022587 
Liver 234 6 33.003 11.111 0.00655 0.15065 0.030566 
Pancreas 118 9 40.332 11.111 0.010097 0.22213 0.040387 
Spleen 170 6 34.986 11.111 0.013221 0.27763 0.041591 
Skeletal 
Muscle 
123 12 37.715 11.111 0.013368 0.27763 0.041591 
Endoplasmic 
Reticulum 
53 6 32.592 11.111 0.015221 
 
0.28921 0.04262 
Muscle 160 11 33.751 11.111 0.020403 0.36725 0.051934 
Intestine 251 10 28.138 11.111 0.026445 0.44957 0.061706 
Peroxisome 37 4 30.177 11.111 0.03915 0.62639 0.084322 
Kidney 164 3 30.644 11.111 0.056144 0.84217 0.11229 
Testes 72 3 27.652 11.111 0.075069 1 0.13352 
Epidermis 216 14 19.683 11.111 0.083604 1 0.13352 
Brain 122 2 28.166 11.111 0.084332 1 0.13352 
Bladder 87 4 27.032 11.111 0.085832 1 0.13352 
Nerve Cells 35 3 24.348 11.111 0.10749 1 0.15841 
Platelet 108 4 21.689 11.111 0.11541 1 0.16157 
Erythrocyte 34 2 22.464 11.111 0.12858 1 0.17144 
Fibroblasts 183 9 16.865 11.111 0.18428 1 0.23454 
Prostate 267 29 11.889 11.111 0.32783 1 0.39909 
Heart 8 1 5.5794 11.111 0.51117 1 0.55049 
Neuron 69 1 5.5794 11.111 0.51117 1 0.55049 
Smooth 
Muscle 
9 1 5.5794 11.111 0.51117 1 0.55049 
Nervous 
Tissue 
12 1 0.61959 11.111 0.82888 1 0.85958 
Adrenal 
Gland 
30 1 0.32677 11.111 0.87536 1 0.87536 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.11. Enrichment analysis results of organ, tissue, and subcellular structures predicted to 
be altered when comparing DCVC treatment at 20 µM during syncytialization to DCVC 
treatment at 10 µM during syncytialization based on the metabolite alterations. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Kidney 164 3 37.021 11.111 0.02904 0.81313 0.4497 
Erythrocyte 34 2 31.171 11.111 0.047391 1 0.4497 
Brain 122 2 26.426 11.111 0.076237 1 0.4497 
Nerve Cells 35 3 25.121 11.111 0.079957 1 0.4497 
Intestine 251 10 22.033 11.111 0.10562 1 0.4497 
Testes 72 3 21.826 11.111 0.12601 1 0.4497 
Pancreas 118 9 21.744 11.111 0.12836 1 0.4497 
Placenta 183 10 19.016 11.111 0.13907 1 0.4497 
Spleen 170 6 19.927 11.111 0.14454 1 0.4497 
Platelet 108 4 18.297 11.111 0.18956 1 0.53077 
Skin 125 4 15.767 11.111 0.23142 1 0.54163 
Fibroblasts 183 9 15.163 11.111 0.24749 1 0.54163 
Bladder 87 4 15.039 11.111 0.25147 1 0.54163 
Muscle 160 11 13.72 11.111 0.27588 1 0.55177 
Skeletal 
Muscle 
123 12 12.419 11.111 0.31066 1 0.57991 
Prostate 267 29 10.92 11.111 0.3647 1 0.63822 
Epidermis 216 14 8.1654 11.111 0.49547 1 0.7592 
Liver 234 6 8.4086 11.111 0.5117 1 0.7592 
Peroxisome 37 4 7.1375 11.111 0.53123 1 0.7592 
Mitochondria 98 7 7.301 11.111 0.54598 1 0.7592 
Endoplasmic 
Reticulum 
53 6 6.5705 11.111 0.59479 1 0.7592 
Adrenal 
Gland 
30 1 3.1958 11.111 0.62121 1 0.7592 
Thyroid 
Gland 
12 1 3.1523 11.111 0.62363 1 0.7592 
Heart 8 1 0.7057 11.111 0.81753 1 0.86405 
Neuron 69 1 0.7057 11.111 0.81753 1 0.86405 
Smooth 
Muscle 
9 1 0.7057 11.111 0.81753 1 0.86405 
Golgi 
Apparatus 
14 2 1.7081 11.111 0.83319 1 0.86405 
Nervous 
Tissue 
12 1 0.001744 11.111 0.99087 1 0.99087 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.12. Enrichment analysis results of top 13 drug pathways altered by forskolin-
stimulated syncytialization (comparison of vehicle control versus forskolin-only treatment). All 
other drug pathways had a raw p-value of greater than 0.05. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm 
p 
FDRb 
Abacavir Action 
Pathway 
5 2 33.127 11.111 0.02765 1 0.36464 
Delavirdine 
Action Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Didanosine 
Action Pathway 
6 2 33.127 11.111 0.02765 1 0.36464 
Efavirenz Action 
Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Emtricitabine 
Action Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Lamivudine 
Action Pathway 
5 2 33.127 11.111 0.02765 1 0.36464 
Nevirapine 
Action Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Rilpivirine 
Action Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Stavudine Action 
Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Zalcitabine 
Action Pathway 
5 2 33.127 11.111 0.02765 1 0.36464 
Zidovudine 
Action Pathway 
4 2 33.127 11.111 0.02765 1 0.36464 
Disulfiram 
Action Pathway 
79 8 25.719 11.111 0.04253
6 
1 0.36464 
Valproic Acid 
Metabolism 
Pathway 
37 7 23.614 11.111 0.04314
3 
1 0.36464 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.13. Enrichment analysis results of the top 6 drug pathways altered when comparing 
DCVC treatment at 10 µM during syncytialization compared to forskolin-stimulated 
syncytialization alone. All other drug pathways had a raw p-value of greater than 0.1. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Morphine 
Metabolism 
Pathway 
6 2 45.833 11.111 0.027439 1 0.93648 
Sorafenib 
Metabolism 
Pathway 
9 2 45.833 11.111 0.027439 1 0.93648 
Celecoxib 
Metabolism 
Pathway 
13 3 32.099 11.111 0.035559 1 0.93648 
Ibuprofen 
Metabolism 
Pathway 
15 3 32.099 11.111 0.035559 1 0.93648 
Tamoxifen 
Action 
Pathway 
27 4 23.884 11.111 0.097934 1 0.93648 
Tamoxifen 
Metabolism 
Pathway 
27 4 23.884 11.111 0.097934 1 0.93648 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.14. Enrichment analysis results of the top 30 drug pathways altered when comparing 
DCVC treatment at 20 µM during syncytialization compared to forskolin-stimulated 
syncytialization alone. The next highest raw p-value was 0.00428 (for morphine metabolism 
pathway and sorafenib metabolism pathway). 
  
Total 
Compound
s 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm 
p 
FDRb 
Amikacin Action 
Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Arbekacin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Azithromycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Chloramphenico
l Action 
Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Clarithromycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Clindamycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Clomocycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Demeclocycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Doxycycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Erythromycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Gentamicin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Josamycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Kanamycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Lincomycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Lymecycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Methacycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Minocycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Neomycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
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Netilmicin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Oxytetracycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Paromomycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Rolitetracycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Roxithromycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Spectinomycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Streptomycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Telithromycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Tetracycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Tigecycline 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Tobramycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
Troleandomycin 
Action Pathway 
20 12 49.233 11.111 0.000382 0.1363 0.004543 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate. 
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Table S6.15. Enrichment analysis results of the top 4 drug pathways altered when comparing 
DCVC treatment at 20 µM during syncytialization compared to DCVC treatment at 10 µM 
during syncytialization. The next highest raw p-value was 0.21366, shared by 118 different drug 
pathways. 
  
Total 
Compounds 
Hits Statistic 
Qa 
Expected 
Qa 
Raw p Holm p FDRb 
Glibenclamide 
Action 
Pathway 
5 1 23.804 11.111 0.15256 1 0.3789 
Gliclazide 
Action 
Pathway 
6 1 23.804 11.111 0.15256 1 0.3789 
Nateglinide 
Action 
Pathway 
5 1 23.804 11.111 0.15256 1 0.3789 
Repaglinide 
Action 
Pathway 
5 1 23.804 11.111 0.15256 1 0.3789 
 
aThe equation for the Q statistics can be found in Goeman et al. 2004 (Goeman et al., 2004). Q 
can be considered as a squared covariance aggregate between metabolite concentrations and 
treatment. bFDR refers to false discovery rate.  
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Chapter VII. Conclusions 
The objective of this dissertation is to investigate mechanisms of trichloroethylene 
(TCE)-stimulated toxicity and potential modulation of TCE reproductive and developmental 
toxicity by targeting TCE metabolism in timed-pregnant Wistar rats and human placental 
trophoblast BeWo cells (Pattillo and Gey, 1968). Whereas the timed-pregnant Wistar rat has 
been used in the context of TCE previously (Loch-Caruso et al., 2019), BeWo cells (Pattillo and 
Gey, 1968), which represent a villous placental cell type capable of syncytialization in vitro 
(Potgens et al., 2002; Wang et al., 2014), have not been previously used to study TCE toxicity. 
TCE, an organic solvent with multiple industrial purposes (Agency for Toxic Substances and 
Disease Registry, 2019), is known to target the reproductive (Healy et al., 1982; Manson et al., 
1984; Lamb and Hentz, 2006; Loch-Caruso et al., 2019) and developmental systems (Saillenfait 
et al., 1995). The findings of this dissertation provide mechanistic evidence to support 
epidemiological associations between TCE exposure and adverse pregnancy outcomes 
(Rodenbeck et al., 2000; Forand et al., 2012; Ruckart et al., 2014). 
Using the TCE metabolite S-(1,2-dichlorovinyl)-L-cysteine (DCVC), prior reports 
suggest that TCE toxicity is at least partially attributable to CCBL activity from the glutathione 
(GSH) conjugation metabolic pathway of TCE metabolism because aminooxyacetic acid 
(AOAA) inhibits cysteine conjugate β-lyase (CCBL) activity in kidney cells and reduces DCVC-
stimulated toxicity (Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994). N-acetyl-L-
cysteine metabolism releases an acetyl group (Aldini et al., 2018), which may augment DCVC 
metabolism to N-acetyl DCVC (NAcDCVC) (Lash et al., 2014a). Prior studies have shown 
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mitochondrial dysfunction and apoptosis as mechanisms associated with DCVC-stimulated 
toxicity in kidney cells (Xu et al., 2008; Lash et al., 2014b). Importantly, reactive oxygen species 
(ROS) generation, pro-inflammatory response, apoptosis, mitochondrial dysfunction, and energy 
metabolism alteration are mechanisms of DCVC-stimulated toxicity in HTR-8/SVneo 
extravillous placental cells (Hassan et al., 2016; Elkin et al., 2018; Elkin et al., 2019; Elkin et al., 
2020). In contrast, metabolites from the cytochrome P450-dependent oxidative pathway of TCE 
metabolism, trichloroacetic acid (TCA) and dichloroacetic acid (DCA) (Lash et al., 2014a), do 
not produce toxicity in HTR-8/SVneo cells (unpublished data). In vivo, TCE exposure reduces 
fetal weight and increases markers of oxidative stress in timed-pregnant Wistar rats (Loch-
Caruso et al., 2019). 
 Because the toxicity of TCE is dependent on its metabolism, we hypothesized that NAC 
and AOAA would modify TCE- or DCVC-stimulated toxicity in Wistar rats and BeWo cells, 
respectively. This dissertation is the first to show that AOAA pre/co-treatment to TCE prevents 
TCE-stimulated decreased fetal weight (Chapter 2). This finding suggests that TCE-induced 
reduction of fetal weight is dependent on CCBL activity that converts DCVC to the toxic 
metabolite 1,2-dichlorovinylthiol (DCVT), consistent with prior studies with kidney cells 
(Elfarra and Anders, 1984; Lash et al., 1986; Lash et al., 1994). Significantly, AOAA reduced 
CCBL activity in maternal kidney but not maternal liver or placenta in the present study, 
suggesting that kidney may have a role in the AOAA-stimulated prevention of fetal weight 
decrease (Chapter 2). NAC pre/co-treatment to TCE altered placental dimensions consistent with 
a delayed developmental progression (Furukawa et al., 2011), indicating that NAC pre/co-
treatment to TCE could have an adverse effect on placenta. In support of this, NAC pre/co-
treatment exacerbated DCVC-stimulated hydrogen peroxide abundance (Chapter 5). 
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Immunohistochemistry staining of placenta revealed that expression of enzymes known to 
bioactivate TCE differed as a function of placenta zone, indicating that placental capability to 
bioactivate TCE depends on placental zone. By itself, TCE did not stimulate many changes to rat 
placenta. This is contrary to previous studies of TCE or DCVC-stimulated toxicity in placenta 
(Hassan et al., 2016; Elkin et al., 2018; Elkin et al., 2019; Loch-Caruso et al., 2019; Elkin et al., 
2020) and findings in this dissertation that DCVC stimulated effects in human placental BeWo 
cells (Chapters 4, 5, and 6). 
 A significant portion of the dissertation investigated responses in energy metabolism in 
response to TCE exposure of timed-pregnant Wistar rats and DCVC exposure of BeWo cells 
undergoing forskolin-stimulated syncytialization (Chapters 3 and 6, respectively). 
Syncytialization is the multinucleation and fusion process of the placenta (Potgens et al., 2002; 
Wang et al., 2014). Because metabolomics analyses have been widely used to identify energy 
metabolism metabolites that are associated with adverse pregnancy outcomes (Romero et al., 
2010; Menon et al., 2014; Huang et al., 2017; Virgiliou et al., 2017; Gil and Duarte, 2018), we 
hypothesized that TCE would modify energy metabolites of rat amniotic fluid that have 
relevance to pregnancy. Similarly, because multinucleation in slime molds involve changes in 
energy metabolism (Allen et al., 1985; Allen et al., 1988) and DCVC targets energy metabolism 
in HTR-8/SVneo placental cells (Elkin et al., 2020), we hypothesized that DCVC would alter 
energy metabolites in BeWo cells undergoing syncytialization. Significantly, we found that 
TCE-stimulated decreases in metabolites responsible for direct energy supply, including 
adenosine triphosphate (ATP), adenosine diphosphate (ADP), and guanosine diphosphate (GDP) 
in amniotic fluid for both male and female fetal sex. KEGG pathways altered by TCE in 
amniotic fluid of both sexes as discovered from Metaboanalyst 4.0 analysis included folate 
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biosynthesis and pentose phosphate pathway. A sex-specific difference was noted for TCE-
stimulated increased arginine in females but not males, which relates to arginine and proline 
metabolism. This suggests that the decreased susceptibility of females to TCE toxicity (Chapter 
2) may be related, at least in part, to increased ability to vasodilate as a consequence of increased 
arginine (Aouache et al., 2018). A similar metabolomics approach could yield important results 
for other environmental toxicants or interventions. 
Novel insights inform how DCVC exposure during forskolin-stimulated syncytialization 
of BeWo cells could exacerbate or reverse the energy metabolism responses observed with 
syncytialization. Whereas DCVC treatment further decreased the syncytialization-stimulated 
decrease in aspartate and uridine diphosphate (UDP)-D-glucose, DCVC treatment during 
syncytialization decreased the syncytialization-stimulated increase in oleic acid. Together, these 
show the complex relationship between syncytialization and DCVC treatment during 
syncytialization. Some similar KEGG pathways were altered by both syncytialization and DCVC 
treatment during syncytialization, including starch and sucrose metabolism and histidine 
metabolism. Purine metabolism was a KEGG pathway in which metabolite ratios altered by 
syncytialization were reversed by DCVC treatment during syncytialization. For example, 
whereas syncytialization increased adenosine monophosphate at the expense of adenosine 
diphoshphate (ADP), DCVC treatment during syncytialization increased ADP at the expense of 
AMP. Following up on the oleic acid finding by investigating matrix metalloproteinases 
(MMPs), some of which are positively associated with oleic acid and are important in 
syncytialization (Sawicki et al., 2000; Xu et al., 2002; Yamaguchi et al., 2002; Soto-Guzman et 
al., 2010), we found that MMP-2 increased with syncytialization but decreased with DCVC 
treatment during sycytialization. Because MMP-2 has a critical role in polarization of 
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syncytiotrophoblasts (Sawicki et al., 2000), we suggest DCVC hinders proper syncytialization. 
We also found that DCVC treatment during syncytialization increased MMP-1 relative to 
syncytialization only. Importantly and with regard to metabolomics-specific findings, we also 
found many more changes in response to DCVC exposure in cells compared to those for TCE 
exposure in rats.  
This dissertation showed that DCVC stimulated apoptosis in unsyncytialized BeWo cells, 
BeWo cells undergoing syncytialization, and syncytialized BeWo cells. Importantly, we showed 
that DCVC was more toxic to syncytialized BeWo cells and to BeWo cells undergoing 
syncytialization compared to unsyncytialized BeWo cells. Increased caspase 3/7 activity, 
increased nuclear condensation or fragmentation, increased cytotoxicity, and decreased cell 
viability were stimulated by DCVC in BeWo cells regardless of differentiation state. 
Importantly, the apoptosis in unsyncytialized BeWo cells, BeWo cells undergoing 
syncytialization, and syncytialized BeWo cells was characterized by increased hydrogen 
peroxide generation and decreased PRDX2 mRNA expression, consistent with increased cellular 
ROS generation. However, the decreased nuclear factor kappa B subunit 1 NFKB1 mRNA 
expression and decreased tumor necrosis factor receptor 1 (TNF-R1) was observed only in 
syncytialized BeWo cells, suggesting that a pro-inflammatory response may be more relevant to 
DCVC toxicity on syncytialized BeWo cells compared to unsyncytialized BeWo cells or BeWo 
cells undergoing syncytialization. We also found some novel responses regarding 
syncytialization, including increased interleukin-6 in media and decreased hydrogen peroxide 
abundance, suggesting a need to further characterize the process. 
This dissertation also investigated how NAC and AOAA pre/co-treatment modulated 
DCVC-stimulated toxicity in BeWo cells. NAC was found to either exacerbate or not affect 
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DCVC-stimulated toxicity. In particular, the exacerbation of hydrogen peroxide abundance in 
unsyncytialized BeWo cells and BeWo cells undergoing sycytialization by NAC showed that 
NAC was not functioning strictly as an antioxidant, a property of NAC (Aldini et al., 2018). Of 
novelty, we showed that the effect of NAC but not DCVC was statistically significant for 
CYP3A4 mRNA expression in unsyncytialized BeWo cells and syncytialized BeWo cells. This is 
important because increased CYP3A4 mRNA favors increased production of N-acetyl DCVC 
sulfoxide (NAcDCVCS), a toxic DCVC metabolite (Werner et al., 1996; Lash et al., 2014a), and 
NAC could provide an acetyl group (Aldini et al., 2018) to promote the production of 
NAcDCVCS. Because CYP3A4 inhibition with ketaconazole pre/co-treatment was not sufficient 
to reduce toxicity in unsyncytialized BeWo cells and BeWo cells, it is possibile that 
aminoacylase III contributed to metabolism to the reactive DCVT (Lash et al., 2014a) and would 
also need to be inhibited to prevent regeneration of DCVC in order to reduce toxicity. Similar to 
the finding that AOAA exerted no effect on CCBL activity in rat placenta, AOAA exerted no 
effect on CCBL activity in unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, 
and syncytialized BeWo cells. However, a significant observation from the CCBL activity assays 
in BeWo cells was that syncytialized BeWo cells have higher CCBL activity than 
unsyncytialized BeWo cells. This may explain why syncytialized BeWo cells were more 
susceptible to DCVC-stimulated toxicity than unsyncytialized BeWo cells and suggests that 
differences in DCVC toxicity as a function of cell differentiation state can be considerable. 
 Strengths arose from the use of the Wistar rat model that could not have been achieved 
through use of BeWo cells alone. Firstly, the Wistar rat model allowed investigation into organs 
other than the placenta. Our results of cysteine conjugate β-lyase (CCBL) activity suggest that 
the kidney, as opposed to liver or placenta, may have a more significant role for the AOAA-
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stimulated prevention of TCE-stimulated decreased fetal weight. Within the placenta, the 
histology and immunohistochemistry (IHC) findings revealed regions of the placenta most 
capable of TCE biotransformation or responsible for toxic outcomes. Finally, including sex of 
the placenta in our analysis allowed us to identify sex-specific changes in response to TCE 
treatment. Future studies investigating TCE reproductive toxicity are likely to encounter similar 
important nuances in effects and should expand upon them. 
 The in vitro BeWo human placental trophoblast cell model complemented the rat model 
in this thesis. Firstly, AOAA as an ineffective modulator of CCBL was confirmed in both the rat 
model and the BeWo cells. This novel finding contrasts from findings in kidney cells (Elfarra 
and Anders, 1984; Lash et al., 1986; Lash et al., 1994) and suggests that the composition of 
CCBL enzymes in rat placenta is more similar to human placenta compared to rat kidney. 
Additionally, the use of the BeWo cell line allowed us to observe a placenta process, 
syncytialization, in vitro, which would be more difficult to accomplish in an in vivo rat model. 
Given that notable differences between rats and humans may exist in enzymes responsible for 
TCE biotransformation (Lash et al., 2000; Lash et al., 2014a; Rusyn et al., 2014), the importance 
of work that translates the relevance of findings from laboratory animals to humans cannot be 
overstated as a crucial future direction. 
 In general, we observed that treatment with the TCE metabolite, S-(1,2-dichlorovinyl)-L-
cysteine (DCVC), stimulated more responses in BeWo cells than treatment with TCE to timed-
pregnant Wistar rats. This was seen with the metabolomics studies (Chapters 3 and 6), 
particularly with the pathway and ratio analysis. Additionally, we observed that DCVC 
stimulates apoptosis in BeWo cells but that TCE failed to stimulate several apoptotic responses 
in rat placenta (Chapters 2, 4, and 5). The difference in concentrations at the target cells is one 
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possible explanation for the differences in response. Although concentrations of DCVC and 
dosage of TCE were chosen as relevant to occupational exposures (Lash et al., 1999; Agency for 
Toxic Substances and Disease Registry, 2007), it remains unknown how relevant a dosage of 480 
mg TCE/kg/day is to an in vitro concentration of 20 µM DCVC. Another consideration is the 
difference in species between the in vivo model (rat) and the BeWo model (human) because there 
are notable differences in TCE biotransformation between humans and rats. An example is the 
higher activity of CCBL in rat kidney compared to human kidney (Stevens et al., 1986; Elfarra et 
al., 1987; Lash et al., 1990). Although our CCBL values in BeWo cells versus rat placenta did 
not suggest that rats have higher CCBL activity than humans, understanding CCBL activity 
variation by organ and species is crucial to comprehending differences in susceptibility to DCVC 
toxicity. Finally, the role that other organs can exert on TCE toxicity in vivo but not in vitro can 
be considerable. For example, because the liver is a major site of CYP-dependent metabolism of 
TCE (Lash et al., 2014a), the rats could be exposed to higher concentrations of TCE metabolites 
through the CYP-dependent metabolic pathway of TCE (Lash et al., 2014a) compared to the 
BeWo cells. 
 Despite aforementioned differences between BeWo cell responses to DCVC and rat 
responses to TCE, notable similarities exist between results from the two models. In both 
models, NAC was found to either exacerbate or not affect TCE or DCVC responses but failed to 
minimize a TCE or DCVC response. We suggest that NAC could push metabolism towards 
increased production of the toxic N-acetyl DCVC sulfoxide (NAcDCVCS), but actual detection 
of metabolites would strengthen this speculation. As a whole, the NAC studies challenge the 
notion of NAC administration as a protective measure for TCE toxicity, and suggest instead that 
the provision of NAC could be detrimental if administred with TCE or DCVC. Accordingly, the 
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argument for NAC toxicity is more specific to the context of TCE or DCVC metabolism than by 
itself. 
AOAA failed to inhibit CCBL activity in rat placenta as well as in BeWo cells, regardless 
of BeWo differentiation status. Furthermore, the finding that syncytialized BeWo cells exhibited 
greater CCBL activity than unsyncytialized BeWo cells supports the notion that placenta cell 
differentiation states have differing levels of CCBL, consistent with findings of differential 
distribution of CCBL in placental zones of rats. These findings suggest that different placental 
cell types have different abilities for bioactivating DCVC and potentially other toxicants. 
Discovering the exact composition of CCBLs in placenta and the relationship to other organs 
remains important future work. 
 Although this dissertation did not observe many effects in rat placenta, the rat study 
contributes significantly to the current understanding of TCE toxicity to the placenta. Firstly, this 
dissertation is the first to show that modification of CCBL activity by AOAA prevented TCE-
induced decreased fetal weight, implying that the GSH conjugation pathway of TCE metabolism 
downstream of DCVC is important for fetal growth. In the absence of TCE exposure, AOAA 
decreased fetal weight, showing that the impact of AOAA depended on the presence of TCE. 
These findings highlight that DCVC metabolism was critical to TCE toxicity in pregnancy. This 
dissertation shows that CCBL activity was profoundly different across tissues, which supports 
and expands upon previous literature (Lash, 2010). Nonetheless, our finding of placental CCBL 
activity was the first to indicate that placenta has CCBL activity but also acknowledges that there 
is a need to further characterize exact placental enzymes capable of CCBL activity and develop 
or identify inhibitors of CCBL for tissues besides the kidney. This dissertation would also be 
bolstered by the detection of 1,2-dichlorovinylthiol (DCVT) and other metabolites downstream 
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of DCVC via CCBL activity. In light of findings that DCVC has been found at low 
concentrations in mouse serum (Kim et al., 2009a; Kim et al., 2009b; Luo et al., 2018), 
important future directions also include the need to consider if rats are more capable of 
generating DCVC than mice or if low concentrations of DCVC in vivo are sufficient to produce 
the observed fetal weight effects. Secondly, our work suggests a need to understand further the 
enzymes involved in TCE metabolism in placenta. 
 In summary, this dissertation contributes to our understanding of TCE and DCVC 
toxicity during pregnancy. In the Wistar rat, because few changes were observed in placenta in 
response to TCE exposure, we were unable to infer a sequence of events that could contribute to 
an adverse outcome, such as decreased fetal weight. However, the AOAA effect on CCBL 
activity in maternal kidney suggests that AOAA-stimulated prevention of TCE-stimulated 
deceased fetal weight may be attributable to maternal kidney. Additionally, the effect of NAC 
pre/co-treatment to TCE, suggestive to favor delayed placenta development, supports the 
possibility that NAC in combination with TCE or DCVC could be harmful. The BeWo cells 
provided insight into DCVC-stimulated mechanisms underlying apoptosis, allowing separate 
analysis of effects on unsyncytialized BeWo cells, BeWo cells undergoing syncytialization, and 
syncytialized BeWo cells. Significantly, we found that the syncytialized BeWo cells responded 
differently to DCVC compared to unsyncytialized BeWo cells and BeWo cells undergoing 
syncytialization. The syncytialized BeWo cell response involved more interaction with factors 
regulating pro-inflammatory response, notably tumor necrosis factor receptor 1 (TNF-R1) and 
mRNA of NFKB1. Regardless of the differentiation state of the BeWo cells, reactive oxygen 
species generation was suggested to play a major role in apoptosis. Also significant was the 
finding that syncytialized BeWo cells have greater CCBL activity than unsyncytialized BeWo 
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cells, which may explain why syncytialized BeWo cells are more susceptible to DCVC toxicity 
than unsyncytialized BeWo cells. Metabolomics analysis suggest that DCVC in BeWo cells or 
TCE in Wistar rats affect direct energy supply involving purine metabolism. A simplified 
depiction of a model of TCE and DCVC toxicity from this dissertation is shown in Figure 7.1. 
Overall, we suggest that TCE exposure is toxic during pregnancy and this toxicity likely 
is attributable to metabolism downstream of DCVC. Importantly, we suggest that modulation of 
enzymes capable of bioactivation of TCE or DCVC is a potentially promising method for 
reducing TCE stimulated toxicity, as demonstrated by the AOAA prevention of TCE-stimulated 
decreased fetal weight. Targeting additional mechanisms by which TCE or DCVC could 
stimulate apoptosis, such as the generation of reactive oxygen species, is also promising. Major 
considerations for future work include improved analytical methods to detect TCE metabolites, 
especially reactive metabolites thought to contribute to TCE toxicity. An important future 
consideration is the in vivo exposure correlation and relation to an in vitro exposure. Finally, 
agents thought to be protective, such as NAC, should be individually evaluated for possibility of 
toxicant bioactivation or other mechanisms that could actually be of harm to health. 
 
 
 
367 
 
 
 
Figure 7.1. Simplified model of TCE or DCVC toxicity from this dissertation. We found that 
TCE decreased fetal weight in timed-pregnant Wistar rats, an effect prevented by AOAA but not 
NAC pre/co-treatment (Chapter 2). TCE stimulated modest changes in rat placenta (Chapter 2). 
This dissertation found and discussed some metabolites in energy metabolism in amniotic fluid 
that were altered by TCE treatment (Chapter 3). We saw that DCVC could stimulate some 
distinct mechanisms towards apoptosis dependent on the differentiation state of the BeWo cells, 
or whether the BeWo cells were unsyncytialized, undergoing syncytialization, or syncytialized 
(Chapter 4). This dissertation found that NAC or AOAA pre/co-treatment did not prevent 
DCVC-stimulated toxicity in unsyncytialized BeWo cells, BeWo cells undergoing 
syncytialization, and syncytialized BeWo cells and that NAC could exacerbate some DCVC-
stimulated responses (Chapter 5). Significantly, syncytialized BeWo cells have more CCBL 
activity than unsyncytialized BeWo cells, which can explain why syncytialized BeWo cells are 
more susceptible to DCVC toxicity than unsyncytialized BeWo cells (Chapters 4 and 5). Finally, 
this dissertation showed how DCVC-treatment during BeWo cell syncytialization could 
stimulate changes in metabolites in energy metabolism, some changes that furthered a change 
stimulated by syncytialization and some changes that reversed a change stimulated by 
syncytialization (Chapter 6). 
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